

402683

MEDICAL SURVEY OF THE PEOPLE OF RONGELAP AND UTIRIK ISLANDS ELEVEN AND TWELVE YEARS AFTER EXPOSURE TO FALLOUT RADIATION (MARCH 1965 AND MARCH 1966)

ROBERT A. CONARD, M.D., LEO M. MEYER, M.D., WATARU W. SUTOW, M.D., JAMES S. ROBERTSON, M.D., PH.D., JOSEPH E. RALL, M.D., PH.D., JACOB ROBBINS, M.D., JOHN E. JESSEPH, M.D., JOSEPH B. DEISHER, M.D., AROBATI HICKING, PRACTITIONER, ISAAC LANWI, PRACTITIONER, ERNEST A. GUSMANO, PH.D., AND MAYNARD EICHER



PRIVACY ACT MATERIAL REMOVED

PRIVACY ACT MATERIAL REMOVED

BROOKHAVEN NATIONAL LABORATORY

ASSOCIATED UNIVERSITIES, INC.

under contract with the

UNITED STATES ATOMIC ENERGY COMMISSION

LEGAL NOTICE

This report was prepared as an account of Government sponsored work. Neither the United States, nor the Commission, nor any person acting on behalf of the Commission:

A. Makes any warranty or representation, expressed or implied, with respect to the accuracy, completeness, or usefulness of the information contained in this report, or that the use of any information, apparatus, method, or process disclosed in this report may not infringe privately owned rights; or

B. Assumes any liabilities with respect to the use of, or for damages resulting from the use of any information, apparatus, method, or process disclosed in this report.

As used in the above, "person acting on behalf of the Commission" includes any employee or contractor of the Commission, or employee of such contractor, to the extent that such employee or contractor of the Commission, or employee of such contractor prepares, disseminates, or provides access to, any information pursuant to his employment or contract with the Commission, or his employment with such contractor.

Printed in the United States of America Available from Clearinghouse for Federal Scientific and Technical Information National Bureau of Standards, U.S. Department of Commerce Springfield, Virginia 22151 Price: Printed Copy \$3.00; Microfiche \$0.65

April 1967

Ŧ

ł

Ţ

1150 copies

MEDICAL SURVEY OF THE PEOPLE OF RONGELAP AND UTIRIK ISLANDS ELEVEN AND TWELVE YEARS AFTER EXPOSURE TO FALLOUT RADIATION (MARCH 1965 AND MARCH 1966)

ELEVEN-YEAR SURVEY

ROBERT A. CONARD, M.D.,¹ LEO M. MEYER, M.D.,² WATARU W. SUTOW, M.D.,³ JAMES S. ROBERTSON, M.D., PH.D.,¹ JOSEPH E. RALL, M.D., PH.D.,⁴ JOHN E. JESSEPH, M.D.,¹ AROBATI HICKING, PRACTITIONER,⁵ ISAAC LANWI, PRACTITIONER,⁵ ERNEST A. GUSMANO, PH.D.,¹ AND MAYNARD EICHER⁶

> with the technical assistance of William A. Scott,¹ Douglas Clareus,¹ Lawrence Cook,¹ Ernest Libby,³ Kosang Mizutoni,⁵ Sebio Shoniber,⁵ W. Gays,⁵ And Kalman Kittien⁵

TWELVE-YEAR SURVEY

ROBERT A. CONARD, M.D.,¹ JACOB ROBBINS, M.D.,⁴ JOSEPH B. DEISHER, M.D.,⁵ AND AROBATI HICKING, PRACTITIONER⁵

with the technical assistance of

WILLIAM A. SCOTT,¹ DOUGLAS CLAREUS,¹ SEBIO SHONIBER,⁵ AND NELSON ZETKEIA⁵

¹Brookhaven National Laboratory, Upton, New York 11973
²Long Island Jewish Hospital, Queen's Hospital Center Affiliation, Jamaica, New York 11432

í

⁴National Institutes of Health, Bethesda, Maryland 20014
⁵Department of Medical Services, Trust Territory of the Pacific Islands, Saipan, Mariana Islands 96950

³M.D. Anderson Hespital, University of Texas, Houston, Texas 77025

*Naval Medical Research Institute, Bethesda, Maryland 20014

BROOKHAVEN NATIONAL LABORATORY UPTON, NEW YORK 11973

CONTENTS

1

t .

l

: :

ļ

| Introduction | 1 |
|--|-----|
| Summary of Past Findings | 2 |
| Penetrating Radiation | 3 |
| Beta Irradiation of the Skin | 5 |
| Internal Irradiation | . 5 |
| Other Studies | 6 |
| Other Background Information | 8 |
| Comparison Populations | 8 |
| Organization | 10 |
| The 1965 Survey | 10 |
| The 1966 Survey | 10 |
| Findings | 11 |
| Interval Medical History | 11 |
| Illnesses | 11 |
| Deaths | 12 |
| Births | 14 |
| Congenital Anomalies | 14 |
| Sex Ratio | 14 |
| Miscarriages and Stillbirths | 14 |
| Vital Statistics on the Utirik People | 15 |
| Physical Examinations | 16 |
| Adult Examinations | 16 |
| Pediatric Examinations | 19 |
| Thyroid Findings | 24 |
| The Radiation Dose to the Thyroid Glands | 24 |
| Previous Thyroid Studies | 25 |
| Protein-Bound Iodine | 25 |
| Dietary Iodine and Urinary Excretion of Iodine | 26 |
| Thyroid Uptake of Radioiodine | 26 |
| Serum Cholesterol | 27 |
| Discussion of Previous Thyroid Studies | 27 |
| Development of Thyroid Abnormalities | 29 |

| | · · · | | · ·, - | |
|---------------|---|---|---|---------------------------|
| | | | | • |
| s 4 e | | CONTENTS | | |
| ·r | | | | , |
| _ | | | · <u>美</u> " | |
| SUMMARY | ••••••••••••••••••••••••••••••••••••••• | * | | 64 |
| Interval Med | dical History | | ····· | 64 |
| Physical Fin | dings | | | 64 |
| Thyroid Fine | dings | | | 64 |
| Other Studi | es | | | 65 _; |
| Estimation of | of Internal Body Burden | of Radionuclides | | 65 |
| Acknowledgm | (ENTS | | | 65 |
| References | | | • | 66 |
| | | | | |
| Approvery 1 | Ribliography. | | | 69 |
| APPENDIX 1. | LICRI 12273 - Fetim | ate of Radiation Dose to T | byroids of the Rongelan | 00 |
| APPENDIX 2. | Children Following the | Bravo Event and Calculatio | n of Urinary Radioiodine | |
| | Excretion | Time in | | 79 |
| Appendix 3. | Individual Serum Iodir | ne Determinations | | 96 |
| A | of Marshall Island Pop | ulations Under Study | | 00 |
| APPENDIX 4. | Urinary Iodine Excreti | on | | 95 |
| APPENDIX 5. | Cholesterol Levels | | | 94 |
| APPENDIX 6. | Hospital Summaries of | Thyroid Surgical Cases | | 96 |
| Appendix 7. | Malignancies Recorde Number of Patients W | ed in Marshall Islands, May ith Malignand Neoplasms Di | 1952 – October 1962 and scharged From Hospitals, | 110 |
| Approx. 9 | - 1902 – 1903 | Control Moon Pland Courses | •••••• | 110 |
| APPENDIX 0. | at Various Times After | Exposure | | 112 |
| Appendix 9. | Ailingnae Group and C at Various Times After | Control Mean Blood Counts Exposure | | 113 |
| Appendix 10. | Utirik Group Mean Bl | ood Counts at Various Times | After Exposure | 114 |
| Appendix 11. | Individual Hematologi | ical Findings, 1965 | · · · · · · · · · · · · · · · · · · · | 115 |
| Appendix 12. | Individual Hematologi | ical Findings, 1966 | * | 127 |
| APPENDIX 13 | Individual Basophil D | eterminations 1965 | | ;;; ≉135 ^{#*} |
| APPENDIX 14 | Chromosome Studie | on Marshallese reople Expose | d to Faller Radiation | 137 |
| APPENDIX 15 | Total Blood and Red (| Cell Volume Data | | 149 |
| Appendix 16 | Studies on Australia A | ntigen in Micronesian Popula | itions | 150 |
| ADDENTITY 17 | Gamma Spectrograph | ic Data Rongelan People 10 | 65 × | 154 |
| ADDENTIN 19 | Colum-137 and Street | time-90 Retention | | |
| SFFEMDIA 10. | Following an Acte In | gestion of Rongelap Food | | 15 9 °, |
| | | | | |

Î

v

CONTENTS

F.4

F

3

ł

I

| Surgical Cases | 31 |
|--|------------|
| Gross Appearance | 31 |
| Microscopic Appearance | 33 |
| Thyroid Function Tests Related to Thyroid Abnormalities and Growth Retardation | 33 |
| Results of Thyroid Hormone Therapy | 40 |
| Discussion of Thyroid Findings | 40 |
| Aging Studies | 43 |
| Methods | 43 |
| Integument | 43 |
| Special Senses | 44 |
| Cardiovascular Changes | 44 |
| Neurological and Neuromuscular Function | 44 |
| Miscellaneous Tests | 45 |
| Correlation of Data | 45 |
| Results of Aging Studies | 4 6 |
| Discussion of Aging Studies | 46 |
| Hematological Studies | 51 |
| Rongelap Population | 51 |
| Ailingnae Population | 54 |
| Utirik Population | 54 |
| Children of Exposed Parents | 55 |
| Leukemia Survey | 55 |
| Statistical Analysis of Rongelap Blood Data | 55 |
| Chromosome Studies | 55 |
| Other Laboratory Studies | 57 |
| Total Blood Volume and Red Cell Volume | 57 |
| Test for Australia Antigen | 58 |
| Estimation of Internal Body Burdens of Radionuclides | 58 |
| Whole-Body Counting | 58 |
| Radiochemical Analysis of Urine | 59 |
| Results and Discussion of Body Burden Estimation | 61 |
| Comparison of ¹³⁷ Cs Levels in Marshallese and Alaskan Eskimos | 63 |
| Radiochemical Analysis of Coconut Crabs | 63 |

MEDICAL SURVEY OF THE PEOPLE OF RONGELAP AND UTIRIK ISLANDS ELEVEN AND TWELVE YEARS AFTER EXPOSURE TO FALLOUT RADIATION (MARCH 1965 AND MARCH 1966)

Introduction

The results of a medical survey of the people of Rongelap in the Marshall Islands, carried out in March 1965 and March 1966, 11 and 12 years after the accident, are presented in this report. These people had been accidently exposed to fallout radiation following a detonation of a high vield thermonuclear device during experiments at Bikini in the Pacific Proving Grounds in March 1954. An unpredicted shift in winds caused a deposition of significant amounts of fallout on four inhabited Marshall Islands to the east of Bikini (see Figure 1) and also on 23 Japanese fishermen aboard their fishing vessel, the Lucky Dragon. Of the inhabitants of the island of Rongelap, 105 nautical miles away from the detonation, 64 received the largest fallout exposure: an estimated dose of 175 rads of whole-body gamma radiation, contamination of the skin sufficient to result in beta burns, and slight internal absorption of radioactive materials through inhalation and ingestion. Another 18 Rongelap people away on a nearby island (Ailingnae), where less fallout occurred, re-

1

1

BIKINI ALINGINAE RONGELAP TKWAJALEIN

Figure 1. Map of fallout area, Marshall Islands, March 1, 1954. ceived only an external gamma dose of about 69 rads. There were 28 American servicemen on the island of Rongerik further to the east who received about the same amount of radiation as did the Rongelap people on Ailingnae. Lastly, 157 Marshallese on Utirik Island, about 200 miles further east, received an estimated 14 rads of whole-body radiation. The fallout was not visible on this island and no skin effects developed.

The exposed people were executed from these islands by plane and ship about 2 days after the accident and taken to Kwajalein Naval Base about 150 miles to the south, where they received extensive examinations for the following 3 months. During this period vigorous efforts were necessary to decontaminate the skin completely (see Figure 2).

In view of the generally negative findings on the American servicemen, they were later returned to their duty stations. The Utirik people were also allowed to return to their home island, where radioactive contamination was slight enough to allow safe habitation. Because Rongelap Atoll was considered to be too highly contaminated, a tempo-



Figure 2. Marshallese bathing in lagoon at Kwajalein in March 1954 to decontaminate skin and hair after fallout contamination.

PRIVACY ACT MATERIAL REMOVED



I

phocytes were considerably depressed and that significant doses of radiation had probably been received. In addition to the whole-body dose of radiation and the beta irradiation of the skin, radiochemical analyses of the urine showed that measurable amounts of radioactive material had also been absorbed internally. The effects of the radiation can best be summarized under three headings according to the mode of exposure: penetrating irradiation, skin irradiation, and internal irradiation.

PENETRATING RADIATION

One of the earliest findings indicative of a significant exposure in these people was lowering of levels of leukocytestind plateletting the peripheral blood. This was most marked in the 64 people on Rongelap who had received 175 rads, and was less marked in the other groups receiving less exposure. The hemicoictic depression was roughly proportional to the dose of radiation received. Even in the 157 Utirik people who received only an estimated 14 rads, it was possible to distinguish slight platelet depression in the group as a whole. The smaller group on Ailingase and Rongerik showed peripheral blood levels between those of the high and low exposure groups. The chronological records of blood findings on the group exposed on Rongelap are presented in Figures 49, 50, 56, and 65 and Appendix 8, and on the Ailingnae and Utirik groups in Appendices 9 and 10.

ī

9

Lymphopenia of about half the level of the comparison Marshallese population was evident when the peopie exposed on Rongelap-were first examined on their arrival at Kwajalein 3 days after exposure (see Figures 49, 50, and 65). In children <5 years of age the lymphocytes dropped to 25% of the levels in the comparison children, but showed a slight rise during the following weeks. The lymphocyte level showed a slight increase by 1 year. In the following year mean counts approached the levels of the comparison population but remained slightly below (see Figures 50 and 65).

Neutrophil levels fluctuated considerably during the first month; possibly this was related to the prevalence of beta burns of the skin during that period. Neutrophil depression became evident by 5 and 6 weeks post exposure (see Figures 49 and 65), with levels reaching about half that of the comparison population in the adults and slightly lower in the children <5 years of age. This degree of neutropenia was insufficient to result in any apparent increased infectious processes, and, indeed, it was noted that neutrophilic leukocytosis was possible in people showing casual infections at this time. Neutrophil levels recovered more rapidly than lymphocyte levels and reached near control levels by 1 year. Subsequent annual surveys have revealed that recovery does not appear to have been complete, particularly in younger and older age groups, during the 10-year period.

Early *platelet* counts showed less fluctuation than other blood counts and fairly consistently showed increasing depression, reaching levels of about 30% that of the comparison population by the 4th week. A spurt of recovery to about 75% of comparison levels occurred during the following few weeks, which was followed by slower recovery but with mean levels never reaching higher than 90 to 95% that of the comparison population during the 10 years post exposure (see Figures 56 and 65).

Erythropoietic depression has not been a consistent finding as with the leukocytes and thrombocytes. Slight depression of red blood counts, hematocrits, and hemoglobin has been noted at times. Bone marrow smears taken at 6 months showed no gross abnormalities. Smears taken at 8, 9, and 10 years showed an alteration in the myeloid-erythroid ratio manifested by an increased number of red cell precursors. Depression of peripheral blood elements in the Ailingnae and Rongerik groups was not so pronounced as in the Rongelap group. However, a slight lag in complete recovery in the Ailingnae peripheral blood count has also been noted. The persistent depression of peripheral blood elements in the exposed people makes it appear likely that there is slight residual bone marrow damage.

A general *anemic* tendency has been evident in both exposed and unexposed Marshallese. Price-Jones curves, on the average, showed a slight microcytic tendency. Serum iron levels have been generally normal, and the cause of this anemic tendency has been undetermined.

Reticulocyte counts have been about the same in the exposed as in the unexposed people.

Clinical findings, except for radiation-induced lesions of the skin, patchy epilation, and early gastrointestinal symptoms, revealed no clear-cut disease processes or symptoms which could be rerary village was constructed for the Rongelap people (including the 18 from Ailingnae) on Majuro Atoll several hundred miles to the south, where they lived for the following $3\frac{1}{2}$ years and were examined at yearly intervals by a special medical team. In July 1957, after careful evaluation of radioactive contamination, Rongelap Island was considered safe for habitation. A new village was constructed, and the Rongelap people were moved there by Navy ship. The annual medical surveys have since been carried out on Rongelap Island.

A group of more than 100 Rongelap people, who were relatives of the exposed people but had been away from the island at the time of the accident, moved back with the Rongelap people to their home island and have served as an ideal comparison population for the studies. The number has since increased to >200. Following the initial survey of the Utirik people on Kwajalein in 1954, repeat surveys have been carried out on these people about every 3 years, including the 12year survey. In addition, during the past survey, as in the previous surveys, a visit was made to Kwajalein and Majuro Atolls for examination of a number of Rongelap people now residing at these atolls, and also groups of children who represent parts of the control group used for the growth and development studies of the exposed children.

The accumulation of data from these surveys is becoming increasingly voluminous. Since conditions have not been favorable for performance of extensive statistical analyses or use of electronic computing procedures to store and manipulate the data, the annual survey reports published by this Laboratory are made as complete as possible. This report, therefore, includes a considerable amount of raw data, much of it in appendices, so that others may have an opportunity to make further calculations if desired.

Table 1 lists exposure data on the various populations involved in the fallout. In the following summary, except where data are broken down into more detail, the exposed group includes the people exposed on Rongelap and on Ailingnae (subject Nos. 1 to 86).

Summary of Past Findings

Reports have been published on the medical findings of surveys made at the following times after exposure: initial examination,¹ 6 months,² 1 year,³ 2 years,⁴ 3 years,⁵ 4 years,⁶ 5 and 6 years,⁷ 7 years,⁸ 8 years,⁹ and 9 and 10 years.¹⁰ Appendix 1 gives a more complete list of reports, including outside publications, on the results of medical surveys of the Marshallese exposed to fallout and includes a section on the radiation ecological studies of these Islands published largely by the University of Washington group. The following is a brief summary of the medical findings previously reported.

During the first 24 to 48 hr after exposure, about $\frac{24}{5}$ of the people exposed on Rongelap Island experienced anorexia and nausea. A few vomited and had diarrhea, many also experienced itching and burning of the skin, and a few complained of lacrimation and burning of the eyes. None of these symptoms was noted in the Utirik people (14-rad group). Following this, the people remained asymptomatic until about 2 weeks after the accident, when cutaneous lesions and loss of hair developed, due largely to beta irradiation of the skin. It was apparent when the people were first examined, a few days after exposure, that the lym-

| Table 1 | | | | | | | | | |
|---|-----------------|---------------------|-----|------------------------------|--|--|--|--|--|
| Summary of Fallout Effects | | | | | | | | | |
| Group* Composition Fallout observed dose (rads) Extent of | | | | | | | | | |
| Rongelap | 64 Marshallese | Heavy (snowlike) | 175 | Extensive | | | | | |
| Ailingnae | 18 Marshallese | Moderate (mistlike) | 69 | Less extensive | | | | | |
| Rongerik | 28 Americans | Moderate (mistlike) | 78 | Slight | | | | | |
| Utirik | 157 Marshallese | None | 14 | No skin lesions or epilation | | | | | |

*Also exposed were 23 Japanese fishermen who received a sublethal dose.

uals of the same age groups showed no apparent differences. A biological age score was calculated for individuals and groups by use of an average percentage score. *Life shortening* effects of radiation have not been apparent. As noted, the mortality rate was about the same in the exposed as in the unexposed people.

Development of thyroid pathology was noted in 1963 when a teen-age exposed girl was found to have a nodule of the thyroid gland. In 1964, two additional teen-age girls were found to have nodules. These cases were operated upon, and the nodules were found to be benign adenomatoid goiters. These abnormalities are believed to be the result of exposure of the thyroid to radioiodines from the fallout and to the gamma radiation. The dose to the child's thyroid was estimated as between 700 and 1400 rads from radioiodines and an additional 175 rads from gamma radiation for the group exposed to 175 rads. No nodules were detected in the unexposed children.

Two cases of *cancer* have developed in the exposed group. The first appeared at 5 years post exposure, too soon, it is believed, to have been radiation induced. The second occurred at 8 years post exposure.

Leukemia surveys including physical findings, studies of leukocyte counts and morphology, alkaline phosphatase staining, and basophil counts of 4000 white cells showed no evidence of leukemia or leukemic tendency. One child in the irradiated group has had slightly elevated basophil counts but no other positive findings. The cardiovascular and arthritis surveys, as well as the general results of the physical examinations, have not shown any apparent increased incidence of degenerative diseases in the exposed people. No radiation-induced cataracts have been observed in any of the exposed people.

Genetic effects have not been specifically studied because of the small number of people involved. No apparent radiation-induced genetic changes have been detected on routine physical examinations in the first-generation children of exposed parents, with the possible exception of suggestive evidence of increased miscarriages and stillbirths in the exposed women.

BETA IRRADIATION OF THE SKIN

It was impossible to get an accurate estimate of the radiation dose to the skin. Beta burns of the

skin and epilation appeared about 2 weeks after exposure, largely on parts of the body not covered by clothing. About 90% of the people exposed on Rongelap had these burns, and a smaller number developed spotty epilation of the scalp. Most of the lesions were superficial; they exhibited pigmentation and dry, scaly desquamation, and were associated with itching and burning sensations. Rapid healing and repigmentation followed. Some lesions were deeper, showed wet desquamation, and were more painful. A few burns became secondarily infected and had to be treated with antibiotics. Repigmentation of the lesions gradually took place in most instances, and the skin appeared normal within a few weeks. However, in about 15% of the people, deeper lesions, particularly on the dorsum of the feet, continued to show lack of repigmentation with varying degrees of scarring and atrophy of the skin. At 10 years these conditions were still evident in a number of cases. During the past several years an increased number of pigmented maculae and moles have been noted in previously irradiated areas of the skin, but these have appeared to be quite benign.

Numerous histopathological studies have been made,^{1.4.5} and the changes found have been consistent with radiation damage. At no time have changes been observed either grossly or microscopically indicative of malignant or premalignant change. Spotty epilation on the heads was short lived, regrowth of hair occurring about 3 months after exposure and complete regrowth of normal hair by 6 months. No further evidence of epilation has been seen.

An interesting observation noted during the first few months after exposure was the development of bluish-brown pigmentation of the semilunar areas of the fingernails and toenails in about 90% of the people exposed on Rongelap. By 6 months this pigmentation had disappeared, having grown out with the nail. The cause of this phenomenon has not been explained.

INTERNAL IRRADIATION

Radiochemical analyses of numerous urine samples of the exposed population showed internal absorption of radioactive materials, probably brought about largely through eating and drinking contaminated food and water and to a lesser extent through inhalation. During the first few lated directly to radiation effects during the first few years post exposure. No prophylactic or specific therapy for radiation effects was ever considered necessary or given. Epidemics of chicken pox and measles that occurred during the first year showed no greater incidence or severity in the exposed than in the unexposed Marshalles people.

During the first months post exposure about $\frac{24}{3}$ of the exposed people exhibited *loss of weight* of several pounds. This may possibly have been related to their radiation exposure, although it was difficult to rule out possible effects due to change of environment.

At 3 years post exposure the *immune response* to primary and secondary tetanus antitoxin was tested and found not to be significantly different in the exposed compared with the unexposed populations.

There were 10 deaths in the exposed populations over the 10-year period (see Table 6). Of these, 2 deaths were recorded as due to malignancies. The 10 deaths that have occurred in the exposed population represent a mortality rate of 12.2 per 1000 population per annum, compared with 8.3 for the Marshall Islands as a whole (1960). The somewhat higher death rate in the exposed group is partly offset by the higher proportion of older people; those >65 years of age were originally 20% in the exposed group and only 7% in the unexposed group.

Growth and development studies on the children (height, weight, anthropometric measurements, and radiographic studies for bone age) have revealed slight retardation in growth and development in the boys exposed on Rongelap who were < 12 years of age at the time of exposure, particularly those 12 to 18 months of age at exposure. Only slight immaturity was noted in the female children of this group. In studies of children born of exposed parent(s), it was noted that males showed a slight growth retardation and slightly lower levels of peripheral blood elements compared with male children of unexposed parents; however, this latter finding has not been evident since 1963. The slight growth difference does not appear to justify a conclusion that there is an association with exposure of the parent.

It was difficult to evaluate the effects on fertility. However, a review of the *birth rate* of the exposed groups over the past 10 years seems to indicate no noticeable effects of their exposure on fertility. The 50 births represent a rate of 61 per 1000 population per annum compared with 37.3 for the Marshall Islands (1957). The incidence of *miscarriages* and *stillbirths* in these exposed women was about twice that in the unexposed women during the first 4 years after exposure, but no difference has been noted since then (see Table 8).

A cardiovascular survey of the adults (1959)⁷ showed no outstanding differences between the exposed and unexposed groups. The Marshallese people appeared to have less hypertension on the whole than is noted in people in the continental United States.

An arthritis survey $(1959)^{7}$ showed no great differences between the exposed and the unexposed people, and about the same incidence as is seen in American populations.

Ophthalmological surveys showed no remarkable differences between the exposed and unexposed groups except possibly a slightly greater number of cases of pterygia, pingueculae, and corneal scars in the exposed groups. It is not known whether these findings are of any significance in relation to their radiation exposure. Slit-lamp observations showed no opacities of the lens characteristic of radiation exposure. As a whole, visual and accommodation levels in the Marshallese appeared to be above the average in the U.S. population.

Dental surveys⁷ showed no significant differences in caries rate between exposed and unexposed groups. However, the incidence and severity of peridontal disease was slightly greater in the exposed group. It is not known whether or not this finding is related to radiation effects. The poor oral hygiene generally observed in the Marshallese had its usual results, namely, high caries rate in teen-age children, severe peridontal lesions in adults (heavy calculus and loss of alveolar bone), and edentulous mouths in the aged. Radiation exposure did not appear to have affected developing dentition in the exposed children.

Aging studies were done in which various parameters usually associated with aging were measured or estimated on a 0 to 4 + scale (skin looseness, elasticity, and senile changes; graying of the hair and balding; accommodation, visual acuity, and arcus senilis; hearing; cardiovascular changes including blood pressure and degrees of peripheral and retinal arteriosclerosis; neuromuscular function; and hand strength). Comparison of these measurements in exposed and unexposed individ-

4

i

1

pean populations thus far tested and consistent with that of populations living near the equator. The distribution of haptoglobin types showed the population to be relatively homogeneous.¹² Transferrins in all sera were type CC, the common European type.¹² β -Amino-iso-butyric acid urinary levels showed the Marshallese to be the highest excreters of this acid of any population thus far reported.^{13,14} Levels in the exposed group were about the same as in the unexposed group, and no correlation was found with body burden level of radionuclides; this indicates that there is probably no correlation with radiation exposure. Hemoglobin types were considered normal (all had type AA₂). Sickling tests showed no sickling tendency in any of the people. Glucose-6-phosphate dehydrogenase of the red cells appeared to be normal in the Marshallese. Studies of Gm phenotypes showed the Marshallese to have 100% Gm^(a+) and nearly 100% Gm^(b+). There was a complete absence of Gm^x and a high frequency of Gm-like (Gm^e).¹⁵ Serum studies for the Ag system reveal that the Rongelapese compared with other world populations have a high frequency of C.deB. antiserum reactors and a low frequency of New York antiserum reactors.¹⁶ Considerable caution must be exercised in evaluating the results of these studies on genetically inherited characteristics because of the small number of samples tested. The data do seem to indicate relative homogeneity of the population and closet kinship with people of Southeast Asia. These data also may be useful as a base line, should genetic changes appear in later generations, possibly related to radiation exposure. Numerous blood cultures for chromosome analysis have been taken on past surveys. The results of these studies will be presented in this report.

1

1

Other Laboratory Studies: Serum protein levels were generally on the high side of normal; electrophoretic patterns showed the increase in proteins was largely due to an increase in the gamma globulin fraction. The reason for this is not apparent. Numerous chronic infections may be an explanation.

Sodium levels in the urine and food indicated about the same consumption of NaCl as in Americans. The generally lower incidence of hypertension in the Marshallese might be related to the fact that the former native diet was probably lower in salt content than the present more Westernized diet.¹⁷ It will be interesting to see whether the incidence of hypertension will later increase. Serum cholesterol levels (1957, 1959) were somewhat lower in the exposed population than in the comparison or Utirik populations but were in the low normal range. No abnormally high or low readings were noted.

Serum creatinine levels (1957) were in the normal range with no abnormal levels noted.

Serum vitamin B_{12} concentrations (1958, 1959) were generally significantly higher than American levels. The possibility of contamination of the samples with bacteria producing vitamin B_{12} must be considered, since myeloproliferative and liver diseases were not seen.

Folic acid levels were found to be somewhat low in the Rongelap population and probably reflected low dietary folic acid.

Serum protein-bound iodine levels have repeatedly been shown to be generally slightly elevated. Evidence for thyroid dysfunction has only recently been noted in the people along with the recent development of thyroid nodules. Thyroid studies will be reviewed in detail in a later section.

Glucosuria and elevated blood sugar were found in a number of Rongelap people. A relatively high incidence of diabetes is prevalent in the Marshallese people.

A survey for intestinal parasites (1958) showed 75% of the people to be infected with various types.¹⁸ For the three major pathogens found, the over-all infection rates were, for *Entamoeba histolytica*, 18.2%; for hookworm, 5.5%, and for *Truchuris trichiura*, 34.3%.

Eosinophilia (>5%) has consistently been noted in about half the people. The fact that half the cases with eosinophilia showed no helminthic infections at all suggests that other factors besides parasitic infections must be responsible. The eosinophilia may be related to chronic fungus and other infections, particularly of the skin.

Complement fixation studies for parainfluenza 1, 2, and 3, respiratory syncitial, psittacosis, and Q fever showed antibodies to all groups of viruses except that for Asian influenza, which probably had not yet seriously involved the people of the Marshall Islands. The antibody titers appeared to be somewhat lower in the exposed people.

Immunoelectrophoretic analysis showed neither a paraproteinemia nor a typical picture of antibodydeficiency-syndrome, but a high frequency of increases of some of the immunoglobulins was noted. days when the body levels were at their highest, the maximum permissible concentrations were approached or slightly exceeded only in the case of strontium-89 and the isotopes of iodine. At that time the concentrations were believed to be too low to result in any serious effects. Body levels fell rapidly, so that by 2 and 3 years post exposure they were far below the accepted maximum permissible level; even by 6 months activity in the urine was barely detectable.

In 1958 analyses of bone samples on one of the men who died showed a body burden of 3.7 nCi ⁹⁰Sr. Beginning in 1957, gamma spectroscopy by use of a low-level counting chamber was added to the techniques of radiochemical analysis. The return of the Rongelapese to their home island (which after careful survey was considered safe for habitation, despite a persisting low level of radioactive contamination) was reflected in a rise in their body burdens and increased urinary excretion of certain radionuclides. During the 4 years after the original contaminating event, additional weapons tests held in the area contributed slightly to the fission products in the environment. Since the diet includes a variety of imported foods. .ne people may have been delayed in reaching equilibrium with the environmental fission products.

Body burdens of gamma-emitting fission products (such as ¹³⁷Cs and ⁶³Zn) were measured in a whole-body counter and checked by radiochemical analysis of urine specimens. The levels of internal contamination per unit weight appeared to be about the same for juveniles as for adults, male and female. Wide variations in levels of contamination were found, apparently due to differences in diet, metabolism, and age.

Body burdens of ⁹⁰Sr were estimated from urinary excretion as determined by radiochemical analyses. Both the external dose measurements on Rongelap Island and the levels of radioactive isotopes in the food on the Island indicated that some increase in ¹³⁷Cs, ⁶⁵Zn, and ⁹⁰Sr body burdens was to be expected when the people returned there in 1957. The ¹³⁷Cs body burden in 1958 was about 0.68 μ Ci, about 60 times as great as in 1957, and the urinary ¹³⁷Cs level rose by a factor of 140; the mean body burden for 1959 was 0.57 μ Ci. The mean body burden of ⁶⁵Zn estimated from wholebody counting data was, in 1958, after the return to Rongelap, 0.36 μ Ci, 8 times as high as in 1957, and 0.44 μ Ci in 1959. In 1961 the mean ¹³⁷Cs

body burden was 0.67 μ Ci, which is slightly higher than the mean value of a similar group obtained in 1959; it was 300 times that of the medical team. who were measured at the same time for comparison. It appeared at this time that the people were approaching equilibrium with their environment. The ⁶⁵Zn level dropped to 0.071 µCi in 1959. With a larger detector and a longer counting time than previously employed, it was possible to identify and quantify 60Co for the first time in these people; the mean level of ⁶⁰Co was about 11% of the ⁶⁵Zn level (7.6 nCi). A small amount of residual activity was still present after the subtraction of ⁴⁰K and the above radionuclides from the total spectrum. The mean level of urinary excretion of ⁹⁰Sr was 7.2 pCi/l or 14% higher than measured in the 1959 medical survey. In 1962 the mean urinary ⁹⁰Sr level was 114 pCi/g Ca, giving a estimated body burden of 12.0 nCi. Analysis of bones from the deceased Rongelap woman (1962) gave an estimated body burden of 11.4 nCi. These levels represent about a 6-fold increase in "Sr over the 1958 levels. The levels of ⁹⁰Sr in 1962 and 1963 hovered around the 12.0-nCi level in adults and about 22 nCi in children, about 5 and 10% respectively of the maximum permissible level (for members of the population at large).

It thus appears that body burdens of ⁹⁰Sr have reached equilibrium with the environmental ⁹⁰Sr. Little or none of the present body burden of the exposed group can be considered residual from their initial exposure, since little difference has been noted between the body burdens in exposed and unexposed populations living on Rongelap Island. The possible relation of internal absorption of radioiodines initially in the fallout to the recent development of thyroid nodules will be referred to later. No other effects of such exposure have been detected.

OTHER STUDIES

Studies of Genetically Inherited Characteristics: Blood grouping studies in the Marshallese showed a relatively high B gene frequency, a high N gene frequency, an extremely high R¹ gene frequency, and total absence of Kell and Diego factors.¹¹ These characteristics differ from those of Polynesians and suggest relationship with Southeast Asians and Indonesians. Haptoglobin studies showed the frequency of the Hp¹ gene to be higher than in Euro-



Ĩ

T

F

1

Figure 3. Medical survey team, 1965 (upper picture) and 1966.

ł

1

1

Blood volume studies with ⁵¹Cr-labeled sodium chromate showed a significant reduction in red cell mass and/or plasma volume. However, there is some indication that Americans living in the Islands for more than 1 year may also have slightly lowered values. Tritiated water has been used to establish the relationship of blood volume to lean body mass. Further studies on blood volume determinations are presented later.

OTHER BACKGROUND INFORMATION

As mentioned in previous reports, several difficulties were associated with carrying out the examinations as well as interpreting the findings.

1. The language barrier made examinations difficult, since very little English is spoken by the Marshallese. However, there were sufficient English-speaking Marshallese to assist the medical team in most instances.

2. The lack of vital statistics or demographic data on the Marshallese imposes a serious difficulty in interpretation and evaluation of the medical data. Trust Territory officials are attempting to improve registration of such data.

3. There is uncertainty on the part of some of the Marshallese as to their exact ages, particularly

among the older group. This creates certain difficulties in interpreting some of the studies to be outlined.

4. The conditions of field examinations naturally limit the procedures and methods that can be used.

COMPARISON POPULATIONS

During the first 2 years, two separate groups of Marshallese people were used for comparison, each comparable in size with the exposed Rongelap group and matched for age and sex. However, both groups were found to be unstable, with a large attrition rate over the 2 years, which made them unsatisfactory. At the time of the 3-year survey, it was found that during the preceding 12 months the Rongelap population at Majuro Atoll had doubled because of the influx of relatives who had come back from other islands to live with them. These people had been away from Rongelap Atoll at the time of the accidental exposure. This group matched reasonably well for age and sex and was of comparable size. Since the return of the people to Rongelap, however, this group has about doubled in size. Table 2 shows the various Marshallese populations that have been examined since 1954.

| | | Table 2 | | | | | | |
|---|---------------------------------|-------------------------|----------------------------|---------------------|--|--|--|--|
| Marshallese Populations Examined Since 1954 | | | | | | | | |
| Group | Original number in group | Number living (1966) | Frequency of exams | Subject Nos. | | | | |
| Exposed | | | | | | | | |
| Rongelap* | 67 | 58 | Annual | 1- 86 | | | | |
| Ailingnae** | 19 | 15 | Annual | 1- 86 | | | | |
| Utirik | 157 | 133 | 3-4 years | 2101-2257 | | | | |
| Unexposed | | | | | | | | |
| Rongelap | 99 | 168† | Annual since 1957 | 801-1073 | | | | |
| Rita | 57 | | 1955-1956 | 1000-1082 | | | | |
| Majuro | 115 | | 1954 only | 700- 800 | | | | |
| Children Conceived After the | Fallout | | | | | | | |
| Of exposed parent(s) | 63†† | 60 | Annual | 87- 151 | | | | |
| Of unexposed parents | 2-11 | 104 | Annual | 801-1073 | | | | |
| *Includes 3 in utero children **Includes 1 in utero child. | n. †Individual ††Live births | s have been added sin | ce 1957 when this group wa | is first available. | | | | |

rival in March it was gratifying that most of the people had put their money into savings accounts. The Utirik people seemed quite disappointed in not receiving any monetary compensation for their fallout exposure. In a lengthy meeting held with them on arrival of the team, the reason for this – the lack of radiation effects – was carefully explained, and it is believed they accepted the situation in good grace, judging by their cooperation in the examinations and cordiality to the medical team.

Findings

INTERVAL MEDICAL HISTORY

Table 3 shows the populations examined in 1965 and 1966. Table 4 shows the location of the populations under study, and Table 5 shows the percent distribution of the Rongelap population by age and sex.

llinesses

ž

ŀ

]

2

During the past 2 years the Rongelap people have been generally in good health, and their nutritional status appears to have been satisfactory. An epidemic, believed to have been Asiatic influenza, with acute upper respiratory manifestations occurred in about half the population in the spring of 1964. Another influenza-like epidemic of similar proportions occurred in 1965. An outbreak of diarrhea, cause unknown, involved a large segment of the population during January and February 1965. About 15 cases of chicken pox occurred in the spring of 1965. On Ebeye Island, where about 100 Rongelap people live, an outbreak of conjunctivitis occurred during the year, but this responded to topical antibiotic treatment. Four children with varying degrees of paralysis, following a poliomyelitis epedimic in 1963, were treated and fitted with braces at Majuro. Surgery was performed on four cataract cases and one fistula in ano. There were 3 deaths in the exposed group and 3 in the unexposed people (see below). The most outstanding finding since the previous report has been the increasing number of cases of thyroid nodules. By July of 1966, 11 cases had been operated upon, the first 3 in 1964 at the Naval Hospital in Guam. The last 8 cases were brought to the Medical Research Center at Brookhaven National Laboratory for extensive studies



Figure 5. Rongelap girl with toys following annual party, 1966.

Table 3

Numbers of People Examined During the 11- and 12-Year Surveys

| | 1965 | 1966 |
|---|------|------|
| Rongelap and Ailingnae exposed - adults | | |
| (age > 19) | 48 | 49 |
| Rongelap and Ailingnae exposed - children | | |
| (age 11 or 12 to 19) | 23 | 23 |
| Rongelap unexposed - adults (age >19) | 83 | - |
| Rongelap unexposed - children (age < 19) | 108 | - |
| Children born to exposed parent(s) | | |
| (age < 11) | 48 | - |
| Utirik exposed - adults (age >19) | - | 70 |
| Utirik exposed - children (age 12 to 19) | - | 35 |

Organization

THE 1965 SURVEY

The survey team consisted of 12 physicians and technicians from the United States and 6 from the Trust Territory (Figure 3). Examinations were carried out on 71 Rongelap people in the exposed group, 48 children of exposed parent(s), and 191 unexposed Rongelap people (adults and children) comprising the comparison population. A Trust Territory cargo ship was used to transport part of the team and equipment between Rongelap and Kwajalein. In addition, air support was furnished by the Search and Rescue Detachment, U.S. Navy, stationed at Kwajalein. The team lived ashore at Rongelap Island during the period of the examination. Two new air-conditioned trailers were recently installed on Rongelap for examination purposes (see Figure 4). Smaller groups of Rongelap people were also examined at Ebeye (Kwajalein Atoll) and Majuro, with local hospital facilities used for the examinations.

THE 1966 SURVEY

The 12-year medical survey was of a more limited scope than the previous one, with only the exposed groups being examined. A total of 177 examinations were carried out on 72 exposed Rongelap people and 105 exposed Utirik people. Personnel and equipment were transported between islands by a ship operated by a Marshall Island trading company.

Prior to each survey, meetings were held with the people to explain the survey procedures and particularly to discuss why the thyroid cases need hospitalization, surgery, and treatment. They seem to have accepted the situation in regard to the thyroid lesions calmly, and there has been no expression of great concern.

In February 1966, the exposed people of Rongelap received compassionate payment for effects of fallout radiation. Each person received nearly \$11,000 and some an additional amount as inheritance from those exposed people that had died. They were quite happy about this, and on our ar-

l



Figure 4. Newly installed air-conditioned trailer used for examinations at Rongelap.



Figure 6. Medical history being taken by a Marshallese practitioner.

| | | | Tab | le 6 | | | | | |
|-------------|----------------|-------------------------|--|------|----------------|---------|-----------------------------------|--|--|
| | Mortality | | | | | | | | |
| | Exposed | | | | | | Unexposed | | |
| Subject Age | | | | | Subjec | t Age | | | |
| Үеаг | Year No. & sex | o. & sex Probable cause | | | Year No. & sex | | Probable cause | | |
| 1956 | 25 | 46 M | Hypertensive heart disease | 1958 | 857 | 65 M | Cerebral thrombosis(?) | | |
| 1957 | 38 | 78 M | Coronary heart disease, diabetes | 1959 | 854 | 55 F | Infection urinary tract, diabetes | | |
| *1958 | 31 | 35 M | Acute varicella | 1960 | 933 | 56 M | Pneumonia secondary to influenza | | |
| 1959 | 62 | 60 F | Ovarian cancer | 1960 | 927 | 65 M | Pneumonia secondary to influenza | | |
| 1962 | 30 | 60 F | Cancer of cervix** | 1960 | 861 | 68 F | Diabetes, cancer cervix(?) | | |
| 1962 | 46 | 84 M | Arteriosclerotic heart disease | 1962 | 953 | 48 M | Status asthmaticus | | |
| 1962 | 26 | 21 M | Brain damage following fall from tree | 1962 | 848 | 41 F | Neurosyphilis(?) | | |
| 1962 | 56 | 75 F | Fractured vertebrae | 1963 | 886 | 54 M | Asthma(?) | | |
| 1963 | 52 | 55 F | Poliomyelitis, bulbar | 1964 | 893 | 61 F | Diabetes | | |
| 1963 | 57 | 107 F | "Old age"(?) | 1964 | 862 | 91 M | Heart disease | | |
| *1964 | 43 | 77 F | Pneumonia, heart disease | 1964 | 894 | 68 F | Pneumonia | | |
| *1965 | 28 | 79 F | Heart disease | | | | | | |
| *1966 | 29 | 77 M | Asthma, heart failure | | | | | | |
| *Ail | ingn | ae group | ······································ | **No | t confi | rmed by | autopsy or biopsy. | | |

PRIVACY ACT MATERIAL REMOVED

1

۲

ţ

Table 4

| | Rongelap and Ailingnae exposed | | Rongelap and Ailingnae exposed | | Children | Rongelap | unexposed | Utirik | exposed | |
|--------------|-----------------------------------|-------------------------|-----------------------------------|------------------|-----------------------|------------------|-------------------------|--------|---------|--|
| | Adults (age >19) | Children (age 12-19) | of exposed parent(s) | Adults (age >19) | Children (age <19) | Adults (age >19) | Children (age 12-19) | Total | | |
| Majuro | 7 | 4 | 5 | 12 | 12 | 9 | 9 | 58 | | |
| Ebeye | 20 | 11 | 21 | 35 | 41 | 15 | 8 | 151 | | |
| Rongelap | 22 | 5 | 34 | 57 | 75 | 0 | 0 | 193 | | |
| Utirik | 0 | 0 | 0 | 0 | 0 | 56 | 26 | 82 | | |
| Other atolls | 3 | 1 | 0 | 11 | 8 | 5 | 5 | 33 | | |
| Total | 52 | 21* | 60 | 115 | 136 | 85 | 48 | 517 | | |

*Two of the 23 children moved up to the adult group.

Table 5

Percent Distribution by Age and Sex of Rongelap Populations Under Study, 1966

| Rongelap and Ailingnae exposed | | | | | | Unexposed | | | | |
|--------------------------------|-----|----------------|-------------|-------|-----|---------------|--------------|-------|--|--|
| Age group | M | lales | Fe | males | M | ales | Fer | males | | |
| | No. | % | No. | % | No. | % | No. | % | | |
| >12-20 | 15 | 20.6 | 14 | 19.2 | 20 | 12.5 | 24 | 15.0 | | |
| 21-30 | -3 | 4.1 | 9 | 12.3 | 13 | 8.1 | 12 | 7.5 | | |
| 31-40 | 5 | 6.8 | 4 | 5.5 | 16 | 10.0 | 15 | 9.4 | | |
| 41-50 | 4 | 5.5 | 6 | 8.2 | 12 | 7.5 | 8 | 5.0 | | |
| 51-60 | 5 | 6.8 | 1 | 1.4 | 7 | 4.4 | 9 | 5.6 | | |
| 61-70 | 2 | 2.7 | 3 | 4.1 | 10 | 6.3 | 5 | 3.1 | | |
| > 70 | 1 | 1.4 | 1 | 1.4 | 5 | 3.1 | 4 | 2.5 | | |
| Total | 35 | 47.9 | 38 | 52.1 | 83 | 51.9 | 77 | 48.1 | | |
| | | Children of ex | posed paren | t(s) | (| Children of u | nexposed par | rents | | |
| <12 | 28 | 21.1* | 32 | 24.1* | 61 | 23.1* | 43 | 16.3* | | |

and later surgery in Boston: 3 in the summer of 1965 and 5 in the summer of 1966. These cases will be discussed in detail below.

Deaths

Table 6 lists the times and causes of death in both exposed and comparison populations. The deaths subsequent to the 1964 survey were as follows.

A 77-year-old woman in the Ailingnae group (No. 43) died of pneumonia. She had had arteriosclerotic heart disease, asthma, and marked peripheral sclerosis with occlusion of the right radial artery, and was quite senile. A 79-year-old exposed woman in the Ailingnae group (No. 28) died in December 1965 of cardiac decompensation. She had developed ankle edema, dyspnea, cough, and anorexia prior to death. A 77-year-old exposed man, also in the Ailingnae group (No. 29), died in February 1966, probably of asthma.

In the comparison population, a 61-year-old woman (No. 893) died of acute cellulitis of the

. 0

| | | Births and | Fetal Deaths ^a by | 'Year | | | |
|------------------|------------------|-------------------|------------------------------|-------|------|---------------------------|----------------|
| | | | | Chil | dren | | % Pregnancies |
| rear | Women aged 15-45 | Total pregnancies | Live births | M | F | Miscarriages ^a | in miscarriage |
| | | | Exposed ^b | | | | |
| 954° | 19 | 1 | 0 | 0 | 0 | 1 | 100 |
| 1955 | 20 | 6 | 5 | 4 | l | 1 | 17 |
| 1956 | 20 | 6 | 4 | 0 | 4 | 2 | 33 |
| 1957 | 21 | 5 | 2 | 2 | 0 | 3 | 60 |
| 1958 | 22 | 14 | 8 | 4 | 4 | 6 | 43 |
| 1959 | 22 | 6 | 5 | 2 | 3 | 1 | 17 |
| 1960 | 24 | 10 | 9 | 5 | 4 | 1 | 10 |
| 1961 | 23 | 7 | 6 | 2 | 4 | 1 | 0 |
| 1962 | 24 | 4 | 4° | 1 | 3 | 1 | 25 |
| 1963 | 27 | 8 | 7 | 3 | 4 | 1 | 12 |
| 1964 | 26 | 6 | 6 | L | 5 | 0 | 0 |
| 1965 | 30 | 5 | 5 | 3 | 2 | 0 | 0 |
| 966 ^d | 30 | 2 | 2 | 2 | 0 | 0 | 0 |
| | | • | Unexposed | | | | |
| 1956 | 29 | 9 | 7 | 6 | I | 2 | 22 |
| 1957 | 30 | 11 | 9 | 4 | 5 | 2 | 18 |
| 1958 | 30 | 9 | 8 | 5 | 3 | 1 | 11 |
| 1959 | 29 | 10 | 9 | 4 | 5 | 1 | 10 |
| 1960 | 29 | 10 | 8 | 5 | 3 | 2 | 20 |
| 961 | 29 | 10 | 10 | 9 | 1 | 0 | 0 |
| 962 | - 30 | 6 | 5 | 4 | 1 | 1 | 17 |
| 1963 | 32 | 6 | 5 | 2 | 3 | 1 | 17 |
| 964 | 32 | 12 | 10 | 8 | 2 | 2 | 17 |
| 1965 | 32 | 7 | 5 | 3 | 2 | 2 | 29 |
| 966 ^d | 32 | 1 | Ō | 0 | 0 | 1 | 100 |
| | | | | | | | |

Table 8

*Includes stillbirths and neonatal deaths.

 $^{\rm b} Includes$ nonexposed females mated to exposed males.

^cIncludes only children conceived after March 1, 1954.

Vital Statistics on the Utirik People

Since a new health aide was not able to locate medical records covering the past 3 years, vital statistics on the Utirik people were particularly difficult to obtain. It appeared that 9 people of this exposed group had died over the past 2 years. The causes of death could not be determined. This makes a total of 24 deaths in the 157 people during the 12-year period since exposure. No major epidemics of disease were reported. During the summer of 1964 a number of children developed diarrhea, and in about 5 cases bloody stools, fever, and vomiting were noted. No deaths occurred, and the cases improved on antibiotic treatment.

Table 9

^dIncludes data only through March 1966.

*Includes twins.

Sex Distribution of Rongelap Children Born Since 1954 (including some stillborn)

| | Sex of children | | |
|-------------------------------------|-----------------|--------|--|
| Parents | Male | Female | |
| Exposed male and exposed female | 13 | 12 | |
| Unexposed male and exposed female | 12 | 15 | |
| Exposed male and unexposed female | 3 | 7 | |
| Exposed female and unknown male | 2 | 2 | |
| Unexposed male and unexposed female | 61 | 44 | |

| Table 7 | | | | | | | | | |
|---|---------|-------|-------|-------|-------|-------|-------|-------|-----|
| Mortality, 1954-1966, by Age as of 1954 | | | | | | | | | |
| Group Ag | e: <10 | 11-20 | 21-30 | 31-40 | 41-50 | 51-60 | 61-70 | 71-80 | >80 |
| Rongelap (175 rads) | - 0/19* | 1/13 | 0/10 | 0/5 | 2/7 | 2/5 | 1/1 | 2/3 | 1/1 |
| Ailingnae (69 rads) | 0/6 | 0/1 | 0/1 | 1/5 | 0/1 | 0/1 | 3/3 | - | - |
| Unexposed** | 0/56 | 0/28 | 0/30 | 2/18 | 3/21 | 3/17 | 2/7 | 0/1 | 1/1 |

neck and face complicating diabetes, and a 68year-old woman (No. 894) died of pneumonia complicating Asiatic influenza. A 91-year-old male (No. 862) died presumably of cardiovascular disease; he had been quite senile and bedridden for the past few years.

During the past 12 years, 13 deaths have occurred in the exposed group. This represents 13.0 deaths per 1000 per annum (11.7 for the more heavily exposed group and 18.3 for the smaller Ailingnae group) compared with 8.3 per 1000 for the Marshall Islands as a whole in 1960.

In Table 7 mortalities for the exposed Rongelap and Ailingnae groups as well as the unexposed comparison population are presented according to decade of death. A χ^2 test for significance,* comparing groups of exposed and unexposed people, showed that the mortality in the Ailingnae group alone was significantly greater than in the control group. The Rongelap exposed group combined with the Ailingnae exposed also showed a significant difference compared with the unexposed. These results should be interpreted with caution since the numbers of people involved are too small for a sensitive statistical test. None of the deaths in the exposed group can be related directly to radiation exposure. The causes of death are similar to those in the unexposed population. The slightly greater mortality in the exposed Rongelap people may be related in part, at least, to the larger percentage of older people originally in this group. No cases of leukemia have appeared in the exposed population. Two earlier deaths from cancer in exposed women and the recent development of a malignant thyroid nodule, to be described below, make it necessary to keep in mind the possibility of causal relationship with radiation exposure.

Births

Twelve babies were born to exposed parents and 13 to unexposed parents during the period between March 1964 and March 1966. The birth rate per year is calculated from the number of births per women of childbearing age (15 to 45). There were 30 such women in the exposed group (including 3 unexposed women whose spouses are exposed males) and 32 in the unexposed group (see Table 8). From these data, there appears to be no difference in fertility between the two groups. All these babies appeared normal except for the two listed below, who were both offspring of unexposed parents.

Congenital Anomalies. Two abnormal babies were noted during the 1965 survey. One was a hydrocephalic (No. 1061) and the other a mongoloid (No. 1055).

Sex Ratio. Table 9 lists the births by sex in relation to the exposure of the parents. There appears to be no radiation-induced sex ratio alteration.

Miscarriages and Stillbirths. A total of 5 miscarriages occurred over the past 2-year period, all in unexposed women, one of whom (No. 959) had 3.

As had been noted earlier, the exposed women had a somewhat greater incidence of miscarriges and stillbirths over the first 4 years post exposure (see Table 8). During 1954-58 the exposed women had 13 miscarriages of 32 total pregnancies (40.6% incidence), and the unexposed women had 8 miscarriages in 49 pregnancies (16.3% incidence) during the 4-year period 1956-60. A χ^2 test for significance* showed that total miscarriages and stillbirths were significantly greater (at the 5% level) in the exposed women compared with unexposed during the first 4 years, but there was no significant difference after this period. Since 1958 the exposed women have had 5 miscarriages in 48 pregnancies (10.4%) and the unexposed women 10 miscarriages in 62 pregnancies (16.1%).

ī

ļ

Ş

I

^{*}We are grateful to Mr. Keith Thompson of Brookhaven National Laboratory for carrying out the statistical analyses.

1

ł

1

Physical Findings in Rongelap and Utirik Adults, 1965-1966

| | Rongelap exposed (48 examined) | | Rongelap unexpo (81 examined) | sed | Utirik exposed (71 examined) | |
|------------------------------------|--------------------------------|------|--|------------|--|------|
| | Subject Nos. | % | Subject Nos. | % | Subject Nos. | % |
| Deafness Diabetes mellitus – | 1 | 2.1 | 853, 884, 916, 964 853, 855, 898, 915, 917, 918, 936, 991 | 4.9 9.9 | 2101, 2111 | 2.8 |
| Emphysema | | | 853 | 1.2 | | |
| Epilepsy | | | 875 | 1.2 | | |
| Gynecomastia | 55 | 2.1 | 964 | 1.2 | | |
| Hallux valgus | 50 | 2.1 | 860 | 1.2 | 0110 0150 | |
| Hernia | 1 11 60 | 6 4 | 051 052 056 050 | 12.4 | 2112, 2152 | 2.8 |
| Hypertension (>140/90) | 1, 11, 60 | 0.4 | 898, 908, 947, 961, 963, 982 | 12.4 | 2120, 2146, 2169, 2175, 2186, 2194 | 8.5 |
| Kyphosis, scoliosis | 13, 77 | 4.3 | 860, 864, 964 | 3.7 | 2169, 2186, 2198, 2202, 2223 | 7.1 |
| Lenticular opaciti es | 13, 55, 58, 60, 68, 82 | 13.0 | 856, 858, 859, 878, 884, 897, 899, 908, 915, 929, 935, 936, 941, 947, 961, 991 | 19.7 | 2101, 2112 | 2.8 |
| Leprosy, arrested | 77 | 2.1 | | | | |
| Leukoplakia | • | | 918, 941 | 2.5 | | |
| Liver palpable | 66 | 2.1 | 844, 853, 899, 936, 941 | 6.2 | 2135 | 1.4 |
| (EKG) | 60 | 2.1 | 844, 851, 858, 878, 884, 917, 947, 956, 957, 969, 970 | 13.6 | | |
| Obesity - | 1, 49, 74, 78 | 8.3 | 849, 851, 853, 880, 895, 898, 908, 951, 982, 1041, 1042 | 13.6 | 2128, 2129, 2150, 2157, 2158, 2172, 2215, 2216, 2244, 2246 | 14.1 |
| Osteoarthritis | 13, 29, 50, 55, 60 | 11.0 | 858, 859, 860, 878, 884, 894, 896, 898, 915, 922, 928, 935, 936, 947, 961, 964 | 19.7 | 2140, 2169, 2181, 2186, 2191, 2193, 2198, 2202 | 11.3 |
| Pinguecula | 18, 34, 45, 60, 79 | 11.0 | 842, 843, 844, 895, 899, 917, 941, 951, 966, 991 | 12.4 | 2169 | 1.4 |
| Pregnancies | 12, 22, 24, 64 , 72 | 11.0 | 826, 841, 865, 896 | 4.9 | 2164, 2249 | 2.8 |
| Prostatic hypertrophy | 7, 55, 68 | 8.3 | 853, 884, 899, 915, 948, 961, 1007 | 8.6 | 2169 | 1.4 |
| Proteinuria (>100 mg) | | | 855 | 1.2 | 2118, 2240 | 2.8 |
| Pterygium | 4, 7, 10, 11, | 27.0 | 823, 840, 844, 851, | 37.0 | 2103, 2104, 2110, | 35.2 |
| | 12, 34, 41, | | 852, 853, 858, | | 2112, 2114, | |
| | 45, 64, 66, | | 859, 864, 878, | | 2135, 2137, | |
| | 70, 78, 82 | | 880, 884, 897, | | 2140, 2148, | |
| | | | 898, 908, 918, | | 2161, 2162, | |
| | | | 920, 928, 929, | | 2166, 2181, | |
| | | | 947, 948, 956, | | 2186, 2191, | |
| | | | 957, 961, 969, | | 2193, 2198, | |
| | | | 971, 982, 1007, 1041, 1042 | | 2200, 2206, 2211, 2212, 2214, 2220, 2221, 2240 | |
| Rheumatic heart disease | 76 | 2.1 | | | 2128 | 1.4 |
| Syphilis(?), arrested | 11, 59 | 4.3 | 846, 860, 899 | 3.7 | 2181 | 1.4 |
| Tumor, benign | 7, 10, 37, 41 60 | 11.0 | 844, 859, 864, 880, 897, 922, 964, 1001, 1007 | 11.1 | 2109, 2140, 2162, 2169, 2212 | 7.1 |
| URI | | | 831, 853 | 2.5 | 2109 | 1.4 |

PHYSICAL EXAMINATIONS

Adult Examinations

The general health and nutritional status of the people of Rongelap and Utirik Atolls were satisfactory and about the same in the exposed as in the unexposed populations, with the exception of thyroid abnormalities in the exposed Rongelap population, which will be treated separately below because of the importance of this development. As noted in previous surveys, the variety and distribution of physical abnormalities (with the exception of thyroid nodules) did not appear to be significantly different in the exposed and unexposed populations. The varying incidence from year to year of such findings as cervicitis, prostatic hypertrophy, and arteriosclerosis probably to some extent reflects differences in clinical criteria of judgment among the examiners. There was a marked tendency for extensive dental caries in young adults. Special ophthalmological and slit-lamp observations for lens opacities were not carried out during the past 2 years. Physical abnormalities in the adults are listed in Table 10.



Figure 7. Part of a physical examination.

| | Rongelap exposed (48 examined) | | Rongelap unexpo (81 examined) | Rongelap unexposed (81 examined) | | i) |
|---|--------------------------------|------|---|-------------------------------------|--|---------------|
| | Subject Nos. | % | Subject Nos. | % | Subject Nos. | % |
| Anemia, anemic tendency* | 12, 22, 55, 64 , 70 | 11.0 | 826, 829, 841, 843, 860, 865, 947, | 9.9 | 2128, 2246 | 2.8 |
| Arteriosclerosis, peripheral, mild | 58, 59, 78, 79, 82 | 11.0 | 964 856, 884, 910, 941, 948, 957, 961, 964, 970, 991 | 12.4 | 2146, 2148, 2194, 2244 | 5.6 |
| Arteriosclerosis, peripheral, moderate to severe | 1, 11, 16, 41, 60, 68 | 13.0 | 853, 859, 860, 878, 899, 908, 929, 947 | 9.9 | 2105, 2110, 2175, 2191, 2198, 2214 | 8.5 |
| Asthma | | | 916- | 1.2 | | |
| Auricular fibrillation with myocardial damage | 80 | 2.1 | | | | |
| Bradycardia | 27 | 2.1 | | | | |
| Cardiac enlargement** | 1, 60, 76, 80 | 8.3 | 858, 859, 917, 942, 947 | 6.2 | | |
| Cervical erosion | 63, 74 | 4.3 | | | 2162 | 1.4 |
| Cervical lacerations | 49 | 2.1 | 829 | 1.2 | 2166 | 1.4 |
| Congenital defects | | | | | | |
| Dislocation of hip | 41 | 2.1 | | | | |
| Prominent head of ulna | 14, 28 | 4.3 | 833, 858, 882, 915 | 4.9 | | |
| Bilateral shortening of 5th finger | 1, 41, 75, 78 | 8.3 | 832, 836, 910, 914 | | | |
| Polydactylism | | | 938 | 1.2 | | |
| Dislocated wrist | | | | | 2139, 2161 | 2.8 |
| Flexion deformity, fingers | | | 826, 894 | 2.5 | | |
| Cyst, ovarian | 39 | 2.1 | 832 | 1.2 | | |
| Cystocele | 1, 18, 71, 74 | 8.3 | 835 | 1.2 | | |

 Table 10

 Physical Findings in Rongelap and Utirik Adults, 1965–1966

*RBC: F <3.9 million; M <4.3 million. Hemoglobin: F <11.0 g; M <13.0 g. Hematocrit: F <35%; M <38%. **By x-ray and/or physical examinations.

F

1

1

Ĩ

with the 10-year survey. Table 11 lists the residual skin lesions. No further increase in benign nevi seems to have taken place, and some regression in pigmented areas and scarring may be occurring. No evidence was seen of chronic degenerative changes or cancer of the skin.

Pediatric Examinations

Pediatric studies including a brief interval history, routine clinical examination, a roentgenogram of the left hand and wrist, and physical anthropometry were carried out on exposed and unexposed children in 1965 (23 exposed, 48 born to exposed parents, 108 unexposed; 179 total). In 1966 only the 23 children in the directly exposed group were studied. Special attention was directed during these 2 years to the palpatory findings in the neck and thyroid gland areas.

The abnormal findings on physical examination of the children are listed in Table 12. One child (No. 1061) born to nonexposed parents had hydrocephalus, developmental retardation, and hepa-

| | | 1965 \$ | Survey | | 1966 Survey |
|---|-------------------|--------------------------------------|-------------------------------------|--------------------------------|------------------|
| | Exposed | Unexposed children born before | Unexposed children born after | Children born to exposed | Exposed |
| | children (23)* | 1 Jan. '55 (39) | 1 Jan. '55 (69) | (48) | children (23) |
| Hypertension | 0/21 | 0/29 | 0/18 | - | 0/23 |
| Vitiligo | 1 | 1 | _ | - | _ |
| Café-au-lait spots | 2 | - | 3 | 2 | - |
| Acute skin infection | 2 | 3 | 5 | $\frac{-}{2}$ | 1 |
| Thrush | - | - | - | 1 | - |
| Umbilical hernia | _ | _ | 1 | - | - |
| Papilloma | . 1 | - | - | - | _ |
| Otitis media | • | | | | |
| Acute | 3 | 5 | 7 | 7 | _ |
| Chronic | 5 | 1 | 1 | 2 | |
| Eczema | _ | | | 1 | _ |
| Adenonathy | _ | | 4 | 8 | 3 |
| Palpable spleen | _ | - | | - | - |
| Palpable liver | | - | 2 | 3 | _ |
| Malformation toes (No. 112) | _ | _ | - | 1 | _ |
| Systolic murmur | Q | 14 | 20 | 16 | |
| Keloida | 1 | 17 | 20 | 10 | - |
| Conjunctivitie | 1 | - | - | - | - 1 |
| Bullous lesion line | 1 | 1 | 2 | 2 | 1 |
| Huppportshuroidism (No. 21) | 1 | - | - | - | - |
| Uniletanal breast developments (No. 55) | 1 | - | - | - | - |
| Tracile humanitation | 1 | - | - | - | - |
| I onsus, nypertropny | 2 | / | 12 | 6 | I |
| D is in the second se | - | - | 2 | 4 | - |
| Dermatitis, nonspecific | - | - | 1 | - | - |
| Nevi | 2 | 5 | 3 | 1 | - |
| Polio, residual | - | 5 | 3 | 1 | - |
| Cheilosis | | - | 1 | 1 | - |
| Nystagmus | - | - | 1 | - | - |
| I horactomy scar | - | 1 | - | - | - |
| Mongolism (No. 1055) | - | - | 1 | - | - |
| Hydrocephalus (No. 1061) | - | - | 1 | - | - |
| Detormed hand (burns) | - | - | 1 | - | - |
| Cystic mass, sole of foot (No. 807) | - | - | 1 | - | - |
| Congenital heart disease (Nos. 1032, 1058) | - | - | 2 | - ` | - |
| Tracheostomy scar | l | - | - | - | - |
| Warts | 2 | - | . – | 2 | - |
| Pilonidal sinus | - | | - | - | 1 |
| Pelvic peritonitis | - | - | - | _ | 1 |

Table 12

*Number examined.

As part of the cancer surveys, roentgenograms of the chest on all of the population under study are scheduled every 2 to 3 years. Chest plates on some 100 people were made during the past 2 years. Only 2 cases thought to be tuberculous were noted, and these appeared to be old fibrotic inactive disease in older people. Otherwise evidence for pulmonary and cardiac diseases was minimal. Papanicolaou smears of the vaginal region were obtained on 51 females (1965).* No evidence of malignancy was noted. A rather high incidence of inflammation was noted, possibly related to poor hygiene, and 14% of these women had trichomonas infections. With the exception of a malignancy of the thyroid to be described below, no malignant

*We are grateful to Dr. Genevieve Bader at Memorial Hospital, New York, for these analyses.

lesions were detected, and only a few benign softtissue tumors were found during the past 2 years.

Hospitalization for further examinations, surgery, and other treatment was recommended for a number of people. Some of the recommendations included cervical dilatation and curettage; surgical correction of rectocele, anal fistula, and deformed toe; removal of ovarian cyst, Bartholin's cyst, and cyst on foot; skin biopsy; cataract removal; hip fusion; treatment of diabetes and inflammatory disease; poliomyelitis rehabilitation; neurosurgical consultation on hydrocephalic child; examinations for possible brain tumor in epileptic; and evaluation of a case of leprosy at a sanatorium. Limited treatment was carried out by the medical team during the survey.

Examination of residual "beta burns" in adults and children revealed few changes as compared

| | | | • Residual "Beta Burns"* |
|----------------|------|-----|--|
| Subject No. | Age | Sex | Data |
| 2 | 13 | М | Roughening and pigment variation on front of neck. Several pigmented macules ACF.** Perianal depigmentation. |
| 3 | 12 | М | Mottled pigmentation both axillae. Pigmented area behind left ear. |
| 11 | 61 | М | Pigment changes left ACF. Pigment variation with many moles in and beneath axillae. |
| 12 | 29 | F | Two pigmented moles on back of neck. Small keloid at site of mole removal on right shoulder. |
| 17 | 14 | F | Scarring and pigmentation left ACF. |
| 20 | 18 | М | Pigmented patch back of neck. |
| 23 | 15 · | М | Pigmented macules left axilla, front of neck, and chest. Depigmented spots shaft of penis. |
| 24 | 24 | F | Slight pigment variation on front of neck. Several pigmented macules dorsum left foot. |
| 34 | 56 | F | Moles on front of neck, particularly on left side. |
| 39 | 26 | F | Slight roughening and pigmentation back of neck. Pigment variations and slight hyper- pigmentation dorsum right foot. |
| 49 | 26 | F | Numerous pigmented macules on both sides of neck and a few on arms and ACF. |
| 54 | 12 | Μ | Mottled pigmentation and depigmentation on front of neck. |
| 58 | 71 | F | Moles over front and side of neck and on left side of face. |
| 59 | 46 | F | Mottled pigmentation and depigmentation on back of neck. |
| 63 | 47 | F | Slight rugosity and pigmented ridges on back of neck. |
| 64 | 41 | F | Mole back of neck. Slight pigment variation and a few macules front of neck. |
| 65 | 12 | F | Pigment variation and roughening front of neck. |
| 67 | 25 | F | Depigmented scars dorsum left foot. |
| 74 | 23 | F | Slight roughening and pigmentation back of neck. |
| 75 | 28 | F | Slight pigmented area dorsum right first toe. |
| 78 | 48 | F | Numerous pedunculated moles on sides and front of neck. |
| 79 | 50 | М | Pigmented and depigmented scar on posterior surface of the left ear. |

Table 11

*Includes appearance of moles which may or may not be related to radiation exposure in some cases. **ACF = antecubital fossa.

1

ł

9

ł



Figure 8. Drawings by Rongelap children for Goodenough "Draw a Man" test.



l

ī

F

1

I





Figure 10.

ī

ł

3

Table 13

Assay for Human Growth Hormone (HGH) in Exposed Marshallese Children

| Subject Time after No. insulin, mir | | Blood glucose, mg/100 ml | HGH, ng∕ ml* |
|--|----|-----------------------------|-----------------|
| 2 | 25 | 31.6 | 4.0 |
| 3 | 30 | 89.6 | <2.0 |
| · 6 | 25 | 26.9 | <2.0 |
| 8 | 25 | 29.0 | 5.0 |
| 33 | 25 | 34.0 | < 2.0 |
| 54 | 15 | 67.1 | < 2.0 |
| 54 | 30 | 35.6 | 3.0 |
| 65 | 15 | 33.6 | 4.0 |
| 65 | 27 | 22.6 | 2.0 |
| 83 | 30 | 38.1 | 3.0 |

*Assayed by Dr. J. Roth, National Institutes of Health, Bethesda, Maryland. The normal fasting level is 0 to 3.0 nanograms/ml, with at least a 3- to 5-fold rise 60 min after insulin injection.

tosplenomegaly. Another child (No. 1055), also born to nonexposed parents, had diagnostic stigmata of mongolism. The results of examinations of the neck and thyroid gland are summarized elsewhere in this report. With the exception of the thyroid nodules; no correlation between the development of abnormalities in children and exposure to radiation could be suggested.

In 1965 assays for human growth hormone levels were done on blood specimens obtained from 8 exposed Marshallese children. After an overnight fast, crystalline insulin was injected intravenously at a dose of 0.1 mg/kg body weight. Blood was drawn at 15 and 30 min. The existing circumstances in the field precluded the continuation of the hypoglycemic state beyond 30 min. The hormone values were determined by the method of Glick et al.¹⁹ The results are summarized in Table 13. Even though a higher level of growth hormone secretion might have occurred if hypoglycemia had been prolonged, measurable amounts of human growth hormone were found in all children tested. The 2 markedly physically retarded boys were among the 8 studied. When it is noted that TSH secretion is also adequate in these children (see section on thyroid gland), the results qualitatively document the existence of anterior pituitary gland function.

Goodenough "Draw a Man" tests²⁰ were taken by a number of children. Some of the drawings are shown in Figure 8. Because of language barriers, such tests are difficult to carry out. Cultural, social, and educational variables also complicate the scoring. The figures are being analyzed with the hope that numerical scores may provide some measure of mental development in the growthretarded children.

A detailed analysis of the growth and development data on the Marshallese children during the period 1958 through 1963 has been published.21 The analysis has been extended to include the growth measurements for 1964 and 1965. In 1966 the unexposed (control) children were not examined. The trends revealed previously have continued. Among the girls, there is no significant difference between exposed and unexposed children in either the statural or weight curves (Figures 9 and 10). There is no significant difference in body weight between exposed and unexposed boys (Figure 11). Among the boys only, the statural growth of the exposed lags below that of the unexposed subjects (Figures 12 and 13). This difference in stature is better delineated when age at exposure is considered (Figure 13). Thus, boys exposed at ages >6 years show no difference in statural growth from that of unexposed boys. Boys exposed at ages 2 years and younger show the most prominent retardation. Analysis this year indicates that boys exposed at 3 to 5 years of age are also showing some lag in statural growth. Children born to exposed parents have demonstrated no significant difference in statural and weight growth as compared with children born to unexposed parents (Figures 14 to 17).

Skeletal age assessments by the method of Greulich and Pyle²² have been plotted against chronological age in boys (Figure 18) and in girls (Figure 19). The lines represent the best fitting linear relationships by the least-squares method. While the curves for the exposed group (both boys and girls) fall to the right of the curves for the unexposed, the differences are not statistically significant. The points representing the markedly growthretarded boys are immediately apparent from inspection. The graphs also indicate that the skeletal age assessments at given chronological ages for the Marshallese boys and girls are lower (by about 6 to 12 months) than the Greulich-Pyle standards for American children.

Since September 1965 the exposed children have been given courses of thyroid hormone.



Figure 16.

1

F

Figure 17.



Figure 11.



Figure 12.

Figure 13.

Í

I

F

1

1

roid then resulted in a substantially larger dose. The total estimated **dose from the various fodine** isotopes to the child's gland was about 4000 rads, with a range of 700 to 1400. The glands received an additional 175 rads from external gamma radiation. Details of these calculations have been given by James and Ng and are presented in Appendix 2. Although the skin overlying the thyroid gland was frequently the site of "beta burns" as shown in Figure 20, the deposit of radioactive materials in this area probably did not add significantly to the thyroid dose, since most of the beta irradiations. were too weak to have penetrated to the depth of the gland.

Previous Thyroid Studies

Until 1963 no thyroid abnormality was detected in either the exposed or the comparison population, except for one case of asymptomatic diffuse thyroid enlargement seen in an unexposed woman. It has not been possible to perform basal metabolism rate determinations, but careful physical examination of the thyroid and a variety of tests of thyroid function have been performed during the previous surveys.

Protein-Bound lodine.²⁸ The serum proteinbound iodine has been determined by the methods of Foss et al.²⁹ at Brookhaven National Laboratory, the Boston Medical Laboratories, and Bio-Science Laboratories, Van Nuys, California. In addition, estimation of the butanol-extractable iodine of serum was done at Bio-Science Laboratories, and also column chromatography of the serum iodine by a modification of the method of Galton and Pitt-Rivers.³⁰ In several instances the capacity of thyroxine-binding alpha globulin (TBG) was measured at NIH by a method described previously.⁸⁷

The results of analyses for iodine in serum are shown in Table 14. (See Appendix 3 for complete protein-bound iodine data.) It is apparent that on several occasions and with several different methods the average serum protein-bound iodine in the inhabitants of both Rongelap and Utirik is higher than normal, and that from 16 to 64% of the natives on Rongelap and 90% on Utirik show values that are above the normal range by American standards. No significant differences in the PBI levels have been noted between the group that had been exposed to radiation and the unexposed group. The first results showing an elevated PBI were obtained in 1958, and since that time



Figure 20. "Beta burns" of neck (subject No. 39, March 1954). The area over the thyroid was a frequent site of burns.

care has been taken to ensure that glassware and syringes were not contaminated with iodine. This can be seen by the fact that the total iodine is not markedly greater than the PBI and by the normal values for PBI obtained in 1964 on members of the medical team, whose blood was obtained at the same time and under the same conditions as that of the natives. The elevation in PBI could be due to a general increase in serum PBI in all the Rongelap population, or it could be due to the occurrence of some genetic difference, so that a substantial fraction of the population the sabaormally high PBIs and the population is normal. In the first ease, a plot of the level of PBI versus frequency of occurrence at that level would show a minmal distribution, except that the whole curve would be displaced about 2 µg% upwards. In the period case, the distribution curve would be binedal, and a family tree would show familial clustering, the precise type the pending on the manner of atheritance. Figure 21, a distribution curve of PBI level versus incidence at that level, shows no evidence for a bimodal distribution. The low number of PBI values between 7.75 and 8.0 μ g% seems to be due to statistical fluctuation because of the small numbers of cases. Furthermore, the elevated values (defined as those above 8.0 μ g%) did not show a familial pattern of distribution. It appears, therefore, that the eleva-





Figure 18.

THYROID FINDINGS

During the past 3 years, the development of thyroid abnormalities in a significant number of the people exposed on Rongelap, and in one from the Ailingnae group, has resulted in extensive thyroid studies and surgical intervention in some cases. The examination and therapy of the first 6 cases of nodules of the thyroid gland have been described.^{10,23,24} Since then, the number of cases of nodules and hypothyroidism has increased to 18, and the new cases are described below.

The Radiation Dose to the Thyroid Glands

The dose to the thyroid gland from radioactive iodine is determined by its uptake by the gland, its half-life in the gland, the size of the gland, and the relative proportion of the several radioisotopes of iodine involved. The relative distribution of radioiodines in fallout depends on the type of explosion but in general is well known. In addition to ¹³¹I, the isotopes ¹³³I, ¹³³I, and to a less extent ¹³²I contributed significantly to the thyroid dose. The only direct data available on the Rongelap people are radiochemical analyses of pooled urine samples taken 15 days and longer after the fallout. Three separate estimates have been made of the dose from radioiodines to the thyroid glands of adults



exposed on Rongelap: 150 rads (from direct measurement of urinary ¹³¹I),²⁵ 100 rads (by indirect measurements on pigs removed from Rongelap plus Marshallese urinary excretion data),²⁶ and 160 rads (based on recent recalculations of early data²⁷ - see Appendix 2). The last recalculations were based on analysis of pooled urine samples mainly from adult Rongelap people taken 15 days after the detonation; an estimate of the one-day thyroid content of ¹³¹I was 11.2 µCi (5.6 to 22.4 μ Ci), assuming that 0.1% (0.005 to 0.2%) of the maximum thyroid burden (not corrected for physical decay) was excreted in the urine on the 15th day. The dose of 160 rads to the adult thyroid was calculated from oral intake and inhalation of the various iodine isotopes, considering their fission yield, the average energy deposited in the thyroid gland per disintegration, and the time of absorption. The dose to the thyroid glands of children <4 years old was then calculated by means of these factors with consideration of pulmonary function and the thyroid size of a child that age.27 The main source of iodine ingestion was considered to be water, and since it was being rationed at the time of the fallout, it was assumed that the children drank the same amount of water as adults and therefore had the same thyroid burden of radioiodines. The small size of the childhood thy-

1

ł

7





1

5



creased the background slightly. Mathematical analysis* of these data was done on an IBM 7094 computer with the program of Berman et al.³⁴ No experimental correction was made for extrathyroidal radioactivity "seen" by the counter, since the computer program adjusted the readings over the neck for this factor. A least-squares best fit, assuming exponential thyroid uptake and renal excretion of iodide, produced a "best" value for this factor, termed σ_{31} .

The results of the studies with ¹³²I are shown in Table 15, where they are compared with values obtained from normal individuals residing in the United States. It can be seen that the rate of thyroid uptake and the rate of urinary excretion are both decreased. Since they are decreased more or less proportionately, the calculated asymptotic uptake is normal or slightly elevated. One may use these data plus the urine iodide values to calculate the average daily secretion of thyroid hormone, assuming steady state conditions, using the formula

$$S = \frac{EU}{1 - U},$$

where

- S = amount of iodine secreted by the thyroid $(\mu g/day)$,
- U = fractional thyroid uptake of iodine, and E = urinary iodine (μ g/day).

With $E = 105 \ \mu g/day$ and U = 0.42, the value for S is calculated to be 76 μg iodine/day. This value is

| Table 1 | 5 |
|---------|---|
|---------|---|

Kinetic Studies With 132I

| Group | λ ₂₁ * | λ ₆₁ ** | Theoretical uptake | σ ₃₁ † | No. cases |
|--------------|-------------------|--------------------|-----------------------|-------------------|--------------|
| Marshallese | 0.72 | 0.97 | 42% | 0.08 | 21 |
| U.S. normals | 1.0 | 2.0 | 33% | - | - |

*Fraction of extrathyroidal iodide transferred to the thyroid per day.

**Fraction of extrathyroidal iodide excreted in the urine per day.

†Value derived by the computer for the fraction of extrathyroidal iodide "seen" by the counter.

somewhat higher than similar ones calculated for other groups but is not extraordinarily high.³⁵⁻³⁷

Serum Cholesterol. Serum cholesterol determinations on most of the exposed and an equal number of the unexposed population were carried out in 1957 and 1959. The results are tabulated in Appendix 5. Although the cholesterol levels in the exposed group are about 17% below the levels in the unexposed group, the difference is not quite significant at the 5% level. Individual values were not indicative of thyroid disease.

Discussion of Previous Thyroid Studies. Until the recent development of hypothyroidism in two boys, it had been the concensus of all physicians who examined these people that they were euthyroid. A conceivable explanation for the high PBI could be an elevation of thyroxine-binding proteins in serum which, as in the congenital elevation of thyroxine-binding globulin described by Beierwaltes and Robbins,38 causes an increase in the serum PBI without hyperthyroidism. The levels of the TBG in the Marshallese serum measured by Robbins, however, were within normal limits. The discrepancy between PBI and BEI suggested the presence of an iodoprotein in serum. The chromatography of serum iodine showing an iodoprotein level in the Rongelap people of 2.2 $\mu g\%$ (and higher in the Utirik people) seems to implicate the iodoprotein as the cause for the elevated PBI.

No adequate data are available on the calorigenic potency of serum iodoproteins, but there are some results which show that most of the iodinated amino acids in this protein are monoiodotyrosine and diiodotyrosine.^{39,40} These iodoamino acids are

^{*}We are indebted to Dr. Mones Berman, National Institutes of Health, Bethesda, for this analysis.

| | | Ta | ble 14 | | |
|---------------|---------------------------------------|----------------------|--------------------|------------------------------------|--------------------|
| | | Serui | m Iodine | | |
| | | Serum Prote | in-Bound Iodine | | |
| Date | Group | Average, µg% | Range, µg% | No. samples | Percent over 8 µg% |
| 1959 | Rongelap | 6.2 | 4.1 - 9.2 | 12 | 16 |
| 1962 | Rongelap | 8.6 | 4.6 - 12.0 | 14 | 64 |
| 1963 | Rongelap | 8.1 | 1.9 - 12.0 | 29 | 66 |
| 1964 | Medical team | 4.9 | 2.5 - 6.9 | 10 | - |
| 1964 | Rangelap | 7.1 | 2.0 - 10.2 | I 1 | 36 |
| 1965 | Rongelap exposed | 7.6 | 4.1 - 11.9 | 31 | 42 |
| 1965 | Rongelap unexposed | 7.0 | 3.9 - 10.7 | 19 | 28 |
| 1966 | Rongelap exposed | 6.1 | 3.1 - 11.8 | 19 | 16 |
| 1966 | Utirik exposed | 11.8 | 6.9 - 28.7 | 25 | 92 |
| | · · · · · · · · · · · · · · · · · · · | Serum Butanol- | Extractable Iodine | | |
| 1959 | Rongelap | 4.9 | 2.7 - 8.7 | 12 | |
| | | Serum Iodine | Chromatography | | |
| | Group | Total iodine, Av µg% | Iodoprotein, Av µg | $\mathcal{T}_4 + T_3$, Av μg | 3% No. samples |
| 1959-1964 | Rongelap | 6.98 | 2.22 | 4.53 | 19 |
| 1965-1966 | Rongelap | 7.40 | 2.80 | 4.21 | 18 |
| 1966 | Utirik | 18.10* | 9.20 | 4.00 | 5 |
| 1964-1966 | 6 Americans | 5.09 | 0.80 | 3.76 | 25 |
| · — · _ · _ · | | | | | |

*One Utirik sample was quite high in total iodine $(32.0 \ \mu g\%)$ suggesting contamination of this sample. The remaining 4 samples showed total iodine levels very nearly equal to the combined iodoprotein and thyroxine values.

tion in PBI is a general phenomenon which affects the entire population.

The difference between PBI and BEI in 12 cases was 1.5 μ g%, which is somewhat greater than an average value of 0.6 μ g% in the United States.^{31,32} This was suggestive evidence for the presence of iodoprotein in serum, and the results obtained by column chromatography substantiate this, as an average iodoprotein level of 2.22 μ g% was found. The average value for the amount of thyroxine iodine plus triiodothyronine iodine in these sera was 4.53 μ g%. Five plasma samples from Utirik people assayed in 1966 showed an unusually high average of 9.2 μ g% of iodoprotein. (See Table 14.) These data may be compared with results obtained on 25 normal North American controls residing temporarily in Washington, D.C., who showed an average serum iodoprotein level of 0.8 μ g% and an average $T_4 + T_3$ iodine level of 3.76 μg%.

Dietary lodine and Urinary Excretion of lodine. The supply of iodine in the Marshallese diet has generally been considered adequate in view of the large consumption of seafood. Analysis of 24-hr urine samples from 28 people at the Boston Medical Laboratory in 1965 gave an average value of 105 μ g iodine per day (range: 19.5 to 279), which is within the range of values found in an unselected population living in the Eastern United States.³³ A complete table of urinary iodine excretion data is presented in Appendix 4.

Thyroid Uptake of Radioiodine. Uptake of radioiodine by the thyroid was tested in 1965 on 21 Marshallese (12 exposed and 9 comparison adults) with no known thyroid abnormalities.

Studies with ¹³²I were performed with a collimated 1-in. NaI crystal 25 cm from the patient's neck. The ¹³²I was milked daily from tellurium-132 bound to a resin by elution with 0.1 *M* NH₄OH, and it was calibrated against a ¹³⁷Cs standard. The ¹³²I (5 to 10 μ Ci) was administered by mouth before breakfast, and counts were obtained over the neck at $\approx \frac{1}{2}$, 1, 2, 3, and 4 hr; a single 3-hr urine was assayed for ¹³²I. A predose count of the neck was performed, since a small amount of what was presumed to be ¹³⁷Cs in-

1

İ

The depressed thyroidal iodine uptake rate and renal excretion rate are puzzling, and no explanation for them is available at this time.

Development of Thyroid Abnormalities

1

ł

During the past 3 years, beginning at 9 years after exposure, a total of 18 cases of abnormalities of the thyroid gland have been detected. Nodules of the thyroid gland were found in 16 cases, and 2 cases have hypothyroidism with no nodules. All occurred in the more heavily exposed Rongelap people except for one woman in the less exposed (Ailingnae) group. A thyroid nodule was first noted in 1963 in a 12-year-old girl in the exposed group, and in 1964 two additional cases with nodules were found in exposed girls 13 and 14 years of age.^{10,23} In March 1965 three additional cases in exposed people were noted in boys

| | | | Thyre | oid Abn | ormalities | in Exposed Rongelap People, 1966 |
|--------------|------------------|--------------------|------------------------|-------------------|--------------|--|
| Subje and | ect No. I sex | Present age, yr | Age at exposure, yr | Year | Age, yr | Findings |
| 3 | М | 13 | 1 | 1965 | 12 | Hypothyroid, PBI $< 2 \mu g \%$ March 1965; retardation of growth preceded these findings by a number of years. 3/66 growth spurt and improved appearance on thyroxine. |
| 5 | М | 13 | 1 | 1965 | 12 • | Hypothyroid, PBI $< 2 \mu g\%$ March 1965; retardation of growth preceded these findings by a number of years. 3/66 growth spurt and improved appearance on thyroxine. |
| 17 | F | 15 | 3 | 1963 | 12 | Adenomatous goiter; total thyroidectomy, 1964. No recurrence. |
| 21 | F | 15 | 3 | 1964 | 13 | Adenomatous goiter; total thyroidectomy, parathyroidectomv. 1964. No recurrence. |
| 69 | F | 16 | 4 | 1964 | 14 | Adenomatous goiter, partial thyroidectomy, 1964. No recurrence |
| 2 | М | 13 | 1 | 1965 | 12 | Adenomatous goiter, partial thyroidectomy, 1965. No recurrence |
| 20 | M | | 唐 神经 | 1965 | 18 | Adenomatous goiter, parties shyroidectomy, 1965. No recurrence. |
| 64 : | - F | 42 | 3 0 | 1965 | 41 | Mixed papillary and follicular carcinoma, total thyroidectomy- aurgical and therapeutic radioiodine, 1965; Nantiurrence. |
| 72 | * | 18 | . 6 . | 1965 | 17- | Three-mm nodule left lobe. 9/66 nodule not participation and the second |
| 42 | ŕ. | | | 1965 | 14 | Two-mm nodule right lower lobe. $3/66$ noduler entargement $-1\frac{1}{2} \times normal$) entire gland; firm 5-mm nodule right lobe. 1/66 subtotal thyroidectomy: adenomatous goiter. |
| 61 | Y | 20- | 8 | 1965 | 19 | x to 8-mm mooth nodule left lower pole. 3/66 1-cm nodule at the second s |
| 40 | М | 41 | 29 | 1965 | 40 \$ | Two-mm nodule right lower pole. 3/66 no nodules detected. |
| 59* | F | 46 | 34 | 1965 | 45 | Five-mm nodule midline. 3/66 same. 7/66 subtotal thyroidec- tomy: adenomatous goiter. |
| 54 | Μ | 13 | 1 | 1 9 66 | 13 | Nodular enlargement ($\sim 1\frac{1}{2} \times \text{normal}$) left lobe and isthmus with 2-mm firm nodule. |
| 19 | М | 17 | 5 | 1966 | 17 | Multinodular soft enlargement entire gland ($\sim 1\frac{1}{2} \times \text{normal}$). 1- cm nodule right lower pole. |
| 36 | М | 19 | 7 | 1966 | 19 | Slight nodular enlargement, entire gland. 1-cm nodule, not clearly demarcated, at right lower pole. Many tiny nodules over surface of gland. |
| 33 | F | 13 | 1 | 1966 | 13 | 9/65 questionable irregular gland. 3/66 definite-mm nodule left lobe. 7/66 subtotal thyroidectomy: adenomatous goiter, Hurthle cell adenoma. |
| 65 | F | 13 | 1 | 1966 | 13 | 9/65 questionable small nodule. 3/66 5-mm nodule right lobe. 7/66 right subtotal thyroidectomy: adenomatous goiter. |

Table 17

*Exposed to only 69 rads whole-body radiation and presumably proportionately less thyroid dose.

devoid of physiological activity. Hence an iodoprotein containing only these iodoamino acids is likely to be also physiologically inactive. The reason these individuals have such an iodoprotein in the blood is not clear. The data on normal controls from the Eastern United States, who showed 0.80 μ g% iodoprotein iodine in their serum, suggest that it is a normal, albeit minor, constituent. The method of chromatography employed is such that well under 5% (or 0.2 μ g%) of serum thyroxine iodine appears in the unretarded or iodoprotein fraction. Therefore, the finding of iodoprotein does not appear to be a methodologic artifacted

More recently, with the development of thyroid abnormalities in the exposed Marshallese (to be described), it was possible to examine serum iodoprotein levels in cases with thyroid hypofunction. These data are presented in Table 16. It seems likely that the source of the iodoprotein was largely extrathyroidal, since the levels of iodoprotein were



Ictopencies and a president represent the difference between 2 of 100 and 10

*L-Thyroxine stopped several weeks before sampling. †Treated with L-thyroxine, 0.2 mg per day, for 6 months. Values in brackets are determination made prior to starting thyroxine treatment (1965). near the normally high Marshallese values (a) in cases which had been on suppressive thyroxine therapy, (b) in cases with atrophic glands due to radiation (subjects No. 3 and No. 5), and (c) in thyroidectomized cases. The source of the iodoprotein is not known. The previously reported finding of high plasma proteins,⁵ particularly gamma globulins, in the Marshallese is of interest but may be an unrelated phenomenon. It will be important to see in future studies whether the iodoprotein can be labeled with radioiodine.

The data on urine iodine show values in the normal range. In general, it had been expected that individuals living close to the sea and eating seafood and fish would show relatively higher iodine intake. The inhabitants of the Marshall Islands have fish as one of their main sources of animal protein. Furthermore, these people are constantly exposed to sea spray, since the island at its widest is about ¹/₄ mile across, and its highest point is ≈ 20 ft above high tide.

The date on uring foding were used with the result obtained with "Istudies to calculate the and unit of bodine secreted daily in the throad. The value rear days somewhat higher than the 57 mg/day found by Stanbury et al or 58 mg/day found by Freinkel and Ingbars but croser to the value 70 mg/slay proposed by Ringer Unfortumately, nothing is known about the rate of turnover a location of the strong his to be a strong his the same rate entregradation and the same volume of distribution is thyrefine and it is assumed to have itrongin in the thyroid gland, then one would expect the Marshallese myraids to getrete organic ine presortional to the level of organic iodine in their schum. Addition of iodothyroxine values protein iodine levels for Born Mathanese Americans and mattiplicate of the strice by er value for iodine mal ēd mericina results in 4

 $\frac{2.2 + 4.53}{0.80 + 3.76} \times 58 = 86 \,\mu g/d$

This agrees fairly well with the Tayle fday calculated independently from what and tadioindine studies and is compatible with the clinical status of ceuthyroid status is said an devated PBI and elevated thyroid iodine secretion rate. However, as noted above, it seems somewhat more likely that the serum iodoprotein is not of thyroidal origin.

2

F

1

E
13 and 18 years of age and in a 41-year-old woman, the first adult case. Two cases of hypothyroidism in growth-retarded boys were also noted at this time. In September 1965 a further examination was carried out by two of us (R.A.C. and J.E.R.), and 5 more exposed people were found with nodules varying in size from 2 to 8 mm. One of these was a 45-year-old woman in the group that received only an estimated 69 rads. The cases up to this point were recently reviewed.24 In March 1966 nodules of the thyroid gland were detected in 5 additional exposed children. Table 17 gives some pertinent data on all these cases. Table 18 shows the distribution of the thyroid abnormalities (nodules and hypothyroidism) by age. In Table 19 results are presented on the various populations studied along with the estimated radiation dose to the thyroid gland. It is noteworthy that the preponderance of thyroid abnormalities have occurred in children exposed at < 10 years of age and only in the more heavily exposed group (15 of 19 children, 78.9%). No cases with thyred abnormalities were detected in the children in the lower exposure groups of the same age range 6 Ailingnae children, 40 Utirik children) or in the ried out, including 1321 and the Ic uptake studies 61 unexposed Rongelap children. Two adults with thyroid nodules were noted in the more heavily exposed Rongelap group and one in the Ailingnae group. In the Utirik and unexposed populations a low incidence of thyroid nodules was found, and these occurred only in the older age group.

ī

ł

1

In view of the potential seriousness of the thyroid abnormalities in the Marshallese, it was decided that the exposed people should receive thyroid hormone treatment for the remainder of their lives in order to sub-construction. Such treatment might provide another development of nodules and possibly their regression of exiting nodules. The treatment might also stimulate-growth in retarded children. Accordingly, at the time of the September 1965 survey, their people in the more heavily approaches the people in the more heaving exposed group were har in the non Lthyroxine at aily dose of 0.3 mg to all people <50 years of age and 0.2 mg to all people >50. The new cases with thyroid nodules were left in the Islands under hormone treatment, with the idea that, if at the time of the next survey (March 1966) the nodules had not regressed or further nodules had developed, consideration would be given to bringing them to the United States for study and possible surgery. In March 1966 it was

decided that 5 such cases should be brought to the United States. These cases had not shown reduction in nodule size, though presumably they had been on the hormone therapy for the 6-month period. Four children with thyroid nodules who were not considered to have had an adequate trial therapy with thyroid hormone were left in the Islands to be re-evaluated later. In one 40-year-old man a nodule had disappeared, presumably as a result of therapy.

Surgical Cases

Of the 16 cases with nodules, a total of 11 have had surgery. In 1964, the first 3 cases in teen-age girls were operated upon* at the U.S. Naval Hospital, Guam.^{10,23} In July 1965, 3 cases were brought to the Medical Research Center at Brookhaven National Laboratory (Figure 22) and later taken to the New England Baptist Hospital, Boston, for surgery.** In May 1966, 5 additional cases were brought to Brookhaven for further examinations (Figure 23) Type later to the New England Deacones ricepital in Boston for surgery.** At Brookhaven, detailed thyroid studies were carand scans before and after TSH idministration † and measurement of basal metabolism rate, serum protein-bound ioding, seman thyroline (T_{\star}) level, and serum antithyrer lobalin antibody liter. Brief hospital summary reports on these cases are presented in Appendix 6.

Gross Appearance. In all 9 children operated upon, the send were found at survery to be multinodules although in some case the nodules had appeared mically to be solitary. The nodules varied in districter from a few man to several cm, in consistent from fluctuant of bitively hard, and in cold from pale grey to bit for red. Cyst formation for present in man series from had bemorrhan areas. Figure 24 for the gross ap-plarance in some cases with the second part of the source of the source of the surrounding for the source of the sou nodule, and the surrounding time topsared normal. In the other adult (No. 64, and also did not show multiple notice that the contained two firm, yellow, malignant nodules about 1 cm in diameter (Figure 26).

^{*}Surgery was performed by Captain C.A. Broaddus, MC, USN.

^{**}Surgery was performed by Dr. B.P. Colcock of the Lahey Clinic

[†]We are grateful to Dr. H.L. Atkins for these analyses.

Table 18

| <u></u> | | Nodules | | Hypoth | yroidism | Total abnormalities | | |
|-----------------|-------------|---------|------|--------|----------|---------------------|------------|--|
| Age at exposure | No. exposed | No. | % | No. | % | No. | % of Group | |
| 1- 5 | 13 | 9 | 69.2 | 2 | 15.4 | 11 | 84.6 | |
| 6-10 | 6 | 4 | 66.7 | - | - | 4 | 66.7 | |
| 11-15 | 7 | 0 | 0 | - | _ | 0 | 0 | |
| 16-20 | 5 | 0 | 0 | - | - | 0 | 0 | |
| >20 | 24 | 2 | 8.3 | | - | 2 | 8.3 | |

Rongelap Thyroid Abnormalities, Age Specific Incidence (1966)*

*In 55 living of original 64 Rongelap people in heavily exposed group. One nodule in woman in less exposed group (not included in table).

Table 19

Thyroid Abnormalities (Nodules and Hypothyroidism) in Marshallese Populations Examined 1964-1966

| | | Age (19 | (954) < 10 yr | | Age (1954) 10–19 yr | | | | |
|------------------------------------|-----------------|--------------------------------|---------------------------|------------------|-------------------------------|--------------------------------|--------------------------------|--|--|
| Island group | No. examin | Estin thy ed dos | nated roid re** Abr | % normalities | No. examined | Estimated thyroid dose** | % Abnormalities | | |
| Rongelap | 19 | / 700 γ 175 | -1400 | 78.9 | 12 | / 350600 γ 175 | 0.0 | | |
| Ailingnae† - | 6 | Ι275 γ69 | -550 | 0.0 | l | /175-300 γ69 | 0.0 | | |
| Utirik† | 40 | Ι 55 γ 14 | -110 | 0.0 | 16 | 1 25-55 γ 14 | 0.0 | | |
| Unexposed (Rongelap and Utirik) | 61 | | - | 0.0 | 36 | - | 0.0 | | |
| K. | . A | ge (1954) 20 |)–40 уг | Age (1 | 954) >40 yr* | A | All ages | | |
| | No. examined | Estimated thyroid dose** | % Abnormalitie | No. examined | % Abnormaliti c | No. examined | % Abnormaliti cs | | |
| Rongelap | 14 | / 160 γ 175 | 14.3 | 10 | 0.0 | 55 | 30.9 | | |
| Ailingnaet | 4 | / 54 γ 69 | 25.0 | 3 | 0.0 | 14 | 7.1 | | |
| Utirik† | 22 | Ι16 γ14 | 4.5 | 21 | 4.8 | 99 | 2.0 | | |
| Unexposed (Rongelap and Utirik) | 4 8 | - | 0.0 | 49 | 6.1 | 194 | 1.5 | | |

*Dosage in this group was the same as in the 20 to 40-year group.

**I = Dose from β and γ radionuclides; $\gamma = dose$ from external γ radiation.

†In estimating the thyroid doses to the Ailingnae and Utirik exposed group it was assumed that such doses were proportional to the thyroid doses of the Rongelap exposed group, based on relative whole-body gamma dose received.

1

ž

Į

1

I



Figure 24. Benign thyroid nodules at surgery. Top: exposed thyroid with arrows pointing to nodules. Bottom: sectioned gland from another case. Note multinodular, cystic, and hemorrhagic nature of gland.

Microscopic Appearance. The microscopic appearance of all the benign nodular glands in the children was characteristic of adenomatous goiter and varied mainly in the degree of change. The architecture of the gland was disrupted by the nodules of widely varying sizes. Some of the nodules contained microfollicular elements with and without colloid, others were atrophic, some contained large cysts with colloid, some with hemorrhage, and still others showed extensive proliferation of the epithelial layers with marked infolding, giving an "arboreal" appearance. Figure 25 indicates some of the changes characteristic of these benign nodules. In one case (No. 33), in addition to adenomatoid nodules there also was present a Hurthle's cell adenoma. In another case (No. 61), one pathologist remarked that "some observers might regard the large nodule as a follicular adenoma." In subject No. 59, a 46-year-old woman who had received less than half the radiation dose of the other cases with nodules, there was a solitary adenomatous nodule, well circumscribed, and the surrounding thyroid tissue was normal in appearance. This was in contrast to the other cases in whom the glands were almost entirely abnormal in appearance. A 41-year-old woman (No. 64) had a mixed papillary and follicular carcinoma of the thyroid with localized metastasis to a blood vessel and lymph node (Figure 26). Following complete thyroidectomy by surgery and therapeutic ¹³¹I no recurrence or further metastasis has been noted. In September 1966, at Tripler General Hospital, Hawaii, thyroid uptake studies following TSH stimulation (10 units daily for 2 days), thyroid scans, and skeletal surveys for metastasis showed absence of the thyroid and no detectable metastasis.*

Thyroid Function Tests Related to Thyroid Abnormalities and Growth Retardation

In Table 20 the cases with thyroid abnormalities are listed along with the growth status of children and results of thyroid function tests. The results of kinetic analysis of 132I tests are given in Table 21. Two 12-year-old boys (No. 5 and No. 3) who had been exposed at 15 and 18 months of age respectively have had the greatest retardation of growth and development. Subject No. 3 had shown no change in bone maturation since 1961 and until recently had the bone age of a 3-year old child. The bone age of No. 5 has shown continuing slow growth and in 1965 was 5½ years. Both these boys in 1965 had the height of normal 7-year old Marshallese boys. Their dwarfism was particularly evident in comparison with younger siblings who were taller than they. In 1965 it was found that in both cases the levels of proteinbound iodine had dropped below 2 μ g%. Before that time, they had levels considered to be in the normal range, and there was no reason to relate their dwarfism to hypothyroidism. With the development of the low PBIs they showed definite

^{*}We are grateful to Major Ronald Moore, MC, USA, for carrying out these examinations.

Ĩ

F

1

۱



Figure 22. Rongelap thyroid cases at Brookhaven (July 1965) for studies and later surgery. The two boys had benign adenomatous nodules. The woman had a thyroid malignancy removed.



Figure 23. Marshallese thyroid cases at Brookhaven (June 1966) with Dr Conard. The Marshallese man on the right is an interpreter. All these cases had benign adenomatous nodules removed.

PRIVACY ACT MATERIAL REMOVED

ł

1

Į

2





Figure 26. Top: mixed papillary and follicular carcinoma at surgery (subject No. 64). White nodule is malignant tissue. Bottom left $(21 \times)$: microscopic section showing relatively normal thyroid tissue beneath the malignant tissue. Bottom right $(10 \times)$: local lymph node invasion by the tumor.

ł

]

ī

Į

l



Figure 25. Microscopic sections of adenomatous nodules. Top left $(21 \times)$: characteristic appearance of thyroid glands with wide variation in size of follicles. Some nodules consist of mircofollicular tissue, others of colloid cysts; still others show hyperplasia. Top right $(150 \times)$: hyperplasia with papillary infolding of epithelium. Bottom $(25 \times)$: Hurthle cell adenoma (subject No. 33).

Kinetic Analysis of ¹³²I Studies

| Location and year. | Subject No. | Urine,* per day | Thyroid, ^ь p e r day | Thyroid fraction ^e | Iodide space, liters |
|-----------------------|----------------------------|----------------------|---|----------------------------------|----------------------------|
| Marshalls, March 1965 | Exposed ⁴ | 1.10 (0.34-2.57) | 0.67 (0.33-1.27) | 0.40 (0.25-0.65) | |
| | Unexposed* | 0.81 (0.17-1.99) | 0.79 (0.23–1.47) | 0.52 (0.26–0.77) | |
| BNL, June 1965 | 2 pre TSH post TSH | 1.20 0. 80 | 1.71 1.19 | 0.41 0.60 | |
| | 20 pre TSH post TSH | 2.12 1.10 | 2.30 1.81 | 0.49 0.62 | |
| | 64 pre TSH post TSH | 1.88 0.81 | 1.08 1.56 | 0.36 0. 66 | |
| Marshalls, March 1966 | 3 | 0.52 | 0.005 | 0.01 | |
| | 5 | 0.86 | 0.14 | 0.14 | |
| | 69 (partial thyroidectomy) | 1.13 | 0.15 | 0.12 | 33.3 |
| | 2 (partial thyroidectomy) | 1.53 | 0.92 | 0.37 | 20.0 |
| | 61 (on thyroxine) | 1.26 | 0.58 | 0.31 | 29.0 |
| | 54 | 0.50 | 0.69 | 0.58 | |
| | 65 | 1.08 | 0.72 | 0.40 | 20.4 |
| - | 59 (on thyroxine) | 1.65 | 0.10 | 0.06 | 16.9 |
| BNL, June 1966 | 42 pre TSH post TSH | 1.87 0.69 | 1.29 1.30 | 0.41 0.65 | |
| | 61 pre TSH post TSH | 0.13 0.50 | 0.48 1.67 | 0.78 0.77 | |
| | 33 pre TSH post TSH | 0.20 0.45 | 0.97 1.57 | 0.82 0.78 | |
| | 65 pre TSH post TSH | 1.83 2.35 | 0.82 1.14 | 0.31 0.33 | |
| | 59 pre TSH post TSH | 3.53 1.29 | 1.51 3.09 | 0.30 0.71 | |

*Fraction of extrathyroidal iodide excreted in the urine per day (λ_{s1}).

^bFraction of extrathyroidal iodide transferred to the thyroid per day (λ_{21}) .

"Theoretical thyroid uptake, $\lambda_{21}/(\lambda_{21}+\lambda_{61})$.

^dMean and range of 12 subjects.

Ì

Į

*Mean and range of 9 subjects.

signs of hypothyroidism: coarse facial features, dry skin, and Achilles' reflexes with typical sluggish return. There was no palpable thyroid tissue. They did not show apparent mental retardation. TSH levels (Table 20) were markedly elevated in both boys, corroborating the presence of primary hypothyroidism. Figure 28 shows bone age retardation in one of these boys. Typical bone dysgenesis associated with hypothyroidism⁴³ was noted in 1965 in these boys. Figure 29 shows such changes in the heads of the humeri in one case (No. 5).

From Table 20 indications can be seen that several other children with thyroid abnormalities (subject Nos. 2, 20, 33, and 65), some of whom

Table 20

| | | | | | Gr | owth | Neck at 4 % of c | ¹³² I hr, * | Serum i | odine | <u> </u> |
|----------------|--------------------------|--------------------|----------------------|----------------|-------------------------------------|------------|--------------------------|----------------------------------|-------------------|----------------|---------------------|
| Sut | oject | | | Chrono- | Skeletal | Statural | | | μgʻ | % | Serum |
| No. and sex | Thyroid abnormality - | Year tested | logical . age, yr | ranking, yr | ranking, [*] percentile | Pre TSH | Post TSH | PBI | <i>T</i> , I | TSH,⁰ ng∕ml | |
| 3 | Μ | Atrophy | 1965 1966 | 13 | 3 | <10 | | | 1.4 3.2 | 0.8 1.0 | >120 159 |
| 5 | М | Atrophy | 1965 1966 | 13 | 5¾2 | <10 | 8 | | 1.9 3.1 | 0.8 1.8 | 119 2 4 8 |
| 17 | F | Nodular goiter | 1965 1966⁴ | 15 | 13%2 | 90 | | | 6.8('64) 1.8 | <0.5 | 372 |
| 21 | F | Nodular goiter | 1965 1966⁴ | 15 | 15 | 10–25 | | | 8.1('64) 1.3 | <0.5 | 440 |
| 69 | F | Nodular goiter | 1965⁴ 1966⁴ | 16 | 16 | >90 | 6.5 | | 7.1 5.7 | 1.7 | 125 |
| 2 | Μ | Nodular goiter | 1965 1966ª | 13 | 113/12 | 25-50 | (29) 18 | (23) | 7.9 5.2 | 4.2 2.6 | 9.6 26.6 |
| 20 | М | Nodular goiter | 1965 | 19 | Adult | 25-50 | (31) | (31) | 6.5 | 4.2 | |
| 72 | F | Nodular goiter | 1965 | 18 | 17%12 | >90 | | | 5.3 | | |
| 42 | F | Nodular goiter | 1965 1966 | 15 | 13¾2 | 10 | (15) | (24) | 5.7 | 4.6 | <17 |
| 61 | F | Nodular goiter | 1965 1966 | 20 | Adult | 50-75 | 12•(10) | (24) | 7.9 | 4.9 | |
| 54 | Μ | Nodular goiter | 1965 1966 | 13 | 13 | 90 | 19 | | 8.3 5.0 | 4.3 | <3 <17 |
| 19 | Μ | Nodular goiter | 1965 1966⁴ | 17 | 153/12 | 10 | | | 3.9 | 3.3 | <17 |
| 36 | Μ | Nodular goiter | 1965 1966 | 19 | 18 | 75 | | | 4.1 4.2 | 4.3 | <17 |
| 33 | F | Nodular goiter | 1965 1966 | 13 | 13%2 | >90 | (16) | (24) | 7.0 5.9 | 3.8 | 7.3 197 |
| 65 | F | Nodular goiter | 1965 1966 | 13 | 10%12 | <10 | 17 (9) | (14) | 4.9 3.1 | 2.1 1.9 | 6.6 23.5 |
| 59 | F | Solitary nodule | 1965 1966 | 35 | | | 7•(20) | (38) | 8.2 8.6 | 5.3 4.8 | |
| 64 | F | Carcinoma | 1965 1966⁴ | 31 | | | (19) | (28) | 8.6 4.9 | 3.4 2.0 | |
| 40 | М | Solitary nodule | 1965 | 40 | | | | | 10.3 | | |

Growth and Thyroid Studies in Subjects With Thyroid Abnormalities

*Values in parentheses obtained at BNL.

^bRelative statural growth expressed as percentile ranking compared with growth curves of unexposed Marshallese children.

^cAssays in 1965 could not detect levels below 3 nanograms/ml. Seven unexposed children in the same age group had <3 ng/ml. Assays in 1966 could not detect levels below 17 ng/ml. Three exposed children without thyroid disease (Nos. 6, 8, and 32) had <17 ng/ml. Two children exposed *in utero* (Nos. 84 and 86) and two unexposed children had <17 ng/ml. The 1966 levels were obtained about 3 weeks after cessation of thyroxine therapy, the 1965 levels, before therapy was instituted. We are grateful to Dr. William Odell at the National Institutes of Health for carrying out these assays.

^dPost partial thyroidectomy.

"While taking thyroxine.

1

ł

]

I

During the March 1966 survey, 132I studies were done in 8 subjects with thyroid abnormalities. In addition to urine and neck radioactivity measurements, as described above from the 1965 survey, 6 subjects were given 500 mg KClO₄ by mouth \approx 4 hr after the ¹³²I dose. Neck measurements were continued for 45 min longer. The neck uptake curves in these subjects are shown in Figure 30. In 3 subjects (Nos. 3 and 5, who had severe growth retardation, and No. 69, who had a subtotal thyroidectomy in 1964) the neck uptake was almost entirely due to iodide circulating in the blood, no correction having been made for this factor. In 3 other patients (Nos. 2, 54, and 65) there was a brisk uptake to about 18% of the dose. Following KClO₄, there was no loss of iodine from the neck. If the thyroid gland had contained iodine which had been trapped as iodide but not organified, this should have been discharged by the KClO₄. A phenomenon of this kind has been seen in radiation-damaged thyroid glands after treatment of hyperthyroidism with radioiodine41.42 but was not observed in the Marshallese subjects.

Computer analysis of the ¹³²I data obtained from all the patients so studied is presented in

Table 21. This includes data obtained in the Marshall Islands in March 1966 and preoperatively at BNL in June 1965 and June 1966. Computer analysis of the data obtained at BNL in June 1966 was evaluated in several ways: with or without the corrected neck counts using a lead shield, with or without inclusion of urine data. None of these made an important difference in the value for thyroid accumulation rate, but the uncorrected data gave somewhat greater reliability. The very low urine excretion rates in some cases are probably due to incomplete urine collection, and result in comparable errors, in the opposite sense, in the computed thyroid fraction. In Table 21, uncorrected neck counts are used except for the data at BNL, June 1965. In the Marshall Islands in March 1966, blood ¹³²I was measured at 2 and 4 hr in order to calculate the iodide space. The data obtained in March 1965 on Marshallese without thyroid abnormality are included for comparison. The two cases with severe growth retardation (Nos. 3 and 5) had markedly diminished thyroid accumulation of ¹³²I as did one subject (No. 59) who was on thyroxine therapy and one (No. 69) after partial thyroidectomy. Two subjects (Nos. 2



Figure 29. Bone dysgenesis of heads of humeri in subject No. 5, typical of hypothyroid disease.

1



Figure 27. Thyroid uptake study with ¹³²I, Rongelap Island.

may have some degree of growth retardation, also show evidence of hypofunctioning glands or glands that are functioning at maximum capacity, based on results of thyroid function studies (elevated serum TSH levels or little or no response in ¹³²I uptake following TSH stimulation). One of these (No. 65) had a low serum thyroxine level. The adults with thyroid nodules (Nos. 59 and 64) and two of the children (Nos. 42 and 61) had normal responses to TSH. Several of the studies listed in Table 20 were performed after subtotal thyroidectomy (Nos. 17, 21, 69, 2, and 20). The results indicate inadequate function of the thyroid remnant, even in Nos. 17, 21, and 69, who had been operated upon in June 1964 and had no thyroxine replacement before September 1965. The serum iodoprotein levels (PBI less T_{4} I) ranged from 1.5 to 2.9 and did not differ significantly from values in unexposed Marshallese.



Figure 28. Wrist x rays showing marked retardation of skeletal maturation in dwarfed boy with hypothyrodism (right, subject No. 3, chronological age $10\%_2$ yr) compared with younger brother with normal osseous development (left, subject No. 83, chronological age $8\%_2$ yr).

PRIVACY ACT MATERIAL REMOVED



1

1





A

B

Figure 32. A: Dwarfed boy (subject No. 3) shown at left before thyroid hormone therapy and at right after 6 months therapy with 0.3 mg thyroxine. B: Roentgenograph of wrist of subject No. 3 showing marked improvement in skeletal maturation after 1 year hormone treatment. Compare with Figure 28, before treatment.

PRIVACY ACT MATERIAL REMOVED



Figure 30. Neck accumulation of ¹³²I in subjects with thyroid abnormality. Values are gross neck counts as % of dose, uncorrected for blood background following oral administration of ¹³²I. Computer analysis of these data indicates that 7% of the extrathyroidal iodide pool is "seen" by the neck counter. At the vertical lines, 500 mg KClO, was given by mouth. \triangle , Subject No. 54; \blacksquare , subject No. 2 (partial thyroidectomy); \bigcirc , subject No. 65; \bullet , subject No. 5; \square , subject No. 3; \blacktriangle , subject No. 69 (partial thyroidectomy).

and 20) had little or no response to TSH. The other patients had apparently normal thyroid accumulation rates, and several (Nos. 33, 42, 59, 61, 64, and 65) responded to TSH. Urine excretion rates were variable and, in some instances, very low, probably because of incomplete urine collection. Following TSH, in many instances the urine excretion rate was lower than the control. The reason for this is unknown. The theoretical thyroid fraction following TSH was sometimes elevated despite a fall in thyroid accumulation rate because of a relatively greater fall in urine excretion rate. Incomplete urine collection probably accounts for the very high thyroid fraction in some cases. The thyroid accumulation rate, on the other hand, is relatively unaffected by inaccurate urine collection.

From the data in Tables 20 and 21 it is evident that several of the children who developed thyroid nodules but were not clinically hypothyroid had evidence that their thyroid glands were stimulated by elevated endogenous TSH production, and two of these children were unable to respond further to exogenous TSH.

Results of Thyroid Hormone Therapy

Although it is too soon to evaluate completely the results of thyroid hormone treatment, there are definite indications of beneficial effects. In one

adult a nodule could not be palpated 6 months after treatment was begun. In September 1966, thyroid examinations showed that 4 children with nodules (Nos. 19, 36, 54, and 72) noted previously had evidence of slight regression of the nodules, and it was decided to re-evaluate their cases in March 1967, after another 6 months of therapy. The curves for stature and bone age before and after thyroid hormone administration, plotted for the two most retarded boys (Nos. 3 and 5) in Figure 31, show a definite spurt in growth subsequent to treatment. This acceleration is very prominent for bone development in subject No. 3. Figure 32A shows the remarkable change in appearance of No. 3 after thyroid hormone therapy for 6 months. Figure 32B shows the improvement in bone maturation in wrist bones of No. 3 after 1 year of therapy - compare with Figure 28. These findings indicate that the growth retardation noted among the boys was attributable to functional hypothyroidism. Supporting this assumption is the appearance of epiphyseal dysgenesis in one of these children. Figure 29 shows this dysgenesis in the heads of the humeri. Until 1965, the serum proteinbound iodine (PBI) determinations had yielded results in the euthyroid range. It is possible, however, that the PBI levels actually represented disproportionately high amounts of physiologically inactive serum iodoprotein and inadequate amounts of active hormone. The forthcoming survey in 1967 will be important in assessing further growth stimulation from thyroid hormone treatment.

Discussion of Thyroid Findings

The development of abnormalities of the thyroid glands in the exposed Marshallese people beginning 9 years after fallout is consistent with the known etiological relationship of irradiation of the thyroid gland with the development of such abnormalities. Though the exact mechanism involved in the pathogenesis of such lesions is not clear, it is known that adenomas and cancers of the thyroid gland can be produced in laboratory animals by a variety of agents or regimens which interfere with the ability of the gland to synthesize thyroid hormone. Both benign and malignant neoplasms have been shown to be produced by iodine deficiency,** agents that chemically inhibit thyroxine synthesis such as thiouracil,45-49 x irradiation of the gland, 50-52 and irradiation of the gland with ¹³¹I.⁵³⁻⁵⁵ Furthermore, subtotal thyroidThe results of institution of thyroid hormone therapy in September 1965 are of interest. The rationale for its possible value in inhibiting the development of thyroid nodules appears to be on a firm basis. Bielschowsky⁵⁸ and Astwood and Cassidy⁶⁷ have reviewed the favorable effects of thyroid treatment of patients with nodules of the thyroid gland. The only experimental evidence found directly applicable to the Marshallese situation, however, is in a paper by Nichols et al.⁶⁸ and unpublished data by Godwin⁶⁹ demonstrating a reduced incidence of ¹³¹I-induced adenomas in rats treated with thyroid hormone.

ſ

1

ŗ

1

1

Although the children with thyroid nodules have thus far shown no evidence of thyroid carcinoma, experimental evidence strongly supports the belief that thyroid carcinoma may develop in this exposed population. This likelihood led to the performance of thyroidectomy on all children with thyroid nodules which had failed to disappear on suppressive therapy, even though earlier operative specimens had revealed only adenomatous changes. Since total thyroidectomy was not performed except in a few cases, even the operated patients will have to be followed closely for the possible development of new nodules, and the suppressive effect of thyroid hormone replacement therapy may be important even in them.

The results of the treatment of children with thyroid hormone will also test the thesis of hypothyroid etiology of growth retardation. Early indications are that the treatment is successful, since there has been a spurt in growth in the two most dwarfed boys in the year following institution of the treatment.

AGING STUDIES

During physical examinations, aging effects are usually referred to in a general qualitative sense. In order to evaluate possible aging effects better, a more quantitative approach was indicated. A large number of criteria have at one time or another been regarded as being age dependent. These studies represent an effort to select criteria which could be used under the conditions of these examinations. The over-all objective has been to combine the scores of the various criteria into one "average age score" for each individual and to compare scores in the exposed and unexposed groups of similar age. An earlier attempt to quantify these aging criteria has been presented in previous publications.^{7,70} In this report several new criteria have been added, and further statistical treatment of the data has been undertaken.

Methods

The aging criteria to be presented were recorded only in adults (20 years of age and older). Data were recorded on 91 adults, 36 in the Rongelap and Ailingnae exposed groups and 55 in the larger comparison population. The ages were reasonably well distributed except for the small number of people >60 years of age. The study was hampered by the small number of people involved, lack of vital statistics on the Marshallese people, the language barrier, and uncertainty as to the exact ages in some of the older people. In selecting the criteria to be used, these difficulties limited the extent and usefulness of those tests which require motivation and cooperation on the part of the subject.*

In this report 14 criteria of aging are presented: 4 involving the special sense organs (visual acuity, accommodation, arcus senilis, and hearing loss); 4 involving neurological or neuromuscular function (vibratory sense, reaction time, rapidity of movement, and hand strength); 3 involving the integument (skin looseness, skin elasticity, and hair graving); one cardiovascular test (systolic blood pressure); and 2 miscellaneous tests (serum cholesterol and body potassium). Two of the tests required subjective evaluation on the part of the examiner (hair grayness and arcus senilis); 7 required varying degrees of motivation and cooperation on the part of the subject (visual acuity, accommodation, hearing loss, vibratory sense, reaction time, neuromuscular function, and strength); and 5 tests involved direct measurements (skin looseness, skin elasticity, systolic blood pressure, body potassium, and serum cholesterol).

Integument. A special caliper with constant spring tension was devised for skin examinations.^{7,70,71} (1) Skin Looseness. The skin fold at the junction of the chin and neck was measured in millimeters as described previously. (2) Skin Elasticity. This was measured on the back of the hand by allowing the caliper to pinch a fold of skin for

^{*}Several tests were tried and discarded for these reasons, including vital capacity and cardiovascular response to two-step test. Also not included were several tests that were difficult to quantify such as baldness and retinal and peripheral arteriosclerosis. Other tests, such as serum folic acid and vitamin B_{12} levels, were eliminated because of poor correlation with aging.

ī

ectomy in the rat has been reported to cause adenoma formation in the remaining thyroid tissue 2 years later.56.57 All these procedures produce hypothyroidism which serves as an effective stimulant to the secretion of TSH by the pituitary gland. The thyroid gland under the influence of TSH first undergoes diffuse hyperplasia and hypertrophy and adenoma formation. In the cases of iodine deficiency and partial thyroidectomy, it is probable that no drug or carcinogenic agent is involved. The incidence of carcinomas after a combination of carcinogenic agents (such as radiation or acetylaminofluorene) and any factor that causes hypothyroidism is much higher.58 Radiation by either x rays or ¹³¹I is particularly effective, since it simultaneously acts as a carcinogen and, by impairing the functional capacity of the gland, induces TSH secretion and thyroid stimulation.

The high incidence of adenomatous goiters and hypothyroidism in the more heavily irradiated children exposed at < 10 years of age, compared with no abnormalies in some 100 children in the same age range in the less exposed and unexposed groups, leaves little doubt about the etiological relationship of these lesions with irradiation exposure. The higher incidence in children may be related to increased sensitivity of the child's thyroid to irradiation but is probably related more directly to the relative magnitudes of the radiation doses received, the small child's gland probably having received 5 to 10 times the radiation dose received by the adult's gland. Since most of these lesions appeared in teen-age children, puberty may have been a contributing factor. The incidence of the lesions in female children is only slightly greater than in male children (1.27 to 1). A greater prevalence of thyroid abnormalities in that sex is correctly noted. The increased incidence of thyroid abnormalities, including one case of malignancy, in the adults of the more heavily exposed Rongelap population makes it necessary to consider seriously radiation exposure as the etiological factor. In Appendix 7 statistics on thyroid malignancies in the Marshall Islands and the Trust Territory are presented. A low incidence of solitary nodules was noted in older (>50 years of age) unexposed Marshallese of both Rongelap and Utirik Islands. The single nodule case in the less exposed 46-yearold Ailingnae woman, on the other hand, may well fall into the category of the sporadic type, since the nodule was well encapsulated, and the remainder of the thyroid gland appeared normal.

Urine analyses indicate that iodine intake is adequate. The incidence of nodules and sporadic cases of goiter seen at the Majuro Hospital* is low, and the Marshallese population shows no evidence for goitrogenic factors in their environment.

The sensitivity of children's thyroid glands to the development of neoplastic changes from radiation exposure has been amply demonstrated. A series of retrospective and prospective studies have clearly shown the causal relation of irradiation of the neck region in infants and later development of thyroid cancer.59-62 Although the calculation of the dosage in the Marshallese is subject to large uncertainties, the greater incidence of pathological changes in the glands of the Marshallese may be related to a greater dose of radiation received by their thyroid glands. Lesions similar to those seen in the Marshallese have been reported in children 5 to 11 years old after treatment with ¹³¹I for thyrotoxicosis.63.64 Doniach65 points out that cell division in the growing thyroid gland of the child may be a factor in the increased sensitivity to irradiation. There appears to be an increased incidence of thyroid carcinoma in inhabitants of Hiroshima and Nagasaki exposed to radiation from the atomic bomb explosions.66 These people were exposed to varying doses of external radiation to the thyroid gland but not to internal exposure from radioiodine.

It has been assumed that the slight growth retardation previously noted in some of the exposed children was due to radiation, but the mechanism has been obscure. The growth hormone studies suggested that pituitary function was normal. X rays of the sella turcica showed no evidence of pituitary abnormality. With the recent development of hypothyroidism in two of the most growthretarded boys and evidence of mild hypothyroidism in several other children with thyroid nodules and growth retardation, a hypothyroid etiology seems most likely. Elevated TSH levels indicate that the hypothyroidism is primary. Minimal hypofunction of the gland may have been missed in the past, since the apparently normal PBI levels may have been spuriously high, the true thyroxine level being masked by the elevated iodoprotein component characteristic of the Marshallese.

^{*}In March 1966, two cases of goiter with large, nodular glands were seen at the Majuro Hospital. One may have had mild hyperthyroidism. These cases were not part of the population under study.

In order t

45

each light as it appeared. The total time necessary to extinguish all the lights was measured. This test involved both manual dexterity and mental reaction time⁷² (see Figure 33). (4) Hand Strength. The spring tension of the hand grip was measured in kilograms with a Smedly hand dynamometer.* The maximum squeeze strength in the dominant hand in 3 tries was recorded.

Miscellaneous Tests. (1) Body Potassium Levels (${}^{40}K$). Since loss of muscle mass occurs with aging and total body potassium is closely related to muscle mass, it has been shown that body levels of potassium decrease with age.^{73,74} Whole-body spectrographic analyses were carried out in the Marshallese in a lead-shielded structure. In this way ${}^{40}K$ levels were obtained and presented as K/kg body weight. The accuracy of these data could have been improved by obtaining more precise determinations of lean body mass, such as by measurement of body water.⁷⁴ The values listed are averages of the 1961 and 1965 determinations. (2) Blood Serum Cholesterol Levels. These were obtained in 1957 on sera sent to the United States.**

*S.H. Stoelting Co., Chicago, Ill.

**The analyses were done at the National Institutes of Health by Dr. J.H. Bragdon and Mr. J.C. Lauter.

Correlation of Data. In order to place all the data on a common basis for comparison and combination, the data were converted to a percentage basis for each criterion. In the case of the measured data, values associated with least aging were taken as 0% (sometimes the highest reading, as with hand strength; sometimes the lowest, as with hearing loss), and conversely the values showing most aging were taken as 100%. The estimated criteria with values of 0, 1+, 2+, 3+, and 4+ were presented as 0, 25, 50, 75, and 100%, respectively. The data were examined on an individual basis as well as on a population basis, and comparisons were made largely by using means for each decade age group. Except where indicated, the data used were collected during the 11- and 12-year surveys.

An analysis of variance was used to determine differences among the factors of sex, age, and radiation levels.* These data were programmed and analyzed on a high speed digital computer.** For each criterion, the combined score over sex and radiation level was correlated with age. A curve of

| | Correlation | Correlation with | h radiation | |
|---|-------------|----------------------|-------------------|--|
| | (r value) | Percent | Significance* () | |
| Grayness | 0.87 | + 17.0 | N.S. (0.70) | |
| Arcus senilis | 0.83 | 0.0 | N.S. (1.00) | |
| Accommodation | 0.81 | -14.1 | N.S. (0.11) | |
| Skin retraction | 0.74 | + 7.3 | N.S. (0.68) | |
| Skin looseness | 0.70 | + 1.6 | N.S. (0.82) | |
| Vibratory sense $(M + F)$ | 0.70** | - 1.4(M), + 24.6(F) | N.S. (0.90, 0.20) | |
| Visual acuity | 0.69 | +14.0 | N.S. (0.59) | |
| Hearing loss | 0.67 | + 7.9 | N.S. (0.40) | |
| Hand grip $(M + F)$ | 0.67** | +13.8(M), +13.8(F) | N.S. (0.15, 0.18) | |
| Reaction time $(M+F)$ (light extinction test) | 0.64** | -2.0(M), -10.5(F) | N.S. (0.88, 0.55) | |
| Systolic blood pressure | 0.55 | -11.5 | N.S. (0.30) | |
| Potassium $(M + F)$ | 0.41** | -14.6(M), $+10.6(F)$ | N.S. (0.17, 0.22) | |
| Cholesterol | 0.39 | -17.2 | N.S. (0.05) | |
| Neuromuscular function $(M + F)$ (hand tally) | 0.36** | + 3.2(M), +1.1(F) | N.S. (0.85, 0.95) | |
| Combined score† | 0.99 | + 7.0 | N.S. (0.27) | |

Table 22

[•]Mr. Keith Thompson of Brookhaven National Laboratory did the statistical analyses of these data.

^{**}The Control Data Corporation 6600, at Brookhaven National Laboratory.

1 min and measuring the time for the skin fold to retract to the surrounding skin surface. The exact end point was sometimes difficult to measure in older people, and if the fold had not retracted completely in 90 sec, this time measurement was used at the maximum. (3) *Graying of the Hair*. The degree of graying was expressed on a 0 to 4 + scale as follows: 0, no graying; 1 +, slight "salt and pepper" graying; 2 +, moderate "salt and pepper" graying; 3 +, nearly complete graying; 4 +, complete graying.

Special Senses.* (1) Eyes. All ophthalmological values were obtained during the 1964 survey. (a) Accommodation was measured in diopters by use of the Prince refracting rule. The average reading of the two eyes was used. (b) Visual acuity was measured by Snellen's test. It was found that by taking the square root of the average visual acuity (denominator) of the two eyes the scale was more linear. Thus the best vision, 20/10, was represented as 3.2 (the square root of 10), the worst reading, 20/200, was represented as 14.1 (the square root of 200), and intermediate readings were similarly recorded. (c) Arcus senilis was estimated on a 0 to 4+ scale. Only slight limbic clouding was considered as 1 + with increasing clouding as 2 + or 3 + and marked clouding as4+.

(2) Ears (Hearing). Audiometric examinations were carried out in a special cubicle lined with acoustic tile. A rugged screening type of audiometer was used.** Impairment of hearing was averaged for the two ears as follows: the decibel loss for each of the 6 frequencies (200, 500, 1000, 2000, 4000, 7000) for each ear was averaged, and a mean frequency loss in decibels for the two ears was obtained.

Cardiovascular Changes. Systolic Blood Pressure. Two readings were obtained with the standard aeronoid cuff-type sphygmomanometer, and the average of the two was used. There was no basic or



Figure 33. Marshallese subject taking light-extinguishing test of neuromuscular and mental ability as part of the aging study.

adjusted level of physical activity such as resting for a standard period of time prior to the readings. Pressures were taken from the left arm with the subject supine during the course of the physical examination.

Neurological and Neuromuscular Function. (1) Vibratory Sense. Vibratory perception was measured over the head of the left tibia by an electric vibrometer set at a standard frequency of 120/sec at 20 V. The end point was the voltage intensity required for perception of the vibration. (2) Neuromuscular Function. This was measured by having the subject depress the key of a hand-tally type of blood cell counter as many times as possible in the period of one minute (1964 data). The total number of depressions represented the score. (3) Light Extinction Time.* A battery of lights were connected in random series, and the subject extinguished

Ĩ

3

I

^{*}With regard to the reliability of determinations using the Prince refracting rule, Snellen's test, and hearing acuity, it should be pointed out that these tests were carried out under standardized conditions; but, in view of the necessity of using an interpreter under field conditions, it was not feasible to have the test repeated by more than one examiner. The data from these tests are believed to be sufficiently reproducible to be of relative value, although not so accurate perhaps as might be obtained under more desirable conditions.

^{**}The authors are grateful to the Armed Services Medical Procurement Agency, Fort Totten, New York, for loan of the audiometer.

^{*}We are grateful to Dr. J.W. Hollingsworth of Yale University for information on the construction and use of this instrument.

- -----



Figure 36. Hair grayness.

Figure 37. Arcus senilis (1964).

second degree in age was used when there was a significant departure from linearity. The criteria vibratory sense, hand grip, light extinction time, hand-tally count, and body potassium showed significant sex differences, and were therefore scaled for each sex (0 to 100%).

An attempt to correlate a combined "physiologic" age score with chronological age was done by obtaining a weighted average score for combined criteria for each age group (see Table 22). The absolute values of the correlation coefficients were used as the weighting factor. This has intuitive appeal, since the influence on the final combined score of any particular aging criterion is proportional to the absolute value of its correlation with age.

Results of Aging Studies

The results of these tests are presented graphically in Figures 34 to 48 and in Table 22. The mean values for each decade starting at age 20are plotted at the midpoint of that decade for exposed and unexposed groups separately and combined, along with the standard errors of the means. The number beside each point is the number of people tested. The curve or straight line (whichever best represents the particular data) is drawn and its equation presented. The coefficient of correlation with age and significance is also presented. Most of the criteria show good correlation with aging. It is apparent that most of the criteria show the least change with age in the younger age groups, from 20 to 40 years of age, particularly systolic blood pressure, hearing, visual acuity, neuromuscular function, and skin retraction. Above about 40 years of age the criteria show the greatest change. With a few criteria, changes in the older age group tend to level off or be less steep (accommodation, visual acuity, skin looseness, and cholesterol).

In Table 22 age and radiation dependence of these criteria are presented. The criteria are arranged in descending order of correlation with aging as shown by the correlation coefficients. For those criteria in which sex differences were apparent, the r values for the two sexes were averaged to determine the over-all correlation with aging. Though there were isolated significant differences between the exposed and unexposed age groups for some criteria, no meaningful pattern emerged. The table shows that the correlation with radiation effects, in comparing exposed and unexposed groups, is not significant at the 5% level for any of the criteria. The over-all 7% increase in aging effects in the exposed group is not significant (p = 0.27). In Figure 48 the composite weighted biological or physiologic age scores are plotted against chronological age (means per decade). Combined mean values for exposed and unexposed groups are also presented with standard errors of the means. The over-all correlation of the biological age scores with chronological age is very good. The biological "age curve" (Figure 48) shows that there is less change in the younger age groups than there is after about age 40. Mean values for exposed and unexposed are not significantly different.

Discussion of Aging Studies

Though the criteria presented in this report show changes which are definitely correlated with chronological age on a group basis, such correlation is much less accurate on an individual basis. These tests of aging are least useful in the younger age groups (20 to 40 years of age), since most of the criteria either are not present until later or if present show slight increase during this age period. Therefore, more sensitive tests are needed to show aging in these groups.

Effects of radiation on aging as measured by these parameters were not detected in this population. Perhaps the tests were not sensitive enough to detect such effects at the level of radiation exposure sustained. It is not known if any of the "aging parameters" ordinarily associated with senescence are necessarily associated with irradiation aging, since the latter is very poorly defined or understood. Even if they were, this would not necessarily mean that they are related to mortality, which is a more pertinent correlation. Such criteria as hair graving, arcus senilis, neuromuscular function, etc., would not seem to have any obvious relation to mortality. On the other hand, loss of vigor and organ disfunction could well predispose to the development of old age diseases which would enhance mortality. Increase in mortality and life shortening in the exposed Marshallese is difficult to assay in view of the small numbers of people involved and the slightly greater proportion of older people originally in the exposed group compared with the unexposed group.

One radiation effect which might be classified under aging is the inducement of malignant disease

ī

Į

3

I



Figure 36. Hair grayness.

ĩ

F

Figure 37. Arcus senilis (1964).



ī

ł

I



Figure 41. Systolic blood pressure.

14

10.5

DIOPTERS

7.0

3.5 -

0

204

-175

(mm)

PRESSURE

SYSTOLIC

47

-118

90

90

80

90



Figure 42. Vibratory sense in tibia, males.







Figure 43. Reaction time (light extinction test), males



Figure 45. Hand grip, males.



Figure 46. Potassium, males (1961 and 1965).



Figure 48. Biological age scores.



Figure 47. Cholesterol (1957).

at an earlier time than it would ordinarily be manifest. One aspect of this phenomenon may be related to rapidity of cell proliferation (generation cycle) in a particular tissue, i.e., with more rapidly proliferating cells of the bone marrow, leukemia occurs relatively soon after irradiation, while malignant lesions of the skin would not become manifest until later in this more slowly proliferating tissue. In the Marshallese the high incidence of adenomatoid goiter in the more rapidly proliferating thyroid glands of the children may possibly represent premature appearance of lesions which are known to occur later in life and thus in a sense represent an aging process. On the other hand, the fact that no tumors (except benign nevi) have been noted in the heavily irradiated skin of these people might indicate a longer induction period due to slower cell turnover of the skin.

In considering future aging studies in the Marshallese it is hoped that more sensitive tests of vigor and organ function suitable to the conditions of study may be used. However, it must be borne in mind that such subtle aging effects may not become detectable by ordinary clinical means

1

ļ

| - | |
|---|---|
| - | 1 |
| | 1 |
| | - |

| | Plat. ($\times 10^{-3}$ |) | | WBC $(\times 10^{-3})$ | | | | Neut. $(\times 10^{-3})$ | | | |
|----------------------|---------------------------------|--------------|-------------|------------------------|--------------|---------------|----------------|--------------------------|---------------|-------|--|
| - | 1965 | 1966 | | 965 | 196 | 56 | 1965 | 5 | 196 | 6 | |
| Rongelap exposed | 274± 75*(56)** | _ | 7.39± | 1.7 (56) | 6.82±1 | .8(55) | 3.69 ± 1.2 | (56) | 3.57 ± 1 | 4(54) | |
| Ailingnae exposed | 342 ± 95 (16) | | $7.12 \pm$ | 1.4 (16) | 6.24 ± 2 | .3(15) | 3.77 ± 1.5 | (16) | $3.30 \pm 1.$ | 9(15) | |
| Utirik exposed | | | _ | | 8.05 ± 2 | .3(99) | | | $4.45 \pm 1.$ | 8(98) | |
| Rongelap unexposed | $282 \pm 71(124)$ | _ | $7.34 \pm$ | 2.2(124) | — | | 3.86 ± 1.8 | (125) | _ | | |
| Rongelap children of | | | | | | | | | | | |
| exposed parent(s) | 416±130 (48) | _ | $10.17 \pm$ | 2.5 (48) | - | | 4.41 ± 2.0 | (48) | | | |
| Rongelap children of | | | | | | | | | | | |
| unexposed parents | 366± 96 (69) | - | $9.91 \pm$ | 2.6 (69) | | | 4.52 ± 1.9 | (69) | | | |
| | Lymph. (| Hct. (%) | | | (%) | | BC (×10 | -+) | | | |
| | 1965 | 19 | 966 | 19 | 65 | 1 | .966 | 1 | 965 | 1966 | |
| Rongelap exposed | 2.99 ± 0.8 (56) | 2.45± | 0.8(54) | 40.2 ± 4 | .8 (56) | <u>39</u> ± | =4.3(48) | 427± | :57 (50) | | |
| Ailingnae exposed | 2.73 ± 0.8 (16) | 2.31 ± 0 | 0.9(15) | 39.6±5. | 0 (16) | 39.7± | :4.6(15) | 438± | 53 (16) | | |
| Utirik exposed | <u> </u> | $3.00\pm$ | 1.0(98) | | . , | 41.3 ≓ | z7.0(88) | _ | - ` ` | _ | |
| Rongelap unexposed | $2.82 \pm 1.0(124)$ | - | . , | $40.5 \pm 5.$ | 0(124) | | | 443± | 53(111) | _ | |
| Rongelap children of | | | | | . , | | | | , , | | |
| exposed parent(s) | 4.78±1.9 (48) | | | 37.1 ± 3 | .5 (48) | _ | - | 44 i ± | 41 (44) | _ | |
| Rongelap children of | | | | | | | | | . , | | |
| unexposed parents | 4.55±1.5 (69) | | | 36.4 ± 2 | .4 (69) | | _ | 439± | 34 (64) | | |
| *Standard deviation. | <u></u> | | | **Num | ber of pe | ople in a | roup. | | | | |

Table 23

anal Blood Elements of Populations Under Study

until the organ or tissue shows advanced morbidity. It is hoped that longitudinal studies of aging criteria in Rongelap individuals and groups may be more rewarding as time goes by.

5

F

1

HEMATOLOGICAL STUDIES

Hematological data are summarized in tables and figures below, and the raw data on individuals are presented in the appendices. The more heavily exposed Rongelap group who received 175 rads are designated as "Rongelap exposed," the Rongelap people who received a smaller exposure of 69 rads as "Ailingnae exposed," and the larger unexposed comparison population of Rongelap as "unexposed." Because of the small number of people in the Ailingnae group, their data were not treated as fully as those for the Rongelap groups, and are briefly summarized in a separate paragraph. The Utirik data are summarized separately also. Because of certain differences noted in age and sex groups between the exposed and the unexposed, in addition to the comparisons of mean

levels for entire groups, comparisons are also made of age and sex groups. Ages 12 to 15, >15 to 40, and >40 years for each sex are compared.

The hematological data are summarized in Table 23 and in Figures 49 through 65. In Appendices 8, 9, and 10 are presented summaries of the mean blood counts of the exposed populations and of the various comparison populations since exposure in March 1954. In Appendices 11 and 12 are listed the individual blood counts for 1965 and 1966. In Appendix 13 basophil counts are presented. In 1966, hematological studies (excluding platelets) were done only on the exposed populations of Rongelap, Ailingnae, and Utirik.

Rongelap Population

Leukocytes. The mean leukocyte levels were slightly lower at 11 years than at 10 years post exposure in both exposed and unexposed Rongelap people. At 12 years the exposed (unexposed not done) showed slightly lower levels than in 1965 (see Appendix 8). There was no appreciable difference in the exposed and unexposed leukocyte



Figure 53. Lymphocyte counts of Rongelap exposed females plotted against age. Solid line represents mean level of unexposed female population, 1965.



ł

l

Figure 54. Lymphocyte counts of Rongelap exposed males plotted against age. Solid line represents mean level of unexposed male population, 1965.



Figure 55. Cumulative percent distribution curves for neutrophils, lymphocytes, and platelets, 1965.



Figure 56. Mean platelet values of Rongelap exposed people from time of exposure through 11 years post exposure. Stars represent mean values of unexposed comparison population.



Figure 57. Platelet counts of Rongelap exposed females plotted against age. Solid line represents mean level of unexposed female population, 1965.



Figure 58. Platelet counts of Rongelap exposed males plotted against age. Solid line represents mean level of unexposed male population, 1965.

very different from those of the 11-year survey, and no untoward changes are apparent.

Ailingnae Population

The mean blood counts in the 14 Ailingnae people at 11 years were about the same as in the unexposed comparison population, except that platelet levels were higher. At 12 years the counts



Figure 59. RBC values of Rongelap exposed females plotted against age. Solid line represents mean level of unexposed female population, 1965.



Figure 60. RBC values of Rongelap exposed males plotted against age. Solid line represents mean level of unexposed male population, 1965.

in this group were similar to those in the exposed Rongelap group. Appendix 9 summarizes the Ailingnae counts since 1954.

Utirik Population

The Utirik population, examined in 1966, had mean leukocyte counts and differential counts not very different from those of 3 years previously. No



Figure 61. Hemoglobin values of Rongelap exposed females plotted against age. Solid line represents mean level of unexposed female population, 1965.



Figure 62. Hemoglobin values of Rongelap exposed males plotted against age. Solid line represents mean level of unexposed male population, 1965.

platelet counts were done. The hematocrit levels were slightly increased over levels of 3 years ago, possibly indicating a better state of nutrition. None of the mean counts were very different from those of the unexposed comparison population (1965 counts) except for leukocytes, which were somewhat higher in the Utirik people. Appendix 10 shows levels of blood elements at various times since exposure.



1.4

F

3

E

E

Figure 63. Hematocrit values of Rongelap exposed females plotted against age. Solid line represents mean level of unexposed female population, 1965.



Figure 64. Hematocrit values of Rongelap exposed males plotted against age. Solid line represents mean level of unexposed male population, 1965.

Children of Exposed Parents

Children of exposed parents born since the fallout showed levels of peripheral blood elements about the same as those of children of unexposed parents of the same age range.

Leukemia Survey

No evidence of preleukemia or leukemic state was detected in any of the people examined, either from the blood picture or from physical examination. Counts of 4000 white cells for percent basophils revealed no abnormally high levels (see Appendix 13). Subject No. 3, a 13-year-old boy, continues to show about twice the number of basophils (1.13%) noted in other Rongelapese. He has developed marked hypothyroidism during the past 2 years but shows no evidence of incipient leukemia.

Statistical Analysis of Rongelap Blood Data

In the last report¹⁰ a factorial analysis of variance of Rongelap blood data over the previous 4 years indicated that the slight depression of blood elements (leukocytes and platelets) of the exposed population over this period was highly significant. However, a similar analysis of the 1965 hematological data shows that at this time there was no significant difference (at the 5% level) of platelets, leukocytes, neutrophils, or lymphocytes between the exposed and unexposed Rongelap population.* This was also true for the Ailingnae population. The significantly greater platelet level in this group is unexplained. There was evidence that the leukocyte and platelet levels of the youngest age group in all populations were higher than in adults. No sex differences could be demonstrated in any of the 1965 data. The percent difference in blood levels between exposed and unexposed groups is presented in Table 24 and Figure 65. It can be seen that at 11 years there is no substantial difference between the groups.

CHROMOSOME STUDIES

Since chromosome aberrations have been demonstrated in cultured blood cells from various groups of people exposed to radiation, even years after exposure, it was of interest to see whether any such aberrations were present in the people of

^{*}We are grateful to Mr. Keith Thompson of Brookhaven National Laboratory for the statistical analysis of these data.

very different from those of the 11-year survey, and no untoward changes are apparent.

Ailingnae Population

The mean blood counts in the 14 Ailingnae people at 11 years were about the same as in the unexposed comparison population, except that platelet levels were higher. At 12 years the counts



Figure 59. RBC values of Rongelap exposed females plotted against age. Solid line represents mean level of unexposed female population, 1965.



Figure 60. RBC values of Rongelap exposed males plotted against age. Solid line represents mean level of unexposed male population, 1965.

in this group were similar to those in the exposed Rongelap group. Appendix 9 summarizes the Ailingnae counts since 1954.

Utirik Population

The Utirik population, examined in 1966, had mean leukocyte counts and differential counts not very different from those of 3 years previously. No



Figure 61. Hemoglobin values of Rongelap exposed females plotted against age. Solid line represents mean level of unexposed female population, 1965.



Figure 62. Hemoglobin values of Rongelap exposed males plotted against age. Solid line represents mean level of unexposed male population, 1965.

54

Rongelap as a result of their fallout radiation exposure. Attempts at 8 and 9 years post exposure to obtain suitable blood cultures had not been entirely successful. However, during the 10-year survey a slight modification of the Moorehead technique⁷³ resulted in a series of satisfactory cultures on 51 people: 30 in the higher exposure group (175 rads), 13 in the lower exposure group (69 rads) and 8 from the unexposed Rongelapese who were on another island at the time of the accident. The detailed results of these studies are presented in Appendix 14.*

Table 25 summarizes the results. A higher incidence of an euploid cells was noted in the exposed group, but the difference was not great enough to be significant. Unexpectedly, the lower exposure group showed more aberrations than did the more heavily exposed group, and the latter group showed even less aberrations than the unexposed. However, the incidence of 2-hit aberrations was significantly higher (p < 0.004) in the exposed groups and did appear to be radiation induced. Figure 66 shows a dicentric and a ring form noted in chromosome spreads from two exposed individuals.

1

1

OTHER LABORATORY STUDIES

Total Blood Volume and Red Cell Volume

Previous studies (1961, 1962) with ⁵¹Cr-labeled erythrocytes on Marshallese subjects living in their native environment have shown reduced red cell mass and/or total blood volume with total body weight used as a base line. During the 1963 survey, similar studies were performed on 21 Marshall Islanders, but these data were related to total body water as determined by tritiated water.¹⁰ Results showed that in all instances but one the values for red cell mass and total blood volume fell below normal levels for persons living in temperate zones of the United States.

The present study was undertaken during the surveys in 1965 and 1966. A total of 19 Caucasian Americans (3 females and 16 males) living in the Marshall Islands for periods of 3 months to 9 years were examined by the same techniques.* The results of these studies on each individual are presented in Appendix 15, along with data on the 21 Marshallese in whom these studies were carried out in 1963. The data were programmed and analyzed by a high speed digital computer. Regression lines obtained for the Caucasians and the Marshallese are presented in Figure 67 along with regression lines of Moore⁷⁶ and Siri⁷⁷ for Americans.

The Marshallese regression lines for both blood volume and red cell colume have very nearly the same slopes as the lines of the Siri and Moore groups, but they are significantly below the latter (significant at the 1% level). The Caucasians living in the Marshall Islands also show regression lines for blood volume and red blood cell volume with slopes similar to those of the Marshallese and the Siri and Moore groups. Comparison of the regression lines shows no significant difference between

*We are grateful to Dr. W.E. Siri, University of California, for carrying out the tritium-water analyses.

| 1 | labl | e 25 | |
|---|------|------|--|
| | | | |

| 0 | 2 (1) | T 1 1 1 |
|---------|--------------|----------------|
| | | |
| Junnary | or cantomoso | me rinainys |
| | | |
| | | |

| Group | | | Dercent | No. of persons with aber- rations | Chromosome aberrations | | | | | Total | | |
|---------------------|-------------------|---------------------------|-------------------------------|---|------------------------|-----------------|-------|----------------|---------------------------|--------------------------|--------------------------|---------------------------|
| | No. of persons | No. of cells scored | of cells with $2n \neq 46$ | | Frag- ments | Dicen- trics | Rings | Ex- changes | Total aber- rations | with aber- rations | Chro- matid breaks | Iso- chromatid gaps |
| Exposed 175 rads | 30 | 1500 | 10 | 12 (40%) | 11 | 6 | - | 5 | 22 (1.46%) | 20 (1.33%) | 43 | 15 |
| Exposed 69 rads | 13 | 650 | 8 | 11 (84.6%) | 10 | 2 | 1 | 8 | 21 (3.23%) | 18 (2.77%) | 31 | 4 |
| Unexposed | 8 | 400 | 5.5 | 5 (62.5%) | 9 | - | - | - | 9 (2.25%) | 8 (2.0%) | 6 | 5 |

^{*}We are grateful to Dr. Shields Warren and his group at the Cancer Research Institute in Boston for carrying out the chromosome analyses.

Table 24

| | Plats. | Leuks. | Neuts. | Lymphs. |
|-----------|------------------|----------------------|---------------------|------------------|
| Rongelap | | | | |
| 1959* | - 5.9 | - 5.5 | - 8.2 | - 0.5 |
| 1961 | -14.9(p < 0.01) | - 5.9 | - 6.0 | - 5.5 |
| 1962 | -8.0(p<0.1) | -11.1 (p < 0.01) | -13.6(p < 0.05) | -13.0 (p<0.01) |
| 1963 | -16.0 (p < 0.01) | - 3.5 | - 4.4 | - 3.9 |
| 1964 | - 4.9 | -10.5(p < 0.05) | -23.5(p < 0.01) | - 1.1 |
| 1965 | + 0.1 | + 1.4 | - 5.1 | + 5.7 |
| Ailingnae | | | | |
| 1959 | - 4.4 | - 4.8 | - 6.3 | - 8.4 |
| 1961 | -12.6 (p < 0.1) | - | -13.6 | + 8.1 |
| 1962 | - 6.5 | -15.1 (p < 0.05) | -17.7 (p < 0.1) | -11.0 |
| 1963 | -23.4 (p < 0.01) | - 6.7 | + 3.9 | -20.8 (p < 0.01) |
| 1964 | + 4.8 | $-22.1 \ (p < 0.02)$ | $-26.4 \ (p < 0.1)$ | -11.1 |
| 1965 | +24.8 (p < 0.01) | - 2.7 | - 2.6 | - 3.6 |
| Utirik | | | | |
| 1963 | +22.7 (p < 0.01) | | + 2.0 | - 3.2 |

*Earlier data will be analyzed in the near future. -



Figure 65. Depression of blood elements in Rongelap exposed people compared with average counts of unexposed people.

Figure 66. Two-hit chromosome aberrations in exposed Marshallese. Top: arrow points to dicentric form; bottom; arrow points to ring form.



ľ



Figure 68. Shadow-shield whole-body counter (gamma spectroscopy) in new trailer, with Marshallese subject being counted.

computer. In this program a library of spectra obtained by calibrations with the plastic phantom is used, but the gamma energy peaks extracted are not limited to those represented in the library. The program used was developed at Los Alamos⁸⁰ for an IBM-704 computer, and has been modified for use on the IBM-7094 and the CDC-6600 computers. Its use in the determination of body burdens of radionuclides has been described by Cohn and Gusmano.⁸¹

As in the previous surveys, both the population exposed to fallout in March 1954 and the unexposed population currently living on Rongelap were counted. An effort was made to count every resident. In addition, some Rongelapese currently living on another atoll, Ebeye, were brought back to Rongelap and included in the survey. Members of the AEC and Trust Territory medical teams were also counted. A total of 179 people were counted in the 1965 survey.

Radiochemical Analysis of Urine

In addition to the whole-body counts, information pertinent to the internal body burdens was obtained by radiochemical analysis of urine specimens for ⁹⁰Sr and ¹³⁷Cs, carried out by the Environment Studies Division, Health and Safety Laboratory, AEC, New York.* Twenty-four-hour urine specimens were collected from 23 residents of Rongelap Island and 5 residents of Ebeye Island. In addition, two pooled urine samples were obtained on Rongelap. The urines were analyzed first for ¹³⁷Cs by gamma-ray spectroscopy by counting the wet ashed sample on top of an 8×4-in. NaI (Tl) crystal. Then the residues were dissolved and analyzed radiochemically for ¹³⁷Cs and ⁹⁰Sr. Calcium was determined by the oxalatepermanganate titration method.

^{*}We are grateful to Mr. Edward P. Hardy for carrying out these analyses.

the blood volumes and the red cell volumes of the Caucasians living in the Islands and the Caucasians of the Siri and Moore groups; furthermore, duration of residency in the Islands has no significant effect. Earlier data had suggested that Caucasians living in the Marshall Islands might have reduced blood volumes and red blood cell volumes. Though this may be true for certain individuals, it does not seem to hold true for the group as a whole.

Test for Australia Antigen

The Australia antigen, a serum protein first detected in the serum of the Australian aborigines, was searched for in the Rongelap population.* Details of these studies are presented in Appendix 16. Samples of sera from 250 Rongelap people were examined between 1958 and 1965. Of these, 237 were consistently negative, 11 were consistently positive (4.4%), and 2 were inconsistent. Family studies indicated that positive subjects were homozygous for the genes. This antigen has been found to be relatively common in some forms of leukemia.

*These studies were carried out by Dr. B.S. Blumberg, Institute for Cancer Research, Philadelphia, Pa.



Figure 67.

Since the Rongelap people will be medically examined for many years, it will be interesting to see whether the presence of this antigen is related substantially to disease, particularly leukemia.

ESTIMATION OF INTERNAL BODY BURDENS OF RADIONUCLIDES

In the 1965 survey, the body burdens of radionuclides were determined by use of a portable shadow-shield type of whole-body counter and by radiochemical analysis of 24-hr urine specimens.

Whole-Body Counting

The use of the shadow-shield type of wholebody counter represents a departure from previous surveys, in which a 21-ton steel room had been transported to Rongelap and used for this purpose. Correlations between the two techniques were established by standardizations using the permanent steel room and a duplicate of the shadow shield at Brookhaven National Laboratory. The body ¹⁰K values of the Rongelapese provide another means of correlation.

The shadow-shield counter (Figure 68) is very similar to the one described by Palmer and Roesch⁷⁸ and to the Hanford whole-body counter.79 It was installed on Rongelap in one of the newly acquired air-conditioned trailers. The detector, an 11^{1/2}-in.-diameter NaI (Tl) crystal 4 in. thick (Harshaw), is housed in a lead shielding supported by a steel plate about 14 in. above the bed. The subject to be counted lies on a foam rubber cushion in the trough between the two walls of lead bricks, and is moved to a position under the detector by a motor-driven worm-screw drive. The system was calibrated with a plastic phantom man, both in a stationary position beneath the counter and with movement equivalent to the length of the body during the count.

The signal from the detector was picked up by 7 photomultiplier tubes mounted on the crystal, and the gamma-ray spectrum was analyzed with a 400-channel pulse-height analyzer (RIDL). The gamma-ray spectral data were read out on rolls of adding-machine paper for immediate evaluation, and on punched paper tape for subsequent data processing which involved transfer of the data from the punched paper tape to magnetic tape and subsequent analysis in terms of radioisotopes by a spectral stripping program on an IBM-7094

I

Table 27

| Marshall Island | Radiochemical | Urine Analysis, 1965 |
|-----------------|---------------|----------------------|
|-----------------|---------------|----------------------|

| Subject No.* | Age | Sex | Volume, ml | g Ca/liter | pCi ⁹⁰ Sr/liter | nCi ¹³⁷ Cs/liter |
|--------------|-----|------|------------|------------|--|-----------------------------|
| | - | | Rongelap | Island | ······································ | |
| Po | bol | М | 5130 | 0.088 | 3.6 | 3.5 |
| Po | bol | F | 6080 | 0.058 | 9.6 | 2.1 |
| | | Mean | 5605 | 0.073 | 6.6 | 2.8 |
| 8 | 13 | F | 730 | 0.018 | 8.1 | 5.0 |
| 15 | 18 | F | 730 | 0.008 | 3.2 | 6.2 |
| 51 | 36 | F | 289 | 0.126 | 28.0 | 23.0 |
| 53 | 19 | F | 650 | 0.100 | 10.0 | 4.4 |
| 58 | 70 | F | 710 | 0.104 | 7.9 | 3.4 |
| 59 | 45 | F | 645 | 0.043 | 3.1 | 1.2 |
| 11 | 61 | M | 940 | 0.010 | 1.0 | 2.1 |
| 20 | 18 | М | 500 | 0.096 | 16.0 | 6.0 |
| 27 | 37 | М | 1320 | 0.103 | 5.8 | 5.1 |
| 40 | 40 | M | 560 | 0.192 | 11.0 | 4.7 |
| 41 | 55 | М | 890 | 0.084 | 6.2 | 2.2 |
| 50 | 45 | М | 1800 | 0.062 | 3.6 | 0.6 |
| 73 | 29 | M | • 650 | 0.243 | 12.0 | 19.0 |
| 835 | 31 | F | 550 | 0.041 | 3.5 | 5.2 |
| 843 | 36 | F | 1340 | 0.087 | 5.3 | 1.5 |
| 928 | 52 | F | 1040 | 0.078 | 7.6 | 6.5 |
| 932 | 30 | F | 350 | 0.134 | 24.0 | 9.7 |
| 942 | 50 | F | 540 | 0.238 | 28.0 | 18.0 |
| 822 | 18 | М | 835 | 0.003 | 4.5 | 4.5 |
| 833 - | 32 | М | 1000 | 0.143 | 10.8 | 5.1 |
| 840 | 35 | М | 800 | 0.037 | 6.4 | 6.0 |
| 853 | 60 | М | 1750 | 0.032 | 4.4 | 2.0 |
| 855 | 60 | Μ | 500 | 0.152 | 23.0 | 3.6 |
| | | Mean | 831 | 0.093 | 10.1 | 6.3 |
| | | | Ebeye Is | land | | |
| 12 | 29 | F | 980 | 0.057 | 28 | 07 |
| 45 | 43 | F | 600 | 0.081 | 2.0 | 0.2 |
| 84 | 10 | M | 719 | 0 137 | 4.6 | 0.3 |
| 895 | 35 | F | 860 | 0.194 | 3.3 | 0.1 |
| 920 | 33 | M | 900 | 0.075 | 1.2 | 0.1 |
| | | Mean | 812 | 0.109 | 2.8 | 0.3 |

*Subjects with numbers <84 are members of the exposed population; those with numbers >84, of the unexposed population.

Results and Discussion of Body Burden Estimation

1

ĩ

F

]

Į

Figure 69 shows some representative wholebody gamma-ray spectrographs obtained in the 1965 survey. The AEC team is seen to have a spectrum not markedly different from the background spectrum except for the natural ⁴⁰K peak and a trace of ¹³⁷Cs, whereas the Rongelapese have significantly higher ¹³⁷Cs peaks. Analysis of the curves indicates that the ⁶⁰Co values are also detectable in many of the Rongelapese. As had been anticipated on the basis of its relatively short physical half-time, the ⁶⁵Zn seen in previous surveys had disappeared by 1965.

Table 26 summarizes the whole-body counting results, and the individual values are presented in Appendix 17. The results of the urine radiochemical analyses are displayed in Table 27. Inspection



Figure 69. Unprocessed gamma-ray spectrographs obtained with an 11½-in. NaI (Tl) crystal in a shadowshield whole-body counter. The channel width was 20 keV. Traces of ¹³⁷Cs and ⁶⁰Co are apparent in the background spectrum. The right-hand scale was obtained by calibration with a "standard man" phantom and requires correction for other body sizes; it is adjusted for the ¹³⁷Cs peak.



Figure 70. Estimated body burden of isotopes in Rongelap people at various times since 1954. Values obtained either by gamma spectroscopy or by radiochemical analysis of urine.

| | People residing on Rongelap Atoll | | | | | | | _ | |
|------------------------------------|-----------------------------------|-----------------|-----------------|-----------------|-----------|-----------------|----------|-----------------|------|
| | Male | | Female | | | Rongelapese | US AEC | Trust | |
| | Age <11 | Age 11-15 | Age >15 | Age <11 | Age 11-15 | Age >15 | at Ebeye | team | team |
| Cs (nCi/kg body wt.) | | | | | | | | | |
| Exposed | | 14.0 | 17.1 ± 5.3 | | 16.3 | 11.6 ± 5.0 | | | |
| Unexposed | 20.4 ± 7.2 | 19.9 ±4.3* | 14.7 ± 4.9 | 15.2 ± 5.4 | 15.9 | 11.0 ± 3.8 | | | |
| Mean | 20.4 | 18.1 | 15.5 | 15.2 | 16.1 | 11.2 | 0.89 | 0.16 ± 0.11 | 045 |
| ⁵⁰ Co (pCi/kg body wt.) | | | | | | | | | |
| Exposed | | 26.5 | 40.7 ± 11.5 | | 28.7 | 40.0 ± 31.3 | | | |
| Unexposed | 30.7 ± 17.6 | 31.5 ± 7.3 | 37.6 ± 13.8 | 27.0 ± 15.6 | 28.9 | 31.2 ± 11.2 | | | |
| Mean | 30.7 | 29.9 | 38.6 | 27.0 | 28.8 | 34.7 | 42.6 | 0.0 | 00 |
| Potassium (g/kg body wi | t.) | | | | | | | | |
| Exposed | , | 2.19 | 1.97 ± 0.24 | | 1.92 | 1.52 ± 0.39 | | | |
| Unexposed | 2.42 ± 0.42 | 2.09 ± 0.20 | 1.88 ± 0.32 | 2.42 ± 0.44 | 1.81 | 1.45 ± 0.22 | | | |
| Mean | 2.42 | 2.12 | 1.91 | 2.42 | 1.86 | 1.48 | 1.68 | 1.50 ± 0.18 | 1.61 |
| Number of people | | | | | | | | | |
| Exposed | | 5 | 15 | | 6 | 18 | 5 | | |
| Unexposed | 21 | 11 | 30 | 21 | 7 | 27 | 2 | | |
| Total | 21 | 16 | 45 | 21 | 13 | 45 | 7 | 9 | 2 |

| Table 26 |
|--|
| Summary of Radionuclide Body Burdens of Rongelap People, 1965, Obtained by Whole-Body Counting |

1

from its bremsstrahlung spectrum, but in practice the complications caused by the presence of gamma-ray emitters and by the size of the human body render this method infeasible.)

ī

1

Comparison of the excretion rates of ⁹⁰Sr and ¹³⁷Cs with the body burdens of ¹³⁷Cs measured by whole-body counting provides a clue to the ⁹⁰Sr body burden status. A quantitative value cannot be deduced, however, because the factors relating the behavior of the two nuclides are not sufficiently well established. The study by Hardy, Rivera, and Conard⁸⁴ summarized in Appendix 18 is pertinent to this problem. ¹³⁷Cs and ⁹⁰Sr retentions were followed for 190 days after ingestion of representative Rongelap food items by one of the investigators. The 137Cs ingested was almost quantitatively absorbed from the gastrointestinal tract, but 50% of the ⁹⁰Sr was excreted via the feces in the first 10 days and may be regarded as not having been absorbed. By the end of the study almost all of the ¹³⁷Cs and about 75% of the ⁹⁰Sr had been excreted in the urine and feces. The exact figure for retention is dependent on the correction used for activities ingested in the normal diet, and these were not measured. In this study the biological halftime for 137Cs was estimated as 74 days. For both ¹³⁷Cs and ⁹⁰Sr the urinary excretion rates were markedly elevated during the ingestion period and for a few days afterward. This confirms other results to the effect that the excretion rates found are strongly affected by the recent diet and, when there has been a recent intake of high activity food, the excretion rates do not provide accurate indices of the body burdens.

Comparison of ¹³⁷Cs Levels in Marshallese and Alaskan Eskimos

It is of interest to compare the ¹³⁷Cs body burden findings in the Rongelapese with those reported for certain Alaskan Eskimos. The findings in the Eskimo population in August 1965 are shown in Table 29.⁸⁵ It may be noted that the results for adult Eskimos are equal, within statistical limits, to those for the adult male Rongelapese. For the Eskimo population the 1965 data run about 30% lower than the comparable 1964 data, and this trend parallels the findings in the local caribou, one of the principal components of their diet.⁸⁵ The *Federal Radiation Council Radiation Protection Guides*⁸⁶ is cited as recommending a limit of 3000 nCi ¹³⁷Cs in individual adults for this population,

| 29 | ie | Ы | a | Γ |
|----|----|----|---|---|
| 29 | e | Di | а | ł |

Cesium-137 Body Burdens for Residents of Anaktuvuk Pass, Alaska⁸⁵

| Age, yr | No. persons | Body burden, nCi | nCi per kg body wt. |
|---------|-------------|---------------------|------------------------|
| >21 | 23 | 920±58 | 15.7 ± 1.0 |
| 15-20 | 5 | 490 ± 42 | 9.5 ± 1.0 |
| 3-14 | 22 | 170 ± 17 | 6.2 ± 0.3 |
| >21* | 16 | 900 ± 60 | 16.0 ± 1.3 |

""Controls" - members of a group who were first counted in 1963 and are re-examined periodically.

and opinions are expressed to the effect that the current body burdens do not constitute a radiological health hazard.⁸⁵ These opinions are consistent with those that have governed the policies applicable to the Rongelapese.

Radiochemical Analysis of Coconut Crabs

A food item that has been of special interest throughout the Rongelap medical surveys is the coconut crab (*Birgus latro*). Because of its high ⁹⁰Sr content, it has been banned as a food. The following concentrations of ⁹⁰Sr and ¹³⁷Cs were found in a crab taken from Rongelap Island in 1965 (radiochemical analysis by the Health and Safety Laboratory): ⁹⁰Sr, 66,600 pCi/kg original matter; ¹³⁷Cs, 12,700 pCi/kg original matter; stable Ca, 92.1 g/kg original matter.

Previous analyses of crabs taken from Rongelap Island have been reported in the 7, 8, and 9-10 year reports.⁸⁻¹⁰ For ⁹⁰Sr the results have run: at 7 years 1140 pCi ⁹⁰Sr/g Ca; 8 years 1317, 1086, 1113, and 1378 pCi ⁹⁰Sr/g Ca; and 9-10 years 865, 628, and 780 pCi ⁹⁰Sr/g Ca, and 39,292, 45,318, and 66,234 pCi ¹³⁷Cs/kg. The 1965 results for ⁹⁰Sr are slightly below the average for the previous survey and for ¹³⁷Cs are reduced to about ¹/₄ the previous results. All these results are markedly lower than those that have been obtained with crabs from the more heavily contaminated islets of Eniatok and Kabelle (Figure 71).

The crab data may be compared with the data on Rongelap subject No. 73, who had the highest ¹³⁷Cs body burden (25,400 pCi/kg) and was excreting activity in concentrations of 78,000 pCi ¹³⁷Cs/g Ca and 50 pCi ⁹⁰Sr/g Ca. It seems clear from this that because of its relatively high ⁹⁰Sr content the

 Δ

1

ĩ

ł

9

I

of Table 26 shows that the body burdens of ¹³⁷Cs and ⁶⁰Co are not significantly different among the various subdivisions by age and sex of the Rongelap resident population. The values given for the children may be overestimates, because the calibrations were in terms of an adult-size phantom only and the counting geometry is such that a higher efficiency obtains for the children, especially the smaller ones.

Prior to 1962, the concentration of ⁹⁰Sr in the urine was used as a basis for estimating ⁹⁰Sr body burdens. Subsequently, the ratio of ⁹⁰Sr to Ca in the urine has been used. On this basis the 1965 mean concentrations of 10.1 pCi ⁹⁰Sr/liter and 0.093 g Ca/liter correspond to a body burden of 11.4 nCi. Data were not obtained on children in 1965. In previous years the urinary ⁹⁰Sr to Ca ratios in children have been about twice that for adults. Urines for ⁹⁰Sr analysis were not collected in 1966.

Comparison of the 1965 survey data with the results from previous surveys (Figure 70) shows that the mean levels of ¹³⁷Cs and ⁹⁰Sr have remained nearly constant since 1961, and that ¹³⁷Cs is at about the 1958 level. Further comparison with the 1954 and 1957 results indicates that the activities now being seen are almost entirely due to intake subsequent to the return of the Rongelap population to their home atoll in 1958.

If the ecological cycle were in equilibrium, it would be expected that, by virtue of physical decay, the specific activities of ¹³⁷Cs and ⁹⁰Sr in the food and the corresponding body burdens of these radionuclides would have decreased about 9% during the interim 1961 to 1965. Actually there may have been a small decrease that is masked by the unknown overestimation error in the children. Even with a correction for this, the sustained levels suggest that increasing amounts of the originally contaminated materials are getting into the food chain and thus maintaining the specific activity at the previous levels. This hypothesis is supported by data obtained from E. Held, University of Washington,⁸² to the effect that soil and plant surveys indicate that the ¹³⁷Cs levels in plants have remained about the same since 1961. There is no ready explanation of the mechanism for this. These findings are to be contrasted with those cited below for an Eskimo population.

Table 28 shows the relationship between ¹³⁷Cs body burden and its excretion rate for those resi-

| Fable | 28 |
|--------------|----|
|--------------|----|

Comparison of Body Burdens and Excretion Rates

| Subject No. | body burden, nCi | ¹³⁷ Cs, nCi/ liter | Urine volume, l | ¹³⁷ Cs, nCi/ day | Fraction/ day |
|----------------|------------------------|-------------------------------------|--------------------|-----------------------------------|------------------|
| 8 | 508.9 | 5.0 | 0.730 | 3.65 | 0.00717 |
| 15 | 405.6 | 6.2 | 0.730 | 4.526 | 0.01115 |
| 51 | 484 .8 | 23.0 | 0.289 | 6.647 | 0.01343 |
| 53 | 971.2 | 4.4 | 0.650 | 2.86 | 0.00294 |
| 58 | 575.0 | 3.4 | 0.710 | 2.414 | 0.00419 |
| 59 | 732.7 | 1.2 | 0.645 | 0.774 | 0.00105 |
| 11 | 525.5 | 2.1 | 0.940 | 1.974 | 0.00375 |
| 20 | 773.9 | 6.0 | 0.500 | 3.000 | 0.00387 |
| 27 | 1326.0 | 5.1 | 1.320 | 6.732 | 0.00507 |
| 40 | 1047.0 | 4.7 | 0.560 | 2.63 | 0.00251 |
| 41 | 1209.0 | 2.2 | 0.890 | 1.958 | 0.00161 |
| 50 | 728.9 | 0.6 | 1.800 | 1.08 | 0.00148 |
| 73 | 1861.0 | 19.0 | 0.650 | 12.35 | 0.00663 |
| 835 | 644.8 | 5.2 | 0.550 | 2.86 | 0.00443 |
| 843 | 419.8 | 1.5 | 1.340 | 2.01 | 0.00478 |
| 928 | 491.4 | 6.5 | 1.040 | 6.76 | 0.01375 |
| 932 | 549.6 | 9.7 | 0.350 | 3.395 | 0.00617 |
| 942 | 1058.0 | 18.0 | 0.540 | 9.72 | 0.00918 |
| 822 | 694.6 | 4.5 | 0.835 | 3.758 | 0.00540 |
| 833 | 636.9 | 5.1 | 1.000 | 5.10 | 0.00800 |
| 840 | 1455.0 | 6.0 | 0.800 | 4.80 | 0.00329 |
| 853 | 814.9 | 2.0 | 1.750 | 3.50 | 0.00429 |
| 855 | 606.2 | 3.6 | 0.500 | 1.80 | 0.00296 |
| | | | | Mean | 0.00553 |

dents of Rongelap for whom individual urine specimens were analyzed. An average of 0.553% of the body burden is excreted per day, the range being 0.105% to 1.375%. These values correspond to turnover half-times of 120 days, 660 days, and 50 days, respectively. Except for some of the very slow turnover rates, these values fall within the ranges cited or reported for other populations, in which the means were 75, 74, 87, 115, and 135 days.83 Some of the lowest turnover rates in the Rongelap population may be ascribed to uncertainties in the completeness of the urine collections. Thus it is to be expected that the ¹³⁷Cs value would fall to near-zero levels in a year of living in a noncontaminated environment. That this fall does occur is shown by the results with the Ebeye population, who have been absent from Rongelap for various times from 1 to 18 months.

Because it is not a gamma-ray emitter, ⁹⁰Sr is not detected by the whole-body counting method. (Theoretically it might be possible to estimate ⁹⁰Sr

.

hypothyroidism in the two most growth-retarded boys with subsequent growth response to thyroid hormone treatment. Thyroid function tests in cases with thyroid abnormalities also indicated reduced thyroid function in some other children. Preliminary indications are that thyroid hormone treatment instituted in the exposed population in September 1965 is having a beneficial effect in reducing thyroid nodules and stimulating growth of children. The importance of these thyroid developments in the Marshallese is discussed.

OTHER STUDIES

Hematological studies show that the leukocyte and platelet levels of the peripheral blood of the exposed Rongelap people seem to have recovered to levels equal to those of the unexposed population. The blood levels of the Utirik population showed no obvious abnormalities and were similar to those previously noted.

Chromosome studies of white cells of 51 peripheral blood cultures showed a low incidence of 2-hit aberrations in the exposed people which was quite significant in view of the absence of any such aberrations in the comparison population.

T

ł

1

I

Blood volume and red blood cell volume studies showed that people of Rongelap have significantly reduced levels as compared with Americans. Caucasians living in the Marshall Islands did not generally show this phenomenon.

Aging studies have been repeated with the addition of several new parameters (vibratory sense, light extinction test, body potassium levels, and blood serum cholesterol) and with more refined statistical analysis. Curves of response for each aging parameter and an over-all biological age score curve are presented. No significant increase in aging effects in the exposed population compared with the unexposed population could be detected. The over-all correlation of the biological age scores with chronological age was good. It was concluded that the tests employed may not have been sensitive enough to detect subtle effects of aging at this exposure level.

ESTIMATION OF INTERNAL BODY BURDENS OF RADIONUCLIDES

In the 1965 survey whole-body counting was done on 179 people with an 11¹/₂-in.-diameter NaI (Tl) crystal in a portable shadow-shield type of counter. The Rongelap residents exposed in 1954 and the unexposed residents were indistinguishable by this method, both groups showing elevated ¹³⁷Cs body burdens of 10 to 20 nCi/kg body weight, or slightly less than 1 μ Ci total body burden and about ¹/1000 this much for ⁶⁰Co body burdens. These levels are about the same as or slightly lower than those reported previously for the 1961 survey. Urine specimens were also analyzed radiochemically for ⁹⁰Sr and ¹³⁷Cs. The ⁹⁰Sr levels remain nearly the same as those found in 1961. In a comparison of the ¹³⁷Cs excretion rate with the body burdens, a mean fractional excretion rate of 0.00553/day was found.

Acknowledgments

The cooperation of many agencies and persons was necessary to carry out these surveys successfully. The authors are deeply grateful for valuable assistance to many individuals too numerous to name. We are particularly grateful to the people of Rongelap and Utirik Atolls for their cooperation in these examinations.

Many officials of the Atomic Energy Commission, particularly Dr. Charles L. Dunham and Dr H.D. Bruner and their staff of the Division of Biology and Medicine, and Mr. W.A. Bonnet and Mr. Neil Rassmussen of the Honolulu Operations Office, were most helpful in coordination of arrangements and in supporting the surveys in every wav possible.

We are grateful to the officials of the Department of the Interior, particularly Mrs. Ruth Van Cleeve and the officials of the Trust Territory of the Pacific Islands, including High Commissioners Mr. W.M. Goding and Mr. W.R. Noorwood; the Acting Director of Medical Services. Dr. L.A. Howe; the District Administrator for the Marshall Islands, Mr. Dwight Heine, and his Assistant, Mr. Danny Akimoto; the Director of the Majuro Hospital, Dr. John Iaman, and members of his staff; the Trust Territory Representative at Kwajalein, Mr. R. McKay, and Dr. Ezra Riklon at the Ebeye Hospital; all were most helpful.

The Pacific Missile Range Facility at Kwajalein was of great assistance in furnishing necessary airlifts and materials. Mr. Frank Granich and others
Í

I

use of crab meat as a food item should continue to be avoided. Other foods, however, are responsible for the ¹³⁷Cs levels found.

Summary

Medical surveys were carried out on the exposed people of Rongelap Island in March 1965 and March 1966. In 1965 the comparison population was also examined, and in 1966 the exposed population of Utirik Island was examined.

INTERVAL MEDICAL HISTORY

Juring the past 2 years the Rongelap people have been generally in good health with satisfactory nutritional status. No unusual epidemics of disease occurred. Over the 2-year period 2 deaths had occurred in the Ailingnae group (originally exposed to 69 rads). No autopsy was obtained, but the deaths occurred in older people with no obvious connection with radiation exposure. One death occurred in an older woman of the comparison population. The death rate has been higher in the exposed population than in the unexposed population, which may in part be related to the larger percentage of older people originally in the exposed group. Birth rate has been about equal in the exposed and unexposed groups. No miscarriages or stillbirths were noted in the exposed



Figure 71. Analyses for ⁹⁰Sr, ¹³⁷Cs, and ⁸⁰Co in coconut crabs of northern Rongelap Atoll since 1954. (Courtesy of E. Held, University of Washington.)

women during the past 2 years, but 5 miscarriages occurred in unexposed women. No abnormal babies were born in the exposed group, but two (hydrocephalic and mongoloid) were born to two unexposed women.

The people of Utirik Island appeared to have been in good health and reported few serious medical happenings over the past 3 years. The birth and death rates in this group appeared to be similar to those in the Rongelap group.

PHYSICAL FINDINGS

As noted in previous surveys, the variety and distribution of physical abnormalities (with the exception of thyroid pathology) did not appear to be significantly different in the exposed people as compared with the unexposed population. The trends toward growth retardation in the exposed children, previously noted, have continued. No leukemia or cancer (except one thyroid cancer) was detected.

THYROID FINDINGS

The dosimetric calculation for radiation dose to the thyroid from internal absorption of radioactive iodines from the fallout was reviewed. Early thyroid studies including protein-bound iodine determinations, iodoprotein levels, dietary iodine and urinary excretion of iodine, thyroid uptake of radioiodine, and serum cholesterol levels were reviewed.

Thyroid abnormalities during the past 3 years have increased to 18 cases, 16 with nodules and 2 with hypothyroidism. It is noteworthy that in the higher exposure group thyroid abnormalities occurred in 79% of the children exposed at <10years of age, as compared with no cases in the children of the Ailingnae, Utirik, or unexposed groups. Only one adult in the Ailingnae group developed a thyroid nodule. Several nodules were noted in the thyroid glands of older Utirik and unexposed adults of Rongelap. Surgery was performed in 11 cases: 9 children and 1 adult were found to have adenomatous goiters, and 1 adult a mixed papillary and follicular carcinoma of the thyroid gland with localized metastasis. The gross and microscopic appearance of these lesions was described and depicted. Correlation of growth retardation in exposed children with thyroid pathology was indicated by the recent finding of definite

- 26. COHN, S.H. ET AL., Internal deposition of radionuclides in human beings and animals, in AEC-TID 5358, Chap. 5 (see ref. 1).
- 27. JAMES, R.A. AND Ng, Y.C., UCRL 12273, December 1964 (reproduced in Appendix 2).
- RALL, J.E. AND CONARD, R.A., Elevation of serum protein-bound iodine level in inhabitants of Marshall Islands, Am. J. Med. 40, 883 (1966).
- 29. Foss, O.P., HANKES, L.V., AND VAN SLYKE, D.D., A study of the alkaline ashing method for determination of protein-bound iodine in serum, *Clin. Chim. Acta* 5, 301 (1960).
- 30. GOLTON, V.A. AND PITT-RIVERS, R.A., A quantitative method for the separation of thyroid hormones and related compounds from serum and tissues with an anion-exchange resin, *Biochem. J.* 72, 310 (1959).
- KYDD, D.M., MAN, E.B., AND PETERS, J.P., Concentration of precipitable iodine in the serum, J. Clin. Invest. 29, 1033 (1950).
- 32. MAN, E.B., KYDD, D.M., AND PETERS, J.P., Butanolextractable iodine of serum, J. Clin. Invest. 30, 531 (1951).
- RALL, J.E., The role of radioactive iodine in the diagnosis of thyroid disease, Am. J. Med. 20, 719 (1956).
- BERMAN, M., SHAHN, E., AND WEISS, M.F., Ardigital computer program for the analysis of kinetic data, Bwphys. J. 2, 275 (1962).
- STANBURY, J.B. ET AL., Endemic Goiter The Adaptation of Man to Iodine Deficiency, Harvard University Press, Cambridge, Mass., 1954.

Ē

3

- INGBAR, S.H. AND FREINKEL, N., Simultaneous estimation of rates of thyroxine degradation and thyroid hormone synthesis, J. Clin. Invest. 34, 808 (1955).
- 37. RIGGS, D.S., Quantitative aspects of iodine metabolism in man, *Pharmacol. Rev.* 4, 284 (1952).
- BEIERWALTES, W.H. AND ROBBINS, J., Familial increase in the thyroxine-binding sites in serum alpha globulin, *J. Clin. Invest.* 38, 1683 (1959).
- 39. ROBBINS, J., RALL, J.E., AND RAWSON, R.W., A new serum iodine component in patients with functional carcinoma of the thyroid, *J. Clin. Endocrinol.* 15, 1315 (1955).
- 40. TATA, J.R., RALL, J.E., AND RAWSON, R.W., Studies on an iodinated protein in the serum of subjects with cancer of the thyroid, *J. Clin. Endocrinol.* 16, 1554 (1956).
- 41. KIEFFER, J. ET AL., Perchlorate test in hyperthyroid patients treated with radioactive iodine, *New Engl. J. Med.* 273, 1326 (1965).
- KIRKLAND, R.H., Impaired organic binding of radioiodine by the thyroid following radioiodine treatment of hyperthyroidism, J. Clin. Endocrinol. 14, 565 (1954).
- 43. WILKINS, L., Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence, p. 526, 2nd Ed., Charles C. Thomas, Springfield, Ill., 1957.
- 44. AXELRAD, A. AND LEBLOND, C.P., Thyroid tumor induction in rats by low iodine diet with and without 2acetylaminofluorene, *Proc. Am. Assoc. Cancer Res.* 1, 2 (1953).
- 45. GRIESBACH, W.E., KENNEDY, T.H., AND PURVES, H.D., Studies on experimental goitre. VI. Thyroid adeno-

mata in rats on Brassica seed diet, Brit. J. Exptl. Pathol. 26, 18 (1945).

- PASHKIS, K.E., CANTAROW, A., AND STASNEY, J., Influence of thiouracil on carcinoma induced by 2acetaminofluorene, *Cancer Res.* 8, 257 (1948).
- MONEY, W.L. AND RAWSON, R.W., Experimental production of thyroid tumors in rats exposed to prolonged treatment with thiouracil, *Cancer* 3, 321 (1950).
- MORRIS, H.P. AND GREEN, C.D., Role of thiouracil in induction, growth and transplantability of mouse thyroid tumors, *Science* 114, 44 (1951).
- 49. WOLLMAN, S.H., Production and properties of transplantable tumors of thyroid gland in Fischer rat, *Recent Progr. Hormone Res.* 19, 579 (1963).
- DONIACH, I., Comparison of carcinogenic effect of xirradiation with radioactive iodine on rat's thyroid, *Brit. J. Cancer* 11, 67 (1957).
- KNEELAND, V. ET AL., Comparison of carcinogenic effect of internal and external irradiation of thyroid gland of male Long-Evans rat, *Endocrinology* 61, 574 (1957).
- 52. LINDSAY, S., SHELINE, G.E., POTTER, G.D., AND CHAIKOFF, I.L., Induction of neoplasms in thyroid gland of rat by x-irradiation of gland, *Cancer Res.* 21, 9 (1961).
- 53. GOLDBERG, R.C. AND CHAIKOFF, I.L., Development of thyroid neoplasms in rat following single injection of radioactive iodine, *Proc. Soc. Exptl. Biol. Med.* 76, 563 (1951).
- 54. GOLDBERG, R.C. AND CHAIKOFF, I.L., Induction of thyroid cancer in rat by radioactive iodine, Arch. Pathol. 53, 22 (1952).
- 55. POTTER, G.D., LINDSAY, S., AND CHAIKOFF, I.L., Induction of neoplasms in rat thyroid glands by low doses of radioiodine, *Arch. Pathol.* 69, 257 (1960).
- DONIACH, I. AND WILLIAMS, E.D., Development of thyroid and pituitary tumors in rat two years after partial thyroidectomy, *Brit. J. Cancer* 16, 222 (1962).
- 57. GOLDBERG, R.C., LINDSAY, S., NICHOLS, C.W. JR., AND CHAIKOFF, I.L., Induction of neoplasms in thyroid glands of rats by subtotal thyroidectomy and by injection of one microcurie of I¹³¹, *Cancer Res.* 24, 35 (1964).
- 58. BIELSCHOWSKY, F., Neoplasia and internal environment, Brit. J. Cancer 9, 80 (1955).
- 59. DUFFY, B. J. JR. AND FITZGERALD, P. J., Thyroid cancer in childhood and adolescence: report of 28 cases, *Cancer* 3, 1018 (1950).
- SIMPSON, C.L., HEMPELMANN, L.H., AND FULLER, L.M., Neoplasia in children treated with x-rays in infancy for thymic enlargement, *Radiology* 64, 840 (1955).
- 61. WINSHIP, T.W., Personal communication.
- 62. WARREN, S., ALVIZOURI, M., AND COLCOCK, B.P., Carcinoma of thyroid in childhood and adolescence, *Cancer* 6, 1139 (1953).
- 63. SHELINE, G.E., LINDSAY, S., MCCORMACK, K.R., AND GALANTE, M., Thyroid nodules occurring late after treatment of thyrotoxicosis with radioiodine, J. Clin. Endocrinol. Metab. 22, 8 (1962).
- LINDSAY, S. AND CHAIKOFF, I.L., Effects of irradiation on thyroid gland with particular reference to induction of thyroid neoplasias: review, *Cancer Res.* 24, 1099 (1964).

of Global Associates at Kwajalein, including Dr. Y.C. Smith and Mr. G. Brosky at the Kwajalein Hospital, were extremely helpful.

At Brookhaven National Laboratory, contributions were made by many individuals in many departments, including Medical, Instrumentation and Health Physics, Photography and Graphic Arts, the Shipping Section and others. We are grateful to the following people for their support and advice: Dr. Maurice Goldhaber, Director; Dr. J.B.H. Kuper, Chairman of the Instrumentation and Health Physics Department; Dr. V.P. Bond, Chairman of the Medical Department, and others in his Department, including Drs. D.D. Van Slyke, E.P. Cronkite, and S. Cohn, Messrs. A. Finn, G. Jackson, and W. J. Walsh, and the nursing staff of the Medical Research Center.

In regard to advice and consultation on the thyroid pathology in the Marshallese, we are indebted to Drs. S. Warren and W.A. Meissner of the New England Deaconess Hospital; Dr. J.B. Stanbury, Massachusetts Institute of Technology; Dr. B.P. Colcock, Lahey Clinic; Dr. E.D. Henley, University of Washington; Dr. G.H. Klinck, Armed Forces Institute of Pathology; Dr. S. Lindsay, University of California; Commander C. J. Stahl, U.S. Navy; and Drs. L.K. Dahl, H.L. Atkins, and H.A. Johnson of Brookhaven National Laboratory.

We wish also to thank Miss B.R. Brezisky for her secretarial assistance and Mrs. M. Dienes for her editorial help.

References

- 1. CRONKITE, E.P. ET AL., The Effects of Ionizing Radiation on Human Beings: A Report on the Marshallese and Americans Accidentally Exposed to Radiation Fallout and a Discussion of Radiation Injury in the Human Being, AEC-TID 5358, U.S. Government Printing Office, Washington, D.C., 1956.
- 2. BOND, V.P., CONARD, R.A., ROBERTSON, J.S., AND WEDEN, E.A. JR., Medical Examination of Rongelap People Six Months After Exposure to Fallout, WT-937, Operation Castle Addendum Report 4.1A, April 1955.
- 3. CRONKITE, E.P. ET AL., Twelve-Month Postexposure Survey on Marshallese Exposed to Fallout Radiation, BNL 384 (T-71), August 1955.
- 4. CONARD, R.A. ET AL., Medical survey of Marshallese two years after exposure to fallout radiation J.A.M.A. 164, 1192 (1957).
- 5. CONARD, R.A. ET AL., March 1957 Medical Survey of Rongelap and Utirik People Three Years After Exposure to Radioactive Fallout, BNL 501 (T-119), June 1958.

- 6. CONARD, R.A. ET AL., Medical Survey of Rongelap People, March 1958, Four Years After Exposure to Fallout, BNL 534 (T-135), May 1959.
- 7. CONARD, R.A. ET AL. Medical Survey of Rongelap People Five and Six Years After Exposure to Fallout, BNL 609 (T-179), September 1960.
- 8. CONARD, R.A. ET AL., Medical Survey of Rongelap People Seven Years After Exposure to Fallout, BNL 727 (T-260), May 1962.
- 9. CONARD, R.A. ET AL., Medical Survey of Rongelap People Eight Years After Exposure to Fallout, BNL 780 (T-296), January 1963.
- CONARD, R.A. ET AL., Medical Survey of the People of Rongelap and Utirik Islands Nine and Ten Years After Exposure to Fallout Radiation (March 1963 and March 1964), BNL 908 (T-371), May 1965.
- 11. SUSSMAN, L.N., MEYER, L.M., AND CONARD, R.A., Blood groupings in Marshallese, Science 129, 644 (1959).
- BLUMBERG, B.S., Biochemical polymorphisms in animals: haptoglobins and transferrins, *Proc. Soc. Exptl. Biol. Med.* 104, 25 (1960).
- 13. BLUMBERG, B.S. AND GARTLER, S.M., High prevalence of high-level β -aminoisobutyric acid excretors in Micronesians, *Nature* 184, 1990 (1959).
- 14. GARTLER, S.M., An investigation into the biochemical genetics of β -aminoisobutyric aciduria, Am. J. Human Genet. 11, 257 (1959).
- 15. STEINBERG, A.G., STAUFFER, R., BLUMBERG, B.S., AND FUDENBERG, H., Gm phenotypes and genotypes in U.S. whites and negroes; in American Indians and Eskimos; in Africans and in Micronesians, Am. J. Human Genet. 3, 205 (1961).
- BLUMBERG, B.S., DRAY, S., AND ROBINSON, J.C., Antigen polymorphism of a low density beta-lipoprotein: allotypy in human serum, *Nature* 194, 656 (1962).
- 17. MENEELY, G.R. AND DAHL, L.K., Electrolytes in hypertension: the effects of sodium chloride, *Med. Clin. N. Am.* 45, No. 2, 271 (1961).
- GOLDMAN, M. AND CARVER, R.K., An intestinal parasite survey on Rongelap Atoll in the Marshall Islands, Am. J. Trop. Med. Hyg. 8, 417 (1959).
- GLICK, S.M., ROTH, J., YALOW, R.S., AND BERSON, S.A., Immunoassay of human growth hormone in plasma, *Nature* 199, 784 (1963).
- 20. BAKWIN, R.M., WEIDER, A., AND BAKWIN, H., Mental testing in children, J. Pediat. 33, 384 (1948).
- SUTOW, W.W., CONARD, R.A., AND GRIFFITH, K.M., Growth status of children exposed to fallout radiation on Marshall Islands, *Pediatrics* 36, 721 (1965).
- 22. GREULICH, W.W. AND PYLE, S.I., Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd Ed., Stanford University Press, Stanford, Calif., 1959.
- CONARD, R.A. AND HICKING, A., Medical findings in Marshallese people exposed to fallout radiation: results from a ten-year study. J.A.M.A. 192, 457 (1965).
- CONARD, R.A., RALL, J.E., AND SUTOW, W.W., Thyroid nodules as a late sequela of radioactive fallout, *New Engl. J. Med.* 274, 1392 (1966).
- 25. HARRIS, P., Unpublished data.

ĩ

ł

APPENDIX 1

The following bibliography represents a compilation of reports on the Marshallese people exposed to radioactive fallout in March, 1954. This list includes all known medical reports as of March, 1966. In many of these reports the Marshallese population is reported on only as one of several populations under study. In addition, certain radioecological studies (largely by the Laboratory of Radiation Biology, University of Washington, Seattle) carried out at Rongelap are presented as a supplementary bibliography. A third section of the bibliography comprises reports on the Japanese fishermen who were also exposed to radioactive fallout while on their boat, the Lucky Dragon, in 1954.

A. Marshallese Medical Reports

1

1

Twelve-month post-exposure survey on Marshallese exposed to fallout radiation. E. P. Cronkite, C. L. Dunham, D. Griffin, S. D. McPherson, and K. T. Woodward.

Brookhaven National Laboratory Report, BNL 384(T-71), 1955.

Physical factors and dosimetry in the Marshall Island radiation exposures. C. A. Sondhaus and V. P. Bond. Naval Radiol. Defense Lab., WT 939(Del.), 1955.

Skin lesions, epilation and nail pigmentation in Marshallese and Americans accidentally contaminated with radioactive fallout.
R. A. Conard, N. R. Shulman, D. A. Wood, C. L. Dunham, E. L. Alpen, and
L. E. Browning.
Naval Medical Research Institute and Naval Radiological Defense Laboratory,
NMRI Report NM 006 012. 04.82, 1955.

Response of human beings accidentally exposed to significant fallout radiation from a thermonuclear explosion. E. P. Cronkite, V. P. Bond, R. A. Conard, N. R. Shulman, R. S. Farr, S. H. Cohn, C. L. Dunham, and L. E. Browning. J.A.M.A. 159: 430-434, 1955.

A Naval medical team studies fallout effects. Office of Naval Research, Research Reviews, NAVEXOS P-510, pp. 1-9, November, 1955.

Emergency laboratory organization for the care of large numbers of human beings accidentally exposed to ionizing radiation. C. R. Sipe, P. K. Schork, C. P. A. Strome, W. H. Gibbs. Naval Medical Research Institute, Bethesda, Research Report Project NM 006 012.04.91, Vol. 13, pp. 821-834, 1955.

Medical examination of the Rongelap people six months after exposure to fallout radiation during Operation Castle. V. P. Bond, R. A. Conard, J. S. Robertson, and E. A. Waden, Jr. Operation Castle Addendum Report 4.1A WT-937, April, 1955.

- DONIACH, I., Experimental induction of tumors of thyroid by radiation, Brit. Med. Bull. 14, 181 (1958).
- 66. SOCOLOW, E.L., HASHIZUME, A., NERIISHI, S., AND NIITANI, R., Thyroid carcinoma in man after exposure to ionizing radiation: summary of findings in Hiroshima and Nagasaki, *New Engl. J. Med.* 268, 406 (1963).
- 67. ASTWOOD, E.B. AND CASSIDY, C.E., Treatment of simple goiters and thyroid nodules with thyroid hormone, *Clin. Endocrinol.* 1, 152 (1960).
- NICHOLS, C.W. JR., LINDSAY, S., SHELINE, G.E., AND CHAIKOFF, I.L., Induction of neoplasms in rat thyroid glands by x-irradiation of single lobe, *Arch. Pathol.* 80, 177 (1965).
- 69. GODWIN, J.T., Personal communication.
- 70. CONARD, R.A., An attempt to quantify some clinical criteria of aging, J. Gerontol. 15, 358 (1960).
- 71. HOLLINGSWORTH, J.W., GORO, I., AND CONARD, R.A., Skin aging and hair greying in Hiroshima, *Genatrics* 16, 27 (1961).
- HOLLINGSWORTH, J.W., HASHIZUME, A., AND JABLON, S., Correlations between tests of aging in Hiroshima subjects – an attempt to define physiologic age, *Yale* J. Biol. Med. 38, 11 (1965).
- ANDERSON, E.C. AND LANGHAM, W.H., Average potassium concentration of the human body as a function of age, *Science* 130, 713 (1959).
- 74. ALLEN, T.H., ANDERSON, E.C., AND LANGHAM, W.H., Total body potassium and gram body composition in relation to age, *J. Gerontol.* 15, 348 (1960).
- MOOREHEAD, P.S. ET AL., Chromosome preparations of leukocytes cultured from human peripheral blood, *Exptl. Cell Res.* 20, 613 (1960).
- 76. MOORE, F., The Body Cell Mass and Its Supporting Environment, Saunders, Philadelphia, 1963.

- 77. SIRI, W.E., Personal communication.
- 78. PALMER, H.E. AND ROESCH, W.C., A shadow-shield whole-body counter, *Health Phys.* 11, 1213 (1965).
- 79. BRADY, D.N. AND SWANBERG, F. JR., The Hanford mobile whole-body counter, *Health Phys.* 11, 1221 (1965).
- 80. STRICKFADEN, W.B. AND KLOEPPER, R.M., IBM-704 Programs for Unfolding Complex Gamma-Ray Spectra, LA 2461, 1961.
- COHN, S.H. AND GUSMANO, E., The determination of body burdens of radionuclides by computer analysis of gamma-ray spectral data, *Health Phys.* 11, 109 (1965).
- 82. HELD, E.E., Personal communication.
- 83. COHN, S.H., ROSOFF, B., GUSMANO, E.A., AND SPENCER, H., Long-term Cs¹³⁷ turnover in man as measured by a whole-body counter, *Radiation Res.* 19, 655 (1963).
- 84. HARDY, E.P., RIVERA, J., AND CONARD, R.A., Cesium-137 and strontium-90 retention following an acute ingestion of Rongelap food, in *Radioactive Fallout From Nuclear Weapons Tests (Proc. 2nd Conf., Germantown, Md., Nov. 3-6, 1964)*, A.W. Klement Jr., Editor, AEC Conf. 765, November 1965.
- HANSON, W.C., Cesium-137 body burdens in Alaskan Eskimos during the summer of 1965, Science 153, 525 (1966).
- Joint Committee on Atomic Energy, Federal Radiation Council Radiation Protection Guides, Hearings, 89th Congress, U.S. Government Printing Office, Washington, D.C., 1965.
- ROBBINS, J., Reverse flow zone electrophoresis, a method for detecting thyroxine binding capacity of serum proteins, Arch. Biochim. Biophys. 63, 461 (1956).
- 88. BERENS, C. AND ZUKERMAN, J., Diagnostic Examination of the Eye, p. 179, Lippincott, Philadelphia, 1946.

Medical status of Rongelap people five years after exposure to fallout radiation. R. A. Conard In: Biological and Environmental Effects of Nuclear War, hearings before the Special Subcommittee on Radiation, Joint Committee on Atomic Energy, 86th Congr., 1st sess., June 22-26, 1959, Part 1, pp. 430-2, U. S. Government Printing Office, Washington, D.C., 1959. An intestinal parasite survey on Rongelap Atoll in the Marshall Islands. M. Goldman and R. K. Carver. American J. Tropical Med. and Hygiene 8(4): 417-423, 1959. Blood groupings in Marshallese. L. N. Sussman, L. M. Meyer, and R. A. Conard. Science 129(3349): 644-645, March, 1959. Effects of fallout radiation on a human population. R. A. Conard, L. M. Meyer, J. S. Robertson, W. W. Sutow, W. Wolins, and H. Hechter. Radiation Res. Supplement 1: 280-295, 1959. Health survey of the Trust Territory of the Pacific Islands. Hetzel, A. M. U.S. Armed Forces Medical Journal 10(10): 1199-1222, 1959. High prevalence of high-level 3-amino-isobutyric acid excretors in Micronesians. B. S. Blumberg, and S. M. Gartler. Nature 184(4704): 1990-1992, 1959. Medical survey of Marshallese people five years after exposure to fallout radiation. R. A. Conard. Presented at the symposium on the Immediate and Low Level Effects of Ionizing Radiations, Venice, June, 1959. A special supplement (Suppl. 1) to the Int. J. Radiation Biology, Taylor and Francis, Ltd., London, pp. 269-81, 1960. Radioisotopes and environmental circumstances: The internal radioactive contamination of a Pacific Island Community exposed to local fallout. S. H. Cohn, J. S. Robertson, and R. A. Conard. In: Radioisotopes in the Biosphere, Chapter XXI, Ed. R. S. Caldecott and L. A. Snyder, University of Minnesota Center for Continuation Study of the General Extension Division, pp. 306-36, 1960. Medical status of Marshall Islanders in 1959, five years after exposure to fallout radiation. R. A. Conard, L. M. Meyer, W. W. Sutow, B. S. Blumberg, A. Lowrey, S. H. Cohn, W. H. Lewis, J. W. Hollingsworth, H. W. Lyon. Nuclear-Medizin 1: 314-330, 1960. Medical survey of Rongelap people five and six years after exposure to fallout. R. A. Conard, H. E. MacDonald, A. Lowrey, L. M. Meyer, S. Cohn, W. W. Sutow, B. S. Blumberg, J. W. Hollingsworth, H. W. Lyon, W. H. Lewis, Jr., A. A. Jaffe, M. Eicher, D. Plotter, I. Lanwi, E. Riklon, J. Iaman, and J. Helkena.

ī

3

ł

71

BNL Report 609(T-179), September, 1960.

The effects of fallout radiation on the skin. In: The Shorter Term Biological Hazards of a Fallout Field, AEC-DOD, pp. 135-42, U. S. Government Printing Office, Washington, D.C., 1956.

Some effects of ionizing radiation on human beings: A report of the Marshallese and Americans accidentally exposed to radiation from fallout and a discussion of radiation injury in the human being. E. P. Cronkite, V. P. Bond, and C. L. Dunham, eds. Naval Med. Res. Inst., Naval Radiol. Defense Lab. and Brookhaven Nat. Lab., 114p., TID 5356, 1956.

Response of human beings accidentally exposed to significant fallout radiation from a thermonuclear explosion (summary). R. A. Conard, E. P. Cronkite, V. P. Bond, N. R. Shulman, R. S. Farr, S. H. Cohn, C. L. Dunham, and L. E. Browning. In: Progress in Radiobiology, eds. J. S. Mitchell, B. E. Holmes, and G. G. Smith, Oliver and Boyd, Edinborough, London, pp. 491-493, 1956.

Medical survey of the Marshallese two years after exposure to fallout radiation. R. A. Conard, C. E. Huggins, A. Lowrey, and J. B. Richards. BNL Report 412(T-80), March, 1956. J.A.M.A. 164(11): 1192-1197, 1957.

Measurements on some residents of the Marshall Islands. C. E. Miller, and O. J. Steingraher. Semiannual Report, January-June, 1957, Radiological Physics Division, Argonne Natl. Lab., ANL 5755, pp. 53-7, 1957.

Radioactive contamination of certain areas in the Pacific Ocean from nuclear tests, a summary of the data from the radiological surveys and medical examination. G. M. Dunning, ed.

U. S. Atomic Energy Commission, pp. 45-51, 1957.

ł

17. 14

ł

March 1957 medical survey of Rongelap and Utirik people three years after exposure to radioactive fallout.R. A. Conard, L. M. Meyer, J. E. Rall, A. Lowrey, S. A. Bach, B. Cannon, E. L. Carter, M. Eicher, and H. Hechter.BNL Report 501(T-119), June, 1958.

The determination of internally deposited radioactive isotopes in the Marshallese people by excretion analysis. R. A. Conard. In: Fallout from Nuclear Weapons Tests. Hearings 86th Congr., 1st sess., May 5, 6, 7, and 9, 1959. Joint Comm. on Atomic Energy, Special Subcommittee on Radiation, Washington. U.S. Govt. Printing Off., v.2, pp. 1332-47, 1959.

Medical survey of Rongelap people, March 1958, four years after exposure to fallout.
R. A. Conard, J. S. Robertson, L. M. Meyer, W. W. Sutow, W. Wolins, A. Lowrey, H. C. Urschel, J. M. Barton, M. Goldman, H. Hechter, M. Eicher, R. K. Carver, and D. W. Potter.
BNL Report 534(T-135), May, 1959.

Acute whole-body radiation injury: Pathogenesis, pre- and post-protection. V. P. Bond, E. P. Cronkite, and R. A. Conard. In: Atomic Medicine, Chapter 10, 4th Edition, Ed. C. F. Behrens, The Williams and Wilkins Co., Baltimore, pp. 190-221, 1964.

Fallout radiation: Effects on the skin. R. A. Conard, E. P. Cronkite, and V. P. Bond. In: Atomic Medicine, Chapter 12, 4th Edition, Ed. C. F. Behrens, The Williams and Wilkins Co., Baltimore, pp. 281-302, 1964.

A polio epidemic in the Pacific Ocean. G. S. Brosky. Hospital Management 97: 55-6, 1964.

1

1

Providing for the settlement of claims of certain residents of the Trust Territory of the Pacific Islands. Report No. 1257 from the Committee on Interior and Insular Affairs, 2nd Session of the 88th Congress, Washington, July 29, 1964. (To accompany H.R. 1988).

Health aspects of nuclear weapons testing. G. M. Dunning U.S. Government Printing Office OL-729-548, Superintendent of Documents, Washington, D.C., 56p., 1964.

Cesium-137 and strontium-90 retention following an acute ingestion of Rongelap food.
E. P. Hardy, Jr., J. Rivera, and R. A. Conard.
Presented at the Second Conference on Radioactive Fallout from Nuclear Weapons Tests, Germantown, Maryland, 11/3-6/64.
In: AEC 5th Symposium Series, "Radioactive Fallout from Nuclear Weapons Tests", A. W. Klement, Jr., Ed., USAEC Conf.-765, pp. 743-57, 1965.

Growth status of children exposed to fallout radiation on Marshall Islands. W. W. Sutow, R. A. Conard, and K. M. Griffith. Pediatrics 36(5): 721-731, 1965.

Effects of ionizing radiation in children. W. W. Sutow and R. A. Conard. J. Pediatrics 67(4): 658-673, 1965.

Medical findings in Marshallese people exposed to fallout radiation: Results from a ten-year study. R. A. Conard, and A. Hicking. J.A.M.A. 192(6): 457-459, 1965.

Medical survey of the people of Rongelap and Utirik Islands nine and ten years after exposure to fallout radiation (March 1963 and March 1964). R. A. Conard, L. M. Meyer, W. W. Sutow, A. Lowrey, B. Cannon, W. C. Moloney, A. C. Watne, R. E. Carter, A. Hicking, R. Hammerstrom, B. Bender, I. Lanwi, E. Riklon, and J. Anjain. BNL Report 908(T-371), May, 1965. Addendum: A note on the vegetation of the northern islets of Rongelap Atoll, Marshall Islands, March, 1959. B. S. Blumberg, and R. A. Conard. Ibid., pp. 85-86.

The biological hazards of a fallout field. R. A. Conard.-In: Radioactivity in Man, Ed. G. R. Meneely, Charles C. Thomas, Springfield, Ill., pp. 249-265, 1961.

Electrolytes in hypertension: The effects of sodium chloride. The evidence from animal and human studies. G. R. Meneely, and L. K. Dahl. The Medical Clinics of North America 45(2): 271-283, 1961.

An isoprecipitation reaction distinguishing human serum-protein types. A. C. Allison, B. S. Blumberg. The Lancet 1: 634-637, 1961.

Gm phenotypes and genotypes in U. S. Whites and Negroes; in American Indians and Eskimos; in Africans; and in Micronesians. A. G. Steinberg, R. Stauffer, B. S. Blumberg, H. Fudenberg. Am. J. Hum. Genet. 13: 205-13, 1961.

Possible role of chronic excess salt consumption in the pathogenesis of essential hypertension. Lewis K. Dahl. The Am. J. Cardiology VIII(4): 571-575 and 587-592(panel discussion), 1961.

ĩ

ł

ş

Medical survey of Rongelap people seven years after exposure to fallout. R. A. Conard, H. E. MacDonald, L. M. Meyer, S. Cohn. W. W. Sutow, D. Karnofsky, A. A. Jaffe, and E. Riklon. BNL Report 727(T-260), May, 1962.

Use of a portable whole-body counter to measure internal contamination in a fallout-exposed population. S. H. Cohn, R. A. Conard, E. A. Gusmano, and J. S. Robertson. Health Physics 9: 15-23, 1963.

Medical survey of Rongelap people eight years after exposure to fallout. R. A. Conard, L. M. Meyer, W. W. Sutow, W. L. Moloney, A. Lowrey, A. Hicking, and E. Riklon. BNL Report 780(T-296), January, 1963.

Metabolism of fission products in man: Marshallese experience.S. H. Cohn.I.A.E.A. Int. Symp. on Diagnosis and Treatment of Radioactive Poisoning, 15-18 October 1962, Vienna. International Atomic Energy Agency, Austria, pp. 235-251, 1963.

Long term intra-oral findings in humans after exposure to total body irradiation from sudden radioactive fallout. I. Five years post-detonation studies. H. W. Lyon, R. A. Conard, and K. F. Glassford. J. Amer. Dent. Assoc. 68: 49-56, 1964.

The occurrence of antimony-125, europium-155, iron-55, and other radionuclides in Rongelap Atoll soil. R. F. Palumbo and F. G. Lowman. Office of Technical Services, U. S. Department of Commerce, Washington, D.C., 1958. Long-term effects of radioactive fallout on plants? F. R. Fosberg. Atoll Research Bulletin No. 61, issued by The Pacific Science Board, NAS, Washington, D.C., pp. 1-11, May 15, 1959. Plants and fall-out. F. R. Fosberg. Nature 183: 1448, 1959. Strontium-90 and gross beta activity in the fat and non-fat fractions of coconut crab (Birgus latro) liver collected at Rongelap Atoll during March 1958. D. Chakravarti and R. Eisler. Pacific Science, Vol. XV, no. 1, 1961. Potassium and cesium-137 in Birgus latro (coconut crab) muscle collected at Rongelap Atoll. D. Chakravarti and E. E. Held. Marine Biological Association of India, Vol. 2, no. 1, 1961. Use of the tension lysimeter in glacial till and coral atoll soils. D. W. Cole, S. P. Gessel and E. E. Held. Soils Science Society of America Proceedings, Vol. 25, no. 4, 1961. Nitrogen studies of Rongelap Atoll soils. S. P. Gessel, E. E. Held, and R. B. Walker. Paper presented at the Tenth Pacific Science Congress, Honolulu, August, 1961. Radiocesium in plants grown on Rongelap Atoll soil. R. B. Walker, E. E. Held, and S. P. Gessel. Recent Advances in Botany, University of Toronto Press, 1961. Qualitative distribution of radionuclides at Rongelap Atoll. E. E. Held. In: Radioecology, Rheinhold Publishing Corp., New York, 1963. Moulting behavior of Birgus latro. E. E. Held. Nature 200(4908), 1963. Chemical and radiochemical composition of the Rongelapese diet. D. Chakravarti and E. E. Held. Journal of Food Science, Vol. 28, no. 2, 1963. Ecological observations of sea cucumbers Holothuria atra and H. leucospilota at Rongelap Atoll, Marshall Islands. K. Bonham. Pacific Science, Vol. XVII, no. 3, 1963.

Ī

ł

ļ

F H

I

Fallout of the cold war. Editorial New Eng. J. Med. 274(25): 1462-1463, June 23, 1966.

1

ĩ

1

1

Elevation of the serum protein-bound iodine level in inhabitants of the Marshall Islands. J. E. Rall, and R. A. Conard. Am. J. Med. 40(6): 883-886, 1966.

Thyroid nodules as a late sequela of radioactive fallout in a Marshall Island population exposed in 1954. R. A. Conard, J. E. Rall, W. W. Sutow. New Eng. J. Med. 274: 1392-1399, 1966.

Aging studies in a Marshallese population exposed to radioactive fallout in 1954. R. A. Conard, A. Lowrey, M. Eicher, K. Thompson, W. A. Scott.

Presented at the Colloquium on Radiation and Aging, Semmering, Austria, June 23-24, 1966. To be published.

Etiology and treatment of hyperthyroidism. R. A. Conard. Panel on Hyperthyroidism, American Thyroid Association Meeting, Chicago, October 13, 1966. To be published in J. Clinical Endocrinology.

Radioiodine fallout and its effects in the Marshall Islands. R. A. Conard. Combined Clinical Staff Meeting, NIH, October 20, 1966, on Late Effects of Radioactive Iodine in Fallout. To be published in Annals of Internal Medicine.

B. Radioecological Studies

A radiological study of Rongelap Atoll, Marshall Islands during 1954-1955. Applied Fisheries Laboratory, University of Washington, Seattle. Off. of Technical Services, U. S. Dept. of Commerce, Washington, D.C., 1955.

Radiobiological resurvey of Rongelap and Ailingnae Atoll, Marshall Islands, October-November, 1955. Applied Fisheries Laboratory, University of Washington, Seattle. Off. of Technical Services, U. S. Dept. of Commerce, Washington, D.C., 1955.

The occurrence and distribution of radioactive nonfission products in plants and animals of the Pacific proving ground. F. G. Lowman, R. F. Palumbo, D. J. South. University of Washington Fisheries Laboratory Report UWFL-51, Technical Information Service Extension, Oak Ridge, Tenn., pp. 1-61, June, 1957.

Radiobiological studies of the fish collected at Rongelap and Ailingnae Atolls, July, 1957. A. D. Welander. Office of Technical Services, U. S. Dept. of Commerce, Washington, D.C., 1958. Clinical course of the radiation sickness caused by Bikini ashes. Y. Koyama, T. Kumatori, et al. Iryo, 9(1): 1-55, 1955.

1

ł

1

1

Clinical and hematological studies on Bikini patients. Research in the effects and influences of the nuclear bomb test explosions. Y. Mikamo, K. Miyoshi, K. Shimizu, K. Ishikawa, S. Kuriyama, and T. Kumatori. Japan Society for the Promotion of Science, Research in the Effects and Influences of the Nuclear Bomb Test Explosions, Vol. II, pp. 1313-1331, 1956.

Klinische und Hämatologische Studien an Patienten, Die durch den Radioaktiven Aschenregen bei Bikini nach der Atom Bomben Explosion geschädigt wurden. K. Miyoshi, and T. Kumatori. Fünfter Kongress der Europäischen Gesellschaft fur Hämatologie, 49-53, 1956.

Radiochemical analysis of falling dust on the fishing boat "Fukuryu Maru" on 1st March, 1954.K. Kimura, et al.Research in the Effects and Influences of the Nuclear Bomb Test Explosions, Japan Society for the Promotion of Science, Vol. 1, pp. 497-519, 1956.

Cooperation by the United States in the radiochemical analysis. R. Kobayashi, and I. Nagai. Research in the Effects and Influences of the Nuclear Bomb Test Explosions, Japan Society for the Promotion of Science, Vol. II, pp. 1333-1351, 1956.

Radiochemical analysis of the body of the late K. Kimura, et al. Research in the Effects and Influences of the Nuclear Bomb Test Explosions, Japan Society for the Promotion of Science, Vol. I, pp. 521-527, 1956.

Some observations on the victims of the Bikini H-bomb test. K. Shimizu, K. Ishikawa, et al. Research in the Effects and Influences of the Nuclear Bomb Test Explosions, Japan Society for the Promotion of Science, Vol. II, pp. 1333-1351, 1956.

Characteristics of hematological findings of the Japanese fishermen exposed to radioactive ashes in Bikini area. K. Miyoshi, and T. Kumatori. Proc. VIIIth Intern. Cong. Hem., 1: 29-34, 1962.

Clinical studies on persons injured by radioactive materials. T. Kumatori, and K. Miyoshi. Diagnosis and Treatment of Radioactive Poisoning: 253-272, I.A.E.A., 1963.

Clinical studies and hematological characteristics of Bikini radiation injury. K. Miyoshi, and T. Kumatori. Nihon Ketsuekigaku Zensho, 3: 660-703, 1964.

Chromosome aberrations in human keukocytes irradiated <u>in vivo</u> and <u>in vitro</u>. T. Ishihara, and K. Kumatori. Acta Haem. Jap., 28(3): 291-306, 1965.

PRIVACY ACT MATERIAL REMOVED

Determination of plankton biomass in Rongelap Atoll, Marshall Islands, by use of a multi-net plankton pump. O. Mathisen. Verh. Internat. Verein. Limnol., Vol. XV, 1964.

Autoradiography of sectioned soil cores. E. E. Held. Presented at the International Atomic Energy Agency Symp. on Radioisotope Sample Measurement Techniques in Medicine and Biology, Vienna, Austria, 24-29 May 1965.

Atoll soil types in relation to the distribution of fallout radionuclides. E. E. Held, S. P. Gessel, and R. B. Walker. Laboratory of Radiation Biology, University of Washington, Seattle, UWFL-92, 1965.

<u>Theses</u>

Bottom sediments of Rongelap Lagoon, Marshall Islands. W. A. Anikouchine. (Lab. Rad. Biol., Univ. Wash., Seattle) Thesis for M.S. degree, 1961.

The soils of Rongelap Atoll, Marshall Islands. R. M. Kenady, Jr. (Lab. Rad. Biol., Univ. Wash., Seattle) Thesis for M.F. degree, 1962.

Ī

I

3

I

Effects of the biological specificity of zinc on the distribution of zinc-65 in the fish fauna of a coral atoll lagoon. T. Joyner. (Lab. Rad. Biol., Univ. Wash., Seattle) Thesis for Ph.D. degree, 1962.

A description of nitrogen and phosphorus distribution in some Rongelap Atoll land ecosystems. R. F. Billings. (Lab. Rad. Biol., Univ. Wash., Seattle) Thesis for M.S. degree in Forestry, 1964.

Copepods of Rongelap Atoll. C. V. Mahnken. (Lab. Rad. Biol., Univ. Wash., Seattle) Thesis for M.S. degree. To be published, 1966.

Some autecological properties of <u>Scaevola serica</u> and <u>Messerschmidia</u> <u>argentea</u>. G. Lesko. (Lab. Rad. Biol., Univ. Wash., Seattle) Thesis for Ph.D. degree. To be published, 1966.

C. Medical Reports on the Japanese Fishermen

Clinical and hematological observations on radiation sickness caused by the ashfall at Bikini. K. Miyoshi, and T. Kumatori. Acta Haem. Jap., 18(5): 379-406, 1955. APPENDIX 2 - UCRL 12273

Estimate of Radiation Dose to Thyroids of the Rongelap Children Following the Bravo Event

Ralph A. James

Lawrence Radiation Laboratory, University of California

Livermore, California

December 16, 1964

General Information

The cloud arrival time is given⁽¹⁾ as H + 4 to 6 hours. The duration of the cloud passage is less well known but probably lies in the range of 8 - 16 hours. In all calculations we will assume that cloud passage was in the interval H + 6 to H + 18.

The residents of Rongelap were evacuated at H + 51 hours. Reliable dose rate measurements were not obtained at that time but the gamma dose rate 3 feet above the ground was measured as 375 mr/hr seven days after the detonation. Assuming t decay the H + 24 hour dose rate was then \sim 3.8 rad/hr.

The sources of exposure to the thyroid which must be considered are:

(1) Whole body gamma dose.

I

Į

I

I

(2) Internal deposition of iodine isotopes.

Whole Body Gamma Dose

The whole body dose was estimated⁽¹⁾ to be 175 rad. The exact method of making this estimate is not given, so an independent estimate is made below. In particular, it appears that this estimate does not include the dose from the cloud but only from fallout.

If we assume a linear buildup of fallout from H + 6 to H + 18, t^{-1.2} decay during this interval and use the reading of 375 mr/hr at seven days, the estimated dose from fallout during cloud passage is 47 rad. The dose from the fallout from H + 18 to evacuation at H + 51 is 114 rad. Experience from Sedan indicates that the dose from the cloud, itself, is approximately equal to the dose from fallout during cloud passage. The total estimated dose is then 47 + 47 + 114 = 208 rad.

Within the error of the measurements and the accuracy of the assumptions, this estimate, which does not contain any correction for the small effect of time indoors, does not differ significantly from the value of 175 rad⁽¹⁾. We will, therefore, take the average whole body gamma dose as 175 + 25 rad.

Medical survey of Japanese exposed to fall-out radiation in 1954. A report after 10 years.T. Kumatori, T. Ishihara, T. Jeda, and K. Miyoshi.National Institute of Radiological Sciences Report, Chiba Shi, Japan, pp. 1-14, December, 1965.

Ì

ľ

;

الآلي الله المركز ال المركز
Table I

| | Inhal | ation | Oral Inge | stion |
|------------------------------|-----------------------------------|---------------------------------|----------------------|----------------------|
| - | ¹³³ I/131 _I | ¹³⁵ _{1/131} | ¹³³ 1/131 | ¹³⁵ 1/131 |
| Decay | 0.68 | 0.31 | 0.487 | 0.148 |
| Fission yield ⁽⁶⁾ | 1.38 | 1.23 | 1.38 | 1.23 |
| Energy | 2.00 | 1.50 | 2.00 | 1.50 |
| Net Factor | 1.85 | 0.57 | 1.35 | 0.27 |

Ratio of Doses for the Two Modes of Intake

The dose to the thyroid in rads from all three isotopes is, thus, 3.4 times the dose due to I alone for inhalation and 2.6 times the I dose for oral ingestion. Delay in reaching the thyroid after inhalation or ingestion would lower these factors somewhat. However, the I daughter of the 78 hr Te bas been neglected and would approximately compensate for decay of I and I before reaching the thyroid.

5

E

1

1

We can now proceed to estimate the dose to the thyroids of 3 - 4 year old girls assuming (1) inhalation as the mode of intake and (2) oral ingestion. <u>1. Inhalation:</u> The ratio of volume of air respired by a 3 - 4 year old girl to that of an adult can be estimated in two ways: (a) from the maximum rate of oxygen intake (7) and (b) from the vital capacity (8) and maximum respiration rate. Both methods give a ratio of ~ 0.3 . The thyroid burden of these children would then be $\sim 3.4 \,\mu c$ with a range of 1.7 - 6.8 μc .

Assuming the Rongelap children are similar to those of New York (9) children, the mass of the thyroid of the children is 2.5 ± 0.6 grams.

The most probable dose from 131 I is then 150 rad and the dose from all isotopes is 510 rad. If we consider the range of thyroid burden (1.7 - 6.8 µc) and the variation in thyroid weight (1.9 - 3.1 gms), the dose is in the range of 200 - 1350 rad.

2. Oral Ingestion: At the time of the event the Rongelap people were on a water ration of one pint per day. They were warned not to drink water after the event but most of them admitted they drank water anyway. (10) The method of collecting water by runoff from roofs into cisterns makes it very likely that this was the main source of oral ingestion. There are reports that it "rained a little" on the afternoon of March 1 (D-Day). The village doctor reported that the "water turned yellow." As far as food is concerned, the most likely source is dried fish. Fish were dried on open racks. However, in the interviews none of them listed dried fish as having been eaten during

Internal Deposition of Iodine Isotopes

Unfortunately, no direct measurement was possible on the radioactive iodine content of individuals from Rongelap. Urine samples were taken from which the average thyroid burden of I has been estimated. The Los Alamos Scientific Laboratory collected pooled 24-hour samples 15 days post detonation and estimated (2) the 1-day thyroid content as $11.2 \ \mu c$ of I. USNRDL collected samples from each member of the exposed group 43 and 46 days post detonation and, by an indirect method, estimated the average thyroid content as $6.4 \ \mu c$ I at $1.4 \ ay$. The LASL estimate of $11.2 \ \mu c$ was obtained by direct counting of I in the urine and should be more reliable than the NRDL estimate. The value of $11.2 \ \mu c$ will be used as a basis for all following considerations. This estimate was based on the assumption of 0.1% of the maximum thyroid burden being excreted in the urine on the 15th day. Variation in the biological half-life and other factors indicate that a range of 0.05 - 0.2% should be placed on this number (see following section by Ng). We, therefore, take $5.6 - 22.4 \ \mu c$ as the range of adult I thyroid burden.

The pooled samples represent all age groups. The number of individuals in these age groups and the volume of urine from each age group is approximately as follows:

| Age Group | Number of Individuals | Volume of <u>Urine(ml)</u> | % of Total Volume |
|-----------|--------------------------|-------------------------------|----------------------|
| < 5 | 7 | 1155 | 4.8 |
| 5 - 16 | 11 | 4829 | 20.1 |
| > 16 | 31 | 18011 | 75.0 |

The urine samples are typical of adults and the calculated thyroid burdens are presumably also those of adults.

Associated with this 131 I are the shorter lived isotopes 132 I, 133 I and I. If the iodine entered by way of inhalation, the time of intake was H + 6 to H + 18. On the other hand, if water (and food) were the principal source, the time of ingestion would be extended from H + 6 to H + 51.

Three items contribute to the differences in dose from the various iodine isotopes. These are: (1) radioactive decay before inhalation or oral ingestion, (2) differences in the fission yields of the chains, (6) and (3) the average energy deposited in the thyroid per disintegration. These factors are presented in Table I for 133 I and 13 I. In the case of inhalation, uniform distribution in the cloud was assumed. For oral ingestion it was assumed that, on the average, 1/3 of the intake occurred at H + 10 and 2/3 at H + 30.

REFERENCES

ł

ł

1 Sondhaus, Sharp, Bond and Cronkite, "Radiation Characteristics of the Fallout Material and Determination of the Dose of Radiation," Chapter I of TID-5358, Some Effects of Ionizing Radiation on Human Beings. 2 P. Harris, personal communication, cited by both references 3 and 4. Cohn, Rinehart, Gong, Robertson, Milne, Bond and Cronkite, "Internal Deposition of Radionuclides in Human Beings and Animals," Chapter V of TID-5358. 4 Cohn, Rinehart, Gong, Robertson, Milne, Chapman and Bond, "Internal Radioactive Contamination of Human Beings Accidentally Exposed to Radioactive Fallout Material," USNRDL-TR-86. 5 Ng, Yook, private communication (1964). 6 The fission yields for U^{238} with high energy neutrons as given by Weaver, Strom and Kileen, NRDL-TR-633, were used. 7 Handbook of Biological Data, William B. Spector, Editor, p 352 (W.B. Saunders, Philadelphia, 1956). 8 Document Geigy Scientific Tables, 5th Ed., p 254 (S. Karger, Basel, Switzerland, 1959). Mochizviki, Mowafy and Pasternack, Health Physics, 9, 1299-1301 (1963). 10 Sharp and Chapman, "Exposure of Marshall Islanders and American Military Personnel to Fallout," WT-938, 1957.

ាំ១

the time before evacuation. (10) Under these circumstances it is reasonable to assume that children drank the same amount of water and, therefore, had the same intake as adults; i.e., their thyroid burdens were also 11.2 μ c of I3I (range 5.6 - 22.4 μ c).

1

1

F

1

I

The most probable dose from ^{131}I is then 490 rad and the total dose 1270 rad. Considering a range in the thyroid burden (5.6 - 22.4 μc) and a thyroid weight range of 1.9 - 3.1 gms, the range of total dose is 520 - 3300 rad.

Incidentally, LASL assumed this mode of intake and calculated a dose of 150 rad. ⁽²⁾ The thyroid weight used was not given but was probably 20 grams. We would calculate 160 rad, in very good agreement with the LASL estimate.

Summary

Thyroid Dose (Rads) to Rongelap Girls Ages 3 - 4

| | | Inha | alation | Oral | Ingesti | i on |
|-------------|-----|------|----------------------|------|---------|----------------------|
| | Min | Max | <u>Most Probable</u> | Min | Max | <u>Most Probable</u> |
| Whole Body | 150 | 200 | 175 | 150 | 200 | 175 |
| Radioiodine | 200 | 1350 | 510 | 520 | 3300 | 1270 |
| Total | 350 | 1550 | 685 | 670 | 3500 | 1445 |

The actual intake was undoubtedly a combination of the two modes of intake. The most probable dose is, therefore, in the range 700 - 1400 rad.

| J day ⁻¹ | K day ¹ x 10 ³ | $L \\ da\bar{y}^{1} \times 10^{2}$ | % of I_{Tf}^{dI}/day |
|------------------------|---|------------------------------------|------------------------|
| 3.7 | 4.85 | 7.2 | 0.050 |
| 3.7 | 4.85 | 13.8 | 0.066 |
| 3.7 | 17.15 | 7.2 | 0.16 |
| 3.7 | 17.15 | 13.8 | 0.21 |

I

Urinary Radioiodine Excretion at 15 Days

On the basis of these calculations the normal range of urinary radio-iodine excretion at 15 days was estimated to be 0.05 to 0.2% of the peak thyroid content.

The problem outlined above is a practical application of an analytical study on the uptake and excretion of iodine in man which will be described more fully in a UCRL report entitled, "The Dynamics of Iodine in Man."

Calculation of Urinary Radioiodine Excretion

Yook C. Ng

Lawrence Radiation Laboratory, University of California

Livermore, California

Radioiodine appearing in urine, except for that during a relatively short period following exposure, originates from the thyroid. In the calculation for urinary radioiodine it was assumed that iodine is released from the thyroid only as thyroxine, and that the release of thyroxine and its subsequent degradation in the extrathyroidal hormonal space can be adequately described assuming first order kinetics. Ranges for normal biological half-life of iodine in the thyroid and normal turnover rate of extrathyroidal thyroxine were selected from the best available data in the literature. The uptake of radioiodine was assumed to be exponential with a half-period of increase of 4.5 hours, and 60% of the iodine released when extrathyroidal thyroxine is degraded was assumed to be excreted in urine.

Rates of urinary radioiodine excretion were calculated from the resulting expression shown below.

$$\frac{dI_{U}}{dt} = 0.60LKI_{Tf} \frac{e^{-(K + \lambda)t} - e^{-(L + \lambda)t}}{L - K} - \frac{e^{-(J + K + \lambda)t} - e^{-(L + \lambda)t}}{L - J - K}$$

I_{II} = radioiodine content of urine

L = rate of turnover of extrathyroidal thyroxine

K = rate constant for the release of iodine from the thyroid

 I_{Tf} = peak radioiodine content of the thyroid

 λ = physical decay constant for ¹³¹I

J = rate constant for the uptake of radioiodine in the thyroid

t = time

1

F

1

A summary of the calculations made to determine the normal range of urinary radioiodine excretion at 15 days appears below.

| | | | March 1958 | | | March 1959 | | 1961 | Ma1 1962 | rch 1963 | 1964 | | Mar 196 | ch 5 | . | Sept. 1965 | | Mar 1960 | ch 5 | T | Sept. 1966 |
|----|----------|------|---------------|-----|-----|---------------|-----|------|-------------|-------------|----------|--------------------|------------|---------|-----------------------|---------------|------------|--------------|---------|-----------------------|---------------|
| | | PBL | TI | BEI | PBI | TI | BEI | PBI | PBI | PBI | PBI | PBL | <u>_TI</u> | Ip* | 13 + <u>I</u> 4 | PBI | PBI | TI | Ip | 13 + <u>1</u> 4 | PBI |
| | • | | | | | | | | | 1 | Rongelar | p Expos | ed (co | ntinue | d) | | | | | | |
| | 15 | 12.8 | 12.8 | 7.8 | | | | | | | | 6.4 | | | | | | ł | | | |
| | 17 | | | | | | | | | 7.1** | 6.8 | 2.3 | | | | | 1.8 | | | <0.5 | |
| | 18 | | | | | | | | | | | 11.7 | | | | | | | | | |
| | 19 | 6.4 | 6.4 | | 4.1 | 2.0 | 2.7 | | | 5.6** | | | | | | | 3.9 | | | 3.3 | 7.7 |
| | 20 | 7.0 | 7.0 | | | | | | | 5.5** | | 7.2 6 .1 | 6.5 | 1.3 | 4.2 | | | | | | |
| | 21 | 7.4 | 7.4 | | | | | | 7.7** | | 8.1 | 0.7 | | | | | 1.3 | | | <0.5 | |
| | 22 | 13.6 | 13.6 | 5.8 | | | | | 9.3 | | | | • | | | | | | | | |
| | 23 | 9.6 | 10.2 | | | | | | 10.3** | | | | | | | | | | | | |
| | 27 | 11.0 | 11.2 | | | | | | | | | 7.1 | 6.6 | 1.8 | 4.5 | | | 8.8 | 4.7 | 4.1 | |
| 87 | 30 | 11.8 | 12.8 | | ι | | | | | | | | | | | | | | | | |
| | 32 | 10.8 | 12.0 | | | | | | | 8.7** | | | | | | | 4.6 | | | 4.0 | |
| | 33 | | | | | | | | | 7.1** | | 7.0 | | | | | 6.2 5.6 | | | 4.5 3.1 | |
| | 34 | | | | | | | | | | | 9.1 | | 3.3 | 4.6 | | | 10. 8 | 3.2 | 6.5 | |
| | 35 | 6.0 | 6.0 | | | | | | | | | 4.6 | | | | | | | | | |
| | 36 | 10.6 | 11.8 | | | | | | | 2.7** | | 4.1 | | | | | 4.2 | | | 4.3 | 4.2 |
| | 37 | 11.6 | 12.8 | | | | | | | | | 5.3 | | | | | | | | | |
| | 39 | 10.0 | 14.4 | | 9.7 | | 8.7 | | | | | 11.9 | | | | | | | | | |
| | 40 | 7.0 | 8.0 | | | | | | | | | 10.3 | | | | | | | | | |
| | 41 | | | | | | | | | | | 6.7 | | | | | | | | | |
| | 42 | | | | | | | | 8.8** | 9.0** | | | | | | | 5.0 6.5 | | | 4.8 4.5 | |
| | 44 45 | 10.2 | 11.8 | | 6.7 | | 3.4 | | 7.9** | | 9.1 | 8.4 | | | | | 4.7 | | | 4.8 | |

| | <u> </u> | March 1958 | | 1 | larch 1959 | | 1961 | <u>Ma</u> 1962 | 1963 | <u>1964</u> | | Ma 19 | rch 65 | Ta | Sept. <u>1965</u> | - | Mar 196 | ch 6 | Ta | Sept <u>1966</u> |
|----|----------|---------------|-----|-----|---------------|-----|------|-------------------|--------------|-------------|------------|-----------|-----------|------------|-----------------------------------|--------------------|------------|---------|---|---------------------|
| | PBI | TI | BEI | PBI | TI | BEI | PBI | PBI | PBI | PBI | PBI | <u>TI</u> | Ip* | <u>T</u> 4 | PBI | <u>PB</u> I | TI | Ть | $\frac{\mathbf{T}_{4}}{\mathbf{T}_{4}}$ | PBI |
| | | | | | | | | | F | Rongelap | Expose | d | | | | | | | | |
| 1 | 10.6 | 10.6 | | | | | | 12.0 | 9.4 | | | | | | | | | | | |
| 2 | | | | | | | 8.0 | | 10.2** | | 7.9 6.2 | 7.1 | 2.0 | 4.2 | | 5.2 | | | 2.6 | |
| 3 | | | | | | | 8.8 | 7.2 | 1.9** | | 1.4 1.6 | | 1.0 | 0.8 | | 3.2 | | | 1.0 | |
| 4 | 8.6 | 9.8 | | | | | | | | | | | • | | | | | | | |
| 5 | | | | | | | | 4.6 | 2.5** | | 1.9 1.8 | | 0.8 | 0.8 | 2.5 | 3.1 | | | 1.8 | 2.1 |
| 6 | | | | | | | 10.7 | 9.7 | 7.9 8.7** | | 8.5 | | | | Pre TSH 7.2 Post TSH 7.9 | 5.0 | | | 3.6 | |
| 7 | | | | | | | | | | | | | | | | | 5.0 | 1.7 | 3.0 | |
| 8 | | | | | | | | | 9.0** | | 5.7 | | | | | 5.4 | | | 4.0 | |
| 10 | 11.8 | 11.8 | | 7.0 | 5.0 | 5.0 | | 9.5 | 12.0 | | 8.3 | | | | | | | | | |
| 11 | 10.6 | 10.6 | | | | | | 11.0 | | | 8.4 | | | | | | | | | |
| 12 | 6.6 | 7.8 | | | | | | | 8.8 | | | | | | | | | | | |
| 13 | | | | | | | | | | | 6.9 | | 2.8 | 3.4 | | | 7.8 | 4.0 | 3.9 | |
| 14 | | | | | | | | 10.8 | 8.3 | | 7.1 | | | | | | | | | |

| | | | | | APPENDIX 3 | 3 | | | | | |
|------------|-------|--------|----------------|----|------------|--------|-------------|-------|-------|--------|-----|
| Individual | Serum | Iodine | Determinations | of | Marshall | Island | Populations | Under | Study | (in µg | 3%) |

Pril 10

* Iodoprotein. ** Determinations made in 1966 from frozen sera.

| | | March | | M | arch | | | Ma | <u>rch</u> | | | Mar | ch | | Sept. | | Marc | ch | | Sept. |
|-----|------|-------|-----|-----|-----------|-----|-------------|-------------|-------------|-----------|----------|---------|------------|---------------------------------|-------------|-----|------|------------|----------------|-------------|
| | | 1958 | | | 1959 | | <u>1961</u> | <u>1962</u> | <u>1963</u> | 1964 | <u> </u> | 19 | 65 | Ti | <u>1965</u> | | 196 | 56 | T ₃ | <u>1966</u> |
| | PBI | TI | BEI | PBI | <u>TI</u> | BEI | PBI | PBI | PBI | PBI | PBI | TI | <u>Ip*</u> | ⁺⁹ T ₄ | PBI | PBI | TI | <u>1</u> p | т Т4 | PBI |
| | | | | | | | | | | τ. | | | | | | | | | | |
| | | | | | | | | | Ron | gelap Exp | osed (c | cont in | ued) | | | | i i | | | |
| 73 | | | | | | | | | | | 8.4 | | | | | | | | | |
| 74 | 10.4 | 11.6 | 6.2 | | | | | | | | | | | | | | | | | |
| 75 | | | | | | | | | | | 4.7 | | | | | | | | | 4.5 |
| 76 | 7.4 | 8.4 | | | | | | | | | 4.4 | | | | 4.4 | | | | | 5.6 |
| 81 | 7.0 | 7.6 | | | | | | | | | | | | | | | | | | |
| 82 | 8.6 | 9.2 | | | | | | | | | | | | | | | | | | |
| 83 | | | | | | | 8.1 | 7.4 | | | 6.6 | • | | | | | | | | |
| 84 | | | | | | | | | | 9.3 | | | | | | 6.2 | | | 3.6 | |
| 86 | | | | | | | 12.0 | 9.2 | 8.2 | | | | | | | 7.1 | | | 6.0 | |
| | | | | | | | | | | Rongelag | Unexp | osed | | | | | | | | |
| 814 | | | | | | | | | | | 5.7 | | | 4.3 | | | | | | |
| 815 | 14.6 | 15.2 | 5.8 | 5.3 | | 3.3 | | | | | 6.3 | | | | | | | | | |
| 816 | 9.2 | 9.4 | | | | | | | | | | | | | | | | | | |
| 817 | 9.6 | 10.2 | | | | | | | | | | | | | | | | | | |
| 818 | 11.6 | 12.2 | 6.5 | 9.2 | | 7.5 | | | | | 6.5 | | | | | | | | | |
| 820 | 10.2 | 10.8 | | | | | | | | | 8.8 | | | | | | | | | |
| 821 | 8.0 | 8.8 | | | | | | | | | | | | | | | | | | |
| 822 | 9.8 | 10.4 | | | | | | | | | 5.2 | | | | | | | | | |
| | | | | | | | | | | | | 5.1 | 1.1 | 3.5 | | | | | | |
| 829 | | | | | | | | 8.6 | 7.1 | | | | | | | | | | | |
| 830 | 9.2 | 9.8 | | 6.0 | | 4.4 | | | | | | | | | | | | | | |
| 833 | | | | | | | | | | | 7.3 | 68 | 1.9 | 5.3 | | | | | | |
| | | | | | | | | | | | 7 7 | 0.0 | | | | | | | | |
| 835 | | | | | | | | | | | 1.2 | 6.4 | 2.3 | 3 4.2 | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |

ь.

.

| | | March | | | March | | | Mar | ch | | | Mar | ch | | Sept. | | Marc | h | | Sept. |
|----|------|-------|-----|-----|-------|-----|------|--------|--------|----------|------------|----------|------|-----------------|-----------------|------------|------|------------|------------|-------|
| | | 1958 | | | 1959 | | 1961 | 1962 | 1963 | 1964 | · <u> </u> | 196 | 5 | | 1965 | | 1966 | | | 1966 |
| | | | | | | | _ | | | | | | | т <u>з</u> + | | | | | 13 + | |
| | PBI | TI | BEI | PBI | TI | BEI | PBI | PBI | PBI | PBI | PBI | TI | Ip* | <u>T</u> 4 | PBI | PBI | TI | Ip | <u>T4</u> | PBI |
| | | | | | | | | | Rong | elap Exp | posed (| contin | ued) | | | | | | | |
| 47 | 8.4 | 10.6 | · . | | | | | 7.9** | | τ | | | | | | | | | | 6.2 |
| 48 | 8.8 | 8.8 | | | | | | | | | | | | | | | | | | |
| 50 | 9.2 | 15.0 | | | | | | | | | 10.1 | | | | | | | | | |
| 51 | 8.0 | 8.8 | | | | | | | | | 9.7 | | | | | | | | | |
| 53 | 8.2 | 8.4 | | | | | | | | | 8.5 | | | | | | | | | |
| 54 | | | | | | · | | | 7.8** | | 8.3 | | | | | 5.0 | | | 4.3 | |
| 55 | | | | | | | | | | | 5.7 | | | 3.8 | | | 6.9 | 2.5 1.5 | 3.3 | |
| 58 | 8.6 | 10.4 | | | | | | | | | 9.2 | | | | | | | | | |
| 59 | 9.0 | 10.2 | | | | | | 9.8** | 11.0** | | 8.6 | • 8.2 | 2.8 | 5.3 | 11.1 | 6.4 | 8.6 | 2.7 | 4.5 5.0 | |
| 60 | | | | | | | | | 10.8** | | | | | | | | | | | |
| 61 | 11.4 | 11.4 | | | | | | | 11.5** | | 6.4 | | | | | 8.3 7.5 | | | 4.5 4.9 | |
| 64 | | | | | | | | 10.7** | 12.0** | | 10.0 | 8.6 | 4.5 | 3.4 | | | 5.0 | 2.9 | 2.0 | |
| | | | | | | | | | | | 7.5 | | | | | | | | | |
| 65 | | | | | | | 7.1 | 6.7 | 8.8** | | 7.0 | | | | Pre TSH | 3.1 | | | 1.9 | |
| | | | | | | | | | | | | | | | Post TSH 7.6 | 5.1 | | | 3.6 | |
| 66 | | | | | | | | | | | 8.0 | | | | | | | | | |
| 67 | | | | | | | | | | | 6.6 | | | | | | | | | |
| 68 | | | | | | | | | | | 7.1 | | | 4.6 | | | 11.8 | 6.0 2.7 | 5.8 | |
| 69 | 12.2 | 13.2 | | | | | | 7.8** | 8.7** | 10.2 | 7.1 | | | | | 5.7 | | | 1.7 | 2.8 |
| 70 | | | | | | | | | 8.7 | | | | 1.9 | | | | | | | |
| 71 | | | | | | | | | 8.7 | | | | | | | | | | | |
| 72 | 8.2 | 8.6 | | | | | | | | | | | | | 5.3 | | | | | |

وبر است

.

84/19

| | | | March 1958 | k L | | March 1959 | l ; | 1961 | Ma 1962 | rch 1963 | 1964 | | Ma 1 | rch 965 | | Sept. 1965 | | March 1966 | 1 5 | | Sept. 1966 |
|---|-------------|-----|---------------|--------|-----|---------------|--------|------|------------|-------------|------------|----------------|---------|------------|----------|---------------|------|---------------|--------|----------------------------------|---------------|
| | | PBI | <u></u> | BEI | PBI | TI | BEI | PBI | PBI | PBI | BPI | PBI | TI | Ip* | T3 T4 | PBI | PBI | TI | Ір | T ₄ T ₄ | PBI |
| | | | | | | | | | | F | longelap | Un <u>expo</u> | sed (a | ontinu | ied) | | | | | | |
| | 938 | | | | | | | | | | 5.6 | 3.9 | | | | | | I. | | | |
| | 942 | | | | | | | | | | | 7.5 | | | | | | | | | |
| | 943 | | | | | | | | | | | 6.2 | | | | | | | | | |
| | 944 | | | | | | | | | | 2.0 | | | | | | | | | | |
| | 9 50 | | | | | | | | | | 6.7 | 6.8 | | | | | | | | | |
| | 955 | | | | | | | | | | | 7.9 | 8.00 | 2.8 | 5.1 | | | | | | |
| | 959 | | | | | | | | | | | 6.3 | | | | | | | | | |
| | 0(1) | | | | | | | | | | | - 1 | 6!4 | 2.4 | 3.9 | | | | | | |
| | 961 | | | | | | | | | | | 5.1 | | | 6.2 | | | | | | |
| ٥ | 980 | | | | | | | | | | 6.3 | 6.8 E 0 | | | 6.2 | | | | | | |
| - | 982 | | | | | | | | | | 0.3 | 5.9 | | | | | | | | | |
| | 1005 | | | | | | | | | | 7.9 E 0 | | | | | | | | | | |
| | 1043 | | | | | | | | | | 2.0 | | | | | | | | | | |
| | | | | | | | | | | | Utii | rik Ex | posed | | | | | | | | |
| | 2101 | | | | | | | | | | | | | | | | 14.2 | 12.6 | 7.9 | 3.7 | |
| | 2105 | | | | | | | | | | | | | | | | 10.8 | | | | |
| | 2114 | | | | | | | | | | | | | | | | 8.8 | | | | |
| | 2115 | | | | | | | | | | | | | | | | 7.6 | | | | |
| | 2119 | | | | | | | | | | | | | | | | 13.7 | 11 0 | 0.1 | r 7 | |
| | 2125 | | | | | | | | | | | | | | | | 19.0 | 11.9 | 0.1 | 5.7 | |
| | 2125 | | | | | | | | | | | | | | | | (0 | 32.0 | 14.1 | 5.7 | |
| | 2128 | | | | | | | | | | | | | | | | 0.Y | | | | |
| | 2136 | | | | | | | | | | | | | | | | 0.4 | | | | |
| | 2137 | | | | | | | | | | | | | | | | 28.7 | | | | |
| | 2139 | | | | | | | | | | | | | | | | 9.0 | • | | | |

.

| | | March 1958 | | | March 1959 | | 1961 | <u>Ma</u> 1962 | 1963 | 1964 | | Mar 19 | rch 965 | | Sept. 1965 | | Mar 19 | ch 66 | | Sept. <u>1966</u> |
|-----|------|---------------|-----|-----|---------------|-----|------|-------------------|----------|----------|----------------------------|-------------|------------|----------------------------|--|---------|------------|----------|----------------------|----------------------|
| | PBI | TI | BEI | PBI | TI | BEI | PBI | PBI | PBI | PBI | PBI | <u>, TI</u> | <u>Ip*</u> | T ₃ +7 T4 | PBI | PBI | TI | Ip | т ₄ т4 | PBI |
| | | | | | | | | | Rongelap | Unexpose | ed (con | tinued | i) | e' | | | | | | |
| 843 | | | | | | | | | | | ·7.0 谜, | 36,7 | 3.2 | 3,2 | ŧ. | | ł | | | |
| 849 | | | | | | | | | | | 6.5 t | 6.9 | 2.4 | 4 3 | * * | | | | | |
| 853 | 11.2 | 11.8 | | | | | | | | | 7.0 | | | ÷., | | | | | | |
| 855 | 9.6 | 10.0 | | | | | | | | | 7.0 | | | 1. ji | Ľ | | | | | |
| 861 | 12.0 | 15.6 | | | | | | | | | | . 4. | | el 1, 19 | 5 | | | | | |
| 862 | 7.6 | 7.6 | | | | | | | | | 1.00 | • | | | | | 1 k 1 k | , ,1 | | |
| 863 | 10.0 | 10.6 | | 6.7 | | 4.9 | | | | | , ar a. Sast | | | | | | • | | | |
| 864 | | | | | | | | | | 1.00 | 10.7 | | | | | | • | | | |
| 865 | | | | | | | | 9.1 | 8.2 | | 9.4 | | <i>P</i> , | | 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1 | ʻi L | | | | |
| 867 | 14.0 | 14.0 | | | | | | | | | | | | 12 | i i i i i i i i i i i i i i i i i i i | 14 | | | | |
| 869 | 10.2 | 11.2 | | 5.9 | | 4.7 | | | | · 4. | | | | | | | | | | |
| 871 | 12.0 | 12.2 | | | | | | | | | | | | ્રે કરત હો દાવ | | | | | | |
| 872 | 7.2 | 9.2 | | | | | | | | | | | | | 41) | | | | | |
| 873 | 10.0 | 10.8 | | _ | | | | | | | | | - 4,7 - | | | | , | | | |
| 874 | 7.8 | 8.0 | | 5.2 | | 4.0 | | | | | | | | - 8 1 | | | | | | |
| 882 | | | | | | | | | | | | 7.7 | | | | | | | | |
| 887 | 10.4 | 11.2 | | 6.2 | | 5.0 | | | | | | | | | | | | | | |
| 891 | 10.4 | 11.0 | | | | | | | | | | | | , , | | | | | | |
| 892 | 7.6 | 9.2 | | | | | | | | | | | i à | • | | | | | | |
| 893 | 16.4 | 17.4 | | | | | | | | | | | | | | | | | | |
| 913 | | | | | | | | | | | 6.9 | 6 8 | ·1 9 | 5 1 | | | | | | |
| 928 | | | | | | | | | | | 7.6 | 7,3 | 2.2 | 4.8 | | | | | | |

(and all

.

| Subject No | Age | <u>Sex</u> | Wt. <u>(kg)</u> | 24-hr. Output (m1) | Total I (µg/ml) | μg/ Day | Subject No | Age | Sex | Wt. (kg) | 24-hr. Output (m1) | Total I (μg/ml) | μg/ Day |
|---------------|-----|------------|--------------------|--------------------------|--------------------|------------|---------------|------------|-----|-------------|--------------------------|--------------------|------------|
| 8 | 14 | F | 41 | 775 | 0.048 | 37.2 | 73 | 30 | M | 71 | 660 | 0.270 | 178.2 |
| 11 | 62 | м | 52 | 970 | 0.058 | 56.3 | 84 | 11 | M | 29 | 730 | 0.096 | 70.1 |
| 12 | 30 | F | 62 | 1000 | 0.130 | 130.0 | 822 | • 19 | М | 57 | 850 | 0.106 | 90.1 |
| 15 | 19 | F | 52 | 735 | 0.090 | 66.1 | 833 | <u>3</u> 3 | М | 64 | 1050 | 0.188 | 197.4 |
| 20 | 19 | м | 54 | 410 | 0.118 | 48.4 | 835 | 32 | F | 51 | 560 | 0.062 | 34.7 |
| 27 | 38 | М | 65 | 1355 | 0.102 | 136.2 | 840 | 36 | м | 68 | 835 | 0.128 | 106.8 |
| 40 | 41 | м | 55 | 520 | 0.220 | 114.4 | 843 | 37 | F | 50 | 1350 | 0.030 | 40.5 |
| 41 | 56 | M | 54 | 900 | 0.056 | 50.4 | 853 | 61 | М | 69 | 1770 | 0.082 | 145.1 |
| 45 | 44 | F | 55 | 610 | 0.100 | 61.0 | 855 | 61 | М | 66 | 515 | 0.150 | 82.4 |
| 50 | 46 | м | 84 | 1830 | 0.104 | 190.3 | 895 | 36 | F | 67 | 820 | 0.216 | 177.1 |
| 51 | 37 | м | 44 | 665 | 0.402 | 279.3 | 920 | 34 | м | 62 | 910 | 0.084 | 76.4 |
| 53 | 20 | F | 49 | 300 | 0.252 | 75.0 | 928 | 53 | F | 57 | 1080 | 0.152 | 164.2 |
| 58 | 71 | F | 55 | 715 | 0.148 | 105.8 | 932 | 31 | F | 50 | 355 | 0.128 | 45.4 |
| 59 | 46 | F | 39 | 650 | 0.030 | 19.5 | 942 | 51 | F | 60 | 545 | 0.300 | 163.5 |
| | | | | | | | | | | | Mean | 0.138 | 105.0 |

APPENDIX 4

-

Million

il satti

1

Urinary Iodine Excretion

93

.

14-51

| | | March 1958 | | | March 1959 | | 1961 | <u>Ма</u> 1962 | 1963 | 1964 | | Ma1 | arch 1965 | | Sept. 1965 | | Marcl 196 | h 6 | ۳ <u></u> + ³ | Sept. 1966 |
|------|-----|---------------|-----|-----|---------------|-----|------|-------------------|------|--------|-------|--------|--------------|------------|---------------|------|--------------|-----------|-----------------------------|---------------|
| | PBI | TI | BEI | PBI | TL | BEI | PBI | PBI | PBI | PBI | PBI | TI | <u>Ip*</u> | <u>т</u> 4 | PBI | PBI | <u>TI</u> | <u>Ip</u> | <u> </u> | PBI |
| | | | | | | | | | | Ucirik | Expos | ed (co | ontinue | d | | | | | | |
| 2142 | | | | | | | | | | | | | | | | 8.9 | 1 | | | |
| 2146 | | | | | | | | | | | | | | | | 12.7 | 11.5 | 8.1 | 2.8 | |
| 2150 | | | | | | | | | | | | | | | | 10.5 | | | | |
| 2152 | | | | | | | | | | | | | | | | 26.7 | | | | |
| 2155 | | | | | | | | | | | | | | | | 8.4 | | | | |
| 2166 | | | | | | | | | | | | | | | | 13.1 | 12.7 | 7.8 | 3.7 | |
| 2169 | | | | | | | | | | | | | | | | 10.7 | | | | |
| 2178 | | | | | | | | | | | | | | | | 8.5 | | | | |
| 2193 | | | | | | | | | | | | | | | | 8.1 | | | | |
| 2196 | | | | | | | | | | | | | | | | 9.6 | | | | |
| 2197 | | | | | | | | | | | | | | | | 8.4 | | | | |
| 2215 | | | | | | | | | | | | | | | | 9.8 | | | | |
| 2216 | | | | | | | | | | | | | | | | 8.6 | | | | |
| 2251 | | | | | | | | | | | | | | | | 9.6 | | | | |

.

| | Subject No. | <u>1957</u> | <u>1959</u> | Subject No. | <u>1957</u> | 1959 | Subject No. | <u>1957</u> | <u>1959</u> |
|---|-------------|-------------|-------------|-------------|-------------|-----------|-------------|-------------|-------------|
| | | | | Rongelap | Unexpose | <u>ed</u> | | | |
| | 825 | | 163 | 856 | 249 | 172 | 885 | 122 | |
| | 831 | 259 | ~ | 857 | 232 | | 886 | 167 | |
| | 832 | 152 | | 858 | 259 | 180 | 887 | 127 | |
| | 833 | 159 | | 859 | 249 | 202 | 888 | 200 | |
| | 834 | 175 | | 860 | 379 | 187 | 889 | 183 | 150 |
| | 835 | 136 | | 861 | 325 | 173 | 891 | 142 | |
| | 836 | 183 | 155 | 862 | 305 | | 893 | 158 | |
| | 838 | 215 | | 864 | 191 | 170 | 894 | 183 | 152 |
| | 839 | 191 | | 865 | 159 | | 895 | 158 | 146 |
| 9 | 840 | 232 | | 867 | 167 | | 896 | 218 | 165 |
| Ű | 841 | 224 | 213 | 868 | 191 | 207 | 913 | | 136 |
| | 842 | 305 | | 869 | 224 | | 916 | | 135 |
| | 843 | 191 | 181 | 871 | 158 | 157 | 925 | | 129 |
| | 844 | 191 | 149 | 872 | 192 | | 928 | | 239 |
| | 845 | 183 | | 873 | 174 | 187 | | | |
| | 846 | 199 | | 874 | 135 | | | | |
| | 847 | 167 | · | 875 | 227 | 181 | | | |
| | 848 | 224 | | 876 | 142 | 154 | | | |
| | 849 | 277 | | 878 | 200 | | | | |
| | 850 | 215 | 164 | 879 | 192 | | | | |
| | 851 | 249 | 237 | 880 | 132 | | , | | |
| | 852 | 183 | 162 | 881 | 200 | | | | |
| | 853 | 207 | | 882 | 158 | | | | |
| | 854 | 183 | 192 | 883 | 149 | | | | |
| | 855 | 249 | 208 | 884 | 265 | | | | |

• •

APPENDIX 5

h-10

E hantill

11-2

Cholesterol Levels (mg%)

.

| <u>Subject No.</u> | <u>1957</u> | <u>1959</u> | Subject No. | <u>1957</u> | <u>1959</u> | Subject No. | <u>1957</u> | <u>1959</u> |
|--------------------|-------------|-------------|-----------------|-------------|-------------|-------------|------------------|-------------|
| | | | <u>Rongelap</u> | Exposed | | | | |
| 1 | 173 | 204 | 30 | 183 | | 57 | 249 | |
| 2 | 154 | 148 | 31 | 95 | | 58 | 113 | |
| 3 | 166 | | 32 | 127 | | 59 | 99 | |
| 4 | 270 | 184 | 33 | 106 | | 60 | 249 | |
| 5 | 181 | | 34 | 183 | | 61 | 277 | |
| 6 | 190 | | 35 | 109 | | 62 | 305 | |
| 7 | 190 | | 36 | 123 | 149 | 63 | 159 | 150 |
| 9 | 276 | | 37 | 88 | | 64 | 249 | |
| 10 | 274 | | 38 | 215 | | 65 | 144 | |
| 11 | 203 | 155 | 39 | 106 | | 66 | 144 | |
| 12 | 177 | | 40 | 129 | | 67 | [•] 167 | |
| 13 | 195 | 140 | 41 | 109 | | 69 | 191 | |
| 14 | 228 | 207 | 42 | 101 | | 69 | 136 | |
| 15 | | 135 | 43 | 167 | | 70 | 105 | 132 |
| 16 | 232 | 162 | 44 | 159 | | 71 | 191 | |
| 17 | 136 | | 45 | 191 | | 72 | 167 | 137 |
| 18 | 234 | 149 | 46 | 232 | | 73 | 125 | |
| 19 | 141 | | 47 | 167 | | 74 | 207 | |
| 20 | 162 | | 48 | 96 | 121 | 75 | 128 | |
| 21 | 129 | | 49 | 175 | | 76 | 152 | 134 |
| 22 | 144 | | 50 | 113 | | 77 | 191 | |
| 23 | 88 | 141 | 51 | 95 | | 78 | 183 | 165 |
| 24 | 152 | | 52 | 167 | 182 | 79 | 159 | 127 |
| 26 | 136 | | 53 | 102 | 132 | 80 | 259 | |
| 27 | 136 | | 54 | 121 | | 81 | 167 | 152 |
| 28 | 183 | | 55 | 144 | 143 | 82 | 224 | |
| 29 | 268 | | 56 | 253 | | 83 | 152 | |

| PATIENT NO. | AGE | SEX | HOSPITAL | DATE |
|-------------|-----|-----|----------------------------|--------------|
| 21 | 12 | F | U. S. Naval Hospital, Guam | August, 1964 |

This 12 year old female, native of Rongelap Atoll, was accidentally subjected to radioactive fallout from a nuclear explosion in 1954. She subsequently suffered hematopoietic depression and "beta burns of the skin that healed in several months." Thereafter, she was subjectively and objectively in good health until March, 1964, when examination revealed a grossly irregular (nodular) thyroid gland. Protein bound iodine was reported as normal, and the child was referred to this hospital on August 17, 1964, for surgical management of the pathologic gland.

Admission studies revealed a normal physical examination except for four to five hard nodules in the thyroid, with no palpable lymph nodes. Laboratory studies were negative except for an unexplained leukocytosis of 15,700 (with a normal smear) and a sedative rate of 38. PBI was not repeated.

The increased likelihood of malignant degeneration in thyroid glands exposed to radiation (whether x-irradiation or atomic blasts as in Japan), together with the infrequency of nodular goiter during adolescence among these Island people, made us fairly certain that we were dealing with a malignant tumor of the thyroid.

1

At operation on August 18, 1964, the gross picture was one of malignancy, with the thyroid having a cobble-stone appearance and "feel," the nodules being for the most part extremely indurated and unlike the findings in a nodular goiter. It was decided to remove the entire thyroid gland, with dissection of the anterior compartment of the neck, en bloc. The extreme irregularity of the thyroid gland, with nodules being of different color and consistency, made identification of parathyroid tissue extremely difficult. One parathyroid gland was identified after its pedicle was divided (it was attached to the undersurface of the right lobe of the thyroid gland), and this was implanted in the belly of the right sterno-mastoid gland. No other parathyroids were seen, and none were subsequently found in the specimen by the **pathologist**.

Postoperatively, the patient had attacks of frank tetany on the second and fourth postoperative days, each time responding to intravenous calcium glucoheptonate. Since that time she has been maintained on a high calcium-low phosphorous diet, calcium lactate tablets, Deltalin (vitamin D_2), and amphogel, in varying amounts. At first an attempt was made to wean her of all medications (as her serum calcium and phosphorus suggested return of parathyroid function). However, it was found that she could not tolerate complete withdrawal, so attempts were redirected toward establishing a program that would regulate her calcium/phosphorus balance with a minimum of medication.

As of now this program includes the following: Deltalin 100,000 units daily, calcium lactate two tablets (grains XX) t.i.d., amphogel 30 cc t.i.d., a high calcium/low phosphorus diet, and thyroid extract grains I t.i.d.

The child seems to be doing quite well on this program, has no suggestion of neuromuscular hyperirritability, and participates freely in available activities. Her serum calcium is 9.4, with a serum phosphorus of 5.7, and an alkaline phosphatase of 6 B.U.

APPENDIX 6

Hospital Summaries of Thyroid Surgical Cases

| PATIENT NO. | AGE | SEX | HOSPITAL | DATE |
|-------------|-----|-----|---------------------------|--------------|
| 17 | 14 | F | U.S. Naval Hospital, Guam | August, 1964 |

This 14 year old female, a native of Rongelap Atoll, was referred here for management of a palpable nodule in the left lobe of the thyroid, recently discovered, associated with no symptoms suggestive of dysfunction of the thyroid gland. Rongelap was inadvertently irradiated by fallout from an atomic bomb blast in 1954, when this child was 4 years of age. After the fallout she had developed an anemia, a leukopenia, and second degree burns, all of which lasted for several months.

Admission work-up was within the limits of normal except for the presence of a soft, 1.2 cm nodule in the left lobe of the thyroid, near the isthmus.

Laboratory studies including chest x-ray were within the limits of normal.

She was admitted on 8/17/64, and a total thyroidectomy performed on 8/19/64, with dissection of the anterior compartment of the neck. Postoperatively the patient did well so far as healing of the wound was concerned, but within 24 hours she showed a suggestion of neuromuscular hyperirritability. On that same day a serum calcium was reported as 8.5 with a phosphorus of 4.3. She was begun on oral vitamin B_2 and calcium lactate tablets. A few days later aluminum hydroxide gel was added as another oral medication, and a high calcium, low phosphorus diet was begun. Thereafter the patient began rapidly to show evidence of regeneration of parathyroid function of her own, so that a gradual weaning of medications was begun. By 9/16/64 she was off all medication except the diet and amphojel. These were discontinued on 9/23/64, and when her serum calcium and phosphorus remained normal she was discharged on 10/1/64. Throughout her hospital stay after the completion of her thyroidectomy she was maintained on thyroid extract gr. 1 - 3 times daily. This is believed necessary for replacement therapy, and it is recommended that this be continued indefinitely.

Microscopic examination of the removed thyroid was strongly suggestive of the suspected malignancy. However, review of the slide by the AFIP yielded a final diagnosis of nodular thyroid goiter with no evidence of malignancy.

]

Į

Follow-Up: Since discharge from the hospital the patient has remained asymptomatic on thyroxine therapy. In March, 1966, after being off thyroid hormone for three weeks (temporarily for test purposes), her TSH level was elevated to 342 mµg/ml and ¹³²I uptake nil, indicative of athyroid status. She had maintained a euthyroid status on 3 mg levothyroxine daily and has shown no recurrence of nodules.

PATIENT NO. 69 (continued)

ī

Ŧ

1

day. She was discharged back to her island home on 10-27-64 with the recommendation that she take thyroid extract, grains 2 daily for an indefinite period.

Follow-Up: Following release from the hospital the patient has remained asymptomatic and apparently euthyroid on 3.0 mg of levothyroxine daily. No recurrence of thyroid nodules has been detected. In March, 1966, three weeks after stopping thyroid hormone (temporarily for test purposes) her ¹³²I uptake showed little, if any, thyroid function.

| PATIENT NO. | AGE | SEX | HOSPITAL | DATE |
|-------------|-----|-----|--|------------|
| 2 | 12 | М | Hospital of Medical Research Center, BNL | June, 1965 |

This 12 year old Marshallese boy who was exposed to radioactive fallout in 1954 was admitted to this hospital to evaluate a nodule of the thyroid gland which was discovered this past March.

History of Present Illness: During the annual physical examination (March, 1965) of the Rongelap people who were exposed to fallout radiation in 1954, this boy was found to have a small nodule of the thyroid gland about 2 cm in diameter. He was about 1 year of age at the time of exposure to radioactive fallout. He received an estimated dose of 175-200 rads whole body gamma radiation from the fallout and an undetermined dose of radiation (largely beta) to the skin along with some internal absorption of radioactive materials. It was estimated that the thyroid gland of a child this age had received roughly 700-1400 rads largely from the radioiodines absorbed. He experienced some nausea and vomiting during the first day or so which was believed related to his radiation exposure. His peripheral blood elements dropped to about one-half of the level of unexposed Marshallese people, but recovered to about normal by one year. Beginning about two weeks after exposure, he developed lesions of the skin from fallout deposition. These lesions were confined largely to the anterior neck folds, axillary, scalp and perianal regions. He also had extensive epilation. These lesions healed within several weeks and the hair began regrowing with complete regrowth by six months. He showed no other acute effects from his exposure. However, during the 10-year period since exposure he was found to show some degree of lag in growth, based on anthropometric studies as well as bone age studies. He has lagged a year to a year and one-half behind the unexposed children of the same age. This inhibition in his growth is believed to have been due to his fallout exposure, though the mechanisms involved have not been clear. There has been no evidence of thyroid malfunction. Two PBI readings taken in the past few years were in the normal range for the Marshallese people. Six years ago his cholesterol was 150 mg% and he remained in good health.

<u>Physical Examination</u>: No enlargement of the thyroid was noted. A 2 cm diameter nodule, oval in shape, finely moveable, nontender but firm, was noted in the right lobe. The nodule moved on swallowing. No other nodules and no lymphadenopathy was palpated. The remainder of the physical examination was essentially negative. There were a few scars on the anterior neck region and in the perianal region, residual of previous beta burns.

PATIENT No. 21 (continued)

ī

1

1

We plan on discharging her on this regimen, with the recommendation that she be readmitted in January, 1965, for another attempt to wean her from medications, or at least reduce the amounts of medications necessary.

Regarding the microscopic studies of the removed thyroid gland, here is a summary. Our **p**athologist considered the slides positive for malignancy, but desired confirmation from the AFIP. The report from AFIP, however, though acknowledging the presence of some "bizarre fields on high power examination," concluded that the diagnosis was "nodular, adenomatoid goiter, thyroid gland." The report was signed by G. H. Klinck.

<u>Follow-Up</u>: Following discharge the patient was careless about her treatment regimen and had an episode of tetany a few months later. She then began seriously taking her medication and remained asymptomatic until March, 1965, when she developed swelling of the right knee suggestive of rheumatic fever. She was hospitalized for several days and responded well to salicylates. She has since remained asymptomatic. In March, 1966, the Trousseau was negative, but the Chvostek was positive. At that time she was taken off thyroid hormone for several weeks (temporarily for test purposes), and her TSH was quite high (440 mµg/ml) and an 13^{2} I uptake study showed no uptake, both results proof of completeness of thyroidectomy. She has maintained euthyroid and euparathyroid states on levothyroxine 3 mg daily and vitamin D 50,000 units daily. She has shown no recurrence of thyroid nodules.

| PATIENT NO | D. AGE | SEX | HOSPITAL | DATE |
|------------|--------|-----|---------------------------|---------------|
| 69 | 14 | F | U.S. Naval Hospital, Guam | October, 1964 |

This 14 year old Micronesian female received radioactive fallout on the Island of Rongelap Atol1 in 1954. After recovery from the beta burns and the blood element depression, all of which required several months, the child was well until examination in 1964 revealed several nodules in the thyroid gland. The patient was referred here as had two other girls with similar problems in recent months. These other two girls had undergone total thyroidectomy for what appeared at operation to be diffuse thyroid carcinomatous degeneration, but final pathologic studies by the AFIP yielded a diagnosis of benign multinodular goiter in each case.

The child's preoperative work-up was within the limits of normal except for the nodules in each lobe of the thyroid and acutely inflamed tonsils. The child was therefore placed on warm saline gargles, procaine, penicillin and forced fluids from 10-12-64 until she was ready for thyroid surgery on 10-20-64.

Thyroidectomy was performed on 10-20-64, with removal of the entire right lobe, the isthmus, and the medial one-half of the left lobe. The portion of the left lobe and superior pole that were left were relatively uninvolved with the nodular process that permeated the rest of the thyroid. It is of interest that a nodule overlying the trachea in the region of the so-called sentinal nodule was removed as a separate specimen prior to the thyroidectomy and sent to the laboratory for examination. The nodule was thyroid tissue; yet there was absolutely no connection between this nodule and the rest of the thyroid. The patient's postoperative course was completely benign, with removal of sutures on the second postoperative

PATIENT NO. 20 (continued)

ĩ

ł

2

I

gamma dose of 175 rads, an undetermined dose to the skin surfaces, and some internal absorption of fallout material. It was estimated that the thyroid gland received a dose of somewhere between 700-1,400 rads, largely from radioiodine absorbed in the fallout. He was nauseated the day following the fallout and also complained of some itching and burning of the skin. About two weeks after exposure, he had epilation of the head, along with radiation burns of These lesions were not severe and healed with only the scalp, neck, and toes. slight residual depigmentation in the following weeks. The hair regrew by 6 months. He showed mild leukopenia and platelet depression during the first several months following exposure but with no complications. His blood elements had returned to the normal range by the end of the first year. Since that time he has been generally in good health and has apparently been euthyroid (1963 PBI 5.5 μ g%). Compared with unexposed boys of the same age, however, he has shown a slight degree of retardation in growth based on anthropometric and bone age studies.

<u>Physical Examination</u>: The patient was well nourished and developed but appeared to be somewhat smaller than normal for his age. The thyroid was not enlarged, but a 1.5 cm diameter nodule, firm in character, was noted in the right lower pole of the gland. The nodule was not tender and moved on swallowing. No other nodules were palpated and no regional adenopathy was noted. The remainder of the physical examination was essentially negative.

Laboratory and X-Ray Data: Thyroid Work-Up: PBI 6.1 μ g%, iodine fractionation: total I 6.5 μ g%, iodoprotein 1.3 μ g%, thyronine (T4 + T3) 4.2 μ g%. Thyroid autoantibodies under 1:16. Cholesterol 170 mg% with esters 144 mg%. BMR -12. Thyroid scan (99m Tc) showed "cold" nodule at lower lobe. 132 I uptake studies showed 40% uptake in 6 hours with 32.5% urinary excretion at that time. Following TSH stimulation for three days, the uptake was only 33.7% at 5-1/2 hours, with urinary excretion 18.5%. PBI 6.8 μ g%. The blood count was within normal limits; alkaline phosphatase was slightly low (4.4 units), total protein slightly elevated, 8.2 gm with globulins 3.9 gm. Within normal ranges were: prothrombin time, sedimentation rate, bilirubin, cephalin flocculation, transaminase, Ca, P, thymol turbidity, FBS, BUN, CO₂, Cl, Na, K. Normal also were EKG, slit lamp examination, urinalysis, and stools for ova and parasites. Chest plate showed no active disease in the chest.

<u>Hospital Course</u>: The patient remained asymptomatic while here. On July 5 he was taken to New England Baptist Hospital in Boston, Massachusetts for surgery. Dr. Bentley P. Colcock removed about 3.1 cm of thyroid tissue which contained multiple nodules varying in size up to 1 cm in diameter. They varied from pale grey and firm to pulpy and semicystic and deep red. The pathologic diagnosis was adenomatous goiter. His recovery was rapid and uneventful. He was returned to Brookhaven on July 13 where he remained asymptomatic and was discharged on July 18, 1965, fit to travel back to the Marshall Islands.

Diagnosis: Adenomatous goiter.

<u>Discharge Medication</u>: No immediate drug therapy was recommended. However, this patient will receive desiccated thyroid, 180 mg daily beginning in September, along with the remainder of the exposed Rongelap people.
PATIENT NO. 2 (continued)

Î

Laboratory and X-Ray Data: Thyroid Workup: PBI 6.2 μ g%, iodine fractionation, total I 7.1 μ g%, thyronine fraction (T4+T3) 4.2 μ g%. Cholesterol 167 mg%, with 143 mg% esters. Thyroid autoantibodies titer under 1:16. BMR -23%. Thyroid scan (^{99m}Tc) showed possible nodularity of the right lobe, and to a lesser extent of the lower lobe. Chest x-ray showed no diseases or abnormalities. ¹³²I uptake study showed an uptake of 39% at 6 hours. PBI 5.4. Following TSH stimulation for three days, the uptake showed a slight decrease at 5-1/2 hours over the value before TSH stimulation.

Electrocardiogram normal; sed rate slightly elevated (21 mm). Blood count within normal limits except slightly low RBC (4,100,000) and hemoglobin 12.7 gm. Alkaline phosphatase was slightly low (4.5 units). Total proteins slightly elevated (8.5 gm with globulins up to 4.5 gm). These are typical values for Marshallese people. Normal values were found for prothrombin time, bilirubin, cephalin flocculation, transaminase, calcium, P, thymol turbidity, FBS, BUN, CO₂, C1, Na, K. Urinalysis and stools for ova and parasites were both negative.

<u>Hospital Course</u>: The patient's hospital course here was uneventful, and he was transferred to New England Baptist Hospital, Boston, for surgical exploration of his neck on July 5. Dr. Bentley P. Colcock, under general anesthesia, removed a 1.2 cm diameter nodule from the right lobe of the thyroid gland, including some surrounding thyroid tissue which contained multiple small nodules. The nodules varied in color from pale gray to deep red. From histological examination of the tissues, a pathological diagnosis of adenomatous goiter was made. His recovery from the operation was rapid and subsequent course was uneventful. He was returned to this hospital on 7-13-65 and was discharged on 7-18-65, fit to travel back to the Marshall Islands.

Diagnosis: Adenomatous goiter.

Discharge Medication: No immediate drug therapy. It is anticipated that he will be put on thyroid 180 mg daily for life in September along with the other exposed Rongelap people.

<u>Follow-Up</u>: Patient has remained in good health and apparently euthyroid on 3 mg levothyroxine daily. In March, 1966, he was taken off thyroid therapy for three weeks for test purposes. At that time he showed good thyroidal function by 13^{2} I uptake though his TSH level was slightly elevated (26 mµg/ml). No recurrence of nodules has been noted.

| PATIENT NO. | AGE | SEX | HOSPITAL | DATE |
|-------------|-----|-----|-----------------------------------|--------------------|
| 20 | 18 | М | Hospital of Medical Research Cent | er, BNL June, 1965 |

This 18 year old Marshallese male was admitted to this Hospital for evaluation of a thyroid nodule which was discovered during this past March.

<u>History of Present Illness</u>: During the annual physical examination in March, 1965, this 18 year old boy was found to have a small 1 cm nodule of the right lobe of the thyroid gland. He was one of the group of 64 people who had been accidentally exposed to fallout in 1954. It was estimated that he had received a whole body

PATIENT NO. 20 (continued)

ŗ

1

ł

I

Follow-Up: Since discharge the patient has been asymptomatic and apparently euthyroid even though his thyroid therapy (3 mg levothyroxine daily) has been sporadic. No recurrence of thyroid nodules has been noted.

| PATIENT NO. | AGE | SEX | HOSPITAL | DATE | - |
|-------------|-----|-----|--|------------|---|
| 64 | 41 | F | Hospital of Medical Research Center, BNL | June, 1965 | |

This 41 year old Marshallese woman was admitted to the hospital for evaluation of a thyroid nodule that was discovered during the 1965 annual medical survey of the Rongelap people.

A 1 cm nodule was discovered in the right lobe of History of Present Illness: the thyroid gland of this woman in March, 1965. It was firm, non-tender, and no cervical lymph nodes were palpable. She was one of a group of 64 Rongelap people who had been exposed to fallout 11 years ago. She had received an estimated dose of 175 rads of whole body gamma exposure and in addition radiation exposure to her skin and some internal absorption of radioactive materials. Absorption of radioiodines from the fallout gave an estimated dose to the thyroid gland of 150-160 rads, in addition to the 175 rads from gamma radiation. She had early nausea and vomiting believed to be associated with her radiation exposure and her blood elements were depressed to about one-half normal levels. She developed "beta burns" of the skin beginning about two weeks after exposure, mainly on the back of her neck. These lesions healed within several weeks and her blood elements returned to near normal levels by about one year after exposure. Since that time she has remained in relatively good health with no serious illnesses or injuries. She has had nine children, four of them born since the fallout exposure. She has apparently remained euthyroid. A PBI taken in March was 10.0 μ g% (high normal for the Marshallese) and serum cholesterol in 1958 was 249 mg%.

<u>Physical Examination</u>: The patient was a well nourished, well developed female of about her stated age of 41. Pterygia were noted in the right eye. In the right lower pole of the thyroid there was a deeply fixed 1 cm nodule that moved with the thyroid on swallowing. The overlying skin was not attached to the nodule. The nodule was very hard but not tender and no other nodules were palpable. Regional adenopathy was not noted. The blood pressure was normal. There were no other significant findings on physical examination.

Laboratory and X-Ray Data: Thyroid Work-up revealed the following: Iodine fractionation: total iodine 8.6 μ g%, iodoprotein fraction 4.5 μ g%, thyronine fraction (T4 + T3 iodine) 3.4 μ g%, PBI 7.5 μ g%, serum cholesterol 239 mg% (esters 183 mg%). Basal metabolic rate -27%. Thyroxin autoantibodies titer under 1:16. Thyroid scan showed large "cold" nodule replacing the lower pole of the right lobe of the thyroid gland with nodularity also involving the left lobe, lower pole area. Chest x-ray showed no active disease. Thyroid uptake study using ¹³²I showed a 6-hour uptake of 22.3% with urinary excretion of 33%. After three days of treatment with TSH (I.M.) thyroid uptake had increased to 33% at 5-1/2 hours. PBI 8.0 μ g%. Except for slightly low RBC (3,300,000) and hemoglobin (11.6 gm%), the blood count was normal. Urinalysis was negative and the following blood chemistry studies were negative: bilirubin, cephalin flocculation, transaminase, Ca, P, thymol turbidity, FBS, BUN, CO₂, Na, K. Alkaline phosphatase was slightly low (1.4 units); the globulin fraction of proteins was slightly elevated (4.26 gm%).

1 ml

PATIENT NO. 64 (continued)

1

F

]

The EKG was within normal limits. Stools were negative for ova and parasites. Roentgenograms of the chest and bones for metastasis were negative.

Hospital Course: Her hospital course was uneventful.

Surgery at New England Baptist Hospital, Boston, Massachusetts: The patient was transferred to the Baptist Hospital in Boston on July 5, 1965, and the following day under general anesthesia the neck was explored by Dr. Bentley P. Colcock. The thyroid nodule was found to be malignant, and he performed a subtotal thyroid-ectomy leaving a small portion of the left lobe intact. Microscopic study of the tissues gave the following pathologic diagnosis: "Mixed papillary and follicular carcinoma of the right lobe with blood vessel invasion and metastasis to one lymph node. Negative parathyroid (right). Left lobe of thyroid shows no significant changes." Aside from mild postoperative nausea and vomiting, she recovered very rapidly from the operation. In view of the positive diagnosis of malignancy, on July 15 she was given 30 mc 1^{31} I in order to ablate the remainder of the thyroid gland and any possible residual metastatic foci. She was returned to this hospital on July 16, 1965. She remained in good health and was discharged on July 18, fit for travel back to the Marshall Islands.

<u>Diagnosis</u>: Mixed papillary and follicular carcinoma of the right lobe of the thyroid gland with blood vessel invasion and metastasis to one lymph node.

<u>Discharge Medication</u>: On August 1 she is to begin taking desiccated thyroid, 120 mg daily. She is to remain under the direct supervision of one of the Marshallese practitioners on her return.

<u>Follow-Up</u>: Patient has apparently maintained "euthyroid status" on 3 mg of levothyroxine daily. In March, 1966, she was to have a complete hospital checkup at Tripler Army Hospital in Hawaii but was found to be 5 months pregnant, and the examination was delayed until after birth of her baby. In September, 1966, at Tripler General Hospital, Hawaii, thyroid uptake studies following TSH stimulation (10 units daily for two days), thyroid scans, and skeletal surveys for metastasis showed absence of the thyroid and no detectable metastasis.

| PATIENT | NO. | AGE | SEX | | HOSP | ITAL | DATE | | | |
|---------|-----|-----|-----|----------|------------|----------|--------|------|------|------|
| 33 | | 13 | F | Hospital | of Medical | Research | Center | BNI. | June | 1966 |

This 13 year old Marshallese girl was admitted to evaluate a thyroid nodule which was discovered during the past year.

<u>History of Present Illness</u>: The patient was 1 year old at time of exposure to fallout and received about 175 rads of gamma radiation, radiation of the skin from fallout deposited thereon and some internal absorption of radioisotopes. It was estimated that her thyroid gland received 700-1,400 rads from the radioiodines absorbed in addition to the 175 rads of gamma radiation. Acute effects of her exposure consisted of beta burns of the skin and extensive epilation of the scalp. She also developed transient leukopenia and thrombocytopenia. By one year she had recovered from these acute effects and remained generally in good health. Her growth and development has been about normal with menarche occurring at age 13. In September, 1965, she was thought to have an irregularity of the thyroid gland.

PATIENT NO. 33 (continued)

۳

ļ

ļ

Six months later, in spite of being on thyroid hormone therapy, the thyroid gland had enlarged, and a hard 5 mm nodule was palpable in the lower left lobe with irregularity of the remainder of the gland. She had been thought to be euthyroid. In 1965 her PBI was 7.0 μ g%. However, in March, 1966, a thyroxin iodine level of only 3.1 μ g% was obtained, and it was thought that her Achilles reflexes were somewhat sluggish. Her TSH level was elevated.

<u>Physical Examination</u>: The patient appeared well developed and slightly older than her stated age of 13. A firm 1 cm nodule was palpated in the left lateral thyroid area which was freely movable. There was no regional adenopathy palpable. The remainder of the physical examination was essentially negative.

<u>Laboratory and X-Ray Data</u>: <u>Thyroid Studies</u>: PBI was 6.2 µg% with thyroxin iodine 4.5 µg%; **T3** was 12.8%. BMR was -32 and -19; antithyroglobulin titre under 1:16; thyroid scan with ^{99m}Tc showed slight asymmetry of the gland with the right lobe being slightly larger than the left. There was a suggestion of a "cold" nodule in the isthmus. ¹³²I uptake studies showed normal uptake and normal increase following TSH stimulation. Cholesterol was normal (138 mg% with esters 119 mg%). The sedimentation rate was slightly elevated as is usual with the Marshallese. The homogram, chest plate, EKG, as well as other laboratory findings were all within normal fimits.

Hospital Course: The patient was taken to the New England Deaconess Hospital in Boston, Massachusetts, on June 5, 1966. On June 6, Dr. Bentley P. Colcock of Lahey Clinic carried out a bilateral subtotal thyroidectomy, removing multinodular thyroid tissue from both lobes. One nodule was white and firmer than the rest in the left lobe and proved to be Hurthle cell adenoma without evidence of invasion of the capsule. Dr. W. A. Meissner of the New England Deaconess Hospital examined these tissues and his pathological diagnosis was "adenomatous goiter, both lobes; small follicular adenoma, Hurthle cell type right lobe; one negative parathyroid, left; fragment of thymus." Recovery from surgery was uneventful, and the patient was transferred back to this hospital on June 11. She was started on thyroid hormone therapy (desiccated thyroid), 3 grains daily, indefinitely. By June 16 her wound had healed nicely, she was asymptomatic, and she was discharged in order to return to the Marshall Islands.

Diagnosis: (1) Adenomatous goiter. (2) Small follicular adenoma, Hurthle cell type, right lobe.

Discharge Medication: To continue on thyroid hormone therapy indefinitely.

This patient was seen in September, 1966, in the Marshall Islands, and she was found to be euthyroid on the hormone treatment, with no complications.

| PATIENT NO. | AGE | SEX | HOSPITAL | DATE |
|-------------|-----|-----|--|------------|
| 42 | 15 | F | Hospital of Medical Research Center, BNL | June, 1966 |

This 15 year old Marshallese girl was admitted to this hospital for evaluation of a thyroid nodule which had developed during the past year.

This girl had been exposed at 3 years of age to History of Present Illness: radioactive fallout, receiving an estimated dose of 175 rads of whole-body gamma radiation, irradiation of the exposed skin surfaces from direct deposition of fallout material, and some degree of internal absorption of radioactive materials from ingestion of contaminated food and water. It was estimated that the radioiodine absorbed in the fallout delivered a dose to the thyroid gland in the range of 700-1,400 rads and an additional dose of 175 rads was received by the gland from gamma radiation. She had transient gastrointestinal symptoms during the first two days and subsequently developed a leukopenia and thrombocytopenia. Beginning about two weeks after exposure she developed rather marked "beta burns" of the skin and epilation. All of these acute effects had disappeared at about 1 year post exposure. With the exception of the present illness, subsequent examinations have revealed no serious illnesses or injuries in this girl. Her statural growth over the past 12 years has been slightly below the mean curve for the unexposed Marshallese girls in the comparison population. Menarche occurred in 1965. In September, 1965, a small nodule was noted in the right lower pole of the thyroid. In spite of treatment with thyroid hormone the nodule increased in size to about 0.5 mm by March, 1966. She had always been considered to be euthyroid. Her PBI level in March, 1966, was 5.0 $\mu g\%.$

<u>Physical Examination</u>: A small nodule (2-3 mm) was palpated in its left lower lobe. The remainder of the physical examination was essentially negative except for impetigo-like lesions of the skin.

Laboratory and X-Ray Data: Thyroid Work-Up: PBI was 6.5 μ g% with 4.5 μ g% of thyroxin; 73 12.9%; antithyroglobulin titre under 1:16; thyroid scan with ^{99m}Tc showed normal uptake with several "hot" nodules noted in the right upper lobe, right middle lobe and left upper lobe; ¹³²I uptake was normal and showed normal increase following TSH stimulation. BMR was +25 and +28; cholesterol level was low (118 mg% with 105.8 mg% esters). In contrast to some of the other Marshallese cases, these findings seemed to indicate a slightly increased functioning gland. Chest plate and EKG were normal. The hemogram and the remainder of the laboratory work-up was essentially negative.

Hospital Course: Following the initial examination at this hospital, the patient was removed on June 5 to the New England Deaconess Hospital, Boston. On June 8, 1966, a bilateral subtotal thyroidectomy was performed by Dr. Bentley P. Colcock of the Lahey Clinic, removing thyroid tissue which contained multiple nodules, the largest being about 0.5 cm. Dr. W. A. Meissner of the New England Deaconess Hospital reported that the surgical specimens contained multiple nodules of varying sizes and his pathological diagnosis was: adenomatous goiter. The patient's recovery from surgery was uneventful, and she was returned to Brookhaven on June 11. She was started on desiccated thyroid treatment, 180 mg daily to be continued indefinitely. Her surgical wound healed nicely and she was asymptomatic.

Diagnosis: Adenomatous goiter.

ī

ş

PATIENT NO. 42 (continued)

1

I

I

Discharge Medication: Thyroid hormone medication to be continued indefinitely.

This patient was seen in September, 1966, in the Marshall Islands, and she was found to be euthyroid on the hormone treatment, with no complications.

| PATIENT NO. | AGE | SEX | HOSPITAL | DATE | |
|-------------|-----|-----|--|------------|---|
| 59 | 46 | F | Hospital of Medical Research Center, BNL | June, 1966 | - |

This 46 year old Marshallese woman had been exposed to radioactive fallout in 1954 and was admitted for evaluation of a nodule of the thyroid gland.

History of Present Illness: In September, 1965, during a thyroid survey of the Rongelap people, a 0.5 cm nodule was noted in the left isthmic region of the thyroid. This patient had received a smaller dose of radiation at the time of the fallout than the other Rongelap patients admitted here at this time. The calculated dose to the thyroid gland was about 115 rads (69 rads from whole body gamma radiation, and about 40 rads from radioiodines). She had few signs of acute radiation effects except for mild "beta burns", and slight thrombocytopenia following exposure. Since this time she had remained generally in good health. Her disease history includes chickenpox, mumps, yaws, and gonorrhea. She has had recurring attacks of bronchitis though x-rays of the chest have been considered negative in the past. She had always appeared to be euthyroid with PBIs in 1958 and 1965 in the normal range for the Marshallese. Iodine fractionation studies in March, 1966, were normal.

<u>Physical Examination</u>: On admission the patient was febrile, and it was thought that she might have bronchopneumonia, bronchitis, influenza, or possibly tuberculosis. Thyroid examination showed the gland not to be enlarged, but a freely moveable 1 cm nodule in the lower part of the gland was palpated. There was no lymphadenopathy. The remainder of the physical examination was essentially negative.

Laboratory and X-Ray Data: Pulmonary Studies: Chest plates on May 26 and 27 showed possible pneumonitis in the upper and middle right lobes of the lungs which were believed to be of partly acute, partly chronic nature (Tbc?). A chest plate on 5/31 showed that the middle lobes remained essentially unchanged. PPD showed slight reaction to second strength test. <u>Hemogram</u> showed neutrophilic leukocytosis on admission which returned to normal about 5 days later. <u>Thyroid Studies</u>: BMR -27 and -24. PBI 6.4 μ g%, T3 13.9%, thyroxin iodine 5.0 μ g%. Antithyroid antibodies under 1:16. Cholesterol 102.8 (94.3 esters). Thyroid scan using 99mTc revealed no nodules and normal uptake. 132I showed 19.8% uptake in 6 hours with 45% urinary excretion. Following TSH (10 units daily for 3 days), the uptake increased to 54.9% in 6 hours with urinary excretion rate of 20.3%. EKG was normal. Except for weakly positive VDRL and REITER protein complement fixation test, other laboratory tests were generally negative.

PATIENT NO. 59 (continued)

2

F

1

H

The acute pneumonitis noted on admission responded well to Hospital Course: acromycin and penicillin therapy, and the patient became afebrile and asymptomatic within a few days. The right middle lobe showed clearing, but the upper lobe showed persistent changes, and in view of the slightly positive secondstrength reaction to the PPD, Dr. L. R. Sonders, Boston, felt that tuberculous infection was consistent with the findings though he considered it likely that the process was inactive and not contraindicative to surgery. The results of the thyroid study did not suggest any thyroid metabolic imbalance. Though the BMR was somewhat low and the cholesterol low, the iodine fractionation studies and uptake studies as well as effect of stimulus of TSH were normal. She was admitted to the New England Deaconess Hospital on June 6, and surgical excision of the thyroid isthmus containing a 0.4 cm nodule was accomplished on June 8. The patient withstood the surgery well and the wound healed per primam. The histological diagnosis was adenomatous goiter. She was returned to this hospital on June 11. On Dr. Sonder's recommendation she was placed on isoniazid therapy, 100 mg t.i.d. In view of her positive serology she was placed on penicillin, 600,000 units daily for a total dose of 6.5 million units. In addition, she was started on desiccated thyroid, 180 mg daily. She was discharged on June 16 to return to the Marshall Islands. A letter was sent to the medical authorities in the Marshalls advising them to continue the isoniazid for 2 years and thyroid therapy indefinitely. They would be informed later of the results of the tuberculous cultures, and, if possible, it was recommended that she be placed in the hospital for treatment with PAS.

Diagnosis: (1) Adenomatous goiter. (2) Pulmonary tuberculosis--unspecified activity (002.9). (3) Positive serology (028.3).

Discharge Medication: To continue indefinitely on thyroid hormone medication.

This patient was seen in September, 1966, in the Marshall Islands, and she was found to be euthyroid on the hormone treatment, with no complications.

| PATIENT NO. | AGE | SEX | HOSPITAL | DATE | | | |
|-------------|-----|-----|--------------------------------------|------|------------|--|--|
| 61 | 20 | F | Hospital of Medical Research Center, | BNL | June, 1966 | | |

This 20 year old Marshallese female was admitted to this hospital for evaluation of a thyroid nodule which was discovered during the past year.

<u>History of Present Illness</u>: As a 7 year old girl the patient was exposed to radioactive fallout in 1954. She was exposed to an estimated dose of 175 rads of whole-body gamma radiation, significant amounts of radiation to the exposed skin surfaces from deposition of fallout material thereon, and some internal absorption of fallout. It was estimated that the radioiodines absorbed delivered a dose to the thyroid in a range of 300-1,000 rads in addition to the 175 rads of gamma radiation. She had transient early gastrointestinal symptomatology which was followed some two weeks later by mild beta burns of the skin and moderate degree of epilation of the head. She also had leukopenia and thrombocytopenia within the first six weeks. She had largely recovered from these acute effects by one year post exposure. Her subsequent medical history shows no findings which could be related to radiation exposure. There were no noteworthy illnesses. Her growth

PATIENT NO. 61 (continued)

and development has appeared to be entirely normal, if not somewhat precocious. A l cm nodule of the left lower pole of the thyroid was noted in September, 1965, which did not decrease on thyroid hormone therapy. She appeared to be euthyroid with PBIs in the normal Marshallese range. Her cholesterol was slightly elevated in 1957 (277 mg%)-

<u>Physical Examination</u>: The patient was obese. The remainder of the physical examination was essentially negative except for slight acne and dental caries.

Laboratory and X-Ray Data: Thyroid Studies: PBI was 7.5 μ g% with thyroxin iodine 4.9 μ g%; T3 was 12.9%. Antithyroglobulin titre was 1:32. Cholesterol was 162 mg% (esters 151 mg%). Thyroid scan using ^{99m}Tc showed normal uptake but the gland was asymmetrical, with the right lobe showing uptake only in the upper portion. A "hot" nodule was noted in the lower left pole of the thyroid. 132I uptake was normal and there was normal increase in uptake following TSH stimulation. The chest plate and EKG were normal. The remainder of the laboratory studies were essentially negative except for an increased sedimentation rate which is an unexplained finding in most of the Marshallese.

<u>Hospital Course</u>: Following the studies at this hospital, the patient was transferred to the New England Deaconess Hospital in Boston on June 5, 1966. On June 8, Dr. Bentley P. Colcock of Lahey Clinic performed a bilateral subtotal thyroidectomy removing a 1.5 cm nodule in the left lower thyroid lobe and a small cyst in the right lower lobe. Dr. W. A. Meissner of the New England Deaconess Hospital examined the surgical specimens, and his pathological diagnosis was "adenomatous goiter." Recovery from surgery was uneventful, and the patient was readmitted to this hospital on June 11. She was placed on desiccated thyroid, 180 mg daily, indefinitely. Her wound healed nicely, and she was asymptomatic.

Diagnosis: Adenomatous goiter.

Ī

ł

3

ļ

Discharge Medication: Thyroid hormone therapy to be continued indefinitely.

This patient was seen in September, 1966, in the Marshall Islands, and she was found to be euthyroid on the hormone therapy, with no complications.

| PATIENT NO | . AGE | SEX | | HOSI | PITAL | DATE | | | |
|------------|-------|-----|----------|------------|----------|---------|-----|-------|------|
| 65 | 13 | F | Hospital | of Medical | Research | Center, | BNL | June, | 1966 |

This 13 year old Marshallese girl was admitted to this hospital for evaluation of a 0.5 cm nodule of the right lobe of the thyroid gland discovered during the past year.

<u>History of Present Illness:</u> This child was exposed to fallout radiation in 1954 at 1 year of age and received an estimated dose of 175 rads of whole-body gamma radiation, irradiation of the skin from deposition of fallout material thereon, and absorption of significant amounts of radionuclides from ingestion of contaminated food and water. It was estimated her thyroid gland received a dose in the range of 700-1,400 rads from radioiodines in the fallout and in addition 175 rads from gamma radiation. She had early gastrointestinal symptoms

PATIENT NO. 65 (continued)

7

ł

1

E

E

followed two weeks later by the development of marked beta burns of the skin and epilation of the scalp and leukopenia and thrombocytopenia. She had recovered from these effects by one year. Her subsequent medical history revealed no serious illnesses, but the child was thin and appeared to be somewhat retarded in growth and development. Menarche had not yet occurred. She had recurrent impetigo infections of the skin. On discovery of her thyroid nodule in September, 1965, she was placed on thyroid hormone therapy. The nodule did not reduce in size on this therapy and therefore she was brought here for treatment. Until recently she had been thought to be euthyroid with normal PBI and cholesterol levels. However, by March of this year her thyroxine iodine level was down to $1.9 \ \mu g\%$, and she showed increased TSH levels suggestive of a hypofunctioning thyroid gland.

<u>Physical Examination</u>: This slender girl appeared younger than her stated age. A l cm thyroid nodule was noted in the lower pole of the right thyroid. No lymphadenopathy was noted. The remainder of the physical examination was essentially negative, except for the presence of a small pilonidal sinus.

Laboratory and X-Ray Data: Thyroid Work-Up: Iodine fractionation studies on her plasma revealed thyroxine iodine of $3.5 \ \mu$ g% (however, she had only been off of thyroid hormone therapy for about two weeks). Her TSH levels were quite elevated (125 m μ g/ml). Antithyroglobulin titre was under 1:16. Thyroid scan using 99m Tc showed a small but apparently normal thyroid. Though 99m Tc uptake was normal, the 132 I uptake at 6 hours was somewhat low and little increase was noted after TSH stimulation. These findings are in conformity with a hypofunctioning gland. A chest plate was negative except for suggestive extrinsic pressure on the right side of the trachea at the level of T-1. Alkaline phosphatase level was elevated (13.0 units).

Hospital Course: The patient's hospital course here was uneventful. On June 5 she was transferred to the New England Deaconess Hospital, and on June 6, Dr. Bentley P. Colcock of Lahey Clinic performed thyroid surgery in that hospital. A right subtotal thyroidectomy was performed with removal of the lower right pole of the thyroid as well as a small cyst from the left lobe. The microscopic diagnosis of removed tissues by Dr. W. A. Meissner of the New England Deaconess Hospital was "adenomatous goiter." She was returned to Brookhaven on June 11, and her recovery from surgery was uneventful. She was placed on desiccated thyroid, 180 mg daily, to be continued indefinitely. The wound healed nicely, and she was asymptomatic.

Diagnosis: Adenomatous goiter.

Discharge Medication: To continue thyroid hormone therapy indefinitely.

This patient was seen in September, 1966, in the Marshall Islands, and she was found to be euthyroid on the hormone treatment, with no complications.

| APPENDIX | 7 |
|----------|---|
|----------|---|

1

1

構え

Ţ

3

Į

A. Malignancies Recorded in Marshall Islands, May 1952-October 1962*

| - <u>Malignancy</u> | <u>No. of Cases</u> |
|--|---------------------|
| Ca, cervix | 11 |
| Adenocarcinoma, large bowel | 3 |
| Carcinomatosis, abdominal cavityprimary site unknown | 5 |
| Osteosarcoma | 1 |
| Ovarian ca | 5 |
| Bronchogenic ca (x-ray and clinical) | 3 |
| Bronchogenic ca (autopsy and tissue examination) | 1 |
| Skin (squamous cell ca of lip) * | 1 |
| Adenocarcinoma of thyroid | 2 |
| Adenocarcinoma of breast | 3 |
| Hypernephroma | 1 |
| Ca of liver (exploratory surgery) | 1 |
| Ca of liver (biopsy and/or autopsy) | 3 |
| Leukemia | 2 |

*Statistics obtained from District Director of Public Health, Marshall Islands. Probably represents more than 58% of cases.

VS67 015 012767

B. NUMBER OF PATIENTS WITH MALIGNANT NEOPLASMS, CLASSIFIED BY TYPE DISCHARGED FROM DISTRICT NOSPITALS TRUST TERRITORY, 1962-4965

| | 1 | | DIST | ALCT HO | ICT HOSPITAL | | | | |
|---|-------|--------------------|-----------|----------|--------------|------|--------------------------------|--|--|
| SITE OF MALIENANT NEOPLASM | TOTAL | MARYARA ISLANDS | MARSHALL | PALAS | POBAPE | TRUX | YAP | | |
| ALL SPRES, TOTAL | 182 | 36 | 40 | 23 | 33 | 37 | 13 | | |
| BUCCAL CAVITY AND NASOPHARYNX (140-148), TOTAL | 13 | <u>6</u> | ļ | <u>1</u> | 3 | 2 | = | | |
| Tongue (141) | 1 _ | | | - | | - | 1 - | | |
| SALSVARY GLASS (142) | 2 | - | - | - | . 1 | 1 | - | | |
| FLOOR OF MOUTE (143) Other state of moute the moute subscripting (144) | | - | - | - | 1 | - | - | | |
| ORAL RASOPHARYEX (145) | | | - | 1 | - | 1 | - | | |
| NABOPHARYKX (146) | 5 | 5 | - | - | _ | - | - | | |
| НУРОРНАЯЧКХ (147) Риавчка, инвресіясер (148) | 1 | - | - | - | - | - | - | | |
| DISTRICT ORGANS AND PERITOREUM (150-159). TOTAL | 36 | 7 | 7 | 9 | 6 | | 3 | | |
| EBOPWAGUS (150) | 7 | | - | ů. | Ť | ÷ | 1 | | |
| STCMACH (151) | - 11 | 5 | 2 | 1 | 3 | - | - | | |
| SMALL INTERTINE, INCLUDING BUDDENUM (152) | 1 2 | - | - | | - | - | - | | |
| RECTUM (154) | | | | 3 | | - | - | | |
| BILLARY PAGRAGES AND LIVER (PRIMARY) (155) | 14 | 1 | 3 | 5 | 2 | 1 | 2 | | |
| LIVER (BECONDARY AND UNBFECIFIED)(156) Range De (167) | 2 | - | - | - | - | 1 | ł | | |
| PERITONEOM (157) Peritoneom (158) | 2 | - | - | - | - | 1 | - | | |
| RESPERATORY RYRTEM (160-165), TOTAL Nose, Badal Cavities, Middle EMB and Accessory Ribbers | ц | <u>3</u> | <u>3</u> | 1 | 2 | 5_ | Ţ | | |
| (160) | 1 1 | - | - | - | - | 1 | - | | |
| LARYRX (161) BRANCHING AND VELCHER AND FILME REFERENCE AS RELEASED (187) | ! | | - | - | - | - | - | | |
| LUBG. UNSPECIFIED AS TO WRETHER PRIPARY OF SECONDARY (163) | 3 | | 4 | - | ~ | 3 | | | |
| MED 24372890 (164) | 1 | - | Ī | - | - | | - | | |
| TWORACIC GREAKS (SECONDARY) (165) | 1 | - | - | - | - | 1 | - | | |
| BREAST AND GENETOURINARY SYSTEM (170-181), TOTAL | E | 8 | <u>18</u> | 7 | 13 | 13 | 3_ | | |
| GENVIX UTERI (171) | 24 | | 4 | 2 | 9 | | 7 | | |
| CORPUS UTERS (172) | 6 | 3 | 2 | - | Ĩ | | - | | |
| OTHER PARTS OF UTERUS, INCLUDING CHORIGEPETHELIONA (173) | - | - | - | - | - | - | - | | |
| UTERDA, UNEPECTIED (174) Ovary, Fallopian tune and Angar Escandat (175) | 3 | - | | - | - | 2 | - | | |
| OTHER AND URSPECIFIED FEMALE GENETAL ORGANS (176) | 1 | | - | - | ī | | - | | |
| PROSTATE (177) | 5 | 1 | 1 | 2 | - | | + | | |
| ILETIE (1/0) {TPER AND URRESCIPTED MALE CENTRE DECAME (179) | | - | - | - 2 | - | - | 1 | | |
| KIOPEY (180) | 3 | 1 | 1 | - | ĩ | | - | | |
| BLADDER AND OTHER URINARY ORGANS (181) | 2 | i | - | - | - | - | 1 | | |
| OTHER AND UNSPECIFIED SITES (190-199), TOTAL | 34 | 5_ | <u>1</u> | 2 | 6 | 9 | 5_ | | |
| (TALISHANT MELANDRA OF BRIN (197) Other Malishant neoplasm of Brin (197) | | - | - | - | 2 | | | | |
| Evt (192) | | | | - | - | | - | | |
| BRAIN AND OTHER PARTE OF RERVOUS SYSTEM (193) | 2 | | - | - | · • | - | 2 | | |
| THYROLS GLARD (194) | 5 | 1 | 2 | 2 | | - | - | | |
| BONE (ANGLUBING JAW BONE) (196) | 3 | | - | - | - | - | - | | |
| CONNECTOVE SERANE (197) | 4 | | | - | - | 3 | ī | | |
| SECONDARY ARE UNSPECIFIED MALSONANT REOPLASM OF LYMPH | | | | | | | | | |
| NOOE (198) Other and unspecified bites (199) | 6 | | - 3 | - | 2 | - | . ∔ . . - | | |
| THOUSTER AND DEMITRICIETIE TIRTEE (200-206) | 1 |) . | | | | | | | |
| {VMFROSARCOMA AND RETICULOSARCOMA (200) | 1 5 | 1 1 | 2 | 7 | 1 7 | 7 | 1 | | |
| HOOGKEN'S DISEASE (201) | 1 1 | - | | 1 1 | 1 - | | ~ | | |
| OTHER FORME OF LYMPHOMA (RETICULOSIS) | : | - | - | - | - | - | - | | |
| FINETTEE MYELOMA (PLASMOCYTONA) (203) 1 El Efnia and Alfurenja (204) | 5 | 4 | | 1 7 | 1 2 | ; | 7 | | |
| MYCOSIS FUNGOINES (205) | 1 " | | 1 1 | 1 1 | 1 | | | | |
| · · · · · · · · · · · · · · · · · · · | 1 | 1 | 1 | ł | 1 | 1 1 | | | |

SOURCE: DISEASE SUMMARY CARDS FROM THE HOSPITALS.

111

Ĩ

,

5

-

E

-

7

F

3

Ŧ

| AP | PEND | IX 8 |
|----|------|------|
|----|------|------|

| | WBC (X10 | WBC (X10-3) | | WBC (X10-3) | | ophils 0 ⁻³) | Lymph (X10 | nocytes)-3) | | Pla (X | $telets$ (10^{-4}) | | | Hemato % | ocrit | | RBC (X10-6 |) |
|------------------|-------------|----------------|------|----------------|-----|-----------------------------|---------------|-------------------|----------|-----------|----------------------|-------|----------|-------------|-------|----------|---------------|---|
| | | | | | | | Male | Male | Female | Total | Male | Male | Female | Male | Male | Female | | |
| Postexposure Day | <5 | >5 | <5 | >5 | <5 | >5 | <10 | >10 | All Ages | Group | <15 | >15 | All Ages | <15 | >15 | All Ages | | |
| 3 | 9.0 | 8.2 | 6.4 | 4.7 | 1.8 | 2.2 | | · | | | | | | | | | | |
| 7 | 4.9 | 6.2 | | | | | | | | | | | | | | | | |
| 10 | 6.6 | 7.1 | 3.5 | 4.5 | 2.6 | 2.1 | 28.2 | 22.7 | 24.9 | 24.8 | | | | | | | | |
| 12 | 5.9 | 6.3 | 3.5 | 3.9 | 2.1 | 1.7 | | | | | | | | | | | | |
| 15 | 5.9 | 6.5 | 3.2 | 4.1 | 2.4 | 1.9 | 27.1 | 21.3 | 21.7 | 22.5 | | | | | | | | |
| 18 | 6.7 | 7.2 | 3.4 | 4.7 | 2.4 | 2.1 | 21.8 | 19.1 | 21.8 | 21.0 | | | | | | | | |
| 22 | 7.0 | 7.4 | 4.3 | 5.0 | 2.6 | 2.1 | 16.8 | 14.6 | 15.2 | 15.3 | 37.5 | 43.9 | 39.0 | | | | | |
| 26 | 5.7 | 6.1 | 3.0 | 3.9 | 2.3 | 1.8 | 13.2 | 12.9 | 10.9 | 11.9 | 36.3 | 41.6 | 37.5 | | | | | |
| 30 | 7.6 | 7.8 | 4.0 | 5.3 | 3.2 | 2.1 | 14.1 | 12.3 | 11.8 | 12.3 | 37.9 | 42.2 | 37.1 | | | | | |
| 33 | 6.5 | 6.2 | 3.1 | 3.8 | 3.2 | 2.0 | 17.9 | 16.6 | 15.1 | 16.0 | 37.4 | 42.2 | 36.8 | | | | | |
| 39 | 5.7 | 5.5 | 3.0 | 3.3 | 2.6 | 2.0 | 29.5 | 22.0 | 22.4 | 22.8 | 37.8 | 42.4 | 37.4 | | | | | |
| 43 | 5.2 | 5.2 | 2.0 | 2.6 | 2.9 | 2.3 | 26.8 | 20.9 | 23.2 | 23.2 | 37.3 | 41.8 | 37.6 | | | | | |
| 47 | 5.9 | 5.8 | 2.6 | 3.3 | 3.1 | 2.4 | 24.6 | 20.6 | 23.9 | 23.1 | 39.0 | 43.4 | 38.3 | | | | | |
| 51 | 6.7 | 5.6 | 2.6 | 3.5 | 3.4 | 2.1 | 22.1 | 17.5 | 21.2 | 20.3 | | | | | | | | |
| 56 | 7.0 | 6.0 | 3.5 | 3.5 | 3.7 | 2.4 | | | | | | | | | | | | |
| 63 | 7.7 | 6.0 | 3.9 | 3.6 | 3.7 | 2.3 | 23.1 | 18.2 | 20.2 | 20.1 | | | | | | | | |
| 70 | /.6 | 6.5 | 3.8 | 4.0 | 3.3 | 2.2 | 26 2 | 21 7 | 24.7 | 2/ 1 | | | | | | | | |
| 74 | | | | | | | 20.2 | 21.7 | 24.7 | 24.1 | 20 0 | / 1 7 | 20 2 | | | | | |
| 6-mo survey | 8.5 | 6.6 | 4.6 | 4.2 | 3.6 | 2.2 | 24.4 | 20.3 | 23.2 | 22.6 | 30.0 | 41.7 | 30.2 | | | | | |
| l-yr survey | 10.1 | 8.1 | 4.7 | 4.8 | 4.9 | 2.8 | 20.0 | 19.5 | 2/.0 | 24.9 | 2/.2 | 41.1 | 20.9 | | | | | |
| 2-yr survey | 11.8 | 8.6 | 5.9 | 4.8 | 4./ | 3.1 | 30.0 | 21.4 | 23.3 | 24.7 | 35.6 | 38 7 | 35.4 | | | | | |
| 3-yr survey | 8.6 | 6.9 | 4.1 | 3.1 | 3.1 | 2.1 | 32.0 | 22.1 | 20.1 | | 35.6 | /1 0 | 35.8 | | | | | |
| 4-yr survey | 8.9 | /.2 | 3.3 | 3.4 | 4.0 | 3.0 | 22.2 | 2/.1 | 27.6 | | 55.0 | 41.0 | 55.0 | 4 45 | 4 71 | 4 21 | | |
| 5-yr survey | 13.5 | 9.5 | 0.9 | 4.0 | 0.0 | 4.0 | 32.5 | 24.4 | 27.0 | | | | | 4.45 | 4./1 | 4.21 | | |
| 6-yr survey | | 6.5 | | 3.5 | | 2.7 | | | 27 2 | | 27 6 | 41 7 | 27 0 | · · · | 1.45 | 4 11 | | |
| 7-yr survey | | 7.4 | | 3.9 | | 2.9 | | 24.0 [~] | 27.5 | | 20 5 | 41.7 | 37.0 | 4.54 | 4.45 | 4.11 | | |
| 8-yr survey | | 6.9 | | 3.0 | | 2.6 | | 32.04 | 32.1 | | 20.1 | 43.0 | 39.5 | 4.00 | 4.07 | 4.44 | | |
| 9-yr survey | | 1.4 | | 3.7 | | 3.0 | | 23.1~ | 20.4 | | 29.1 60 6 | 43.7 | 20.4 | 4.29 | 4.50 | 4.12 | | |
| 10-yr survey | | 8.2 | | 3.8 | | 3.5 | | 32.0 | 27.2 | | 20.0 | 43.5 | 27.5 | 1 65 | 1 60 | 3 9/ | | |
| ll-yr survey | | 1.4 | | 3.1 | | 3.0 | | 20.3 | 40.0 | | 38.8 | 44.0 | 38.3 | 4.05 | 4,00 | 3.74 | | |
| 12-yr survey | 12 2 | 0.0 | 1. 0 | 2.0 | 7 / | 2.5 | 41 2 | 25 8 | 36 5 | 33 4 | 39.6 | 46 0 | 39.9 | | | | | |
| Majuro controls | 13.4 | 9.1 | 4.0 | 4.0 | 1.4 | 4.1 | 35 0 | 27.3 | 30.9 | 30.4 | | | | | | | | |
| Rita cont. 6 mo | 10.7 | 1.0 | 5.4 | 5.2 | 4./ | 5.7 | 37.5 | 24.5 | 29.4 | 27 6 | | | | | | | | |
| Rita cont. 1 yr | 1/ 0 | 0 0 | 7 0 | <u> </u> | 5 6 | 3 6 | 35 5 | 24.3 | 31 2 | 29.5 | 38 9 | 42 1 | 39.8 | | | | | |
| Kita cont. 2 yr | 14.0 | 6.9 | 1.0 | 4.4 | 5.0 | 29 | 32 6 | 26.9 | 30.0 | | 35.6 | 41.0 | 35.9 | | | | | |
| Kong. cont. 3 yr | 7.0 | 8 0 | 4.0 | 3.4 | 4.7 | 3 7 | 38.8 | 30.7 | 34.0 | | 35.5 | 42.8 | 35.1 | | | | | |
| Rong, cont. 4 yr | 13 7 | 10 1 | 4.0 | 5.2 | 6.2 | 4 1 | 35.8 | 28.0 | 33.6 | | | | | 4.60 | 4.80 | 4.40 | | |
| Rong cont 7 yr | 12.1 | 7 8 | | 4.2 | | 3.1 | | 28.58 | 31.4 | | 37.2 | 44.4 | 37.0 | 4.52 | 4.68 | 4.12 | | |
| Rong, cont. 7 yr | | 4.5 | | 7.5 | | 2.0 | | 34 8t | 34.5 | | 38.3 | 44.1 | 39.0 | 4.60 | 4.90 | 4.47 | | |

^aIncludes all males >7.

Rong. cont. 8 yr ---- 7.7 Rong. cont. 9 yr ---- 7.7 Rong. cont. 9 yr ---- 7.7 Rong. cont.10 yr ---- 9.1 Rong. cont.11 yr ---- 7.3

^bIncludes all males >8.

34.8^b 29.1^c 35.4

28.1

_ _ _ _ _

2.9 3.1 3.5

2.8

- - -

4.2

3.9

_ _ _ _

34.5 32.5 37.9

28.3

37.2 44.4 38.3 44.1 39.4 43.8 37.4 44.1

39.6 44.4

37.0 39.0 38.3 38.3

37.6

4.65 4.71 ^cIncludes all males > 9.

4.52 4.68 4.60 4.90 4.33 4.50

4.47 4.13

4.14

61

| | WBC | | Neutro | phils | Lymph | ocyte | s | P1 | atelets | ······ | Н | ematoc | rit | | RBC | |
|--|--|--|--|---|---|---|---|--|--|--|---|--|--|--------------------------------------|--------------------------------------|--------------------------------------|
| | (x10 ⁻ | ³) | (x10 |) ⁻³) | (x1 | .0 ⁻³) | | (| ×10 ⁻⁴) | | | % | | | (x10 | ⁶) |
| Postexposure day | <5 | >5 | | >5 | <5 | >5 | Male < 1 0 | M≞le ▶10 | Female all ages | Total group | Male <15 | Male >15 | Female all ages | Male <15 | Male >15 | Female all ages |
| Postexposure day 3 7 10 12 15 18 22 26 30 33 39 43 47 51 54 6-mo survey 1-yr survey 2-yr survey 4-yr survey 5-yr survey 5-yr survey 6-yr survey 9-yr survey 1-yr su | <5 6.0 5.5 6.3 6.3 7.1 6.8 8.9 8.4 9.6 7.7 7.5 6.9 7.3 8.4 4.6 7.7 11.1 11.0 12.1 11.5 13.2 10.7 | >5 76.7.7.7.8.7.666.5.7.9.7.7.5.12276 7.5.12276 7.5.12276 7.5.12276 7.5.12276 | 3.0 3.0 3.0 3.0 3.0 3.0 4.2 1.8 2.3 2.3 3.0 4.2 4.2 5.3 3.3 2.7 3.5 3.8 4.2 5.3 3.3 2.7 3.5 3.8 4.8 4.2 5.5 2.8 4.9 5.5 2.8 4.9 5.5 2.8 4.9 5.5 2.8 4.9 5.5 2.8 5.5 2.8 5.5 2.8 5.5 2.8 5.5 2.8 5.5 2.8 5.5 2.8 5.5 2 | >5 | <5 2.8 1.9 3.1 4.2 3.7 3.2 3.7 3.5 4.7 3.9 3.4 4.0 3.2 2.7 3.5 4.0 3.2 3.7 4.0 3.2 4.0 3.4 4.0 3.5 4.0 3.4 4.0 3.7 4.0 7.0 4.0 7.0 4.0 7.0 4.0 7.0 4.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7 | >5 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2. | Male <10 22.5 29.0 27.5 20.0 19.5 24.0 26.5 28.0 27.0 37.0 32.0 37.0 25.2 38.7 51.2 40.8 33.2 40.9 | Male >10 22.6 20.2 21.7 17.0 13.8 12.8 12.8 15.8 20.0 19.6 20.0 18.2 19.6 20.0 18.2 19.6 20.0 19.8 21.4 17.4 22.6 20.2 21.7 17.0 13.8 19.6 20.0 19.8 20.6 20.0 19.6 20.0 19.2 21.4 17.4 22.6 20.2 21.7 17.0 13.8 19.6 20.0 19.2 21.4 17.4 22.6 20.2 21.4 17.4 23.4 23.4 23.4 25.6 23.4 25.6 20.5 20.5 20.5 20.5 20.0 19.8 20.6 20.0 19.8 20.6 20.0 19.8 20.5 20.6 20.0 19.2 21.4 17.4 22.6 33.4 5 23.5 25.6 20.2 21.4 22.6 23.5 25.6 20.5 22.6 20.0 22.6 20.0 20.0 22.6 20.0 20.0 22.6 20.0 22.6 20.0 22.6 20.0 22.6 20.0 22.6 20.0 22.6 20.0 22.6 20.5 | remate all ages 20.9 24.6 24.9 22.9 17.4 18.2 22.7 27.0 25.3 26.1 25.0 23.8 23.9 28.3 26.4 31.2 33.6 26.8 28.1 32.7 23.6 41.5 34.7 36.5 30.9 29.4 | Total group 21.3 23.9 24.3 21.3 16.7 16.8 17.6 24.5 23.9 24.5 23.9 24.5 23.9 24.5 23.9 24.5 23.9 24.5 23.9 24.5 23.9 24.5 23.9 24.7 27.5 26.7 | Male <15 37.5 36.5 35.0 35.5 35.0 36.0 35.5 33.0 35.7 37.5 36.0 37.5 36.0 37.5 36.0 37.5 36.0 37.5 36.0 37.5 38.5 38.5 38.5 38.5 | Male >15 43.7 43.2 44.6 43.8 45.6 45.2 46.5 40.1 44.6 45.2 46.5 40.1 44.6 43.8 45.6 45.2 46.0 43.0 44.2 44.0 43.0 43.0 44.2 44.0 43.0 43.0 44.2 44.0 43.0 43.0 43.0 44.2 44.0 43.0 43.0 43.0 44.2 44.0 43.0 43.0 43.0 44.2 44.0 43.0 43.0 43.0 44.2 44.0 43.0 43.0 43.0 44.2 44.0 43.0 43.0 43.0 44.2 44.0 43.0 43.0 43.0 44.2 44.0 43.0 43.0 43.0 43.0 44.0 43.0 43.0 43.0 44.0 43.0 44.0 43.0 44.0 43.0 44.0 43.0 43.0 44.0 43.0 43.0 43.0 43.0 43.0 43.0 44.0 43.0 43.0 43.0 43.0 43.0 43.0 43.0 43.0 43.0 43.0 43.0 43.0 44.0 43.0 44.0 43.0 45.0 4 | remaie all ages 39.2 36.8 36.7 37.3 37.4 36.8 40.2 37.3 36.2 37.5 35.6 35.7 37.0 37.8 38.3 38.3 37.6 37.8 39.9 20.8 | Male <15 | Maie >15 | remate all ages |
| Rita cont. 2 yr Rong. cont. 3 yr Rong. cont. 4 yr Rong. cont. 5 yr Rong. cont. 7 yr Rong. cont. 8 yr Rong. cont. 8 yr Rong. cont. 9 yr Rong. cont.10 yr Rong. cont.11 yr | 14.0 9.8 11.2 13.7 | 8.9 6.9 8.0 10.1 7.8 7.7 7.7 9.1 7.3 | 7.0 4.0 4.0 6.2 3 | 4.4 3.6 5.2 4.2 3.9 4.8 3.9 | 5.6 4.7 6.2 6.2 | 3.6 2.9 3.7 4.1 3.1 2.9 3.1 3.5 2.8 | 35.5 32.6 38.8 35.8 | 24.2 26.9 30.7 28.0 28.5 ^a 34.8 ^b 29.1 ^c 35.4 28.1 | 31.2 30.0 34.0 33.6 31.4 34.5 32.5 37.9 28.3 | 29.5 | 38.9 35.6 35.5 37.2 38.3 39.4 37.4 39.6 | 42.1 41.0 42.8 44.4 44.1 43.8 44.1 44.4 | 39.8 35.9 35.1 37.0 39.0 38.3 38.3 37.6 | 4.60 4.52 4.60 4.33 4.65 | 4.80 4.68 4.90 4.50 4.71 | 4.40 4.12 4.47 4.13 4.14 |

Ailingnae Group and Control Mean Blood Counts at Various Times After Exposure

P**+8

^aIncludes all males > 7.

کينا

^bIncludes all males > 8.

^CIncludes all males > 9.

.

APPENDIX 9

APPENDIX 10

Pr 4

il haddi

Utirik Group Mean Blood Counts at Various Times After Exposure

.

| | WB (X10 | c -3) | Neutro (X10 | ophils - ³) | Lymph (X10 | ocytes ⁻³) | | Plate (X10 | lets -4) | | Hemato % | crit | | RBC (X10- | 6) |
|------------------|------------|----------|----------------|----------------------------|---------------|---------------------------|-------------|---------------|--------------------|-------------|-------------|--------------------|-------------|--------------|--------------------|
| Postexposure Day | <5 | >5 | <5 | >5 | <5 | >5 | Male <10 | Male >10 | Female All Ages | Male <15 | Male >15 | Female All Ages | Male <15 | Male >15 | Female All Ages |
| 4 | 9.4 | 8.2 | 4.7 | 4.2 | 4.9 | 3.2 | | | | | | | | | |
| 14 | 10.0 | 8.6 | 4.1 | 3.2 | 5.1 | 2.9 | | | · | | | | | | |
| 19 | | | | | | | 38.9 | 28.1 | 35.6 | 39.9 | | | | | |
| 29 | 10.1 | 9.7 | 4.9 | 5.8 | 4.8 | 3.2 | 34.5 | 25.6 | 31.7 | 39.9 | 45.1 | 39.4 | | | |
| 3-yr survey | 9.8 | 6.9 | 4.0 | 3.4 | 4.7 | 2.9 | 32.6 | 26.9 | 30.0 | 35.6 | 41.0 | 35.9 | | | |
| 9-yr survey | | 7.6 | | 3.9 | | 3.0 | | 35.6* | 38.9 | 37.9 | 42.4 | 37.7 | 4.42 | 4.39 | 4.12 |
| 12-yr survey | | 8.1 | | 4.5 | | 3.0 | | | | 39.8 | 45.1 | 39.9 | | | |

*Includes all males >9.

1.1

.

APPENDIX 11

Individual Hematological Findings, 1965

head

B 240

.

| | | | | - | | | | | | | Serum | Sed. |
|---------|---------------------------|---------|---------|--------------|----------------------|-----------|-----------------|------|----------------------|------|---------|---------------|
| Subject | Plat | WBC | Neut. | Lymph. | Mono. | Eosin. | Baso. | Hct. | RBC, | Hgb. | Protein | Rate |
| No. | <u>(x10⁻³)</u> | (X10-3) | (X10-3) | (X10-3) | (X10 ⁻³) | (X 10-3) | (X 10 - 2) | _(%) | (X10 ⁻⁴) | _(g) | (g) | <u>(mm)</u> |
| | | | | Ron | gelap Ex | posed Mal | <u>es 11-15</u> | | | | | |
| 2 | 328 | 7 36 | 3 39 | 3 31 | 0.07 | 0 59 | 0 | 40 | 437 | 13.6 | 811 | |
| 2 · | 285 | 13 00 | 5 72 | 3 38 | 0.65 | 3 12 | 1 30 | 37 | 42.9 | 12 8 | 9.0 | 33 |
| 5 | 205 | 7 62 | 4 80 | 2 59 | 0.15 | 0.08 | 0 | 39 | 426 | 12 8 | 79 | 33 |
| 10 | 329 | 7.84 | 6 59 | 0.63 | 0.08 | 0.55 | õ | 46 | 584 | 14 4 | 74 | 7 |
| 23 | 215 | 10 10 | 4 04 | 4 04 | 0.10 | 1 82 | 1 00 | 40 | 504 | 12.8 | 8.4 | • |
| 2.5 | 203 | 9 72 | 3 79 | 4.76 | 0.10 | 0.78 | 0 | 40 | 448 | 12.8 | 7.5 | 9 |
| 54 | 272 | 5.72 | 2 95 | 3 09 | 0.14 | 0.69 | õ | 39 | 453 | 12 4 | 7.2 | 11 |
| 924 | 363 | 7 62 | 3 20 | 3 58 | 0.14 | 0.38 | 0 70 | 38 | 449 | 13 2 | 7.6 | 27 |
| 85* | 205 | 8 30 | 3 32 | 3.57 | 0.17 | 1.00 | 2.50 | 40 | 497 | 13.2 | 7.8 | 25 |
| 0.5. | 205 | 0.50 | 5.52 | 5.57 | 0.0/ | 1 00 | 0 (1) | 30.0 | 1.65 | 12 1 | 7 0 | 20.7 |
| Mean | 300 | 8.71 | 4.20 | 3.21 | 0.24 | 1.00 | 0.61 | 39.9 | 465 | 13.1 | 7.9 | 20.7 |
| | <u>+</u> 54** | 1.8 | 1.1 | 1.1 | | | | 2.5 | 50 | 0.0 | 0.5 | 0.5 |
| | | | | <u>Ail</u> | ingnae E | xposed Ma | les 11-1 | 5 | | | | |
| 6 | 329 | 782 | 1.88 | 4.38 | 0.47 | 0,94 | 1.50 | 39 | 445 | 12.8 | 7.4 | 19 |
| 84* | 568 | 6,36 | 2.80 | 2.93 | 0.13 | 0.51 | 0 | 36 | 421 | 11.8 | 7.8 | |
| Mean | 449 | 7.09 | 2.34 | 3.66 | 0.30 | 0.73 | 0.75 | 37.5 | 433 | 12.3 | 7.6 | 19.0 |
| | | | | Rong | elap Exp | osed Fema | les 11-1 | 5 | | | | |
| 17 | 070 | 7 60 | 2 22 | 2 00 | 0 15 | 0.15 | 1 50 | 33 | 388 | 11.5 | 8.5 | 28 |
| 1/ | 272 | /.00 | 2.23 | 5.77 2.78 | 0.15 | 0 41 | 0 | 36 | 421 | 10.9 | 8.3 | |
| 21 | 290 | 0.19 | 4.03 | 2,70 | 0.10 | 0.36 | 1 20 | 42 | 398 | 14_0 | 7.9 | 40 |
| 33 | 393 | 12.10 | /.02 | 4.40 | 0.12 | 0.25 | 0 | 38 | 402 | 13.6 | 7.3 | 24 |
| 42 | 331 | 0.30 | 4.70 | 2.10 | 0.17 | 0.69 | 0 60 | 37 | 402 | 12.1 | 7.2 | 27 |
| 65 | 353 | 0.29 | 2.64 | 2.09 | 0 13 | 0.05 | 1 30 | 39 | 402 | 12.4 | 8.3 | |
| 69 | 272 | 6.47 | 1.49 | 4.27 | 0.15 | 0.45 | 0.80 | 38 | 441 | 12.8 | 7.4 | 20 |
| 86* | 318 | 8.09 | 4.45 | 3.07 | 0.24 | 0.24 | 0.00 | 50 | | | | |
| Mean | 318 | 8.17 | 4.06 | 3.52 | 0,14 | 0.36 | 0.77 | 37.6 | 408 | 12.5 | 7.8 | 27.8 |
| | <u>+</u> 41 | 1.8 | 1.7 | 0.7 | | | | 2.6 | 16 | 1.0 | 0.5 | |
| | | | | Ai | lingnae | Exposed I | emales 1 | 1-15 | | | | |
| 8 | 383 | 6.52 | 4.50 | 1.50 | 0.13 | 0.33 | 0.60 | 38 | 411 | 13.6 | 7.0 | 19 |

*Exposed in utero. **Standard deviation.

-

| Subject | Plat | WBC | Neut | Lymph | Mono | Fosin | Baso | Vot | DBC | Uab | Serum | Sed. |
|---------|-----------------|--------------|--------------|---------------|-----------------|--------------|-----------------|-------------|------------|-------------|------------------|------|
| No. | (x_{10}^{-3}) | $(X10^{-3})$ | $(X10^{-3})$ | $(X 10^{-3})$ | $(X10^{-3})$ | $(X10^{-3})$ | (x_{10}^{-2}) | (%) | (x 10 - 4) | пдо. (g) | (g) | (mm) |
| | | | | ····· | | | | | <u></u> | | 84 | |
| | | | | Ron | gelap Ex | posed Mal | es >15-40 | <u>)</u> | | | | |
| 10 | 320 | 7.35 | 3.97 | 2.42 | 0.37 | 0.51 | 0.70 | 44 | 488 | 14.8 | 7.4 | 25 |
| 20 | 276 | 6.81 | 3.75 | 2.86 | 0.14 | 0.07 | 0 | 49 | 535 | 16.0 | 7.3 _i | 16 |
| 27 | 183 | 6.73 | 1.88 | 4.23 | 0.34 | 0.27 | 0 | 40 | 429 | 14.0 | 7.2 | 19 |
| 35 | 2 58 | 7.86 | 4.79 | 2.51 | 0.24 | 0.24 | 0.80 | 52 | 510 | 16.0 | 7.6 | |
| 36 | 222 | 10.28 | 6.07 | 3.39 | 0.41 | 0.41 | 0 | 46 | | 13.6 | 8.5 | |
| 37 | 230 | 6.24 | 3.06 | 2.56 | 0.06 | 0.44 | 1.20 | 44 | 456 | 14.4 | 7.2 | |
| 40 | 3 53 | 7.36 | 3.31 | 3.31 | 0.29 | 0.44 | 0 | 42 | 437 | 12.6 | 6.6 | 3 |
| 47 | 227 | 7.90 | 4.50 | 2.61 | 0.16 | 0.63 | 0 | 45 | | 14.8 | 7.9 | |
| 73 | 210 | 7.64 | 5.04 | 2.55 | 0 | 0.15 | 0 | 49 | 528 | 11,8 | 7.5 | 5 |
| 76 | 183 | 6.77 | 3.32 | 2.84 | 0.20 | 0.34 | 0.70 | 46 | | 13.6 | 7.7 | |
| 77 | 253 | 7.35 | 3.67 | 3.01 | 0.51 | 0.15 | ° . | 49 | 523 | 16.4 | 8.5 | 25 |
| Mean | 247 | 7 48 | 3 94 | 2 93 | 0.25 | 0.33 | 0.31 | 46.0 | 488 | 14.5 | 7.6 | 15.5 |
| neun | +51 | 1.0 | 1.1 | 0.5 | - • • • • • | | | 3.3 | 39 | 1.7 | 0.5 | 8.7 |
| | <u> </u> | • • | | • - | | | | | | | | |
| | | | | Ron | gelap <u>Ex</u> | posed Fem | ales >15- | · <u>40</u> | | | | |
| 12 | 237 | 7.71 | 3.31 | 3.54 | 0.31 | 0.46 | 0.80 | 42 | 453 | 13.2 | 7.8 | 40 |
| 14 | 293 | 7.24 | 3.40 | 3.33 | 0.07 | 0.43 | 0 | 36 | 376 | 12.1 | 7.5 | |
| 15 | 412 | 6.26 | 2.44 | 2.88 | 0.25 | 0.69 | 0 | 33 | 342 | 10.0 | 7.6 | 21 |
| 18 | 239 | 5,00 | 3,15 | 1.35 | 0.10 | 0.40 | 0 | 35 | 386 | 11.2 | 6.8 | 22 |
| 24 | 213 | 7,10 | 3.34 | 2,98 | 0.71 | 0.07 | 0 | 34 | 358 | 10,6 | 7.2 | 39 |
| 39 | 230 | 7.78 | 4.75 | 2.65 | 0.08 | 0.31 | 0 | 39 | 402 | 12.4 | 7.5 | 43 |
| 49 | 275 | 7.10 | 4.05 | 3.48 | 0,16 | 0.41 | 0 | 36 | 399 | 11.7 | 7.7 | 35 |
| 61 | 462 | 9.44 | 4.63 | 4.34 | 0.19 | 0.28 | 0 | 38 | 404 | 12.1 | 7.8 | 41 |
| 66 | 212 | 4.54 | 1.45 | 2.81 | 0.05 | 0.23 | 0 | 37 | 392 | 12.1 | 7.5 | 29 |
| 67 | 238 | 5,55 | 4.16 | 0.78 | 0.33 | 0.17 | 1.10 | 43 | | 14.0 | 8.1 | |
| 71 | 143 | 9.62 | 4.71 | 4.14 | 0.38 | 0.38 | 0 | 42 | 454 | 14.8 | 8.0 | 46 |
| 72 | 272 | 7.54 | 4.75 | 2.11 | 0.38 | 0.22 | 0.80 | 35 | 379 | 12.4 | 7.5 | |
| 74 | 260 | 10.70 | 5.99 | 3,53 | 0.21 | 0.96 | 0 | 43 | 472 | 14.8 | 8.8 | |
| 75 | 129 | 6.55 | 3.47 | 1.83 | 0 | 1.11 | 0 | 42 | | 13.2 | 8.3 | |
| Maan | 258 | 7 37 | 3 83 | 2.84 | 0.23 | 0.44 | 0,19 | 38.2 | 401 | 12.5 | 7.7 | 35.1 |
| 110 011 | +91 | 1.7 | 1.1 | 1.0 | · • · | | | 3.5 | 38 | 1.4 | 0.5 | 8.5 |
| | <u> </u> | ~ . / | | | | | | | | | | |

1.1

| | Subject No. | Plat (X10 ⁻³) | WBC (X10 ⁻³) | Neut. (X10 ⁻³) | Lymph. (X10 ⁻³) | Mono, (X10 ⁻³) | Eosin. (X10- ³) | Baso. (X10-2) | Hct. (%) | RBC (X10-4) | Нgb. (g) | Serum Protein (g) | Sed. Rate (mm) |
|----|----------------|------------------------------|-----------------------------|-------------------------------|--------------------------------|-------------------------------|--------------------------------|------------------|-------------|----------------|-------------|-------------------------|------------------------|
| | | | | | <u>Ailir</u> | ngnae Exp | osed Fema | les >15-4 | <u>0</u> | | | I. | |
| | 48 | 319 | 7.12 | 4.91 | 1.92 | 0.21 | 0.07 | 0 | 39 | 433 | 13.6 | 7.7 | 37 |
| | 51 | 430 | 6.57 | 3.48 | 2.76 | 0.07 | 0.20 | 0.70 | 40 | 401 | 12.6 | 7.7 | 41 |
| | 53 | 425 | 7.16 | 4.01 | 2.94 | 0.14 | 0.07 | 0 | 39 | 434 | 12.4 | 8.3 | 49 |
| | 70· | 273 | 8.90 | 6.59 | 1,69 | 0.36 | 0.27 | 0 | 27 | 462 | 7.3 | 9.0 | 19 |
| | 81 | 287 | 8.37 | 5.36 | 2.51 | 0.17 | 0.33 | 0 | 35 | 3,58 | 11.5 | | |
| | Mean | 347 | 7.62 | 4.87 | 2.36 | 0.19 | 0,19 | 0.14 | 36.0 | 418 | 11.7 | 8.2 | 36.5 |
| | | | | | Ror | ngelap Ex | posed Mal | es >40 | | | | | |
| | 4 | 223 | 7 18 | 2.80 | 3.95 | 0.14 | 0.29 | 0 | 44 | 503 | 15.2 | 7.6 | 25 |
| 1 | 7 | 418 | 5.70 | 2,45 | 2.79 | 0.23 | 0.17 | 0,60 | 41 | 433 | 13.6 | 7.7 | 26 |
| ~1 | 11 | 307 | 4.38 | 2.54 | 1.58 | 0.13 | 0.13 | 0 | 37 | 368 | 12.1 | 6.7 | |
| | 55 | 227 | 5.34 | 1,82 | 3.10 | 0.32 | 0.05 | 0.50 | 30 | 323 | 9.7 | 7.2 | 25 |
| | 68 | 193 | 7.91 | 3.56 | 3.24 | 0.08 | 1.03 | 0 | 45 | 448 | 15.2 | 7.4 | 33 |
| | 79 | 120 | 6.07 | 2.49 | 3.10 | 0.36 | 0.12 | 0 | 49 | 493 | 16.0 | 7.7 | 18 |
| | 80 | 212 | 6.19 | 3.03 | 2.85 | 0.19 | 0.06 | 0.60 | 42 | 440 | 14.0 | 7.2 | 34 |
| | 82 | 260 | 5.48 | 2.30 | 2.47 | 0.11 | 0.60 | 0 | 42 | 445 | 14.0 | 7.7 | 32 |
| | Mean | 245 | 6.03 | 2.62 | 2.88 | 0.19 | 0.31 | 0.21 | 41.3 | 432 | 13.7 | 7.4 | 37.6 |
| | | <u>+</u> 82 | 1.0 | 0.5 | 0.7 | | | | 5.3 | 56 | 1.9 | 0.3 | 5.3 |
| | | | | | Ail | lingnae E | xposed Ma | 1 e s >40 | | | | | |
| | 16 | 259 | 5,38 | 2.64 | 2.10 | 0.22 | 0.33 | 1.10 | 46 | 5.88 | 14.0 | 7.4 | 22 |
| | 29 | 215 | 9.04 | 4.88 | 3,53 | 0.27 | 0.36 | 0 | 49 | 505 | 16.4 | 8.3 | 31 |
| | 41 | 278 | 5,72 | 2.34 | 3.15 | 0.11 | 0.11 | 0 | 42 | 457 | 14.4 | 7.0 | |
| | 50 | 360 | 9.45 | 6.43 | 1.89 | 0.66 | 0.37 | 0.90 | 46 | 485 | 15.2 | 7.9 | 29 |
| | Mean | 278 | 7.40 | 4.07 | 2.66 | 0.32 | 0.29 | 0.50 | 46.0 | 509 | 15,0 | 7.7 | 27.3 |

| Subject No. | Plat (X10 ⁻³) | WBC (X 10 ⁻³) | Neut. (X10 ⁻³) | Lymph. (X10 ⁻³) | Mono. (X10 ⁻³) | Eosin. (X10 ⁻³) | Baso. (X10 ⁻²) | Hct. (%) | RBC (X10 ⁻⁴) | Hgb. (g) | Serum Protein (g) | Sed. Rate (mm) |
|----------------|------------------------------|------------------------------|-------------------------------|--------------------------------|-------------------------------|--------------------------------|-------------------------------|-------------|-----------------------------|-------------|-------------------------|-----------------------|
| | | | - · · · | Ron | gelap Ex | posed Fem | ales >40 | | | | | |
| | | | | • | | | | | | | | |
| 13 | 335 | 5.52 | 2.93 | 1.82 | 0.22 | 0.50 | 0.60 | 32 | 329 | 10.0 | 6.9 | 37 |
| 34 | 296 | 6.79 | 3.26 | 3.19 | 0.13 | 0.20 | 0 | 37 | 315 | 11.2 | 6.9 | 43 |
| 58 | 233 | 5,57 | 2,28 | 2.95 | 0.11 | 0.22 | 0 | 39 | 389 | 13.6 | 7.7 | 29 |
| 60 | 231 | 8.28 | 3,15 | 4.06 | 0.08 | 0.99 | 0 | 33 | 354 | 10.6 | 7.5 | 33 |
| 63 | 283 | 5.54 | 2.99 | 1.72 | 0.22 | 0.55 | 0.60 | 42 | 433 | 14.0 | 7.3 | |
| 64 | 292 | 5.35 | 2.62 | 2.35 | 0.21 | 0.11 | 0.50 | 37 | 388 | 12.4 | 7.9 | 21 |
| 78 | 473 | 8.03 | 5.06 | 2.65 | 0.32 | 0 | 0 | 40 | 388 | 13.2 | 1.1 | 26 |
| Maan | 306 | 6 44 | 3 18 | 2 67 | 0 18 | 0.37 | 0.24 | 37.1 | 371 | 12.1 | 7.4 | 31.5 |
| ricali | <u>+</u> 76 | 1.1 | 0.8 | 0.8 | | | | 3.5 | 39 | 1.4 | 0.4 | 7.2 |
| | | | | <u>Ail</u> | ingnae E | xposed Fe | emales, >4(| <u>)</u> | | | | |
| 1 | 383 | 6.35 | 2.92 | 2.67 | 0,32 | 0.32 | 1.30 | 41 | 438 | 13.6 | 8.0 | 46 |
| 28 | 228 | 5.89 | 2.06 | 3.42 | 0 | 0.41 | 0 | 41 | 393 | 13.2 | 8.4 | 47 |
| 45 | 255 | 4.84 | 2.08 | 2.08 | 0.05 | 0.62 | 0 | 37 | 380 | 12.1 | 7.7 | 37 |
| 59 | 484 | 8,51 | 3.49 | 4.26 | 0.17 | 0.60 | 0 | 39 | 402 | 13.2 | 8.5 | 41 |
| Mean | 338 | 6.40 | 2.63 | 3.10 | 0.14 | 0.49 | 0.32 | 39.5 | 403 | 13.0 | 8,2 | 42.8 |
| | | | M | lale Child | ren of E | xposed Pa | arent(s) / | Age <11 | | | | |
| | | | | | | 4 | | | 200 | 11 0 | 7 0 | 10 |
| 88 | 353 | 7.11 | 2.70 | 3.84 | 0.21 | 0.36 | 0 | 35 | 399 | 11.0 | 1.2 | 19 |
| 89 | 355 | 7.63 | 1.90 | 4.50 | 0.23 | 0.99 | 0 | 38 | 372 | 11.0 | 0.0 | J |
| 90 | 422 | 9.72 | 6.03 | 2.72 | 0.49 | 0.49 | 0 | 35 | 400 | 11.0 | 0.0 | 20 |
| 91 | 368 | 9.01 | 4.60 | 3.87 | 0.27 | 0.27 | 0 | 38 | 421 | 13,2 | 7.0 | 20 |
| 93 | 400 | 15.80 | 8.85 | 5.06 | 0.47 | 1.42 | 0 | 37 | 409 | 11.0 | /.0 | 20 |
| 96 | 285 | 8,52 | 3.75 | 3.83 | 0.26 | 0.51 | 1.70 | 37 | 421 | 11.2 | | |
| 97 | 313 | 7.44 | 4.09 | 2.98 | 0.15 | 0.15 | 0.70 | 39 | 4/0 | 12.4 | | 15 |
| 98 | 285 | 8.59 | 3.95 | 3.78 | 0.34 | 0.43 | 0.90 | <u>اد</u> | 445 | 11,3 | 76 | 73 |
| 104 | 430 | 10.60 | 4.45 | 5.62 | 0.21 | 0.32 | U | 57 | 470 | 12.4 | /.0 | 23 |
| 109 | 498 | 11.20 | 5.49 | 4.59 | 0.56 | 0.56 | 0 | 55 | 402 | 12.1 | | 7 |
| 110 | 395 | 10.00 | 5.50 | 3.20 | 0.60 | 0.60 | 1,00 | 31 | 505 | 12.1 | | ' |

PH 28

| Subject | Plat. (X10 ⁻³) | WBC (X10 ⁻³) | Neut. (X10 ⁻³) | Lymph. _(X10 ⁻³) | Mono. (X10 ⁻³) | Eosin. (X10-3) | Baso. (X10 ⁻²) | Hct. | RBC (X10 ⁻⁴) | Hgb. _(g) | Serum Protein (g) | Sed. Rate (mm) |
|---------|-------------------------------|-----------------------------|-------------------------------|---------------------------------|-------------------------------|-------------------|-------------------------------|------------------|-----------------------------|--------------|-------------------------|----------------------|
| | | | м | ale Child | ren of E | xposed Pa | rent(s)/ | Age < 11 (| (cont'd) | | | |
| | | | - | | | يتمتحد فاسعام | | 191 | £ | | | |
| 111 | 630 | 10.10 | 5.25 | 4.25 | 0.20 | 0.40 | 0 | 33 | 420 | 10.6 | 7.2 | 23 |
| 113 | 450 | 8.95 | 5.01 | 2.95 | 0.81 | 0.81 | 0 | 39 | 493 | 12.4 | | |
| 115 | 443 | 14.10 | 7.05 | 6.10 | 0.42 | 0.99 | 0. | 35 | 370 | 11.5 | 7.3 | |
| 116 | 570 | 12.70 | 7.62 | 3.56 | 0.76 | 0.76 | 0 | 42 | 497 | 13.2 | , | |
| 113 | 515 | 10.16 | 2.84 | 6.81 | 0 | 0.51 | 0 | 39 | 447 | 12.8 | | |
| 126 | 510 | 6.35 | 3.56 | 2.22 | 0.25 | 0.32 | 0 | 36 | 456 | 10.9 | | |
| 130 | 465 | 8.60 | 1.55 | 5.93 | 0.26 | 0. 69 | 1.70 | 35 | 456 | 8,8 | | |
| 131 | 348 | 7.66 | 3.45 | 3.52 | 0.30 | 0.30 | 0.80 | 42 | 479 | 13.2 | | |
| 132 | 490 | 10.60 | 1.38 | 8.90 | 0.21 | 0.11 | .) | 34 | 431 | 11.5 | | |
| Mean | 426 | 9.74 | 4.45 | 4.41 | 0.32 | 0.55 | 0.34 | 36.9 | 438 | 11.9 | 7.3 | 18.3 |
| | · <u>+</u> 90 | 2.3 | 1.9 | 1.7 | | | | 2.5 | +40 | 1.0 | 0.4 | 8.7 |
| | | | Fema | <u>le Childr</u> | en of Ex | posed Par | ent(s) A | <u>ge <11</u> | | | | |
| 87 | 300 | 5.50 | 0.99 | 3.41 | 0.22 | 0.83 | 0.60 | 38 | 448 | 12. 8 | | |
| 92 | 273 | 11,20 | 7.50 | 2.24 | 0.22 | 1.23 | 0 | 39 | 469 | 12.8 | 7.5 | 33 |
| 94 | 31.0 | 11.70 | 8.89 | 2.11 | 0.23 | 0.47 | 0 | 43 | 515 | 14.4 | | 36 |
| 100 | 208 | 6.84 | 3.90 | 2.53 | 0,07 | 0.34 | 0 | 36 | 402 | 12.4 | | 26 |
| 101 | 350 | 14.90 | 2.68 | 10.13 | 0.15 | 1.79 | 1.50 | 39 | 445 | 12.8 | | |
| 103 | 535 | 12.40 | 7.07 | 4.84 | 0 | 0.50 | 0 | 35 | 482 | 12.1 | 6.5 | 23 |
| 1.05 | 225 | 11.00 | 5.3 9 | 3.41 | 0.55 | 1.65 | 0 | 37 | 457 | 11.2 | 7.2 | 25 |
| 106 | 435 | 8.08 | 3.07 | 4.12 | 0.16 | 0.73 | 0 | 40 | 460 | 13.2 | | 34 |
| 108 | 425 | 10.35 | 5.07 | 3.31 | 0.21 | 1.66 | 0 | 40 | | 12.1 | | |
| 112 | 431 | 7.15 | 1.72 | 5.14 | 0 | 0.29 | 0 | 34 | 426 | 10.9 | 7.5 | 24 |
| 117 | 573 | 8.16 | 2.77 | 4.73 | 0.16 | 0.33 | 1.60 | 39 | 402 | 11.5 | | |
| 119 | 199 | 9.43 | 4.90 | 3,68 | 0.19 | 0.66 | 0 | 35 | 434 | 12.1 | | |
| 120 | 290 | 9,85 | 3.84 | 5.32 | 0.30 | 0.39 | 0 | 39 | 467 | 13.2 | | |
| 121 | 360 | 10.67 | 5.01 | 3.84 | 0.21 | 1.28 | 3.20 | 38 | | 10.9 | | |
| 122 | 363 | 8.25 | 2.81 | 4.95 | 0.17 | 0.33 | 0 | 44 | 400 | 11.9 | | 23 |
| 123 | 333 | 10.47 | 6.91 | 2.51 | 0.31 | 0.63 | 1.90 | 36 | | 1).9 | | |
| 124 | 430 | 14.60 | 6,28 | 7.74 | 0.15 | 0.29 | 1.50 | 38 | 454 | 12.4 | | |
| 125 | 543 | 8.41 | 3.53 | 3.70 | 0.50 | 0.67 | 0 | 35 | 437 | 12.1 | | |
| 127 | 512 | 9,30 | 1.21 | 7.63 | 0.09 | 0.37 | 0 | 38 | 414 | 12.8 | | |
| 128 | 358 | 11.40 | 4.79 | 4.90 | 0.57 | 1.14 | 0 | 42 | 500 | 13.6 | | |
| 134 | 31.3 | 9.90 | 4.55 | 4.2 6 | J. 30 | 0.79 | 0 | 33 | 399 | 13.0 | | |
| 135 | 975 | 15.30 | 9.62 | 5.22 | 0.33 | 0,82 | 3.30 | 34 | 490 | 9.0 | | |
| 137 | <u>4</u> 07 | 14.20 | 2.84 | 10.79 | 0.28 | 0.14 | 1.40 | 31 | 402 | 13.6 | | |
| 138 | 460 | 9.09 | 2.91 | 5.27 | 0.18 | 0.64 | 0,90 | 33 | 448 | 10.6 | | |

.

| Subject | Plat. (X1)-3) | WBC (X10)-3) | Neat. (X10-3) | Lymph. (X1-)-3) | Mono. (X10-3) | Eosin. (X1)-3) | Baso, (X11)-2) | Hct. (1%) | RBC (3(11)-4) | Hgb. (g) | Serum Protein (3) | Sed. Rate (uun) |
|------------|------------------|-----------------|------------------|--------------------|------------------|-------------------|--------------------|------------------|------------------|-------------|-------------------------|-----------------------|
| | | | Fema | le Childı | en of Ex | posed Par | en c(s) Aa | e <1 1 | (cont'd) | | | |
| 1.0.0 | 24.0 | | | 2 - 6 | ' | | 0 | | | 10.0 | | |
| 139 | 362 | 14.80 | 6.66 | 7.55 | 0.30 | 0.30 | 0 | 31 | 374 | 10.3 | | |
| 140 | 525 | 10.90 | 2.07 | 7.96 | 0.44 | 0.33 | 1.10 | 41 | 525 | 15.2 | ł. | |
| 143 | 540 | 8.26 | 3.33 | 4.30 | 0.17 | J. 25 J. 17 | 0 | - 3.3 - 27 | 351 | 10.0 | | |
| 145 | 427 | 10.31 | 2.17 | 5.07 | 9.21 | 2.17 | 1.00 | 20 | | 10.0 | | |
| Mean | 410 | 10.48 | 4 38 | 5 04 | 0 24 | 0.75 | 9.61 | 37 3 | 443 | 11.8 | 7.2 | 28.0 |
| incan | <u>+150</u> | 2.6 | 2.2 | 2.2 | | / | | 4.0 | 41 | 1.4 | | 5.0 |
| | | | | | | | | | | | | |
| | | | | Une | cposed Ma | <u>les 11 -</u> | 15 | | | | | |
| 012 | A A F | 7 4 1 | 2 () | 2 90 | 0.1/ | 2 59 | 0 • | 25 | 411 | 12.1 | 6.0 | 1.3 |
| 813 | 335 | 1.22 | 3.61 | 2.39 | 0.14 | 0.00 | 0 | 37 41 | 411 | 12.1 | 0.9 | 34 |
| 814 | 302 | 9.90 | J. 7/ 0.00 | 3.00 | 0.30 | 0.00 | 0 | 41 | 494 | 14 4 | 8.2 | 30 |
| 017 | 124 | 7 96 | 2.32 | 2.05 | 0.22 | 0.22 | 0 80 | 39 | 454 | 12.8 | 7 2 | 3.0 |
| 017 919 | 200 | 7.90 | J. 50 | 2.17 | 0.14 | 0 43 | 0 | 43 | 498 | 14.0 | 7.5 | 17 |
| 863 | 269 | 5 76 | 3 23 | 1 70 | 0.23 | 0.45 | 0.60 | 47 | 515 | 15.6 | 7.7 | 30 |
| 012 | 333 | 7 06 | 3 74 | 2.33 | 0.14 | 0.78 | 0.70 | 33 | 409 | 11.5 | 7.5 | 19 |
| 913 | 413 | 5.78 | 3.76 | 1.21 | 0.23 | 0.46 | 1.20 | 39 | 518 | 13.2 | 7.6 | 17 |
| 921 | 385 | 6.95 | 3.96 | 1.39 | 0.35 | 1.11 | 1.40 | 39 | 467 | 12.4 | 7.6 | 17 |
| 931 | 425 | 10.60 | 4.35 | 4.66 | 0.11 | 1.38 | 1.10 | 38 | 445 | 12.4 | 7.6 | 25 |
| 981 | 343 | 7.07 | 3.11 | 3.68 | 0.21 | 0.07 | 0 | 38 | 444 | 13.2 | 8.0 | |
| 1033 | 243 | 5.40 | 2.05 | 3.19 | 0.11 | 0 | 0.50 | 42 | 505 | 14.0 | 7.9 | 33 |
| 1036 | 240 | 6.83 | 3.28 | 3.01 | 0.27 | 0.27 | 0 | 39 | 469 | 13.6 | 7.5 | 20 |
| 1052 | 523 | 6.99 | 3.43 | 3.22 | 0.21 | 0.07 | 0.70 | 38 | 429 | 12.8 | 7.2 | 16 |
| Mean | 326 | 7,16 | 3.66 | 2.71 | 0.21 | 0.52 | 0.50 | 39.6 | 465 | 13.3 | 7.6 | 22.6 |
| | <u>+</u> 98 | 1.5 | 0.9 | 0.9 | | | | 3.3 | 36 | 1.0 | 0.4 | 7.0 |
| | | | | Unexpose | ed Female | <u>s 11 - 15</u> | <u>5</u> | | | | | |
| 805 | 433 | 6 64 | 1.39 | 3.72 | 0.40 | 1.00 | 0.13 | 39 | 477 | 12.8 | 8.0 | 20 |
| 811 | 433 | 7 74 | 3 10 | 3.79 | 0.23 | 0.62 | 0 | 34 | 393 | 12.4 | 7.4 | 0 |
| 812 | 330 | 7 11 | 3 48 | 2.92 | 0.14 | 0.57 | 0 | 39 | 473 | 11.8 | 8.0 | 27 |

r 18

120

<u></u>

*

| Subject No. | Plat. (X10 ⁻³) | wвс (x10-3) | Neut.) (X10-3) | Lymph. (X10-3) | Mono. (X10-3) | Eosin. (X10- ³) | Baso. (X10-2) | Hct. (%) | RBC (X10-4) | Hgb. (g) | Serum Protein (g) | Sed. Rate (mm) |
|----------------|-------------------------------|----------------|--------------------|-------------------|------------------|--------------------------------|------------------|-------------|----------------|-------------|-------------------------|----------------------|
| | | | | <u>t</u> | Inexposed | Females | <u>11 - 15 (</u> | cont'd) | | | | |
| | | | | | | t | | | | | | |
| 816 | 305 | 5.31 | 3.29 | 1.43 | 0.21 | 0.32 | 0,50 | 38 | 420 | 12.1 | 7.4 | 24 |
| 879 | 257 | 9.00 | 3.60 | 4.14 | 0.09 | 1.17 | 0 | 39 | 441 | 12.8 | 8.Þ | 25 |
| 909 | 228 | 10.60 | 5.19 | 3.50 | 0.42 | 1.48 | 0 | 40 | 426 | 12.1 | | 27 |
| 911 | 373 | 6.96 | 4.32 | 1.95 | 0.28 | 0.42 | 0 | 35 | 416 | 11.5 | 8.0 | 39 |
| 925 | 250 | 7.85 | 4.63 | 2.36 | 0.31 | 0.55 | 0 | 40 | | 12.4 | 9.3 | |
| 926 | 268 | 9.52 | 4.76 | 4.28 | 0 | 0.48 | 0 | 40 | 521 | 13.6 | 8.0 | 26 |
| 937 | 210 | 6.70 | 3.75 | 2.35 | 0.27 | 0.34 | 0 | 40 | | 13.2 | 8.0 | |
| 946 | 25 8 | 8.90 | 5.70 | 2.67 | 0.27 | 0.27 | 0 | 40 | 442 | 14.0 | 7.7 | 44 |
| 955 | 262 | 7.07 | 4.74 | 1.48 | 0.14 | 0.70 | 0 | 39 | 405 | 12.4 | 8.1 | 40 |
| 960 | 266 | 14.00 | 11.59 | 1.82 | 0.28 | 0.42 | 0 | 34 | 388 | 11.2 | 7.3 | 28 |
| 962 | 273 | 8.13 | 4.07 | 2.68 | 0.16 | 1.06 | 1.60 | 37 | 449 | 11.8 | 8.4 | |
| 978 | 288 | 10.80 | 4.75 | 4.64 | 0.22 | 1.08 | 1.10 | 40 | 467 | 14.4 | 8.0 | |
| 980 | 308 | 6.2 9 | 3.46 | 2.39 | 0 | 0.44 | 0 | 43 | 477 | 13.6 | 7.6 | 28 |
| 996 | 232 | 8. 8 0 | 5.72 | 2.11 | 0.26 | 0.70 | 0 | 37 | 420 | 11.5 | 7.8 | 38 |
| 1035 | 438 | 9.88 | 3.85 | 5.43 | 0.10 | 0.49 | 0 | 40 | 442 | 12.8 | | 27 |
| Mean | 300 | 8.39 | 4.52 | 2.98 | 0.21 | 0.67 | 0.19 | 38.6 | 441 | 12.6 | 8.0 | 28.1 |
| | <u>+</u> 68 | 2.1 | 2.0 | 1.1 | | | | 2.4 | 34 | 0.9 | 0.5 | 10.4 |
| | | | | 1 | Inavnosad | Malec >1 | 5-40 | | | | | |
| | | | | - | nexposed | Plates /1 | <u>J-40</u> | | | | | |
| 819 | 210 | 5 78 | 2 54 | 2 60 | 0.06 | 0.58 | 0 | 39 | 442 | 12.4 | 7.5 | |
| 820 | 240 | 6 60 | 2.34 | 3 10 | 0.13 | 0.66 | 0 | 48 | 528 | 15.2 | 7.9 | 13 |
| 822 | 240 | 5 86 | 2.71 | 3 03 | 0 18 | 0.18 | 0.60 | 44 | 483 | 14.0 | 7.0 | 9 |
| 822 | 220 | 5 25 | 2.40 | 1 68 | 0.32 | 0.26 | 0.50 | 45 | 453 | 14.4 | 7.0 | 18 |
| 023 | 270 | 6 46 | 3.62 | 2.65 | 0.06 | 0 32 | 0 | 47 | 486 | 14.4 | 7.8 | 8 |
| 027 | 169 | 5 87 | 3.52 | 1 53 | 0.41 | 0.41 | õ | 44 | 449 | 14.8 | 7.0 | 18 |
| 921 | 220 | 7 45 | 2 91 | 3 50 | 0.45 | 0.60 | Õ | 52 | | 15.2 | 7.7 | |
| 1001 | 220 | 7.4J 7.60 | 1 74 | 2 44 | 0 23 | 0.23 | 0.50 | 48 | 555 | 16.0 | 7.5 | 8 |
| 836 | 220 | 9.07 | 5 19 | 3 72 | 0 10 | 0.78 | 0 | 48 | 539 | 16.0 | 8.2 | 14 |
| 840 | 237 | 9.00 8.01 | J. 17 | 3 28 | 0 24 | 0.24 | 0.80 | 48 | 586 | 16.0 | . – | 9 |
| 04U 945 | 210 | 6 1 2 | 7.1/ | 3 06 | 0.12 | 0.18 | 0.60 | 46 | 481 | 14.4 | 7.2 | 14 |
| 043 | 220 | 7 17 | 2.07 | 4 44 | 0 07 | 0.29 | 0.70 | 46 | 469 | 15.6 | 7.3 | 15 |
| 004 | 244 | 9.65 | 2.27 | 4.77 | 0 43 | 0.52 | 0 | 44 | 459 | 14.8 | 8.0 | 32 |
| 001 | 214 | 5 7/ | 2.05 | 2 35 | 0.06 | 0.29 | 0 | 44 | 506 | 14.8 | 7.3 | 10 |
| 007 | 1177 | 1.14 | | <u></u> | ~, ~ ~ | · • - • | - | | | | | |

Ma

121

i-1

| Subject No. | Plat. (X10 ⁻³) | WBC (X10-3) | Neut. (X10 ⁻³) | Lymph. (X10 ⁻³) | Mono. (X10-3) | Eosin.) (X10 ⁻³) | Baso. (X10-2) | Hct. (%) | RBC (X10-4) | Hgb. (g) | Serum Protein (g) | Sed. Rate (mm) |
|----------------|-------------------------------|----------------|-------------------------------|--------------------------------|------------------|----------------------------------|----------------------|-------------|----------------|-------------|-------------------------|----------------------|
| | | | | | Unexpos | ed Males | > 15-40 (c | ont'd) | | | | |
| 885 | 213 | 20.75 | 14.73 | 3.74 | 1.25 | 1.04 | 0 | 54 | | 16.9 | 8.3 | |
| 892 | 240 | 11.00 | 4.84 | 5.17 | 0.44 | 0.44 | 1.10 | 44 | 497 | 14.8 | 8,6 | |
| 920 | 210 | 9.32 | 6.06 | 2.24 | 0.47 | 0.56 | 0 | 50 - | 505 | 16.9 | 7.9 | |
| 940 | 283 | 7.82 | 2.97 | 3.75 | 0.39 | 0.70 | 0.80 | 43 | 509 | 14.8 | 8.2 | |
| 943 | 220 | 10.45 | 5.43 | 4.18 | 0.52 | 0.31 | 0 | 48 | | 15.2 | 7.9 | |
| 966 | 268 | 8.57 | 6.08 | 2.14 | 0.17 | 0.17 | 0 | 45 | 462 | 13.6 | 7.2 | 18 |
| 967 | 208 | 6.67 | 4.00 | 2.00 | 0.13 | 0.53 | 0 | 47 | 479 | 14.4 | 7.3 | 9 |
| 971 | 259 | 5.63 | 3.49 | 1.91 | 0.17 | 0 | 0.60 | 47 | | 14.4 | 7.9 | |
| 976 | 232 | 8.28 | 4.30 | 3.64 | 0.33 | 0 | 0 | 45 | 527 | 15.2 | 7.3 | |
| 1501 | 222 | 6.80 | 3.94 | 2.38 | 0.20 | 0.27 | 0 | 45 | 510 | 15.2 | 8.0 | 19 |
| Mean | 247 | 7.86 | 4.10 | 3.05 | 0.29 | 0.40 | 0.26 | 46.3 | 496 | 14.9 | 7.6 | 14.3 |
| | <u>+</u> 42 | 3.1 | 2.5 | 1.0 | | | | 4.9 | 37 | 1.0 | 0.4 | 6.1 |
| | | | | | Unexpos | ed Female | es >15-40 | | | | | |
| 821 | 371 | 7.27 | 2.84 | 3.78 | 0.29 | 0.36 | 0 | 36 | 399 | 12.1 | 7.2 | |
| 826 | 175 | 7.27 | 5.38 | 1.82 | 0.07 | 0 | 0 | 30 | | 8.5 | | |
| 829 | 219 | 5.66 | 4.08 | 1.36 | 0 | 0.23 | 0 | 28 | 295 | 8.8 | 7.1 | 25 |
| 832 | 321 | 6.56 | 3.80 | 1.77 | 0.26 | 0.72 | 0 | 39 | 435 | 12.1 | 7.9 | 34 |
| 835 | 265 | 6.80 | 2,85 | 3.60 | 0.14 | 0.20 | 0 | 36 | 414 | 12.4 | 6.7 | 13 |
| 841 | 223 | 6.56 | 4.79 | 1,38 | 0,20 | 0.20 | 0 | 30 | 348 | 9.4 | 7.1 | 34 |
| 843 | 235 | 4.73 | 2.19 | 2.10 | 0.19 | 0.29 | 0 | 32 | 324 | 10.9 | 6.5 | 10 |
| 865 | 268 | 6.22 | 3.98 | 1.74 | 0.12 | 0.19 | 0.60 | 28 | 306 | 10.3 | 6.4 | 23 |
| 891 | 258 | 6.44 | 2.51 | 3.16 | 0.64 | 0.06 | 0.60 | 42 | 437 | 14.8 | 7.8 | |
| 895 | 303 | 9.76 | 4,68 | 4.10 | 0.39 | 0.59 | 0 | 43 | 467 | 14.8 | 7.2 | |
| 896 | 342 | 6.76 | 3.52 | 2.70 | 0.14 | 0.41 | 0 | 35 | 388 | 13.2 | 7.0 | 36 |
| 914 | 305 | 7.28 | 3.71 | 2.62 | 0.22 | 0,73 | 0 | 35 | 391 | 11.5 | 6.8 | |
| 932 | 290 | 5.06 | 2.73 | 1.77 | 0.10 | 0.46 | 0 | 36 | . 392 | 11.5 | 7.5 | 25 |
| 934 | 326 | 7.86 | 3.38 | 4.24 | 0.08 | 0.16 | 0 | 38 | 442 | 13.2 | 8.1 | 27 |
| 938 | 271 | 7.49 | 5.39 | 1.80 | 0.15 | 0.15 | 0 | 36 | 409 | 12.1 | 7.6 | |
| 945 | 278 | 11.40 | 9.12 | 1.60 | 0.23 | 0.46 | 0 | 47 | 506 | 15.6 | 8.2 | |
| 951 | 208 | 7.15 | 2.86 | 4.15 | 0.07 | 0 | 0.70 | 45 | | 13.2 | 7.8 | |

- -

122

.

| Subject No. | Plat. (X10 ⁻³) | WBC (X10-3) | Neut. (X10- ³) | Lymph. (X10 ⁻³) | Mono. (X10- ³) | Eosin. (X10-3) | Baso. (X10-2) | Hct. (%) | RBC (X10-4) | Hgb. (g) | Serum Protein (g) | Sed. Rate (mm) |
|----------------|-------------------------------|----------------|-------------------------------|--------------------------------|-------------------------------|-------------------|-------------------|-------------|----------------|-------------|-------------------------|----------------------|
| | | | | | | | | | | | | |
| | | | | <u>Un</u> | exposed H | emales > | <u>15 - 40 (c</u> | ont'd) | | | | |
| 05.0 | 205 | | 2 (7 | 1.04 | 0.00 | 0.44 | 0 | | | 10.0 | 7.0 | 27 |
| 959 | 225 | 6.56 | 3.6/ | 1.84 | 0.39 | 0.66 | 0 | 38 | 400 | 12.8 | 1.3 | 34 |
| 993 | 201 | 5.23 | 2.30 | 2.46 | 0.16 | 0.21 | 1.00 | 42 | | 12.4 | V .9 | |
| 998 | 317 | 8.33 | 4.58 | 3.08 | 0.17 | 0.50 | 0 | 35 | 412 | 12.8 | 8.3 | |
| 1001 | 226 | 5.06 | 3.14 | 1.62 | 0.10 | 0.20 | 0 | 39 | 460 | 12.4 | 7.3 | 19 |
| 1050 | 333 | 8.74 | 4.80 | 3.58 | 0.09 | 0.26 | 0 | 36 | 389 | 12.1 | 8.0 | 37 |
| 1502 | 216 | 6.41 | 2.43 | 3.27 | 0.19 | 0.38 | 1.30 | 36 | 393 | 13.2 | 8.2 | 36 |
| Mean | 269 | 6.98 | 3.86 | 2.59 | 0.19 | 0.32 | 0.18 | 36.6 | 400 | 12.2 | 7.4 | 27. 2 |
| | <u>+</u> 51 | 1.5 | 1.5 | 0.9 | | | | 5.0 | 51 | 1.7 | 0.6 | 8.7 |

Unexposed Males > 40

.

| 842 | 235 | 9.74 | 4.31 | 4.01 | 0.10 | 1.27 | 1.00 | 52 | 503 | 17.9 | 7.9 | 16 |
|-----|-----|-------|------|------|------|------|------|----|-----|------|-----|------|
| 849 | 273 | 11.40 | 5.36 | 4.45 | 0.11 | 1.48 | 0 | 48 | 515 | 16.0 | 8.1 | 3 |
| 850 | 117 | 5.96 | 2.80 | 2.68 | 0.24 | 0.24 | 0 | 43 | 453 | 14.0 | 7.8 | 22 |
| 853 | 273 | 5.77 | 2.42 | 3.00 | 0.23 | 0.06 | 0 | 41 | 429 | 13.2 | 8.3 | 33 |
| 855 | 265 | 10,40 | 7.59 | 2.70 | 0.10 | 0 | 0 | 44 | 421 | 14.0 | 8.0 | - 33 |
| 856 | 235 | 6.07 | 2.31 | 2.73 | 0.06 | 0.97 | 0 | 38 | 407 | 12.8 | 7.5 | 23 |
| 860 | 373 | 5.00 | 2.25 | 1.85 | 0.15 | 0.75 | 0 | 35 | 376 | 11.2 | 8.0 | 30 |
| 875 | 218 | 6,31 | 4.29 | 1.70 | 0.06 | 0.25 | 0 | 52 | 528 | 16.4 | 7.7 | 9 |
| 878 | 194 | 4,90 | 1.76 | 2.40 | 0.15 | 0.54 | 0.50 | 39 | 465 | 12,1 | 9.0 | 25 |
| 880 | 265 | 9.06 | 5.07 | 3.90 | 0 | 0.09 | 0 | 46 | 518 | 15.6 | 7.8 | |
| 884 | 283 | 8,95 | 5.64 | 2,69 | 0.27 | 0.36 | 0 | 40 | 442 | 12.1 | 8.8 | 35 |
| 897 | 266 | 8.24 | 4.70 | 3.05 | 0.16 | 0.41 | 0 | 42 | 441 | 14.0 | 9.0 | |
| 899 | 240 | 5.10 | 2.75 | 1.99 | 0.15 | 0.20 | 0 | 39 | 407 | 12.4 | 7.4 | |
| 915 | 240 | 4.16 | 1.87 | 1.62 | 0.08 | 0.50 | 0.80 | 41 | 425 | 15.6 | 7.4 | 15 |
| 917 | 215 | 8.89 | 6.67 | 1.87 | 0.27 | 0.09 | 0 | 49 | 570 | 16.4 | 8.3 | 10 |
| 935 | 223 | 5,39 | 2.47 | 2.43 | 0.32 | 0.16 | 0 | 41 | 423 | 14.0 | 8.1 | 34 |
| 947 | 249 | 7.76 | 5.43 | 1.62 | 0.23 | 0.47 | 0 | 37 | 382 | 12.1 | 7.1 | 20 |
| 948 | 245 | 5.17 | 2.17 | 2.59 | 0.26 | 0.16 | 0 | 40 | 433 | 14.0 | 7.0 | 17 |
| 961 | 151 | 8.55 | 3.76 | 2.91 | 0.26 | 1.54 | 0.90 | 44 | | 14.4 | 8.2 | |
| 963 | 205 | 5,10 | 1.84 | 2.75 | 0.15 | 0.36 | 0 | 49 | | 15.2 | 7.2 | |
| 964 | 243 | 4 38 | 2 54 | 1.66 | 0.04 | 0.13 | 0 | 37 | 351 | 12.4 | 7.2 | 31 |
| 969 | 505 | 9.75 | 6.44 | 2.73 | 0.29 | 0,29 | 0 | 40 | 492 | 11.8 | 8.3 | 19 |
| | | | | | | | | | | | | |

| Subject No. | Plat: (X10 ⁻³) | WBC ₃) | Neut (X10 ⁻³) | Lymph. (X10-3) | Mono, (X10-3) | Eosin. (X10-3) | Baso. (X10-2) | Hct. (%) | RBC (X10-4) | Hgb. (g) | Serum Protein (g) | Sed. Rate (mm) |
|----------------|-------------------------------|--------------------|------------------------------|-------------------|------------------|-------------------|-------------------|-------------|----------------|-------------|-------------------------|----------------------|
| | | | | | | Nolos N | 40 (| | | | | |
| | | | | <u>u</u> | nexposed | Mares / | <u>40 (cont d</u> | 2 | | | | |
| 1007 | 290 | 6.41 | 3.85 | 2.05 | 0.26 | 0.19 | 0.60 | 41 | 448 | 12.8 | 8. 0 | 26 |
| 1041 | 147 | 4.94 | 2.47 | 2.17 | 0.10 | 0.15 | 0.50 | 42 | 450 | 14.6 | 8.0 | 32 |
| Mean | 248 | 6.98 | 3.78 | 2.56 | 0.17 | 0.44 | 0.18 | 42.5 | 449 | 14.0 | 7.9 | 22.8 |
| · | <u>+</u> 74 | 2.1 | 1.7 | 0.7 | | | | 1.4 | 53 | 1.0 | 0.5 | 9.2 |
| | | | | <u>U</u> | nexposed | Females | >40 | | | | | |
| 0// | 111 | . 71 | 2 60 | 1 4 2 | 0.10 | 0 42 | 0 | 37 - | 421 | 11 5 | 73 | 3/4 |
| 844 | 323 | 4.71 | 2.09 | 1.42 | 0.19 | 0.42 | 0 | 40 | 421 | 13.2 | 8.6 | 41 |
| 040 951 | 218 | 5.81 | 2.01 | 3 25 | 0.12 | 0.06 | 0 60 | 35 | 376 | 12 4 | 7 0 | 28 |
| 852 | 210 | 8 97 | 3 23 | 5 38 | 0.12 | 0.09 | 0.90 | 38 | 423 | 11.8 | 8.0 | 39 |
| 858 | 201 | 4 81 | 2 31 | 1 97 | 0.14 | 0.38 | 0 | 37 | 402 | 11.8 | 7.5 | 41 |
| 850 | 410 | 7 93 | 4 83 | 2 70 | 0 | 0 40 | 0 | 39 | 390 | 12.4 | 7.5 | 30 |
| 808 | 197 | 8.67 | 4.68 | 3 38 | 0.17 | 0.43 | Õ | 40 | 414 | 12.8 | 8.3 | |
| 9090 | 238 | 6 90 | 1 52 | 5 11 | 0.07 | 0.21 | Ō | 44 | 401 | 14.4 | | |
| 916 | 311 | 7 86 | 2 67 | 4 56 | 0.16 | 0.47 | 0 | 38 | 405 | 14.0 | 7.8 | 39 |
| 922 | 260 | 6 81 | 3 95 | 1.97 | 0.27 | 0.62 | 0 | 36 | | 10.6 | 8.5 | |
| 928 | 325 | 5 84 | 3 50 | 2.10 | 0.18 | 0.06 | 0 | 35 | 366 | 11.2 | 8.3 | 43 |
| 929 | 242 | 5.35 | 2.46 | 2.68 | 0.21 | 0 | 0 | 36 | | 12.4 | 8.5 | |
| 936 | 262 | 8.20 | 3.85 | 4.18 | 0 | 0.16 | 0 | 37 | 391 | 13.2 | 8.4 | 39 |
| 941 | 245 | 6.43 | 3.86 | 2.12 | 0.13 | 0.32 | 0 | 38 | 407 | 12.1 | 7.6 | 40 |
| 942 | 215 | 4.95 | 2.38 | 2.23 | 0.15 | 0.20 | 0 | 40 | 414 | 13.2 | 8.0 | 40 |
| 956 | 323 | 4.40 | 1.98 | 1.98 | 0.09 | 0.35 | 0 | 35 | 386 | 11.5 | 7.2 | 37 |
| 957 | 328 | 6.57 | 2.76 | 3.29 | 0 | 0.46 | 0,60 | 36 | 377 | 12.1 | 7.4 | 39 |
| 970 | 353 | 8,00 | 2.32 | 5.52 | 0 | 0.08 | 0,80 | 38 | 433 | 12.4 | 8.0 | 38 |
| 982 | 200 | 8.50 | 4.42 | 3.66 | 0.09 | 0.26 | 0.90 | 40 | 452 | 13.2 | 7.5 | |
| 991 | 223 | 7.94 | 6.11 | 1.35 | 0.08 | 0.40 | 0 | 42 | 460 | 16.0 | 7.5 | |
| 1042 | 235 | 6.93 | 4.02 | 1.80 | 0.62 | 0.49 | 0 | 36 | 392 | 12.1 | 7.4 | 34 |
| Mean | 284 | 6.77 | 3.27 | 3.04 | 0.16 | 0.29 | 0.18 | 38.0 | 407 | 12.6 | 7.8 | 37.5 |
| | <u>+</u> 64 | 1.4 | 1.1 | 1.3 | | | | 2.3 | 24 | 1.2 | 0.5 | 4.0 |

e rati

.

| Subject No. | Plat. (X10 ⁻³) | WBC (X10- ³) | Neut. (X10- ³) | Lymph. (X10-3) | Mono. (X10- ³) | Eosin (X10-3) | Baso. (X10-2) | Hct. (%) | RBC (X10-4) | Нgb. (g) | Serum Protein (g) | Sed. Rate (mm) |
|----------------|-------------------------------|-----------------------------|-------------------------------|-------------------|-------------------------------|------------------|------------------|-------------|----------------|-------------|-------------------------|----------------------|
| | | | | | Unexpos | ed Males | <11 | | | | | |
| 801 | 305 | 7.86 | 1.89 | 4.72 | 0.16 | 1.10 | 0 | 39 | 459 | 12.8 | 7.4 | 10 |
| 802 | 403 | 8.23 | 5.18 | 2.80 | 0 | 0.25 | 0 | 37 | 435 | 12 1 | 6.5 | 6 |
| 803 | 273 | 13.60 | 7.21 | 4.90 | 0.14 | 1.36 | Õ | 37 | 409 | 12.4 | 7.9 | 20 |
| 806 | 270 | 9.19 | 3.95 | 4.32 | 0.18 | 0.64 | 0.90 | 37 | 433 | 12.1 | 8.0 | 26 |
| 807 | 267 | 9.48 | 5.50 | 3.03 | 0.76 | 0.19 | 0 | 35 | 414 | 11.5 | 6.8 | 11 |
| 809 | 268 | 9.40 | 5.17 | 2.82 | 0.47 | 0.85 | 0.90 | 33 | 389 | 11.2 | 8.2 | 26 |
| 870 | 418 | 9.46 | 4.45 | 3.03 | 0.47 | 1.42 | 0.90 | 39 | 465 | 12.4 | 7.4 | 16 |
| 904 | 434 | 9.20 | 3.59 | 4.69 | 0.37 | 0.55 | 0 | 37 | 412 | 12.1 | 7.6 | |
| 905 | 350 | 7.38 | 3.25 | 3.17 | 0.22 | 0.59 | 1.50 | 37 | 468 | 12.1 | 7.3 | 20 |
| 952 | 428 | 9.55 | 3.82 | 5.06 | 0.29 | 0.19 | 1.90 | 35 | 421 | 11.8 | | |
| 972 | 363 | 6.74 | 2.63 | 3.24 | 0.13 | 0.74 | 0 | 39 | 470 | 12.4 | 7.9 | 32 |
| 004 | 548 | 13.70 | 6.30 | 5.62 | 0.41 | 1.23 | 140 | 35 | 401 | 11.8 | 7.6 | 23 |
| 006 | 218 | 12.30 | 5.41 | 5,53 | 0.37 | 0.98 | 0 | 40 | 452 | 12.4 | 8.1 | |
| 009 | 312 | 6.57 | 2.30 | 3.15 | 0.39 | 0.72 | 0 | 38 | | 12.1 | | |
| 010 | 481 | 9.79 | 6.17 | 3.23 | 0.20 | 0.20 | 0 | 36 | 423 | 12.1 | 8.1 | 30 |
| 013 | 238 | 13.55 | 7.45 | 4.47 | 0.27 | 1.36 | 0 | 35 | | 10.9 | | - |
| 014 | 288 | 6.83 | 2,05 | 4.17 | 0.14 | 0.41 | 0.70 | 35 | 423 | 11.2 | 7.5 | |
| 015 | 194 | 10.40 | 4.58 | 4.47 | 0.21 | 1.04 | 1.00 | 35 | | 11.2 | 7.2 | |
| 018 | 485 | 11.20 | 5.49 | 4.59 | 0.22 | 0.78 | 2.20 | 36 | 472 | 10.6 | | 13 |
| 024 | 245 | 6.74 | 3.84 | 2.63 | 0.07 | 0.20 | 0 | 35 | 459 | 11.8 | 7.4 | 11 |
| 027 | 393 | 6.24 | 1.68 | 4.37 | 0.12 | 0.06 | 0 | 38 | 420 | 11.5 | | |
| 028 | 525 | 11 60 | 5 34 | 5.45 | 0.23 | 0.58 | 0 | 37 | 426 | 11.2 | | |
| 029 | 330 | 10.30 | 4.43 | 5.56 | 0.31 | 0 | 0 | 39 | 486 | 11.8 | | |
| 030 | 265 | 16 30 | 6.85 | 6.85 | 0.49 | 1.96 | 1.60 | 39 | 465 | 13.2 | | |
| 032 | 507 | 6.91 | 3.46 | 3.11 | 0.21 | 0.14 | 0 | 40 | 473 | 14.0 | 7.7 | 25 |
| 037 | 449 | 6.65 | 2.19 | 4.19 | 0.13 | 0.07 | 0.70 | 36 | 401 | 12.1 | | |
| 038 | 459 | 8.25 | 4.54 | 2.06 | 0.17 | 1.49 | 0 | 35 | 396 | 10.3 | | |
| 039 | 545 | 15.00 | 10.05 | 4.80 | 0.15 | 0 | 0 | 38 | 460 | 12.8 | | |
| 040 | 348 | 7.86 | 5.90 | 1.41 | 0.24 | 0.24 | 0.80 | 36 | 481 | 11.2 | | |
| 046 | 283 | 7.87 | 2.36 | 4.49 | 0.08 | 0.94 | 0 | 35 | 441 | 10.6 | | |
| 047 | 334 | 11.20 | 5.04 | 5.82 | 0 | 0.34 | 0 | 36 | 463 | 11.5 | | |
| 049 | 328 | 15.30 | 7.34 | 7.80 | 0 | 0.15 | 0 | 38 | 513 | 12.4 | 7.9 | 23 |
| 053 | 315 | 10.50 | 8.08 | 1.89 | 0 | 0.53 | 0 | 38 | 467 | 12.4 | 7.3 | 25 |
| 054 | 420 | 8.75 | 3.06 | 4,99 | 0.18 | 0.53 | 0 | 40 | 517 | 12.1 | | |
| 056 | 530 | 7.61 | 2.59 | 4.49 | 0.23 | 0.15 | 1.50 | 35 | 444 | 10.0 | | |
| 058 | 520 | 13.10 | 5.90 | 6.29 | 0.52 | 0.39 | 0 | 33 | 518 | 10.0 | | |
| 059 | 333 | 10.40 | 5.93 | 4.06 | 0.42 | 0 | 0 | 35 | 441 | 12.1 | | |
| 061 | 347 | 10.80 | 2.59 | 7.13 | 0.32 | 0.43 | 3.20 | 30 | 391 | 11.8 | | |
| 062 | 535 | 8.99 | 1.16 | 7.01 | 0.36 | 0.45 | 0 | 34 | 434 | 10.9 | | |
| ~ • • • | 222 | | - · • V | | | - | | | | | | |

M 81

125

5

14.23

| Subject | Plat. (X10 ⁻³) | WBC (X10-3) | Neut. (X10 ⁻³) | Lymph. (X10 ⁻³) | Mono. (X10-3) | Eosin (X10-3) | Baso. (X10 - ²) | Hct. (%) | RBC (X10-4) | Hgb. (g) | Serum Protein (g) | Sed. Rate (mm) |
|---------|-------------------------------|----------------|-------------------------------|--------------------------------|------------------|------------------|--------------------------------|-------------|----------------|-------------|-------------------------|----------------------|
| | | | | <u>U</u> | nexposed | Males < | <u>11 (cont'</u> | <u>d)</u> | | | | |
| 1063 | 1/15 | 12 10 | 2 18 | 9.56 | 0.24 | 0.12 | 0 | 30 | 300 | 10.0 | | |
| 1503 | 245 | 7 66 | 1.99 | 5 13 | 0.38 | 0.12 | 0 | 37 | 469 | 12.8 | 78 | 30 |
| 1504 | 406 | 13.00 | 8.32 | 3.77 | 0.26 | 0,65 | 0 | 40 | 450 | 14.0 | | 00 |
| Mean | 365 | 9.94 | 4.55 | 4.38 | 0.25 | 0.58 | 0.46 | 36.5 | 445 | 11.8 | 7.6 | 20.4 |
| neun | <u>+106</u> | 2.6 | 2.1 | 1.6 | | | | 2.4 | 34 | 0.9 | 0.4 | 7.7 |
| | | | | | | | | | | | , | |
| | | | | U | nexposed | Females < | < 11 | | | | | |
| 808 | 270 | 11 10 | E 00 | 2 22 | 0.17 | 1 22 | 1 10 | 10 | | 10 / | 0 7 | 20 |
| 808 | 378 | 11.10 | 2.88 | 3.33 | 0.44 | 1.33 | 1.10 | 40 | 452 | 12.4 | 8./ | 30 |
| 810 | 330 | 9.49 | 4.75 | 3.89 | 0.19 | 0.47 | 1.90 | 00 | 344 | 12.5 | 7.8 | 10 |
| 000 | 210 | 6 99 | 4.42 | 3.19 | 0.33 | 0.25 | 0 70 | 40 | 439 | 13.0 | 7.5 | 52 40 |
| 900 | 258 | 0.00 | 4.33 | 2.00 | 0.20 | 0.35 | 0.70 | 36 | 575 1/37 | 11.5 | 7.0 | 40 26 |
| 901 | 305 | 6 69 | 2.20 | 2.77 | 0.33 | 0.30 | 0 | 35 | 437 | 11.0 | 7.0 | 20 |
| 902 | 773 | 0.00 | 2.74 | J. 21 1/ 53 | 0.33 | 0.20 | 0 | 35 | 414 | 11.0 | 8.2 | 38 |
| 906 | 2/8 | 6 74 | 2 09 | 4.55 | 0.37 | 0.50 | 0 | 38 | 410 | 14 0 | 79 | 26 |
| 900 | 435 | 11 40 | 5 59 | 4.04 | 0.20 | 0.40 | 0 | 39 | 456 | 13.6 | 7.8 | 37 |
| 930 | 295 | 13 90 | 5.00 | 6 53 | 0.54 | 1 67 | 1 40 | 38 | 452 | 13.0 | 7.0 | 57 |
| 954 | 395 | 13.40 | 8 31 | 4 29 | 0.27 | 0.54 | 0 | 35 | 400 | 11 8 | 7.6 | |
| 979 | 310 | 9 79 | 4 21 | 4.69 | 0.27 | 0.39 | 1.00 | 39 | 400 | 12.8 | 7.0 | 25 |
| 995 | 223 | 12.11 | 5 69 | 4.05 | 0.48 | 1.20 | 0 | 35 | | 11.5 | 7.7 | |
| 1008 | 208 | 9.10 | 3,17 | 4.98 | 0.27 | 0.63 | 0 | 38 | | 12.8 | 7.7 | |
| 1011 | 425 | 11.80 | 5.42 | 4.84 | 0.47 | 0.94 | 1.20 | 36 | 468 | 11.8 | | 31 |
| 1012 | 413 | 8.08 | 3.31 | 3.72 | 0.40 | 0.65 | 0 | 34 | 402 | 12.4 | 7.3 | 30 |
| 1020 | 402 | 9.64 | 2.89 | 6.46 | 0.19 | 0.10 | 0 | 31 | 390 | 10.0 | | 13 |
| 1021 | 337 | 13.00 | 5.98 | 5.59 | 0.26 | 1.04 | 1.30 | 39 | 445 | 12.4 | | |
| 1022 | 341 | 6.33 | 2.28 | 3.17 | 0.32 | 0.57 | 0 | 35 | 410 | 11.8 | 7.1 | 19 |
| 1025 | 423 | 13.60 | 6.94 | 5.58 | 0.68 | 0.41 | 0 | 38 | 483 | 12.1 | | |
| 1026 | 413 | 7.07 | 2.26 | 3.89 | 0.28 | 0.64 | 0 | 35 | 409 | 10,9 | 7.5 | 36 |
| 1031 | 557 | 10.40 | 5.41 | 3.95 | 0.21 | 0.73 | 1.00 | 35 | 407 | 11.2 | | |
| 1034 | 323 | 11.70 | 8.07 | 2.57 | 0.35 | 0.70 | 0 | 39 | 490 | 12.4 | 7.7 | 39 |
| 1044 | 388 | 6.58 | 2.63 | 3.36 | 0.33 | 0.26 | 0 | 34 | 410 | 9.7 | | |
| 1055 | 415 | 8.86 | 4.25 | 3.46 | 0.53 | 0.53 | 0.90 | 40 | 483 | 12.1 | | |
| 1057 | 446 | 15.20 | 4.56 | 10.34 | 0 | 0 | 1.50 | 33 | 409 | 9.4 | | |
| 1060 | 363 | 9.10 | 2.37 | 6.19 | 0.18 | 0.27 | 0.90 | 33 | 407 | 11.2 | | |
| Mean | 367 | 9.87 | 4.43 | 4.44 | 0.34 | 0.56 | 0.48 | 36.3 | 430 | 11.9 | 7.7 | 28.7 |
| | <u>+</u> 80 | 2.5 | 1.7 | 1.6 | | | | 2.4 | 35 | 1.1 | 0.4 | 8.1 |

126

....

| | | | | | | | | | | | Serun |
|----------------|-------------------------------|----------------|------------------|-------------------|------------------|--------------------------------|-------------------------------|-------------|-----------------------------|----------------------|----------------|
| Subject No. | Plat. (X10 ⁻³) | WBC (X10-3) | Neut. (X10-3) | Lymph. (X10-3) | Mono. (X10-3) | Eosin. (X10 ⁻³) | Baso. (X10 ⁻²) | Hct. (%) | RBC (X10 ⁻⁴) | Н g b. (g) | Protein (g) |
| | | | | <u>Rongela</u> | p Exposed N | 1ales 12-15 | | | | | |
| 2 | | 12.84 | 7.44 | 3.85 | 0.51 | 1.03 | 0.0 | 39 | ł | | |
| 3 | | 5.79 | 2.49 | 2.08 | 0.12 | 0.93 | 1.70 | 37 | | | |
| 5 | | 6.61 | 2.97 | 2.97 | 0.13 | 0.53 | 0.0 | 39 | | | |
| 19 | | 8.95 | 4.83 | 2.86 | 0.27 | 0.98 | 0.90 | | | 13.0 | |
| 32 | | 6.57 | 2.63 | 2.83 | 0.07 | 0.92 | 1.30 | 41 | | | |
| 54 | | 3.70 | 1.00 | 1.73 | 0.07 | 0.85 | 0.40 | 40 | | | |
| 83* | | 8.19 | 4.75 | 2.78 | 0.25 | 0.33 | 0.80 | 38 | | | |
| 85* | | 9.57 | 4.98 | 3.82 | 0.48 | 0.29 | 0.0 | 38 | | | |
| Mean | | 7.77 | 3.88 | 2.86 | 0.24 | 0.73. | 0.64 | 38.8 | | 13.0 | |
| | | +2.16** | 1.9 | 0.8 | | | | 2.2 | | | |
| | | | · · | Ailingn | ae Exposed | Males 12-1 | 5 | | | | |
| 6 | | 7.58 | 3.87 | 2.58 | 0.38 | 0.76 | 0.0 | 40 | | | |
| 84* | | 4.87 | 1.31 | 2.97 | 0.10 | 0.44 | 0.50 | . 37 | | | |
| | | 6.22 | 2.59 | 2.78 | 0.24 | 0.60 | 0.25 | 38.5 | | | |
| | | | | <u>Rongela</u> | p Exposed | Females 12. | <u>-15</u> | | | | |
| 17 | | 5.78 | 2.20 | 2.49 | 0.17 | 0.92 | 0.0 | 33 | | | |
| 21 | | 5.74 | 2,58 | 2.41 | 0.17 | 0.46 | 1.10 | 37 | | | |
| 33 | | 5.37 | 2.95 | 1.66 | 0.11 | 0.64 | 0.0 | 42 | | | |
| 42 | | 6.69 | 3.81 | 1.94 | 0.0 | 0.80 | 1.30 | 38 | | | |
| 65 | | 7.40 | 5.03 | 1.70 | 0.37 | 0.22 | 0.70 | 39 | | | |
| 86* | | 9.81 | 3.63 | 3.24 | 0.0 | 2.84 | 1.00 | 40 | | | |
| | | 6.79 | 3.36 | 2.24 | 0.14 | 0.98 | 0.68 | 38.1 | | | |
| | | ±1.5 | 0.9 | 0.5 | | | | 3.5 | | | |
| | | | | Ailingna | e Exposed | Females 12. | -15 | | | | |
| 8 | | 12.45 | 9.71 | 2.24 | 0.37 | 0.0 | 1.30 | 36 | | | |

APPENDIX 12

PH 48

C manifi

Individual Hematological Findings, 1966

14.21

.

*Exposed in utero. **Standard deviation.

بصح

| Subject <u>No</u> , | Plat. (X10 ⁻³) | WBC (X10-3) | Neut. (X10-3) | Lymph. (X10-3) | Mono. (X10 ⁻³) | Eosin. (X10-3) | Baso. (X10-2) | Hct. (%) | RBC (X10~4) | Hgb. (g) | Serum Protein (g) |
|------------------------|-------------------------------|----------------|------------------|-------------------|-------------------------------|-------------------|------------------|-------------|----------------|-------------|-------------------------|
| | | | | Rongelap | Exposed Ma | ales > 15-4 | 0 | | | | |
| 9 | | 8.04 | 3.38 | 3.94 | 0.24 | 0.32 | 1.60 | 44 | | | |
| 10 | | 4.92 | 2.61 | 2.02 | 0.15 | 0.15 | 0.0 | 37 | | | |
| 20 | | 5.90 | 2.89 | 2.24 | 0.12 | 0.53 | 1.20 | | | 16.0 | |
| 27 | | 6.64 | 3.78 | 2.19 | 0.07 | 0.40 | 1.30 | 43 | | | |
| 36 | | 7.53 | 3.39 | 3.24 | 0.30 | 0.53 | 0.80 | | | ' 15.0 | |
| 37 | | 7.48 | 3.81 | 2.84 | 0.52 | 0.30 | 0.0 | 50 | | | |
| 47 | | 4.63 | 2.13 | 1.71 | 0.09 | 0.65 | 0.40 | | | 16.0 | |
| 73 | | 7.04 | 3.80 | 2.39 | 0.28 | 0.42 | 1.40 | 45 | | | |
| 76 | | 6.38 | 2.62 | 3.00 | 0.19 | 0,51 | 0.60 | | | 14.6 | |
| 77 | | 4.92 | 3.10 | 1.48 | 0.20 | 0.10 | 0.50 | 50 | | | |
| Mean | | 6.35 | 3.15 | 2.51 | 0.22 | 0.39 | 0.78 | 44.8 | | 15.4 | |
| | | <u>+</u> 1.1 | 0.5 | 0.7 | | • | | 3.6 | | | |
| | | | | Ailingna | e Exposed | Males > 15- | -40 | | | | |
| 44 | | 4.99 | 2.44 | 1.85 | 0.10 | 0.50 | 1.00 | 40 | | | |
| | | | | Rongelap | Exposed Fe | males > 15. | -40 | | | | |
| 12 | | 5.72 | 3.83 | 1.54 | 0.11 | 0.23 | 0.0 | 34 | | | |
| 14 | | 6.84 | 3.49 | 2.12 | 0.14 | 1.03 | 0.70 | 36 | | | |
| 15 | | 6.36 | 2.99 | 2.73 | 0.19 | 0.38 | 0.60 | 39 | | | |
| 18 | | 9.80 | 6.76 | 2.01 | 0.29 | 0.59 | 1.00 | 40 | | | |
| 22 | | 7.80 | 4.99 | 1.95 | 0.0 | 0.70 | 1.60 | 31 | | | |
| 24 | | 6.32 | | | | | | 37 | | | |
| 39 | | 3.80 | 1.29 | 1.94 | 0.15 | 0.30 | 1.10 | 40 | | | |
| 49 | | 6.24 | 3.37 | 2.24 | 0.19 | 0.37 | 0.60 | 36 | | | |
| 61 | | 6.36 | 3.75 | 2.16 | 0.19 | 0.19 | 0.60 | 41 | | | |
| 67 | | 9.90 | 2.87 | 5.64 | 0.10 | 1.19 | 1.00 | | | 13.0 | |
| 69 | | 6.32 | 2.40 | 3.16 | 0.19 | 0.51 | 0.60 | 41 | | | |
| 71 | | 6.36 | 3.56 | 1.97 | 0.19 | 0.57 | 0.0 | 43 | | | |
| 74 | | 9.72 | 6.03 | 2.43 | 0.19 | 0.97 | 1.00 | 46 | | 10 - | |
| 75 | | 10.75 | 7.63 | 2.04 | 0.11 | 0.86 | 1.10 | | | 12.5 | |
| Mean | | 7.30 +1.9 | 4.07 1.7 | 2.46 1.0 | 0.16 | 0.61 | 0.76 | 38.7 3.9 | | 12.8 | |

-* 1

P.148

ii nat

BC 7948

| Subject No. | Plat. (X10 ⁻³) | WBC (X10-3) | Neut. (X10- ³) | Lymph. (X10-3) | Mono. (X10 ⁻³) | Eosin. (X10 ⁻³) | Baso. (X10-2) | Hct. (%) | RB C (X10-4) | Hgb. (g) | Serum Protein (g) |
|----------------|-------------------------------|----------------|-------------------------------|-------------------|-------------------------------|--------------------------------|------------------|-------------|------------------------|-------------|-------------------------|
| | | | | Ailingnae | Exposed Fe | emales > 15 | -40 | | | | |
| 48 | | 7.78 | 3.89 | 3.03 | 0.16 | 0.62 | 0.80 | 40 | 1 | | |
| 51 | | 5.36 | 2.84 | 2.09 | 0.21 | 0.16 | 0.50 | 39 | | | |
| 53 | | 7.68 | 4.15 | 3.00 | 0.08 | 0.46 | 0.0 | 39 | | | |
| 70 | | 3.96 | 2.45 | 1.19 | 0.16 | 0,16 | 0.0 | 26 | | | • |
| 81 | | 5.58 | 3.07 | 1.84 | 0.28 | 0.33 | 0,60 | 40 | | | |
| Mean | | 6.07 | 3.28 | 2.23 | 0.18 | 0.35 | 0.38 | 36.8 | | | |
| | | | | Ronge | lap Exposed | l Males> 40 | 2 | | | | |
| 4 | | 5.88 | 1.82 | 3.41 | 0.18 | 0.41 | 0.60 | 43 | | | |
| 7 | | 5.68 | 3.12 | 1.99 | 0.28 | 0.17 | 1.10 | 39 | | | |
| 11 | | 5.88 | 3.41 | 1.76 | 0.29 | 0.41 | 0.0 | 36 | | | |
| 40 | | 6.48 | 2.85 | 2.98 | 0.26 | 0.32 | 0.60 | 44 | | | |
| 55 | | 4.79 | 2.59 | 1.96 | 0.14 | 0.10 | 0.0 | 33 | | | |
| 68 | | 4.76 | 2.33 | 1.95 | 0.05 | 0.42 | 0.0 | 45 | | | |
| 79 | | 7.55 | 4.30 | 2.87 | 0.15 | 0.23 | 0.0 | 48 | | | |
| 8 0 | | 9.00 | 5.22 | 3.15 | 0.27 | 0.36 | 0.0 | 44 | | | |
| 82 | | 6.68 | 3.81 | 2.07 | 0.27 | 0.47 | 0.70 | 40 | | | |
| Mean | | 6.30 | 3.27 | 2.46 | 0.21 | 0.32 | 0.33 | 41.3 | | | |
| | | <u>+</u> 1.2 | 1.0 | 0.6 | | | | 3.8 | | | |
| | | | | Ailing | nae Exposed | l Males> 40 | <u>)</u> | | | | |
| 16 | | 3.64 | 2.07 | 1.42 | 0.11 | 0.04 | 0.0 | 47 | | | |
| 41 | | 4.16 | 2.12 | 1.74 | 0.17 | 0.17 | 0.0 | 44 | | | |
| 50 | | 9.02 | 3.07 | 5.20 | 0.27 | 0.36 | 0.90 | 46 | | | |
| Mean | | 5.60 | 2.42 | 2.79 | 0.18 | 0.19 | 0.30 | 45.6 | | | |

1 14

.

.

· •

129

•

| Subject No. | Plat. (X10-3) | WBC (X10-3) | Neut. (X10-3) | Lymph. (X10-3) | Mono. (X10 ⁻³) | Eosin. (X10-3) | Baso. (X10-2) | Hct. (%) | RBC (X10-4) | Hgb. (g) | Serum Protein (g) |
|-----------------------|------------------|----------------|------------------|-------------------|-------------------------------|-------------------|------------------|-------------|----------------|-------------|-------------------------|
| | | | | Ronge1a | ap Exposed | Females>40 | 1 | | | | |
| 13 | | 7.28 | 4.88 | 1.67 | 0.17 | 0.51 | 0.0 | 37 | | | |
| 34 | | 7.04 | 3.80 | 2.53 | 0.14 | 0.56 | 0.0 | 37 | | | |
| 58 | | 5.96 | 3.10 | 2.32 | 0.24 | 0.24 | 0.60 | 41 | | | |
| 60 | | 6.64 | 3.20 | 2.72 | 0.20 | 0.40 | 0.0 | 36 | | | |
| 63 | | 4.32 | 1.99 | 2.16 | 0.08 | 0.08 | 0.0 | 43 | 1 | | |
| 64 | | 5.76 | 3.92 | 1.32 | 0.29 | 0.17 | 0.60 | 31 | | * | |
| 66 | | 6.20 | 3.22 | 2.48 | 0.12 | 0.37 | 0.0 | 38 | | | |
| 78 | | 6.44 | 3.74 | 2.32 | 0.0 | 0.32 | 0.60 | 40 | | | |
| | | 6.20 | 3.48 | 2.19 | 0.16 | 0.33 | 0.23 | 37.8 | | · | |
| | | ±0.9 | 0.8 | 0.4 | | | | 3.3 | | | |
| | | · | | Ailing | nae Exposed | Females>4 | 0 | | | | |
| 1 | | 5.46 | 3.33 | 1.64 | 0.16 | 0.22 | 0.60 | 41 | | | |
| 45 | | 5.08 | 2.69 | 1.73 | 0.25 | 0.41 | 0.0 | 39 | | | |
| 59 | | 6.04 | 2.47 | 2.17 | 0.24 | 1.09 | 0.60 | 41 | | | |
| | | 5.52 | 2.83 | 1.85 | 0.22 | 0.57 | 0.40 | 40.3 | | | |
| | | | | Utiril | k Exposed M | ales 12-15 | | | | | |
| 2115 | | 12.24 | 6.12 | 5.39 | 0.37 | 0.24 | 1.20 | 42 | | | |
| 2102 | | 10.47 | 4.29 | 5.44 | 0.31 | 0.21 | 2.10 | 39 | | | |
| 2102 | | 5,90 | 2.18 | 2.77 | 0.41 | 0.53 | 0.0 | 38 | | | |
| 2124 | | 5.80 | 2.78 | 2.61 | 0.17 | 0.23 | 0.0 | 41 | | | |
| 2150 | | 5.11 | 2.20 | 2.61 | 0.15 | 0.10 | 0.50 | 41 | | | |
| 2151 | | 7.53 | 2.86 | 4.21 | 0.30 | 0.0 | 0.80 | 39 | | | |
| 2152 | | 9.88 | 4.84 | 4.45 | 0.30 | 0.30 | 0.0 | 36 | | | |
| 2155 | | 6.27 | 2.19 | 3.76 | 0.13 | 0.19 | 0.0 | 37 | | | |
| 2133 | | 10.89 | 6.43 | 3.38 | 0.22 | 0.54 | 3.30 | 39 | | | |
| 2174 | | 6.26 | 1.94 | 3.44 | 0.31 | 0.56 | 0.0 | 39 | | | |
| 21/2 | | 7.64 | 3.82 | 3.29 | 0.07 | 0.31 | 0.0 | 41 | | | |
| 2232 | | 9.33 | 4.94 | 3.73 | 0.19 | 0.37 | 0.90 | | | 12.1 | |
| 2230 | | 7.40 | 4 44 | 2.29 | 0.30 | 0.37 | 0.0 | 39 | | | |
| 2242 | | 5.76 | | • | | | | 46 | | | |
| 2233 | | 5.10 | | | | | | | | | |
| Mean | | 7.89 +2.2 | 3.77 1.5 | 3.64 1.0 | 0.25 | 0.30 | 0.68 | 39.8 2.4 | | 12.1 | |

| Subject No | Plat. (X10 ⁻³) | WBC (X10 ⁻³) | Neut. (X10-3) | Lymph. (X10 ⁻³) | Mono, (X10 ⁻³) | Eosin. (X10 ⁻³) | Baso. (X10 ⁻²) | Hct. (%) | RBC (X10-4) | Hgb. (g) | Serum Protein (g) |
|---------------|-------------------------------|-----------------------------|------------------|--------------------------------|-------------------------------|--------------------------------|-------------------------------|-------------|----------------|-------------|-------------------------|
| | | | | <u>Utirik</u> | Exposed Fe | emales 12-1 | <u>5</u> | | | | |
| 2111 | | 7.92 | 3.72 | 3.56 | 0.16 | 0.40 | 0.80 | 46 | | | |
| 2113 | | 10.63 | 5.63 | 3.83 | 0.32 | 0.85 | 0.0 | 40 | ł | | |
| 2130 | | 8.50 | 4.25 | 3.15 | 0.42 | 0.60 | 0.80 | 36 | | | |
| 2132 | | 7.23 | 3.69 | 2.75 | 0.29 | 0.43 | 0.70 | | | 11.1 | |
| 2 210 | | 9.78 | 5.77 | 3.13 | 0.0 | 0.88 | 0.0 | 40 | | | |
| 2218 | | 12.40 | 6.70 | 5.08 | 0.12 | 0.50 | 0.0 | 46 | | | |
| 2227 | | 8.55 | 5.81 | 2.22 | 0.09 | 0.43 | 0.0 | 40 | | | |
| 2277 | | 14.43 | 10.10 | 3.75 | 0.29 | 0.29 | 0.0 | 39 | | | |
| Mean | | 9.93 | 5.70 | 3.43 | 0.21 | 0.55 | 0.29 | 41.0 | | 11.1 | |
| | | ±2.3 | 1.9 | 0.8 | | • | | 3.0 | | | |
| | | | | <u>Utirik</u> | Exposed Ma | $les \ge 15-4$ | <u>0</u> | | | | |
| 2123 | | 7.86 | 5.97 | 1.10 | 0.31 | 0.39 | 0.80 | 50 | | | |
| 2135 | | 9.04 | 5.88 | 2.53 | 0.18 | 0.45 | 0.0 | 50 | | | |
| 2137 | | 6.54 | 2.81 | 3.20 | 0.06 | 0.39 | 0.60 | 44 | | ÷ | |
| 2142 | | 7.90 | 3.56 | 3.63 | 0.08 | 0.63 | 0.0 | 44 | | | |
| 2144 | | 6.28 | 3.64 | 2.20 | 0.38 | 0.06 | 0.0 | 50 | | | |
| 2150 | | 8.42 | 5.30 | 2.95 | 0.17 | 0.0 | 0.0 | 48 | | | |
| 2152 | | 5.67 | 3.52 | 1.87 | 0.17 | 0.11 | 0.0 | 45 | | | |
| 2157 | | 8.97 | 5.11 | 3.23 | 0.45 | 0.18 | 0.0 | 44 | | | |
| 2165 | | 5.36 | 1.77 | 3.27 | 0.05 | 0.21 | 0.50 | 43 | | | |
| 2167 | | 7.92 | 4.67 | 2.38 | 0.55 | 0.33 | 0.0 | 47 | | | |
| 2168 | | 7.16 | 3.65 | 2 .8 6 | 0.07 | 0.57 | 0.0 | 45 | | | |
| 2176 | | 7.05 | 3.74 | 2.75 | 0.28 | 0.21 | 0.70 | 46 | | | |
| 2178 | | 7.03 | 2.81 | 3.59 | 0.42 | 0.14 | 0.70 | 44 | | | |
| 2188 | | 7.16 | 2.00 | 4.51 | 0.29 | 0.36 | 0.0 | 47 | | | |
| 2207 | | 9.58 | 6.42 | 2.20 | 0.38 | 0.48 | 1.00 | | | 11.8 | |
| 2250 | | 7.48 | 2.62 | 3.44 | 0.30 | 1.12 | 0.0 | 44 | | | |
| 2257 | | 8.15 | 5.95 | 1.79 | 0.16 | 0.24 | 0.0 | 48 | | | |
| Mean | | 7.50 | 4.08 | 2.79 | 0.25 | 0.35 | 0.25 | 46.2 | | | |
| | | <u>+</u> 1.1 | 1.4 | 0.8 | | | | 2.2 | | | |

PH 26

-

14-1

•

| Subject | Plat. (X10 ⁻³) | WBC (X10 ⁻³) | Neut. (X10 ⁻³) | Lymph. (X10-3) | Mono. (X10 ⁻³) | Eosin. (X10-3) | Baso. (X10-2) | Hct. (%) | RBC (X10-4) | Hgb. (g) | Serum Protein (g) |
|---------|-------------------------------|-----------------------------|-------------------------------|-------------------|-------------------------------|-------------------|------------------|-------------|----------------|-------------|-------------------------|
| | | | | <u>Utirik</u> | Exposed Fe | males > 15- | -40 | | | 1 | |
| 2104 | | 7.19 | 5.03 | 1.86 | 0.07 | 0.22 | 0.0 | 39 | | | |
| 2119 | | 5.74 | 2.35 | 2.87 | 0.17 | 0.34 | 0.0 | 45 | | | |
| 2128 | | 6.03 | 3.32 | 2.65 | 0.06 | 0.0 | 0.0 | 33 | | | |
| 2129 | | 8.60 | 4,90 | 3.18 | 0.17 | 0.26 | 0.90 | 40 | | | |
| 2138 | | 8.10 | 5.18 | 2.43 | 0.08 | 0.32 | 0.80 | | | 11.1 | |
| 2139 | | 9.52 | 3.81 | 3.62 | 0.10 | 1.90 | 1.00 | 43 | | | |
| 2147 | | 7.10 | 2.20 | 4.47 | 0.14 | 0.28 | 0.0 | | | 11.8 | |
| 2159 | | 11.48 | 9.87 | 1.38 | 0.23 | 0.0 • | 0.0 | 43 | | | |
| 2160 | | 10.92 | 6.44 | 3.28 | 0.55 | 0.55 | 0.0 | 48 | | | |
| 2164 | | 6.67 | 4.14 | 2.07 | 0.0 | 0.40 | 0.70 | 37 | | | |
| 2172 | | 8.47 | 3.98 | 3.56 | 0.25 | 0.59 | 0.80 | 43 | | | |
| 2189 | | 7.50 | 4.58 | 2.48 | 0.15 | 0.22 | 0.80 | | | 12.5 | |
| 2195 | | 7.09 | 4.25 | 2.27 | 0.21 | 0.21 | 1.40 | 41 | | | |
| 2197 | | 9.41 | 5.55 | 3.58 | 0.0 | 0.19 | 0.90 | 36 | | | |
| 2217 | | 9.10 | 4.46 | 4.19 | 0.09 | 0.27 | 0.90 | | | 11.4 | |
| 2220 | | 8.62 | 5.43 | 2.59 | 0.09 | 0.52 | 0.0 | 41 | | | |
| 2225 | | 8.73 | 5.59 | 2.53 | 0.17 | 0.35 | 0.90 | | | 10.8 | |
| 2228 | | 12.98 | 7.53 | 5.06 | 0.13 | 0.26 | 0.0 | 40 | | | |
| 2230 | | 8.58 | 4.72 | 3.09 | 0.17 | 0.51 | 0.90 | | | 12.5 | |
| 2246 | | 9.97 | 4.59 | 4.09 | 0.0 | 1.30 | 0.0 | 30 | | | |
| 2247 | | 11.30 | 4.97 | 5.42 | 0.34 | 0.34 | 2.30 | 36 | | | |
| 2251 | | 9.28 | 5.01 | 3.71 | 0.09 | 0.37 | 0.90 | 42 | | | |
| 2254 | | 8.24 | 4.20 | 3.38 | 0.16 | 0.49 | 0.0 | 39 | | | |
| 2256 | | 5.68 | 2.90 | 2.27 | 0.17 | 0.28 | 0.60 | 44 | | | |
| Mean | | 8.59 | 4 .79 | 3.17 | 0.15 | 0.42 | 0,58 | 40.0 | | 11.7 | |
| | | +1.8 | 1.6 | 1.0 | | | | 4.3 | | 0.7 | |

.

| Subject No | Plat. (X10 ⁻³) | WBC (X10 ⁻³) | Neut. (X10 ⁻³) | Lymph. (X10 ⁻³) | Mono. (X10-3) | Eosin. (X10 ⁻³) | Baso. (X10 ⁻²) | Hct. (%) | RBC (X10-4) | Hgb. (g) | Serum Protein (g) |
|----------------------|-------------------------------|-----------------------------|-------------------------------|--------------------------------|------------------|--------------------------------|-------------------------------|-------------|----------------|-------------|-------------------------|
| | | | | <u>Utiri</u> | k Exposed 1 | Males >40 | | | | | |
| 2101 | | 7.08 | 4.11 | 2.62 | 0.21 | 0.07 | 0.70 | 43 | | | |
| 2103 | | 5.65 | 3.45 | 1.98 | 0.11 | 0.0 | 1.10 | 40 | | | |
| 2105 | | 7.68 | 4.30 | 2.84 | 0.23 | 0.31 • | 0.0 | 45 | | | |
| 2110 | | 6.40 | 4.16 | 1.98 | 0.13 | 0.13 | 0.0 | 45 | | | |
| 2114 | | 7.44 | 4.98 | 2.01 | 0.07 | 0.37 | 0.0 | 44 | | | |
| 2125 | | 7.91 | 5.38 | 1.82 | 0.32 | 0.31 | 2.30 | 48 | | | |
| 2145 | | 6.29 | 2.33 | 3.84 | 0.0 | 0.06 | 0.60 | 47 | | | |
| 2148 | | 6.27 | 3.32 | 2.57 | 0.19 | 0.19 | 0.0 | 44 | | | |
| 2166 | | 5.41 | 2.11 | 3.02 | 0.11 | 0.16 | 0.0 | 41 | | | |
| 2169 | | 4.29 | 1.72 | 2.19 | 0.13 | 0.20 | 0.40 | 43 | | | |
| 2175 | | 4.19 | 2.10 | 1,93 | 0.08 | 0.04 | 0.40 | 42 | | | |
| 2181 | | 7.19 | 5.25 | 1.44 | 0.07 | 0.43 | 0.0 | 40 | | | |
| 2206 | | 7.35 | 4.63 | 2.65 | 0.07 | 0.0 | 0.0 | 47 | | | |
| 2211 | | 5.16 | 2.32 | 2.22 | 0.21 | 0.36 | 0.50 | 50 | | | |
| 2214 | | 11.56 | 7.86 | 2.31 | 0.12 | 1.27 | 0.0 | 40 | | | |
| 2240 | | 8.17 | 5.31 | 2.29 | 0.16 | 0.33 | 0.80 | 4 3 | | | |
| Mean | | 6.75 +1.7 | 3.96 1.6 | 2.36 0.6 | 0.14 | 0.26 | 0.43 | 43.9 2.8 | | | |

per all

ł

14:21

| Subject No. | Plat. (X10 ⁻³) | WBC (X10 ⁻³) | Neut. (X10 ⁻³) | Lymph. (X10-3) | Mono. (X10 ⁻³) | Eosin. (X10-3) | Baso. (X10-2) | Hct. <u>(%)</u> | RBC (X10-4) | Hgb. (g) | Serum Protein (g) |
|----------------|-------------------------------|-----------------------------|-------------------------------|-------------------|-------------------------------|-------------------|------------------|--------------------|----------------|-------------|-------------------------|
| | | | | <u>Utiri</u> | lk Exposed | Females >40 | 2 | | | ł | |
| 2109 | | 19.12 | 10.70 | 7.27 | 0.38 | 0.76 | 0.0 | | | 12.5 | |
| 2140 | | 6.44 | 3.48 | 2.45 | 0.26 | 0.13 | 0.60 | 43 | | | |
| 2146 | | 5.46 | 2.02 | 2.95 | 0.0 | 0.49 | 0.0 | 42 | | | |
| 2158 | | 5.45 | 2.62 | 2.62 | 0.11 | 0.05 | 0.50 | 36 | | | |
| 2161 | | 8.70 | 6.35 | 1.83 | 0.44 | 0.09 | 0.0 | 39 | | | |
| 2162 | | 11.47 | 8.37 | 2.87 | 0.23 | 0.0 | 0.0 | 36 | | | |
| 2186 | | 5.74 | 2.35 | 2.30 | 0.29 | 0.69 . | 0.60 | 39 | | | |
| 2191 | | 7.83 | 5.35 | 2.04 | 0.16 | 0.23 | 0.80 | 35 | | | |
| 2193 | | 8.49 | 3.99 | 3.91 | 0.17 | 0.34 | 0.80 | 38 | | | |
| 2194 | | 8.88 | 4.88 | 3.20 | 0.18 | 0.53 | 0.90* | | | 11.8 | |
| 2196 | | 7.90 | 3.16 | 3.71 | 0.24 | 0.63 | 1.60 | 41 | | | |
| 2198 | | 4.93 | 2.07 | 2.61 | 0.05 | 0.15 | 0.50 | 39 | | | |
| 2200 | | 6.23 | 4.17 | 1.81 | 0.06 | 0.19 | 0.0 | 45 | | | |
| 2202 | | 10.43 | 6.57 | 3.23 | 0.21 | 0.42 | 0.0 | 40 | | | |
| 2212 | | 7.53 | 3.24 | 3.24 | 0.08 | 0.83 | 1.50 | 41 | | | |
| 2215 | | 8.78 | 5.88 | 2.46 | 0.18 | 0.26 | 0.0 | 41 | | | |
| 2216 | | 8.85 | 5.22 | 3.19 | 0.18 | 0.09 | 1.80 | 39 | | | |
| 2221 | | 9.54 | 6.85 | 1.05 | 0.57 | 1.14 | 1.90 | 39 | | | |
| 2223 | | 4.13 | 2.35 | 1.49 | 0.04 | 0.21 | 0.0 | 37 | | | |
| 2224 | | 9.68 | 4.65 | 4.07 | 0.29 | 0.58 | 1.00 | 39 | | | |
| Mean | | 8.27 | 4.71 | 2.92 | 0.21 | 0.39 | 0.63 | 39.4 | | 12.2 | |
| | | +3.1 | 2.2 | 1.3 | | | | 2.5 | | | |

P14

-

80.37HB

ited

APPENDIX 13

Ì

.

Ŧ

.

1

1

Individual Basophil Determinations, 1965

| Subject No. | % Baso./ 4000 Cell Count | Subject <u>No.</u> | % Baso./ 4000 Cell Count | Subject No | % Baso./ 4000 Cell Count |
|----------------|-----------------------------|-----------------------|-----------------------------|---------------|-----------------------------|
| 1 | 0.75 | 61 | 0.53 | 113 | 0.53 |
| 2 | 0.55 | 63 | 0.48 | 115 | 0.25 |
| - 3 | 1 13 | 64 | 0.48 | 116 | 0.35 |
| 4 | 0.70 | 65 | 0.58 | 117 | 0.53 |
| 5 | 0.45 | 66 | 0.65 | 118 | 0.35 |
| 6 | 0.65 | 67 | 0.38 | 110 | 0.38 |
| 7 | 0.50 | 68 | 0.30 | 120 | 0.30 |
| 8 | 0.55 | 69 | 0.73 | 120 | 0.50 |
| 10 | 0.68 | 70 | 0.53 | 121 | 0.45 |
| 11 | 0 38 | 71 | 0.25 | 122 | 0.50 |
| 12 | 0.50 | 72 | 0.35 | 125 | 0.50 |
| 13 | 0.53 | 73 | 0.40 | 124 | 0.45 |
| 14 | 0.40 | 74 | 0 48 | 125 | 0.23 |
| 15 | 0.40 | 75 | 0 30 | 120 | 0.35 |
| 16 | 0.60 | 76 | 0.45 | 127 | 0.58 |
| 17 | 0.53 | 77 | 0.50 | 130 | 0.40 |
| 18 | 0.50 | 78 | 0.50 | 131 | 0.40 |
| 19 | 0.45 | 79 | 0.43 | 122 | 0.48 |
| 20 | - 0.45 | 80 | 0.30 | 134 | 0.43 |
| 21 | 0 38 | 81 | 0.50 | 125 | 0.45 |
| 23 | 0.45 | 82 | 0.40 | 135 | 0.30 |
| 24 | 0.50 | 83 | 0.38 | 120 | 0.38 |
| 27 | 0.45 | 84 | 0.50 | 120 | 0.48 |
| 28 | 0 53 | 85 | 0.40 | 139 | 0.40 |
| 29 | 0.50 | 86 | 0.63 | 140 | 0.58 |
| 32 | 0.50 | 87 | 0.43 | 145 | 0.45 . |
| 33 | 0.43 | 88 | 0.38 | 901 | 0.43 |
| 34 | 0.55 | 89 | 0.48 | 802 | 0.55 |
| 35 | 0.45 | 90 | 0.50 | 802 | 0.30 |
| 36 | 0 30 | 91 | 0.50 | 805 | 0.60 |
| 37 | 0.75 | 92 | 0.35 | 805 | 0.48 |
| 39 | 0.43 | 93 | 0.30 | 808 | 0.53 |
| 40 | 0.28 | 9/ | 0.30 | 807 | 0.38 |
| 40 | 0.58 | 96 | 0.58 | 808 | 0.40 |
| 42 | 0.38 | 90 | 0.50 | 809 | 0.55 |
| 45 | 0.38 | 09 | 0.50 | 810 | 0.48 |
| 47 | 0.50 | 100 | 0.65 | 811 | 0.53 |
| 47 | 0.50 | 100 | 0.50 | 812 | 0.25 |
| 40 | 0.65 | 101 | 0.45 | 813 | 0.35 |
| 50 | 0.45 | 105 | 0.50 | 814 | 0.58 |
| 51 | 0.50 | 104 | 0.55 | 815 | 0.50 |
| 53 | 0.48 | 105 | 0.40 | 816 | 0.38 |
| 54 | 0.55 | 100 | 0.40 | 81/ | 0.48 |
| 55 | 0.00 | 100 | 0.10 | 818 | 0.38 |
| 59 | 0.33 | 110 | 0.48 | 819 | 0.50 |
| 50 | 0.55 | 110 | 0.48 | 820 | 0.50 |
| 59 | 0.30 | | 0.55 | 821 | 0.53 |
| 00 | 0.38 | 112 | 0.40 | 822 | 0.45 |

| Subject No. | % Baso./ 4000 Cell Count | Subject No. | % Baso./ 4000 Cell Count | Subject No. | % Baso./ 4000 Cell Count |
|----------------|-----------------------------|----------------|-----------------------------|----------------|-----------------------------|
| | | | | | |
| 832 | 0.35 | 913 | 0.45 | 1001 | 0.43 |
| 826 | 0.28 | 914 | 0.45 | 1004 | 0.53 |
| 827 | 0.43 | 915 | 0.58 | 1006 | 0.58 |
| 820 | 0.25 | 916 | 0.50 | 1007 | 0.33 |
| 831 | 0.38 | 917 | 0.40 | 1008 | 0.33 |
| 832 | 0.30- | 920 | 0.40 | 1009 | 0.23 |
| 833 | 0.48 | 921 | 0.25 | 1010 | 0.43 |
| 835 | 0.30 | 922 | 0.40 | 1011 | 0.25 |
| 836 | 0.45 | 923 | 0.48 | 1012 | 0.40 |
| 840 | 0.50 | 925 | 0.25 | 1013 | 0.38 |
| 841 | 0.45 | 926 | 0.30 | 1014 | 0.48 |
| 842 | 0.43 | 928 | 0.45 | 1015 | 0.40 |
| 843 | 0.58 | 929 | 0.25 | 1018 | 0.45 |
| 844 | 0.28 | 930 | 0.28 | 1020 | 0.50 |
| 845 | 0.48 | 931 | 0.40 | 1021 | 0.43 |
| 846 | 0.43 | 932 | 0.48 | 1022 | 0.45 |
| 849 | 0.38 | 934 | 0.55 | 1024 | 0.50 |
| 850 | 0.60 | 936 | 0.48 | 1025 | 0.30 |
| 851 | 0.50 | 937 | 0.40 | 1026 | 0.48 |
| 852 | 0.53 | 938 | 0.45 | 1027 | 0.30 |
| 853 | 0.30 | 940 | 0.50 | 1028 | 0.43 |
| 855 | 0.23 | 941 | • 0.28 | 1029 | 0.28 |
| 856 | 0.38 | 942 | 0.50 | 1030 | 0.23 |
| 858 | 0.48 | 943 | 0.55 | 1031 | 0.53 |
| 859 | 0.28 | 945 | 0.48 | 1032 | 0.43 |
| 860 | 0.30 | 946 | 0.38 | 1033 | 0.30 |
| 863 | 0.48 | 947 | 0.43 | 1034 | 0.43 |
| 864 | 0.28 | 948 | 0.43 | 1035 | 0.45 |
| 865 | 0.43 | 951 | 0.38 | 1036 | 0.48 |
| 866 | 0.43 | 952 | 0.45 | 1037 | 0.43 |
| 870 | 0.53 | 954 | 0.40 | 1038 | 0.35 |
| 875 | 0.58 | 955 | 0.35 | 1039 | 0.40 |
| 878 | 0.50 | 956 | 0.43 | 1040 | 0.48 |
| 879 | 0.38 | 957 | 0.50 | 1041 | 0.58 |
| 880 | 0.50 | 959 | 0.48 | 1042 | 0.38 |
| 881 | 0.48 | 960 | 0.50 | 1044 | 0.43 |
| 882 | 0.53 | 961 | 0.60 | 1046 | 0.28 |
| 884 | 0.28 | 962 | 0.50 | 1047 | 0.45 |
| 885 | 0.20 | 963 | 0.38 | 1049 | 0.25 |
| 891 | 0.30 | 964 | . 0.43 | 1050 | 0.30 |
| 892 | 0.40 | 966 | 0.28 | 1052 | 0.53 |
| 895 | 0.23 | 967 | 0.38 | 1053 | 0.25 |
| 896 | 0.30 | 969 | 0.35 | 1054 | 0.50 |
| 897 | 0.35 | 970 | 0.48 | 1055 | 0.50 |
| 898 | 0.25 | 971 | 0.20 | 1056 | 0.48 |
| 899 | 0.53 | 972 | 0.33 | 1057 | 0.58 |
| 900 | 0.55 | 976 | 0.38 | 1058 | 0.40 |
| 901 | 0.48 | 978 | 0.25 | 1060 | 0.45 |
| 902 | 0.35 | 979 | 0.40 | 1061 | 0.65 |
| 903 | 0.48 | 980 | 0.28 | 1062 | 0.50 |
| 904 | 0.43 | 981 | 0.35 | 1063 | 0.50 |
| 905 | 0.48 | 982 | 0.48 | 1501 | 0.35 |
| 906 | 0.55 | 991 | 0.25 | 1502 | 0.48 |
| 907 | 0.40 | 993 | 0.30 | 1503 | 0.25 |
| 909 | 0.43 | 995 | 0.35 | 1504 | 0.40 |
| 911 | 0.40 | 996 | 0.40 | 1509 | 0.40 |
| 912 | 0.25 | 998 | 0.48 | | |

İ

`
APPENDIX 14

Chromosome Studies on Marshallese People

Exposed to Fallout Radiation

Hermann Lisco, M.D., and Robert A. Conard, M.D.

Chromosome aberrations in blood lymphocytes have been demonstrated in a number of population groups exposed to ionizing radiation. These have included patients during and after radio-therapy for ankylosing spondylitis (1,2) and malignant tumors (3,4,5), persons exposed in diagnostic procedures (6), and others exposed in the course of their work (7). Similar findings have been reported in individuals involved in radiation accidents (8,9) and in survivors of the atomic bombings in Hiroshima and Nagasaki in 1945 (10,11,12). One of the more interesting and possibly significant points in all of these studies was the observation that chromosome aberrations can persist in circulating lymphocytes in variable degree for many years following exposure. It seemed of interest to determine whether residual damage of this type could be found in Marshallese people who had been exposed to fallout radiation (13).

The accidental exposure of these people to radioactive fallout occurred on Rongelap Island in the Pacific Ocean in 1954. This was caused by an unpredicted shift in winds following detonation of a high yield nuclear device at Bikini 100 miles away. There were 64 people living on the island who received an estimated dose of 175 rads whole-body gamma-ray exposure. Eighteen other Rongelap people were away fishing on another island nearby and received an estimated dose of 70 rads. The exposure resulted in temporary blood cell depression, skin burns from beta radiation, and internal absorption of radionuclides, the most important of which were iodine and strontium. It was estimated that the thyroid glands of the adults received 150 rads and those of the children as much as 1,000 rads from absorbed radioiodine in addition to the whole-body gamma-ray exposure. The recent development of thyroid pathology is believed to be a consequence of this exposure (14).

Chromosome preparations were obtained on 51 individuals during the annual medical review of the Marshallese people in 1964. Of these, 30 had been exposed to 175 rads and 13 to 70 rads of gamma rays. Eight Marshallese who had not been exposed served as a comparison group. There were 20 males and 20 females in the exposed group and the ages ranged from an embryo in <u>utero</u> to 67 years at the time of exposure. Twenty-one were below and 22 above the age of 20, with males and females in about equal numbers. Of the comparison group, three were males and five females, ranging in age from 10 to 71 years. Unfortunately, it was not possible to examine a larger number of unexposed individuals matched to the exposed with respect to age and sex.

*New England Deaconess Hospital, Boston, Massachusetts.

ł

]

E

Methods

Į

1

Cultures of peripheral blood lymphocytes were made using a modification of the method of Moorhead et al (15). It had been determined from previous attempts of leukocyte cultures in these people that the chances of successful cultures were greatly enhanced if most of the plasma above the buffy coat in the settled blood sample was discarded and only a few ml of plasma used for culture along with the buffy coat. Cultures were harvested at 48 and 72 hours. The slides were stained with aceto-orcein and examined with phase microscopy. Intact and well-spread cells in metaphase were selected by scanning the slides with low-power magnification. Each cell thus selected was then examined with oil immersion. Examination was begun by comparing aberration rates seen in 48-hour and 72-hour cultures No significant differences were found. from 5 subjects chosen at random. Thereafter, with the exception of one case, all other examinations were made on 50 cells of each individual from the 72-hour cultures only. Thus, a total of 2150 cells was examined in the 43 exposed and 400 cells in the 8 comparison individuals.

Aberrations were scored as follows: 1) aneuploidy, including polyploid cells, 2) chromosome aberrations, and 3) chromatid aberrations. Karyotypes were made in cases where the counts were equivocal or where chromosomes of questionable morphology were seen. Only those aberrations were included in the final tabulation that were agreed upon by four observers. Additional karyotypes were made from eight euploid cells showing no gross abnormalities from each of four subjects who showed more aberrations than most others. This was done in an effort to detect in a small sample of this population minor structural abnormalities such as small deletions or inversions that could easily escape notice on microscopic examination. Finally, bone marrow preparations were made from two exposed persons and one control. Only one preparation from an exposed subject contained enough suitable cells in metaphase to warrant evaluation.

Results

As seen in Table I, aneuploid cells ranged from 5.5 per cent in the unexposed people to 10 per cent in the high exposure group, the low exposure group falling between the two with 8 per cent. In the majority of cells aneuploidy was due to loss of chromosomes. Although the percentage of aneuploid cells in the high exposure group was almost twice that seen in the comparison group, an incidence of 10 per cent may be considered at the upper limits of normal. Polyploid cells were seen with about equal frequency in all three groups.

The number of chromatid gaps and breaks and of isochromatid gaps were 2.75 per cent in the unexposed, 3.86 per cent in the high exposure and 5.31 per cent in the low exposure group. These differences were not significant.

Chromosome-type aberrations were found in 23 of the 43 exposed people and 5 of the 8 unexposed individuals (Table II). Proportionally, the largest number of persons with chromosome aberrations was found in the low exposure group with 84 per cent. The unexposed group was next with 62 per cent and this was followed by the high exposure group in which only 40 per cent of the people showed aberrations. In each of the two exposure groups one half of the aberrations consisted of two-hit events such as dicentric chromosomes, exchanges and a ring, the remainder being acentric fragments. The incidence of acentric fragments was unusually high in the unexposed group, but in contrast to the exposed people no two-hit aberrations were found among them. The difference between the exposed and unexposed groups with regard to the incidence of two-hit aberrations was found to be significant at the 1 per cent level (p<0.001).

Aberrations ranged from one to four per person. Sixteen of the 23 exposed people (70%) with chromosome aberrations had more than one such aberration; two of the 5 unexposed (40%) had multiple aberrations. In most instances no more than one aberration was noted per cell.

There was no correlation between the occurrence of thyroid pathology and chromosome aberrations. Ten of the exposed people included in this group developed thyroid pathology since these examinations were made. Only four of them had shown chromosome aberrations earlier; three were children and one an adult at the time of exposure.

No aberrations were found in the karyotypes that had been made from the 32 grossly intact cells from the four subjects showing relatively high aberration rates. Likewise, no abnormalities were seen in 50 cells from the bone marrow of one of the exposed subjects.

Discussion

Ţ

F

1

Ł

The results of this study demonstrate that a small but significant number of chromosome aberrations has persisted in blood lymphocytes of some of the Marshallese people for ten years following exposure to wholebody gamma radiation from fallout. This conclusion rests on the finding of the large number of two-hit aberrations (dicentrics, exchanges and a ring chromosome) in the exposed people which constituted one half of all chromosome aberrations seen. This was in striking contrast to the findings in the unexposed people in whom no two-hit aberrations were found even though the overall number of chromosome aberrations in this group was about the same and even a fraction higher than that in the exposed people taken as one group. Since two-hit aberrations were seen only in the people who had whole-body gamma ray exposure and not in the unexposed group, we interpret this finding as a residual effect of radiation.

We are unable to explain the greater incidence of chromosome aberrations in the group exposed to 70 rads as compared to the group that received 175 rads. We are also unable to account for the unusually high incidence of acentric fragments in the unexposed and their relative defecit in the exposed people. One might consider causative factors such as the low levels of internal radiation exposure from absorption of radionuclides such as ^{137}Cs , ^{65}Zn , ^{90}Sr , or exposure to such things as virus infections or chemicals (14, 16, 17). However, such factors are probably not involved since they did not produce a similar effect in the irradiated group who were exposed to the same factors.

Correlation of chromosomal aberrations and severity of early radiation syndrome in the Marshallese was not apparent. For instance, the degree of early hematological depression did not seem to correlate with the. occurrence or number of chromosomal aberrations on an individual basis. And, as was pointed out, the lower dose group had a higher incidence of chromosomal aberrations than did the higher dose group, though the radiation effects were more pronounced in the latter. These findings are in conformity with those of the ABCC studies (12) which failed to show correlation of chromosomal aberrations with severity of early radiation illness.

There was also no correlation of chromosomal findings in the Marshallese with age or sex. Neither did the presence or absence of thyroid pathology appear to be related. However, the development of thyroid abnormalities was related to the dose to the thyroid gland from internally absorbed radioiodines (based largely on the size of the gland) rather than the whole-body exposure.

Similar chromosome aberrations have been reported in the Japanese fishermen exposed to radiation from the same fallout (11). The incidence of aberrations, excluding aneuploid cells, was 2.1 per cent and thus identical with that seen in the Marshallese people. The majority were two-hit aberrations. The incidence of acentric fragments in a control population of Japanese studied by the same authors was 0.11 per cent; this is twenty times less than that seen among the eight unexposed Marshallese in the present study.

In a carefully controlled cytogenetic study of a sample of survivors of the atomic bombings in Hiroshima and Nagasaki, Bloom <u>et al</u>.have found an incidence of chromosome aberrations of 0.6 per cent in 94 persons 20 years after exposure (12). Thirty-eight per cent of the aberrations were of the multiple-hit type and the rest acentric fragments. Only a single minute fragment was seen in 8847 cells of the 94 controls, an unusually low incidence indeed. The low number of aberrations and the fact that only 35 per cent of the survivors showed aberrations is not surprising since 20 years have elapsed since exposure.

Although the Marshallese and Japanese exposed population and the conditions of their exposures are not strictly comparable, it is interesting that in the Marshallese people who were examined 10 years after exposure, the aberration rate as well as the number of aberration-positive individuals (53 per cent) was somewhat higher, as might have been expected.

Acknowledgements

ſ

ŧ

We are greatly indebted for expert technical assistance to V. Estey, R. Hammerstrom, I. Irwin, W. Merrill and W. Waithe. We wish to thank Dr. Shields Warren for his interest in this work. We are most grateful to many individuals in the U. S. Atomic Energy Commission, Brookhaven National Laboratory and the Trust Territory of the Pacific Islands for their support of the medical surveys of the Marshallese people exposed to fallout. We also wish to thank P. Crumrine and W. A. Scott for valuable assistance.

This investigation was supported in part by U. S. Public Health Service Grant CA 06930 and U. S. Atomic Energy Commission Contract AT(30-1)-3777 with the New England Deaconess Hospital.

]

1

F

1

141

TABLE I Analysis of Ploidy

Ĩ

I

I

| Subject | | | | | | |
|---------|---------------|-----------|-----------|-----------|---------------|------------------|
| No. | <u><45</u> | <u>45</u> | <u>46</u> | <u>47</u> | <u>>47</u> | <u>Polyploid</u> |
| | | Ex | posed-1 | 75 rads | | |
| 2 | | 1 | 49 | - | - | - |
| 3 | - | 2 | 48 | - | - | - |
| 4 | - | 4 | 46 | - | - | - |
| 18 | - | 1 | 48 | - | 1 | - |
| 19 | - | 1 | 46 | 1 | - | 2 |
| 23 | - | 3 | 46 | 1 | - | - |
| 24 | 1 | 2 | 47 | - | - | - . |
| 27 | - | 2 | 47 | 1 | - | - |
| 32 | 2 | 1 | 45 | - | - | 2 |
| 34 | 2 | 4 | 43 | - | 1 | - |
| 35 | - | 3 | 45 | 1 | - | 1 |
| 37 | - | 3 | 46 | - | 1 | - |
| 39 | - | 2 | 48 | - | - | - |
| 40 | 1 | 4 | . 43 | 1 | 1 | - |
| 42 | 1 | 6 | 41 | 1 | - | 1 |
| 49 | - | 6 | 42 | 2 | - | - |
| 54 | 1 | 1 | 45 | 3 | - | - |
| 58 | - | 6 | 43 | - | 1 | - |
| 60 | 1 | 3 | 45 | 1 | - | - |
| 61 | 2 | 7 | 41 | - | - | - |
| 63- | - | 3 | 45 | 2 | - | - |
| 64 | - | - | 46 | 1 | - | 3 |
| 68 | - | 1 | 48 | - | - | 1 |
| 69 | - | 3 | 47 | - | - | - |
| 73 | 1 | 1 | 47 | 1 | - | - |
| 74 | 1 | 3 | 44 | - | - | 2 |
| 78 | 4 | 6 | 40 | - | - | - |
| 79 | 2 | 4 | 42 | 2 | - | - |
| 80 | 4 | 5 | 41 | - | - | - |
| 82 | 1 | 1 | 45 | 2 | - | 1 |
| | | | | | | |
| | | E | cposed-/ | 0 rads | | |
| 1 | | 1 . | 49 | - | - | - |
| 29 | - | 5 | 43 | 1 | - | 1 |
| 41 | - | 1 | 49 | - | - | - |
| 43 | - | 6 | 43 | - | - | 1 |
| 45 | 1 | 2 | 46 | 1 | - | - |
| 48 | - | 2 | 48 | - | - | - |
| 50 | - | 2 | 47 | 1 | - | - |
| 51 | - | 2 | 47 | 1 | - | - |
| 53 | 2 | 3 | 42 | 3 | - | - |
| 59 | 1 | 1 | 46 | 1 | - | 1 |
| 70 | 1 | 2 | 45 | 1 | - | 1 |
| 81 | - | 1 | 49 | - | - | - |
| 84 | - | 1 | 44 | 5 | - | - |

| <u><45</u> | <u>45</u> | <u>46</u> | <u>47</u> | <u>>47</u> | Polyploid |
|---------------|--|--|--|---|---|
| | | Unexpo | osed | | |
| - | - | 48 | 1 | - | 1 |
| - | 2 | 48 | - | - | - |
| - | 2 | 48 | - | - | - |
| - | 1 | 48 | 1 | - | - |
| - | 2 | 48 | - | - | - |
| 1 | 2 | 46 | - | - | 1 |
| 3 | 2 | 45 | - | - | - |
| - | 4 | 46 | - | - | - |
| | <u><45</u> - - 1 3 - | $\begin{array}{cccc} < 45 & 45 \\ \hline - & - & 2 \\ - & 2 \\ - & 1 \\ - & 2 \\ 1 & 2 \\ 1 & 2 \\ 3 & 2 \\ - & 4 \end{array}$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |

•

Ī

I

ī

F

1

Ē

ł

| Subject No. | Age+ | Sex | Frag- ments | Dicen- trics | Rings | Exch- anges | No. of Chromosome Aberrations | No. of Cells with <u>Aberrations</u> | Chromatid Breaks | Isogaps | Remarks* |
|----------------|------|-----|----------------|-----------------|-------|----------------|-------------------------------------|--|---------------------|---------|---|
| | | | | | | | Exposed, 175 | rad | | | |
| 2 | 12 | М | 2 | | | | 2 | 2 | 1 | 1 ' | Thyroid pathology |
| 3 | 11 | М | | | | | | | 4 | | Thyroid pathology |
| 4 | 48 | М | | 2 | | | 2 | 2 | 1 | | |
| 18 | 31 | F | | | | | | | 1 | 1 | |
| 19 | 15 | М | | | | | | | | | Thyroid pathology |
| 23 | 14 | М | | | | | | | | | |
| 24 | 23 | F | 2 | 2 | | | 4 | • 3 | 1 | | |
| 27 | 36 | М | | | | | | | 3 | 2 | 2 breaks scored for one quadriradial |
| 32 | 13 | M | 1 | | | | 1 | 1 | | | |
| 34 | 55 | F | | | | | | | 3 | | |
| 35 | 23 | М | | 1 | | | 1 | 1 | 1 | | |
| 37 | 30 | М | | | | | | | | | |
| 39 | 25 | F | | | | | | | 3 | | |
| 40 | 39 | М | | | | | | | × | | Thyroid pathology |
| 42 | 13 | F | | | | 1 | 1 | 1 | 4 | | Thyroid pathology |
| 49 | 25 | F | | | | | | | 1 | 2 | |
| 54 | 11 | м | | | | | | | 4 | | Thyroid pathology |
| 58 | 69 | F | | 1 | | 1 | 2 | 2 | 1 | | |
| 60 | 66 | F | | | | 1 | 1 | 1 | 1 | | |
| 61 | 18 | F | 1 | | | 1 | 2 | 2 | | 1 | Thyroid pathology |

TABLE II Analysis of Structural Aberrations

⁺Age in years at time of examination, i.e., 10 years after exposure.

| Subject No | Age | <u>Sex</u> | Frag- ments | Dicen- trics | <u>Rings</u> | Exch- anges | No. of Chromosome Aberrations | No. of Cells with Aberrations | Chromatid Breaks | Isogaps | Remarks* |
|---------------|-----|------------|----------------|-----------------|--------------|----------------|-------------------------------------|-------------------------------------|---------------------|---------|-------------------|
| | | | | | | E> | posed, 175 rad | (continued) | | | |
| 63 | 46 | F | | | | | | | 1 | | |
| 64 | 40 | F | | | | | 1 | | 1 | 3 | Thyroid pathology |
| 68 | 55 | м | | | | | | | 2 | 1 | i |
| 69 | 14 | F | | | | | | | 1 | | Thyroid pathology |
| 73 | 28 | м | 2 | | | | 2 | 2 | 2 | | |
| 74 | 26 | F | 1 | | | | 1 | 1 | 5 | 3 | |
| 78 | 47 | F | | | | | | | 1 | | |
| 79 | 49 | М | | | | | | | 1 | 1 | |
| 80 | 56 | М | | | | | | | | | |
| 82 | 60 | М | 2 | | | | 3 | 2 | 1 | | |
| | | | | | | | | | | | |

التشغا

.

| | | | | | | | | Exposed, 70 rac | <u>1</u> | | | |
|---|----|----|---|---|---|---|---|-----------------|----------|----|---|-------------------|
| | 1 | 64 | F | | | | | | | 3 | | |
| | 29 | 75 | М | 2 | | | 1 | 3 | 2 | 1 | | |
| | 41 | 54 | М | 1 | | 1 | | 2 | 2 | 1 | | |
| | 43 | 77 | F | 1 | | | 1 | 2 | 2 | 2 | | |
| • | 45 | 42 | F | 2 | | | | 2 | 2 | 2 | | |
| | 48 | 16 | F | | 1 | | | 1 | 1 | | 1 | |
| | 50 | 44 | м | | | | | | | 2 | 1 | |
| | 51 | 35 | F | 1 | | | 1 | 2 | 2 | 1 | 1 | |
| | 53 | 18 | F | 1 | | | 2 | 3 | 1 | 11 | | |
| | 59 | 44 | F | 1 | 1 | | | 2 | 2 | 4 | 1 | Thyroid pathology |

par all

| Subject <u>No.</u> | Age | <u>Sex</u> | Frag- ments | Dicen- trics | <u>Rings</u> | Exch- anges | No. of Chromosome Aberrations | No. of Cells with <u>Aberrations</u> | Chromatid Breaks | Isogaps | Remarks* |
|-----------------------|-----|------------|----------------|-----------------|--------------|----------------|-------------------------------------|--|---------------------|---------|--------------------------------|
| | | | | | | Exp | osed, 70 rad (cc | ontinued) | | | |
| 70 | 25 | F | | | | 1 | 1 | 1 | | | ł. |
| 81 | 18 | F | 1 | | | | 1 | 1 | 2 | | |
| 84 | 9 | М | | | | 2 | 2 | 2 | 2 | | Exposed <u>in</u> <u>utero</u> |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | Unexposed | • | | | |
| 105 | 5 | F | | | | | | | 1 | | Child of exposed |
| 830 | 25 | М | | | | | | | 1 | | |
| 859 | 71 | F | 1 | | | | 1 | 1 | 1 | 1 | |
| 931 | 10 | М | 1 | | | | 1 | 1 | | | |
| 938 | 25 | F | 1 | | | | 1 | 1 | | 1 | |
| 982 | 43 | F | | | | | | | | | |
| 1005 | 31 | м | 3 | | | | 3 | 3 | 1 | | |
| 1043 | 29 | F | 3 | | | | 3 | 2 | 2 | 3 | |

part (10

* Except for Subject Nos. 3 and 64, all thyroid pathology was adenomatous goiter. Case 3 is a hypothyroid child. Case 64 had a mixed papillary and follicular carcinoma of the thyroid.

References

1

ł

1

- Tough, I. M., Buckton, K. E., Baikie, A. G., Court-Brown, W. M. X-ray induced chromosome damage in man. Lancet II: 849-851, 1960.
- Buckton, K. E., Jacobs, P. A., Court-Brown, W. M., Doll, R. A. A study of the chromosome damage persisting after x-ray therapy for ankylosing spondylitis. Lancet II: 676-682, 1962.
- 3. Warren, S., Meisner, L. Chromosomal changes in leukocytes of patients receiving irradiation therapy. J.A.M.A. 193: 351-358, 1956.
- 4. Millard, R. E. Abnormalities of human chromosomes following therapeutic irradiation. Cytogenetics 4: 277-294, 1965.
- Bauchinger, M., Hug, O. Chromosomenaberrationen nach Radium-Roentgentherapie Gynaekologischer Tumoren. Strahlentherapie 131: 109-121, 1966.
- 6. Bloom, A. D., Tjio, J. H. <u>In vivo</u> effects of diagnostic x-irradiation on human chromosomes. New Eng. J. Med. 270: 1341-1344, 1964.
- Norman, A., Sasaki, M., Ottoman, R. E., Veomett, R. C., Chromosome aberrations in radiation workers. Rad. Res. 23: 282-289, 1964.
- Bender, M. A., Gooch, P. C. Persistent chromosome aberrations in irradiated human subjects. II. Three and one-half year investigation. Rad. Res. 18: 389-396, 1963.
- Bender, M. A., Gooch, P. C. Somatic chromosome aberrations induced by human whole-body irradiation: The "recuplex" criticality accident. Rad. Res. 29: 568-582, 1966.
- Doida, Y., Sugahara, T., and Horikawa, M. Studies on some radiationinduced chromosome aberrations in man. Rad. Res. 26: 69-83, 1965.
- 11. Ishihara, T., and Kumatori, T. Chromosome aberrations in human leukocytes irradiated <u>in vivo</u> and <u>in vitro</u>. Acta Haem. Jap. 28: 291-307, 1965.
- 12. Bloom, A. D., Neriishi, S., Kamada, N., Iseki, T., Keehn, R. J. Cytogenetic investigation of survivors of the atomic bombings of Hiroshima and Nagasaki. Lancet II: 672-674, 1966.
- 13. Conard, R. A., and Hicking, A. Medical findings in Marshallese people exposed to fallout radiation. J.A.M.A. 192: 457-459, 1965.
- 14. Conard, R. A., Rall, J. E., and Sutow, W. W. Thyroid nodules as a late sequela of radioactive fallout. New Eng. J. Med. 274: 1391-1399, 1966.
- Moorhead, P. S., Nowell, P. C., Mellman, W. J., Battips, D. M., Hungerford, D. A. Chromosome preparations of leukocytes cultures from human peripheral blood. Exptl. Cell Res. 20: 613-616, 1960.

- 16. Nasjleti, C. E., and Spencer, H. H. Chromosome damage and poliploidization induced in human peripheral leukocytes in vivo and in vitro with nitrogen mustard, 6-Mercaptopurine and A-649. Cancer Res. 26(1): 2437-2443, 1966.
- 17. Nichols, W. W. The role of viruses in the etiology of chromosomal abnormalities. Am. J. Hum. Genet. 18(1): 81-92, 1966.

I

٨

ź

K

APPENDIX 15

7

ī

F

1

1

Total Blood and Red Cell Volume Data

(WT=gross weight; TBW=total body water; FAT=fat as % gross weight; LBM=lean body mass; RCV=red cell volume; BV=blood volume)

| Subject | WT | TBW | TBW | FAT | LBM | RCV | BV | RCV/LBM | BV/LBM |
|---------|-------------|------------|------------|---------------|-------------|---------|------------|----------------|----------------|
| No. | <u>(kg)</u> | <u>(1)</u> | <u>(%)</u> | (%) | <u>(kg)</u> | (1) | <u>(1)</u> | <u>(ml/kg)</u> | <u>(ml/kg)</u> |
| | | | | <u>A - Ma</u> | rshalle | se | | | |
| 822 | 54.54 | 38.1 | 68.8 | 4.4 | 52.1 | 1.402 | 3.260 | 26,9 | 62.6 |
| 832 | 46.36 | 25.0 | 53.0 | 26.4 | 34.1 | 0.849 | 2.358 | 24.9 | 69.2 |
| 836 | 56.36 | 35.3 | 61.7 | 14.3 | 48.3 | 1.428 | 3.320 | 29.6 | 68.7 |
| 838 | 66.13 | 41.7 | 62.2 | 13.6 | 57.1 | 2.108 | 4.053 | 36.9 | 71.0 |
| 841 | 66.81 | 31.9 | 47.0 | 34.7 | 43.6 | 1.150 | 3.196 | 26.4 | 73.3 |
| 873 | 61.36 | 43.2 | 69.4 | 3.6 | 59.1 | 1.670 | 3.631 | 28.3 | 61.4 |
| 881 | 68.63 | 32.8 | 47.1 | 34.6 | 44.7 | 1.996 | 4.247 | 44.7 | 95.0 |
| 882 | 54.77 | 39.9 | 71.8 | 0.3 | 54.6 | 1.131 | 3.426 | 20.7 | 62.7 |
| 885 | 61.81 | 41.0 | 65.3 | 9.3 | 56.1 | 1.760 | 3.825 | 31.4 | 68.2 |
| 895 | 55.90 | 29.0 | 51.5 | 28.5 | 40.0 | 1.070 | 2.488 | 26.8 | 62.2 |
| 916 | 63.63 | 32.6 | 50.4 * | 30.0 | 44.5 | 1.091 | 3.031 | 24.5 | 68.1 |
| 928 | 46.30 | 26.2 | 55.7 | 22.6 | 35.8 | 1.274 | 2.963 | 35.6 | 82.8 |
| 938 | 40.00 | 22.0 | 54.1 | 24.9 | 30.1 | 0.886 | 2.331 | 29.4 | 77.4 |
| 942 | 57.72 | 27.6 | 47.1 | 34.5 | 37.8 | 0.860 | 2.150 | 22.8 | 56.9 |
| 959 | 60.00 | 32.2 | 52.8 | 26.7 | 44.0 | 1.151 | 2.877 | 26.2 | 65.4 |
| 960 | 38.63 | 24.8 | 63.1 | 12.4 | 33.9 | 0.774 | 2.150 | 22.8 | 63.4 |
| 1007 . | 71.36 | 41.2 | 56.9 | 21.0 | 56.4 | 1.620 | 4.155 | 28.7 | 73.7 |
| 1043 | 41.81 | 26.4 | 62.3 | 13.5 | 36.2 | 1.066 | 2.664 | 29.4 | 73.6 |
| 1501 | 66.81 | 43.3 | 64.0 | 11.2 | 59.3 | 1.843 | 3.840 | 31.1 | 64.8 |
| 2000 | 63.18 | 39.8 | 61.9 | 14.0 | 54.4 | 1.310 | 2.675 | 24.1 | 49.2 |
| | MEAN | 33.5 | | | | 1.303 | 3.102 | 28.3 | 68.2 |
| | B | - Cau | casians I | Residin | ig in Pa | cific O | cean Area | <u>a</u> | |
| G.B. | 104.55 | 52.7 | 49.65 | 31.0 | 72.1 | 2.425 | 5.390 | 33.6 | 74.8 |
| D.B. | 71.36 | 45.9 | 63.34 | 12.0 | 62.8 | 1.747 | 3.970 | 27.8 | 63.2 |
| J.C. | 75.91 | 45.2 | 58.56 | 18.6 | 61.7 | 1.809 | 4.308 | 29.3 | 69.8 |
| P.C. | 68.18 | 36.0 | 52.10 | 27.6 | 49.3 | 1.588 | 3.379 | 32.2 | 68.5 |
| A.C. | 90.91 | 55.2 | 59.88 | 16.8 | 75.61 | 2.097 | 5.116 | 27.7 | 67.7 |
| W.D. | 84.09 | 51.9 | 60.73 | 15.6 | 70.9 | 2.412 | 5.610 | 34.0 | 79.1 |
| R.J. | 86.36 | 50.2 | 57.18 | 20.5 | 68.6 | 2.457 | 5.341 | 35.8 | 77.9 |
| D.J. | 70.45 | 44.3 | 61.83 | 14.1 | 60.5 | 1.794 | 4.078 | 29.7 | 67.4 |
| C.P. | 84.09 | 43.8 | 51.23 | 28.8 | 59.8 | 2.657 | 5.776 | 44.4 | 96.6 |
| J.S. | 84.09 | 50.8 | 59.47 | 17.4 | 69.5 | 2.428 | 5.518 | 34.9 | 79.4 |
| C.T. | 80.91 | 44.6 | 54.25 | 24.6 | 61.0 | 2.540 | 5.405 | 41.6 | 88.6 |
| A.T. | 61.36 | 37.5 | 60.19 | 16.4 | 51.3 | 1.199 | 4.064 | 23.3 | 79.2 |
| I.W. | 77.27 | 50.1 | 63.74 | 11.4 | 68.4 | 2.575 | 5.479 | 37.6 | 80.1 |
| Α.Β. | 65.91 | 33.9 | 50.69 | 29.6 | 46.4 | 1.986 | 4.225 | 42.8 | 91.1 |
| Т.В. | 67.27 | 33.8 | 49.44 | 31.3 | 46.2 | 1.424 | 3.561 | 30.8 | 77.1 |
| B.C. | 60.00 | 30.7 | 50.40 | 30.0 | 42.0 | 1.714 | 4.181 | 40.8 | 99.5 |
| C.M. | 60.91 | 32.1 | 51.98 | 27.8 | 44.0 | 1.672 | 4.181 | 38.5 | 95.0 |
| D.P. | 52.27 | 27.8 | 52.42 | 27.2 | 38.1 | 1.149 | 3.023 | 30.2 | 79.3 |
| P.R. | 72.73 | 42.8 | 57.98 | 19.5 | 58.5 | 2.006 | 4.458 | 34.3 | 76.2 |
| | MEAN | 42.6 | | | | 1.983 | 4.582 | 34.2 | 79.5 |

APPENDIX 16

Studies on Australia Antigen in Micronesian Populations

l

I

Ş

ł

Baruch S. Blumberg, The Institute for Cancer Research, Philadelphia, Pa.

Australia antigen is a serum protein first detected in the serum of Australian aborigines, using an antiserum developed in a hemophilia patient who had received a large number of transfusions.⁽¹⁾ The distribution of this trait has now been studied in more than 50 human populations. (See Table 1.) It was very rare in normal United States populations (none in 1,500 sera) but fairly common (3-6%) in sera collected from Marshall Islanders, Australian aborigines, Vietnamese, Filipinos, Polynesians, and other Southeast Asian populations. It is less common in Mediteranean populations and is extremely rare in Northern European populations and in most autochthonous New World populations. In addition to the relevance of this trait to studies on cancer (see below), it is of interest in anthropological studies of human populations.

Australia antigen migrates as an alpha protein on immuno-electrophoresis. The precipitin band which forms between the hemophilia antiserum and the serum containing Australia antigen stains faintly with Sudan black, indicating that the protein contains some lipid. Australia antigen has a specific gravity between 1.063 and 1.30, that is, it is more dense than low density lipoprotein but less so than most other serum proteins. It appears in the first peak in Sephadex G200 column chromotography, indicating that it is a high molecular weight serum protein. It is found in the fifth and sixth peaks on DEAE column chromotography and high speed ultracentrifugation. The antibody in the hemophilia serum which reacts with the Australia antigen travels in the I G (7S) gamma globulin fraction. (2)

Antisera against the protein have been produced by the immunization of rabbits with serum containing Australia antigen and the subsequent absorption of the antiserum with the sera of normal persons. (3)

In order to initiate studies on the inheritance of Australia antigen, it was necessary to determine if the trait was persistent over the course of weeks, months, or years. Sera collected from the population of Rongelap Atoll over the course of up to eight years were available. Samples from a total of 300 Micronesians from Rongelap were collected from the period 1958 to 1965. Of these, serial samples were available from 250 individuals. Of the latter, 237 were consistently negative, eleven were consistently positive and two were inconsistent. In each case, the inconsistency was apparent in only one of multiple sera. (See Figure 1.)

Family studies were undertaken on a total of 36 families, including 5 families from Rongelap. The results were consistent with the hypothesis that individuals homozygous for a gene termed $\underline{Au^1}$ (genotype $\underline{Au^1}/\underline{Au^1}$) have detectable Australia antigen in their blood (phenotype Au (1)). Individuals

homozygous for the alternate allele (genotype $\underline{Au}/\underline{Au}$) or heterozygotes (Au¹/Au) do not have detectable Australia antigen (phenotype Au (0)).(4)

Although Au (1) has not been found in normal United States populations, it is relatively common in some forms of leukemia, i.e., 18% of acute myelogenous leukemia, 17% of chronic lymphocytic leukemia. It has not as yet been found in chronic myelogenous leukemia. A consideration of the United States data alone, therefore, would suggest that Australia antigen is a leukemiaspecific antigen and may be associated with an increased risk of developing leukemia. It has also been found in high frequency (approximately 30%) in patients with Mongolism (Down's syndrome), a disease characterized by a high risk of developing leukemia. (5) During our studies in Cebu, we found that Australia antigen is significantly more common in patients with lepromatous leprosy than those with tuberculoid leprosy or non-leprosy individuals from the same area. (6)

Consideration of all the patient data suggests that a common factor in the various diseases in which the trait is found is a deficiency of the immunological system associated in some as yet unexplained manner with the presence of Australia antigen. Since the Rongelap people will be medically examined for many years, it will be of considerable interest to see if there is a differential susceptibility to disease, particularly leukemia, in respect to Australia antigen.

In several populations, including Marshall Islanders, a significant decrease in Australia antigen frequency with age has been detected. This may be due to selection against individuals with this trait, presumably compensated for by some, at present unknown, selective advantage in respect to one of the genotypes.

References

1

1

I

I

- Blumberg, B.S., Alter, J.J., and Visnich, S., A "new" antigen in leukemia sera. J. Am. Med. Assoc., 191: 541-546, February, 1965.
- 2. Alter, H.J., and Blumberg, B.S., Studies on a "new" human isoprecipitin system (Australia antigen). Blood, 27(3): 297-309, 1966.
- 3. Melartin, L. and Blumberg, B.S., Production of antibody against "Australia antigen" in rabbits. Nature, 210: 1340, 1966.
- 4. Blumberg, B.S., Melartin, L., Guinto, R.A., and Werner, B., Family studies of human serum isoantigen system (Australia antigen). Am. J. Human Genetics, in press, 1966.
- 5. Blumberg, B.S., An inherited serum isoantigen in leukemia and Down's syndrome. J. Clin. Invest., <u>45</u>: 988, 1966.
- 6. Blumberg, B.S. and Melartin, L., Conjectures on inherited susceptibility to lepromatous leprosy. Intern. J. Leprosy, <u>34(1)</u>: 60-64, 1966.

Table 1

Ĩ

I

1

Į

Australia Antigen in Non-Hospitalized Populations (from Blumberg et al. (4))

| Population | Location | <u>No. Tested</u> | No. Pos. | <u>% Pos.</u> |
|---------------------|-------------------|-------------------|----------|---------------|
| AMERICAS | | | | |
| Eskimos | Alaska, U.S.A. | 394 | 1 | 0.3 |
| Indians, Athabascan | Alaska, U.S.A. | 204 | 0 | 0 |
| Indians, Cashinahua | Peru | 89 | 18 | 20.2 |
| Indians, Haida | Canada | 338 | 0 | 0 |
| Indians, Mexico | Mexico | 252 | 1 | 0.4 |
| Indians, Ouechua | Peru | 102 | 0 | 0 |
| Indians, Sioux | S. Dakota, U.S.A. | 130 | 0 | 0 |
| Negros | Ga., Md., U.S.A. | 607 | 0 | 0 |
| Whites | Ga., Md., U.S.A. | 896 | 0 | 0 |
| AFRICA | | | | |
| Pare | Tanzania | 120 | 1 | 0.8 |
| Tristan da Cunha | Tristan da Cunha | 42 | . 0 | 0 |
| Ghanese | Ghana | 95 | 9 | 9.5 |
| ASIA | | | | |
| Japanese | Osaka, Japan | 301 | 1 | 0.3 |
| Chinese | U.S.A., Taiwan | 100 | 0 | 0 |
| Taiwanese | Taiwan | 23 | 3 | 13.0 |
| Israelis | Israel | 340 | 4 | 1.2 |
| Jordanese | Jordan | 40 | 0 | 0 |
| Filipinos | Cebu, P.I. | 764 | 37 | 4.8 |
| Filipinos | Manila, P.I. | 197 | 9 | 4.6 |
| Vietnamese | Vietnam | 128 | 8 | 6.3 |
| EUROPE | | | | |
| Finns | Finland | 924 | 1 | 0.1 |
| Lapps & Finnlapps | Finland | 127 | 0 | 0 |
| Italians | Ferara | 101 | 0 | 0 |
| Greeks | Greece | 857 | 15 | 1.8 |
| Portugese | Hawaii | 44 | 1 | 2.2 |
| OCEANIA | | | | |
| Aborigines | Australia | 233 | 12 | 5.1 |
| Maoris | New Zealand | 4 | 1 | 0 |
| Melanesians | New Guinea | 166 | 6 | 3.6 |
| Micronesians | Marshall Is. | 474 | 34 | 7.2 |
| Polynesians | Bora Bora | 119 | 3 | 2.5 |
| Polynesians | Hawaii | 43 | 1 | 2.3 |
| - | | 0.05/ | 144 | |
| Total | | 8,254 | 100 | - |



Ĩ

7

Ŧ

Į

E



Studies on the persistence of Australia antigen in blood samples collected serially from apparently normal individuals on Rongelap. The subject numbers are shown on the left. The reactions of sera collected in the years indicated at the top are given in the body of the figure.

(from Blumberg et al.⁽⁴⁾)

T

F

3

Į

I

| Subject | 100 | | Potassium | 137 Cs | 60 Co |
|-------------|--------|------------------|--|-------------------|-----------------|
| NO | Age | WC(KE) | g/kg body wc. | HOL/Kg BOdy WL. | pci/kg body wt. |
| | - | Ronge | elap Exposed Males | (Age 11-15) | |
| 83* | 11 | 33.6 | 2.11 | 9.0 | 18 8 |
| 54 | 12 | 40.4 | 2.03 | 12.6 | 28 5 |
| 2 | 13 | 32.4 | 2.26 | 18.4 | 41.0 |
| 6 | 13 | 30.7 | 2.34 | 17.8 | 17.0 |
| 19 | 14 | 42.3 | 2.21 | 12.4 | 27.2 |
| Mean | | | 2.19 | 14.0 | 26.5 |
| | | Ronge | lap Unexposed Male | s (Age 11-15) | |
| 921 | 11 | 29.3 | 1.78 | 22.5 | 32.3 |
| 813 | 11 | 27.7 | 1.84 | 27.8 | 31.6 |
| 912 | 12 | 28.9 | 2.32 | 20.0 | 39.6 |
| 1052 | 12 | 37.1 | 2.19 | 18.9 | 22.7 |
| 814 | 13 | 35.1 | 2.33 | 23.3 | 31.9 |
| 1036 | 13 | 34.4 | 2.08 | 13.9 | 29.3 |
| 1033 | 14 | 57.3 | 1.80 | 13.1 | 27.7 |
| 818 | 14 | 41.4 | 2.14 | 23.5 | 32.5 |
| 913 | 14 | 39.1 | 2.06 | 15.9 | 31.2 |
| 815 | 15 | 47.7 | 2.32 | 17.7 | 19.1 |
| 863 | 15 | 50.0 | 2.13 | 22.6 | 48.1 |
| Mean | | | 2 09 | 19.9 | 31 5 |
| | - | | +0.20** | +4.3 | +7 3 |
| | | Dene | | | <u> </u> |
| | | Konge | elap Exposed remai | es (Age 11-15) | |
| 86* | 11 | 24.3 | 2.45 | 15.2 | 6.5 |
| 65 | 12 | 26.6 | 2.28 | 11.9 | 42.5 |
| 33 | 12 | 45.5 | 1.82 | 21.0 | 29.8 |
| 8 | 13 | 40.3 | 1.67 | 12.6 | 36.6 |
| 42 | 14 | 36.3 | 1.69 | 16.5 | 42.9 |
| 17 | 14 | 49.7 | 1.61 | 20.4 | 13.8 |
| Mean | | | 1.92 | 16.3 | 28.7 |
| | | Rong | elap Unexposed Fe | males (Age 11-15) | |
| 811 | 11 | 29.4 | 2.13 | 19.2 | 37.1 |
| 805 | 11 | 32.3 | 1.64 | 14.5 | 38.5 |
| 911 | 12 | 41.6 | 1.93 | 19.9 | 23.5 |
| 955 | 12 | 47.3 | 1.52 | 7.4 | 13.1 |
| 996 | 12 | 34.8 | 2.28 | 20.9 | 29.9 |
| 960 | 15 | 49.5 | 1.82 | 17.0 | 27.8 |
| 816 | 15 | 50.0 | 1.38 | 12.2 | 32.2 |
| Mean | | | 1.81 | 15.9 | 28.9 |
| * Exposed i | n uter | 0. | | | - |
| | | | $(x^2) / (5 - x)^2$ | | |
| ** Standard | deviat | $ion = \sqrt{4}$ | $\frac{2}{N} - \left(\frac{2}{N}\right)$ | | |
| | | • | · · · | | |

Gamma Spectrographic Data, Rongelap People, 1965

| Subject | | | Potassium | ¹³⁷ Cs | 60 |
|---------|---------|--------------|-------------------|-------------------|----------------|
| No. | Age | Wt(Kg) | g/Kg Body Wt. | nCi/Kg Body Wt. | pCi/Kg Body Wr |
| | <u></u> | <u></u> | <u>8/0/1</u> | | <u></u> |
| | | Rong | gelap Exposed Ma | les (Age >15) | |
| 20 | 18 | 54.0 | 2.17 | 14.3 | 36.0 |
| 73 | 29 | 71.2 | 2.17 | 26.1 | 27.6 |
| 10 | 35_ | 63.5 | 2.04 | 17.9 | 40.4 |
| 27 | 37 | 64.9 | 1.88 | 20.4 | 48.0 |
| 40 | 40 | 55.3 | 2.47 | 18.9 | 26.1 |
| 50 | 45 | 85.3 | 1.61 | 8.5 | 36.4 |
| 7 | 47 | 56.7 | 1.97 | 16.5 | 69.3 |
| 4 | 49 | 66.9 | 1.85 | 24 7 | 47 7 |
| 79 | 50 | 65.8 | 1 55 | 12 9 | 31 0 |
| 16 | 50 | 52 2 | 1.55 | 16 5 | 59 5 |
| 41 | 55 | 5/. /. | 2.04 | 22 3 | 13 0 13 1 |
| 41 | 52 | J4.4 E0 E | 1.76 | 10 6 | 43.9 |
| 00 | 50 | 50.5 | 1.70 | 19.0 | 20.0 |
| 80 | 57 | 60.6 | 2.09 | 0.1 | 45.0 |
| 82 | 61 | 57.2 | 1.74 | 19.3 | 36.8 |
| 11 | 61 | 51./ | 2.10 | 10.2 | 36.5 |
| Mean | | | 1.97 | 17.1 | 40.7 |
| | | | <u>+</u> 0.24 | <u>+</u> 5.3 | <u>+</u> 11.5 |
| | | Ronge | elap Unexposed Ma | ales (Age >15) | |
| 820 | 16 | 56.9 | 2.55 | 15.7 | 30.3 |
| 822 | 18 | 56.5 | 2.42 | 12.3 | 43.7 |
| 939 | 19 | 69.4 | 2.08 | 15.6 | 33.5 |
| 832 | 21 | 66.2 | 2.20 | 16.2 | 37.6 |
| 967 | 22 | 63.5 | 2.22 | 15.1 | 19.8 |
| 827 | · 25 | 60.1 | 2.14 | 18.1 | 16.0 |
| 1501 | 28 | 69.2 | 1.78 | 11.9 | 28.0 |
| 882 | 32 | 54.0 | 2.04 | 9.3 | 64.6 |
| 836 | 32 | 63.5 | 1.93 | 10.5 | 11.4 |
| 833 | 32 | 64.4 | 1.68 | 9,9 | 32.1 |
| 881 | 33 | 76.2 | 1.74 | 10.2 | 35.0 |
| 845 | 35 | 69.9 | 2.05 | 14.6 | 29.2 |
| 840 | 35 | 68.0 | 2.03 | 21 4 | 42 7 |
| 864 | 39 | 74.2 | 1.88 | 22 1 | 47 5 |
| 917 | 46 | 83.7 | 1 44 | 12 9 | |
| 875 | 48 | 59.9 | 2 07 | 22.5 | 44. <i>/</i> |
| 850 | 54 | 60.8 | 1 93 | 23.0 | 56 6 |
| 1007 | 54 | 74 4 | 1.55 | 2J.0 | 20.0 |
| 948 | 57 | 75.8 | 1.04 | 11.7 | 30.8 |
| 9/.7 | 56 | /0.0 | 1.4/ | 10.5 | 38.4 |
| 855 | 40 | 49.0 | 2.02 | 18.1 | 57.0 |
| 853 | 60 | 69.0 | 1.58 | 9.2 | 36.8 |
| 10/1 | 60 | 68.9 | 1.46 | 11.8 | 34.7 |
| 1041 | 60 | 83.0 | 1.43 | 16.5 | 32.3 |
| 910 | 62 | 53.1 | 2.11 | 27.4 | 59.8 |
| 8/8 | 65 | 83.0 | 1.39 | 5.7 | 19.0 |
| 935 | 67 | 58.9 | 1.79 | 15.2 | 50.0 |
| 856 | 66 | 55.8 | 1.85 | 14.6 | 25.7 |
| 915 | 68 | 55.3 | 1.94 | 13.4 | 34.7 |
| 860 | 75 | 56.7 | 1.22 | 8.1 | 20.8 |
| Mean | | | 1.88 | 14.7 | 37.6 |
| | | | +0.32 | <u>+</u> 4.9 | +13.8 |

Ì

]

!

| Subject | | | Potassium | 137 Cs | ⁶⁰ |
|---------|-----|---------|------------------|------------------|---------------------------|
| No | Age | Wt (Kg) | g/Kg Body Wt. | nCi/Kg Body Wt. | pCi/Kg Body Wr |
| | | <u></u> | <u>a/</u> | | <u>politika 2000) wet</u> |
| | | Ron | gelap Exposed Fe | males (Age >15) | |
| 48 | 17 | 52.4 | 1.72 | 15.2 | 33.2 |
| 15 | 18 | 52 2 | 2.68 | 7.8 | 161.8 |
| 53 | 19 | 48 5 | 1.91 | 20.0 | 17.1 |
| 61 | 19- | 75 3 | 1 13 | 4 0 | 21 5 |
| 49 | 26 | 68 5 | 1.49 | 6.7 | 31.4 |
| 18 | 32 | 48 9 | 1 40 | 8 1 | 50.6 |
| 14 | 36 | 62 1 | 1 44 | 12 5 | 30.8 |
| 51 | 36 | 43 3 | 1 90 | 11 2 | 46.9 |
| 51 | /\0 | 45.8 | 1 / 9 | 8.6 | 37 2 |
| 64 | 40 | 61 7 | 1 41 | 12 7 | 24.6 |
| 59 | 41 | 38 7 | 1 70 | 18 9 | 51 5 |
| 63 | 45 | 494 | 1.72 | 18.3 | 43.9 |
| 78 | 47 | 68 0 | 1 12 | 11 3 | 32.8 |
| 3/1 | 56 | 62 1 | 1.12 | 10.8 | 38.8 |
| 1 | 65 | 73 0 | 0.96 | 5 4 | 25.8 |
| 60 | 67 | 59 0 | 1 24 | 7 7 | 25.0 |
| 13 | 69 | 33 1 | 1 58 | 19.9 | 31 7 |
| 58 | 70 | 5/ 9 | 1.05 | 10.5 | 15 5 |
| 00 | 70 | 54.7 | 1.05 | 10.9 | 19.9 |
| Mean | | | 1,52 | 11.6 | 40.0 |
| | | | <u>+</u> 0.39 | <u>+</u> 5.0 | <u>+</u> 10.6 |
| | | | | | 32.8* |
| | | | | | +10.6 |
| | | | 1 1 | | _ |
| | | Rong | elap Unexposed F | emales (Age >15) | |
| 959 | 16 | 63.5 | 1.49 | 9.2 | 34.4 |
| 821 | 17 | 59.6 | 1.51 | 7.2 | 16.0 |
| 998 | 18 | 56.2 | 1.62 | 9.3 | 24.4 |
| 896 | 24 | 46.3 | 1.77 | 12.8 | 45.4 |
| 1502 | 26 | 52.2 | 1.75 | 13.5 | 29.6 |
| 832 | 27 | 49.9 | 1.28 | 8.7 | 40.8 |
| 1050 | 30 | 59.4 | 1.48 | 15.7 | 61.6 |
| 932 | 30 | 50.3 | 1.55 | 10.9 | 24.8 |
| 914 | 30 | 45.8 | 1.78 | 14.7 | 25.7 |
| 934 | 30 | 63.7 | 1.44 | 15.2 | 34.2 |
| 835 | 31 | 51.0 | 1.35 | 12.6 | 37.7 |
| 1001 | 31 | 58.5 | 1.33 | 22.0 | 22.0 |
| 841 | 32 | 69.9 | 0.93 | 5.8 | 25.3 |
| 865 | 32 | 49.4 | 1.69 | 11.7 | 35.3 |
| 834 | 36 | 50.3 | 1.56 | 8.3 | 33.0 |
| 945 | 40 | 39.0 | 1.94 | 12.9 | 31.0 |
| 916 | 41 | 61.7 | 1.47 | 7.1 | 28.5 |
| 844 | 46 | 50.3 | 1.44 | 13.8 | 49.1 |
| 1042 | 47 | 58.5 | 1.36 | 12.1 | 24.4 |
| 942 | 50 | 60.1 | 1.43 | 17.6 | 44.0 |

*Mean with subject No. 15 excluded.

Ï

ī

Ţ

| Subject | | | Potassium | ¹³⁷ Cs | 60 _{C0} |
|---------|--------|----------|--------------------------|-------------------|------------------|
| No | Age | Wt(Kg) | g/Kg Body Wt. | nCi/Kg Body Wt. | pCi/Kg Body Wt. |
| | | Rongelap | Unexposed Females | (Age >15)-contd. | |
| 928 | 52 | 56.9 | 1.28 | 8.6 | 22.9 |
| 851 | 56 | 77.6 | 1.15 | 7.0 | 17.7 |
| 956 | 56 | 60.3 | 1.39 | 11.1 | 21.4 |
| 957 | 57 | 72.6 | 1.06 | 7.2 | 7 2 |
| 852 | 61 | 46.3 | 1.41 | 8.1 | 39 5 |
| 858 | 70 | 45.8 | 1 59 | 7 3 | 38.9 |
| 936 | 70 | 54.4 | 1.04 | 7.0 | 27.7 |
| Mean | | | 1.45 | 11.0 | 31.2 |
| nean | | | +0.22 | +3.8 | +11.2 |
| | | Rong | - relan Unexposed Mal | - es (Age <11) | - |
| 1028 | 2 | 15 1 | 1 9/ | 10 5 | 20.1 |
| 1038 | د ا | 15.1 | 1.84 | 19.5 | 20.1 |
| 110 | 2 | 1/.4 | 3.29 | 20.5 | 9.8 |
| 1018 | 5 | 15.3 | 1.73 | 11.1 | 22.1 |
| 111 | 6 | 14.2 | 2.35 | 18.9 | 43.1 |
| 1024 | 6 | 19.1 | 1.92 | 17.8 | 50.5 |
| 1053 | 6 | 17.5 | 2.43 | 35.7 | 33.8 |
| 98 | 7 | 18.2 | 2.22 | 14.1 | 22.8 |
| 905 | 7 | 18.0 | 3.41 | 20.2 | 9.1 |
| 1004 | 7 | 19.0 | 2.60 | 26.2 | 35.4 |
| 904 | 7 | 22.0 | 2.18 | 16.5 | 35.2 |
| 1503 | 7 | 15.7 | 2.17 | 16.0 | 56.8 |
| 93 | 8 | 23.0 | 2.74 | 7.8 | 10.3 |
| 89 | 9 | 22.6 | 2.75 | 16.9 | 0.0 |
| 801 - | 9 | 19.9 | 2.39 | 19.6 | 36.8 |
| 803 | 9 | 23.0 | 2.56 | 15.7 | 37 7 |
| 809 | 9 | 23.3 | 2.67 | 33.2 | 18 / |
| 90 | 9 | 27.8 | 2 56 | 3/- 1 | 27 9 |
| 802 | á | 23.7 | 2.50 | 12 2 | 47.7 |
| 88 | 10 | 25.7 | 2.50 | 13.4 | 42.7 |
| 01 | 10 | 20.0 | 2.02 | 23.0 | 17.4 |
| 807 | 10 | 27.4 | 2.60 | 18.5 | 39.2 |
| Maar | 10 | 20.7 | 1.90 | 22.1 | /5.9 |
| Mean | | | 2,42 | 20.4 | 30.7 |
| | | | <u>+</u> 0.42 | ± 1.2 | <u>+</u> 17.6 |
| | | Rong | elap Unexposed Fem | ales (Age <11) | |
| 140 | <1 | 5.0 | 4.71 | 9.6 | 0.0 |
| 120 | 5 | 17.0 | 2.25 | 17.2 | 38.1 |
| 1026 | 5 | 15.5 | 2.75 | 18.4 | 25.4 |
| 112 | 6 | 15.5 | 2.42 | 15.1 | 43.1 |
| 1020 | 6 | 14.3 | 2.71 | 12.4 | 41.0 |
| 139 | <1 | 5.5 | 2.72 | 1.0 | 0.0 |
| 106 | 6 | 17.5 | 3.01 | 8.2 | 2.0 |
| 1025 | 6 | 14.5 | 2.33 | 14.8 | 25 1 |
| 1022 | 5 | 16 1 | 2 39 | 13 2 | 25.1 |
| 906 | ר ר | 17 7 | 2.59 | 1/ 7 | JJ.4 |
| 700 | 1 | 1/./ | 2.00 | 14./ | 28.1 |

Ĩ

1

F

]

| Subject | | | Potassium | 137 _{Cs} | 60 | | | | |
|---------|------------|---------|--------------------|----------------------|-----------------|--|--|--|--|
| No. | Age | Wt.(Kg) | g/Kg Body Wt. | nCi/Kg Body Wt. | pCi/Kg Body Wt. | | | | |
| | | | | | | | | | |
| | | Ronge | lap Unexposed Fem | ales (Age <11)-contd | <u>-</u> | | | | |
| 1034 | 7 | 20.1 | 2.23 | 22.0 | 13.2 | | | | |
| 902 | 7 | 20.3 | 2.08 | 14.4 | 25.4 | | | | |
| 1012 | 7 | 21.4 | 2.15 | 17.4 | 22.2 | | | | |
| 103 | 7 | - 18.0 | 2.03 | 28.6 | 18.1 | | | | |
| 901 | 8 | 22.3 | 2.35 | 19.3 | 22.5 | | | | |
| 900 | 8 | 23.3 | 2.36 | 14.7 | 32.0 | | | | |
| 92 | 9 | 23.3 | 1.29 | 18.9 | 75.4 | | | | |
| 94 | 9 | 20.5 | 1.39 | 11.8 | 10.4 | | | | |
| 810 | 10 | 28.5 | 2.09 | 11.5 | 30.4 | | | | |
| 808 | 10 | 30.2 | 2.26 | 17.6 | 27.5 | | | | |
| 866 | 10 | 24.5 | 2.65 | 19.0 | 30.4 | | | | |
| Mean | | | 2.42 | 15.2 | 27.0 | | | | |
| | | | <u>+</u> 0.44 | <u>+</u> 5.4 | <u>+</u> 15.6 | | | | |
| | | Rong | elap People Resid | ing At Ebeye | | | | | |
| 85* | 1 I M | 30.2 | 2 01 | 0.89 | 39.0 | | | | |
| 2 | 12M | 36.2 | 1 38 | 0.86 | 32.0 | | | | |
| 81 | 105 | 50.8 | 1.50 | 1 56 | 10 / | | | | |
| 830 | 26M | 74 4 | 1 80 | 0.22 | 8.8 | | | | |
| 70 | 28F | 513 | 1 39 | 0.62 | 25.6 | | | | |
| 71 | -01 39F | 57 4 | 2 17 | 1 85 | 175 0 | | | | |
| 842 | 41M | 72.6 | 1.39 | 0.23 | 7.3 | | | | |
| Mean | | | 1.68 | 0.89 | 42.6 | | | | |
| | - | | | | 20.6** | | | | |
| | | | U. S. Medical 1 | Ceam | | | | | |
| 2-34 | 32 | 100 0 | 1 //3 | 0.30 | 0 | | | | |
| 2-90 | 35 | 78 2 | 1.45 | 0.30 | 0 | | | | |
| 2-91 | 35 | 81 8 | 1.60 | 0.23 | 0 | | | | |
| 2-35 | 40 | 73 6 | 1 39 | 0.13 | 0 | | | | |
| 2-33 | 45 | 83.3 | 1 44 | 0.17 | 0 | | | | |
| 2-89 | 46 | 69.6 | 1 59 | 0.08 | 0 | | | | |
| 3-93 | 48 | 75.0 | 1.55 | 0.00 | 0 ' | | | | |
| 4-32 | 51 | 77.3 | 1.70 | 0.12 | 0 | | | | |
| 4-18 | 59 | 81.8 | 1.24 | 0.12 | Õ | | | | |
| Mean | | | 1.50 | 0.16 | | | | | |
| | | | <u>+</u> 0.18 | ± 0.11 | | | | | |
| | | Tru | ist Territory Medi | ical Team | | | | | |
| 4-52 | 29 | 72.7 | 1.78 | 0.49 | 0 | | | | |
| 3-17 | 37 | 80.9 | 1.43 | 0.42 | Ō | | | | |
| Mean | | | 1.61 | 0.45 | | | | | |

I

I

ł

*Exposed in utero. **Mean excluding subject No. 71.

APPENDIX 18

Cesium-137 and Strontium-90 Retention Following an Acute Ingestion of Rongelap Food

by

Edward P. Hardy Jr. and Joseph Rivera (Health and Safety Laboratory, New York Operations Office, U.S. Atomic Energy Commission) and Robert A. Conard (Brookhaven National Laboratory, Upton, New York). Published in "Radioactive Fallout from Nuclear Weapons Tests, Proceedings from the Second Conference, Germantown, Md., November 3-6, 1964," Ed. A.W. Klement, Jr., AEC Conf. 765, Nov. 1965.

SUMMARY

The cesium-137 and strontium-90 body burdens of people living on Rongelap Island are high compared to most other populations of the world. The reason for this is that the natives consume foods which are contaminated with longlived fission product radioactivity resulting from an accidental fallout incursion in 1954. Their Cs-137 body burdens are comparable to those of people living in other limited areas such as Lapland and northern Alaska where unique ecological conditions are conducive to high concentrations of cesium-137 in indigenous foods. The metabolism of cesium-137 and strontium-90 has been studied in the Lapland and Alaskan groups but not in the Rongelap natives.

Since facilities for a metabolic balance study were not available on Rongelap Island, one of us (R.A.C.) brought several native food items (pandanus fruit and coconut meat and milk) back to Brookhaven and consumed them under controlled conditions. Urinary and fecal specimens were collected and whole body counting measurements were made over a period of 180 days. The intake of strontium-90 over a seven day period was twenty times higher than normal and that of cesium-137, sixty times higher than normal.

Fifty percent of the ingested cesium-137 in the Rongelap food was excreted in urine after 85 days while fourteen percent was eliminated via the feces at the same time. In contrast, most of the strontium-90 was unabsorbed. Fifty percent was excreted in feces at 10 days while only two and one-half percent was excreted in urine. The retention of cesium-137 as determined by both whole body counting and excretion measurements showed a biological half-life of 74 days. Strontium-90 retention as a function of time was best described as a series of exponentials, and approached a value of 25 percent after 140 days.

These findings fall within the range of results of many other studies conducted under a wide variety of natural, accidental, and experimental conditions. Table I and Figures 1-4 summarize the above findings.

1

ļ

I

TABLE I

771

Sr⁹⁰, Ce¹³⁷, AND Ce IN EXCRETA

٠

P.M

٠

ł

| | | | Urine | Stool | pc | sr 90 | l z | Ca | pc | Cs137 | I | | ł | | 1 | 1 | | |
|-------------|------|---------------|-------------|-----------|----------|--------|-------|--------|-------|--------|--------|-------|-------|-------|--------|--------|--------------------|--------------------|
| Sampling | | | total vol. | total wt. | Urine | Stool | Urine | Stool | Urine | Stool | pc Sr9 | 0/dav | g Ca/ | dav | pc Cel | 37/day | pc Sr ⁹ | ⁰ /g Ca |
| period | days | series | ml . | | per 1 | per kg | per 1 | per kg | per 1 | per kg | Urine | Stool | Urine | Stool | Urine | Stool | Urine | Stool |
| | | | | | | | | | | | | | | | | | | |
| 6/26-28/63 | 3 | Pre | 2520 | 64 5 | 3.1 | 48 | 0.25 | 0.84 | 58 | 50 | 2.6 | 10.2 | 0.21 | 0.18 | 49 | 11 | 12 | 57 |
| 6/29-7/1/63 | 3 | ** | 3430 | 573 | 2.6 | 110 | 0.19 | 1.86 | 43 | 73 | 3.0 | 21.0 | 0.21 | 0.35 | 49 | 14 | 14 | 58 |
| 7/2-4/63 | 3 | Rong. food | 4 24 0 | 1081 | 10.8 | 991 | 0.11 | 1.53 | 431 | 707 | 15.3 | 357 | 0.15 | 0.55 | 609 | 255 | 98 | 6 48 |
| 7/5-8/63 | 4 | | 4420 | 809 | 8.6 | 1406 | 0.06 | 1.97 | 617 | 1835 | 9.5 | 284 | 0.06 | 0.39 | 682 | 371 | 143 | 714 |
| 7/9-11/63 | 3 | Post | 3610 | 482 | 10.8 | 264 | 0.13 | 1.28 | 439 | 1102 | 13.0 | 42.4 | 0.15 | 0.20 | 528 | 177 | 83 | 206 |
| 7/12-14/63 | 3 | н | 3900 | 544 | ₩ | 153 | * | 2.49 | * | 709 | * | 27.8 | * | 0.45 | * | 128 | * | 61 |
| 7/19/63 | 1 | •• | 1150 | 327 | 4.7 | * | 0.14 | 0.57 | 508 | 306 | 5.4 | * | 0.16 | 0.18 | 584 | 100 | 34 | * |
| 7/26/63 | 1 | •• | 609 | 211 | 5.9 | 166 | 0.17 | 1,48 | 710 | 514 | 4.1 | 35.0 | 0.12 | 0.31 | 490 | 108 | 35 | 112 |
| 8/2/63 | ī | " | 905 | 186 | 4.7 | 138 | 0.17 | 1.31 | 513 | 581 | 4.2 | 25.7 | 0.15 | 0.24 | 464 | 108 | 28 | 105 |
| 8/9/63 | 1 | | 1900 | 156 | 1.7 | 121 | 0.09 | 2.12 | 218 | 594 | 3.3 | 18.9 | 0.17 | 0.33 | 414 | 93 | 19 | 57 |
| 8/16/63 | 1 | | 1350 | 297 | 3.0 | 104 | 0.15 | 2.22 | 341 | * | 4.0 | 31.9 | 0.20 | 0.66 | 460 | * | 20 | 47 |
| 8/23/63 | 1 | н | 1280 | 270 | 2.4 | 131 | 0.11 | 2.66 | 273 | 350 | 3.1 | 35.4 | 0.14 | 0.72 | 349 | 95 | 22 | 49 |
| 8/30/63 | 1 | •• | 770 | 221 | 3.6 | 75 | 0.16 | 1.15 | 297 | 357 | 2.8 | 16.5 | 0.12 | 0.25 | 229 | 79 | 23 | 65 |
| 9/6/63 | 1 | | 660 | 441. | 3.9 | 46 | 0.19 | 0.79 | * | 135 | 2.6 | 20.2 | 0.12 | 0.35 | * | 60 | 20 | 58 |
| 9/13/63 | 1 | | - | 176 | - | 97 | - | 2.22 | - | 557 | - | 17.0 | - | 0.39 | - | 98 | - | 44 |
| 9/20/63 | 1 | •• | 678 | - | 3.7 | - | 0.29 | - | 295 | - | 2.5 | - | 0.20 | • | 200 | - | 13 | - |
| 9/21/63 | 1 | | 1040 | | 2.9 | - | 0.19 | - | 282 | - | 3.0 | - | 0.20 | - | 293 | - | 15 | • |
| 10/4/63 | 1 | н | 920 | 160 | 3.0 | 105 | 0.26 | 2.30 | 236 | 386 | 2.7 | 16.7 | 0.24 | 0.37 | 217 | 62 | 11 | 46 |
| 10/21/63 | 1 | | 1180 | 230 | 2.6 | 109 | 0,19 | 2.30 | 219 | 274 | 3.0 | 25.1 | 0.22 | 0.53 | 258 | 63 | 13 | 47 |
| 11/5/63 | 1 | ** | 680 | 320 | 4.7 | * | 0.24 | 1.22 | 217 | 299 | 3.2 | * | 0.16 | 0.39 | 148 | 96 | 20 | * |
| 12/6/63 | 1 | 14 | 1100 | 60 | 2.5 | 172 | 0.21 | 3.33 | 128 | 417 | 2.7 | 10.3 | 0.23 | 0.20 | 141 | 25 | 12 | 52 |
| 1/7/64 | 1 | ** | 780 | 94 | 3.2 | 149 | 0.18 | 2.76 | 196 | 356 | 2.5 | 14.0 | 0.14 | 0.26 | 152 | 34 | 18 | 54 |
| ****** | | | | | | | • | | | | 1 | | 1 | | 1 | | • | |

*Sample lost. -No sample received.



I

5

E

]

.



I

,1



;



Î

I

ł

164

 $\langle n \rangle$